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Alzheimer’s disease (AD) is a chronic, progressive neurodegenerative disorder, 
characterized clinically by a progressive loss of memory, cognitive function, ability to 
care for oneself and psychiatric symptoms.  First-line agents for the treatment of AD are 
ChE inhibitors (DON, GAL), whose modest clinical efficacy and the high incidence of 
dose-limiting toxicities limit their clinical utility. 
In addition to AD, ChE inhibitors (PYR) are used for other medical conditions, 
such as myasthenia gravis (MG).  Furthermore, ChE inhibitors (PYR) are used by 
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military personnel prophylactically if impending exposure to chemical warfare agents, 
e.g., soman, is suspected. 
The purpose of this research project was to understand the effect of age on the in-
vitro sensitivity of ChE inhibitors in human RBCs and plasma.  Understanding possible 
covariates, such as age and gender, may assist in optimizing dosing regimens of ChE 
inhibitors and/or developing newer ChE inhibitors with better adverse effect profiles. 
Plasma PHYS concentrations were measured by a validated HPLC-FD method.  
RBC AChE activity and plasma BuChE activity were measured by a modified Ellman’s 
colorimetric method using the model substrates, acetylthiocholine and butyrylthiocholine, 
respectively.  
The kinetics of RBC and plasma ChE activity followed Michaelis-Menten 
kinetics. Acetylthiocholine was found to be a nonselective substrate (RBC AChE Km = 
73 μM; plasma BuChE Km = 117 μM); while butyrylthiocholine was a selective substrate 
for plasma BuChE (RBC AChE Km = 130,000 μM; plasma BuChE Km = 72 μM).  For the 
following studies, RBC AChE activity was measured using acetylthiocholine as the 
substrate and plasma BuChE activity was measured using butyrylthiocholine as the 
substrate. 
This research project was performed in two parts: 
First, mechanistic studies of PHYS, PYR, DON and GAL, explored and 
determined the mechanism of in-vitro inhibition of RBC AChE and plasma BuChE 
inhibition, as well as the in-vitro degradation of PHYS in human whole blood, plasma 
and RBC.  PHYS was rapidly degraded in human whole blood, RBC and plasma and 
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followed Michaelis-Menten kinetics but its degradation clearance - scaled to whole blood 
clearance - was only predicted to account for 4-6% (i.e., 195-261 ml/min) of the reported 
total body clearance for PHYS (4500 ml/min).  RBCs were responsible for 60% of the 
whole blood clearance while plasma accounted for 40% of the whole blood clearance.  
Inhibition results indicated that both PHYS and PYR were nonselective and rapid suicide 
ChE inactivators.  PYR inactivated RBC AChE more rapidly at low concentrations and 
inactivated plasma BuChE more rapidly at high concentrations, but inactivated both more 
rapidly than PHYS.  PHYS was a more potent inactivator than PYR with a Ki for RBC 
AChE of 0.011 μM and 0.063 μM, respectively, and 0.023 μM and 0.036 μM, 
respectively for plasma BuChE.  DON was found to be a noncompetitive inhibitor for 
RBC AChE (Ki,noncomp = 114 μM), but a competitive inhibitor for plasma BuChE (Ki,comp 
= 213 μM).  GAL was found to be a competitive inhibitor for both RBC AChE (Ki,comp = 
66 μM) and plasma BuChE (Ki,comp = 358 μM). 
The second part involved a clinical study with ten young and nine elderly healthy 
subjects, balanced for gender, who donated blood for an in-vitro study in order to assess 
any age- and gender-related differences in in-vitro sensitivity to RBC AChE and plasma 
BuChE inhibition to all four ChE inhibitors.  Elderly adults were found to be 2-3-fold less 
sensitive compared to the young adults for PHYS (BuChE Ki,pss; 0.010 and 0.015 μM, 
young and elderly, respectively) and PYR (AChE Ki,pss; 0.12 and 0.25 μM, young and 
elderly, respectively) only, while neither DON nor GAL showed any age-related 
differences in sensitivity.  The observed differences for PHYS and PYR may be due to 
kinetic differences in ChE inactivation between young and aged adults, rather then a 
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difference in binding affinities/potencies.  These carbamate ChE inhibitors, presumably, 
have a slower decarbamoylation rate in younger adults than elderly adults, which leads to 
the observed difference in in-vitro sensitivity. 
The above in-vitro results were consistent with results of a meta-analysis:  In a 
study by Knapp et al. (1991), young males (n=6), receiving 18 mg, 24 mg and 30 mg 
PHYS tablets, showed similar ex-vivo plasma BuChE sensitivity to (28 %/(ng/ml)) as the 
in-vitro sensitivity for young males in the current study (33 %/(ng/ml)).  On the other 
hand, in the study by Men (2004), elderly males (n=8) and females (n=8), receiving 6.7 
μg/kg PHYS as 30-minute infusion, showed similar ex-vivo RBC AChE sensitivity (12 
%/(ng/ml)) as the in-vitro sensitivity for elderly subjects in the current study (9.7 
%/ng/ml).  This suggests that in-vitro measurement of ChE sensitivity is predictive of ex-
vivo sensitivity in clinical studies. 
The study results suggest that elderly adults may require a 2-3-fold higher blood 
concentration than young adults to achieve the same ChE inhibition.  This may explain 
why for epistigmine, an investigational carbamate ChE inhibitor for the treatment of AD, 
the maximum tolerated dose observed in young adults (40 mg single dose) was lower 
than for older adults (90 mg/day).  Higher sensitivity in young adults prevented further 
dose escalation, while all elderly subjects tolerated higher doses. 
This research may have implications for other diseases and conditions, most 
notably MG and as a prophylaxis of nerve gases poisoning.  As patients with MG age, 
they may become less sensitive to PYR, the most common symptomatic treatment for 
MG, and an increase in dose may be required.  Further, older military personnel assigned 
xx 
to receive PYR, may require increased doses to achieve the targeted 10% RBC AChE 
inhibition, necessary to protect against nerve gas poisoning.  
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Chapter 1 
Introduction 
 
1.1. Alzheimer’s Disease 
Alzheimer’s disease (AD) is a chronic, progressive, neurodegenerative dementia 
disorder characterized by a loss of cognitive function, ability to care for oneself and 
psychiatric symptoms.1  Currently, there are approximately 5.3 million Americans with 
AD.  As the American population ages, the prevalence of AD is expected to more than 
double by the year 2050 to between 11 and 16 million people.   
AD has a very large impact, both socially and economically.2  The burdens upon 
the caregiver can be tremendous.  The care duties range from financial and legal 
responsibilities to bathing and dressing.  This care accounts for 8.5 billion unpaid hours 
by family caregivers.  This burden of caregiving often leads to emotional stress and 
depression, which can further impact the health of the receiver of care and the caregiver.   
Economically, AD costs almost $150 billion per annum in direct and indirect 
costs in 2005 and is expected to grow significantly as the population ages.2  For those 
with AD, the Medicare expenditures triple.  AD patients are also three times more likely 
to experience a hospital stay that lasts longer than other older Americans. 
1 
At this point, the etiology of AD is not well understood; however, it is thought to 
be multifactorial, due to genetic and environmental factors.  The most significant risk 
factor for developing AD is advanced age.2  The incidence of AD in 60-year olds is about 
1%; this increases to approximately 30% for those 85 years old. 3  Other risk factors 
include familial risk and genetic mutations, namely, the ApoE ε4 allele, have been 
associated with AD, but are relatively weak predictors of AD compared to advanced age.  
Genetic tests have been found to have a low sensitivity and specificity for AD.  
Environmental factors that are associated with higher incidences of AD include limited 
level of education, history of head injury and cardiovascular disease (such as 
hypertension and diabetes).1  AD affects both males and females in equal proportions, but 
females have higher lifetime prevalence due to their longer lifespans.   
The histological hallmarks of AD are neuritic plaques of beta-amyloid (Aβ) 
peptide and neurofibrillary tangles of tau protein in brain tissue.1  Microscopically, there 
is a significant loss of neurons, shrinkage of neuronal volume and loss of synaptic 
connections.1, 4  The areas associated with the loss of neurons involve the cerebral cortex, 
amygdalae and hippocampus, which are thought to be responsible for the clinical 
symptoms of AD.   
The focus of research over the past decade has concentrated on the “amyloid 
cascade hypothesis” as a result of the neuritic amyloid plaques.  Evidence for this 
hypothesis in humans includes the observation that (1) early-onset AD results from 
mutation in the amyloid precursor protein (APP); (2) the ApoE ε4 allele results in 
accumulation of amyloid protein; and (3) Down’s syndrome (trisomy 23) results in three 
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copies of the gene for the APP leading to the neuropathological characteristics of AD 
developing in the third decade of life.5  Therapies arising from this hypothesis have 
concentrated on preventing Aβ peptide formation (e.g., gamma secretase inhibitors), 
increasing its solubility (e.g., Aβ aggregation inhibitors) or increasing its clearance 
(vaccines and passive immunization of Aβ).  While several agents and vaccines have 
made it to clinical development, failure to show clinical improvement and unacceptable 
adverse effects in phase III studies have prevented therapies from reaching the market.6, 7   
The “tauopathy hypothesis” represents the other major hypothesis of AD etiology.  
This hypothesis states that hyperphosphorylation of intraneuronal microtubule-associated 
protein Tau leads to the neurofibrillary tangles observed in AD.8-10  The result is 
inflammation and cellular death, which have been implicated in the causal pathway of Aβ 
production.  As the hypothesized causative pathway for Aβ production, therapies aimed 
at Aβ would only treat the downstream event and may explain why limited clinical 
benefits have been observed for anti-Aβ therapy.  Several agents are currently under 
clinical investigation; however, the agent furthest along in clinical development has only 
reached phase IIb studies.11 
The “cholinergic hypothesis” is an older hypothesis and is no longer recognized 
as the causative pathway for AD; however, the cholinergic hypothesis is a useful 
hypothesis for the treatment of downstream pathways of AD (see section 1.2).  According 
to the cholinergic hypothesis, a progressive loss of presynaptic cholinergic function in the 
central nervous system (CNS) significantly contributes to the memory and cognitive 
symptoms of AD.12  ChE inhibitors were the first therapies approved in the U.S. for AD 
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and currently, the first-line agents for the treatment of AD are ChE inhibitors.  They 
inhibit the breakdown of the neurotransmitter acetylcholine (ACh) to increase the amount 
of cholinergic transmission.  While providing symptomatic relief, they do not modify the 
progression of AD.  The ChE inhibitors can be used in any stage of AD (mild to severe).  
No ChE inhibitor to date has been shown to be any more efficacious than another.   
The other approved agent for AD in the U.S. is memantine and is approved for 
moderate to severe AD.  Memantine is thought to modulate NMDA activity and thus 
prevent over activity of glutamate, a major excitatory neurotransmitter; however, it is 
unclear if this approach prevents excitotoxicity since it does not show disease-modifying 
effect.   
 
1.2. Cholinergic Hypothesis 
In the late 1960s and late 1970s, a concerted effort to identify the neurochemical 
abnormality of AD was undertaken.8  This was followed by findings of deficits in choline 
acetyltransferase activity, the rate-limiting enzyme in the biosynthesis of ACh, and 
deficits in ACh itself.  Later discoveries of reduced intraneuronal choline uptake and 
release of ACh indicated a deficit of presynaptic cholinergic neuronal functioning.   
Simultaneously, there was a greater understanding of the importance of the 
cholinergic system on memory, learning and cognition in the mid-to-late 1970s.  Animal 
and human studies have shown the importance of the CNS cholinergic system on 
memory function.13  Anticholinergic agents, both nicotinic and muscarinic antagonists, 
are able to impair memory; however, the memory impairment by nicotinic antagonists 
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may be due to decreased attention and increased sedation rather then a direct memory 
effect.14  In addition, lesions in projections of cholinergic neurons to the cerebral cortex 
are able to produce the same symptoms as AD.15  Abnormalities in these pathways in the 
brains of those with AD correlated well with the level of cognitive decline.15  Together, 
these observations led to the cholinergic hypothesis. 
When first introduced, the cholinergic hypothesis was thought to be the 
predominate pathophysiologic event of AD and the histological abnormalities were a 
result of a reduction in cholinergic activity.  Nearly 30 years later, it is now understood 
that the decreased cholinergic functioning is a downstream event.  Because the 
hypothesis does not address the precipitating pathologic event, and addresses only the 
downstream effect, therapies addressing the cholinergic hypothesis cannot reverse or 
slow the progression of AD, but are able to address the symptoms associated with AD, 
such as memory, attention and cognitive function, at least temporarily. 
 
1.3. Cholinesterase Inhibitors 
ChE inhibitors prevent the breakdown of ACh, increasing the cholinergic 
signaling within the CNS and thereby address the cholinergic hypothesis.  ChE inhibitors 
are the first-line agents for AD.  The U.S. approved ChE inhibitors for AD are tacrine 
(THA), donepezil (DON), rivastigmine and galantamine (GAL).  THA was the first agent 
approved for AD but is no longer marketed, nor preferred, due to hepatotoxicity.  ChE 
inhibitors have demonstrated their efficacy to improve cognitive function at 6 months or 
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longer.16  All ChE inhibitors are equally efficacious and modestly reduce the cognitive 
the symptoms of AD.16 
1.3.1. Physiochemical Properties and Pharmacologic Use of Cholinesterase 
Inhibitors 
The ChE inhibitors of interest in this study are PHYS, PYR, DON and GAL.  
PHYS and PYR are prototypical ChE inhibitors of the carbamate class.  PHYS contains a 
tertiary amine and is able to cross the blood-brain barrier (BBB) while PYR has a 
quaternary amine, thus is only able to exert its effects in the PNS.   
DON and GAL are the top two prescribed ChE inhibitors for AD and differ in 
structure from the carbamate and each other.  They are tertiary amines and thus are able 
to cross the BBB.  Figure 1.3.-1 shows the structures of these ChE inhibitors. 
 
 
Figure 1.3.-1. Structures of the ChE inhibitors, PHYS, PYR, DON and GAL compared to 
ACh 
 
All ChE inhibitors are tertiary or quaternary amines since a cation is required for 
the binding of ChE inhibitors to the sites of interest (see section 1.3.4. on mechanism of 
inhibition).  The pKa of tertiary amines allow for protonation at physiologic pH while the 
Pyridostigmine Galantamine 
Donepezil 
Physostigmine Acetylcholine 
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pKa of primary and secondary amines are too high.  The physiochemical properties are 
shown in the table 1.3.1.-1.   
 
Table 1.3.1.-1. The physiochemical properties of PHYS, PYR DON and GAL17 
 PHYS PYR DON GAL 
Trade names or 
alternative names 
Antilirium, 
Eserine 
Mestinon, 
Regonol Aricept, E2020 
Razadyne, 
Reminyl 
Mol Wt (g/mol) 275.4 261.1 (as Br-) 379.5 368.3 (as HBr-) 
pKa 1.8, 7.9  n/a 8.9 8.2 
Log P 1.6 -3.7 1.09 4.7 
 
PHYS was first isolated from the calabar bean (physostigma venenosum) found in 
Africa.18  Also known as the ordeal bean, for their use in judicial procedures by the native 
Efik tribe, where administration of the beans resulted in death if guilty or rejection of the 
bean from the stomach (emesis) if innocent.  Historically, PHYS was used to reverse 
atropine toxicity, narrow-angle glaucoma and to reverse neuromuscular blockade by 
curare.  Today, physostigmine is not the drug of choice for any condition, however, can 
be used for any of those conditions, as well as myasthenia gravis.  PHYS is soluble in 
water but is more soluble in strong organic solvents.19  PHYS has two basic tertiary 
amines with pKas of 1.8 and 7.9, but only 7.9 is in the physiologic range. 
PYR is a quaternary amine and as such, is very soluble in water (log P = -3.7) and 
poorly soluble in organic solvents.  PYR is approved for myasthenia gravis and for 
military personnel as a prophylactic agent against the warfare nerve agent Soman to 
improve survival. 
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DON is structurally larger and more flexible compared to the other inhibitors that 
are more rigid.20  DON is the most basic of the inhibitors with a pKa of 8.9.  DON was 
approved in 1996 for AD in the U.S. 
GAL was originally isolated from flowers and bulbs in the species in the genus 
Galanthus, such as the Caucasian snowdrop (woronowii).  GAL is the most lipophilic of 
the ChE inhibitors with a log P of 4.7.  GAL was approved in 2001 for AD in the U.S. 
1.3.2. Physiologic Role of Cholinesterase 
Figure 1.3.2.-1 shows the pivotal role ChE plays in the cholinergic synaptic cleft.  
ACh is the endogenous neurotransmitter released by presynaptic cholinergic neurons; 
they can stimulate postsynaptic ACh receptors (AChR) of the nicotinic or muscarinic 
type.  Nicotinic receptors are ligand-gated ion channels, while muscarinic AChR are 
metabotropic receptors.  ACh is rapidly degraded by ChE at the postsynaptic membrane, 
principally by the acetylcholinesterase (AChE) isoform and is responsible for the rapid 
termination of the cholinergic signaling.  AChE is found at all cholinergic synaptic clefts, 
i.e., in the CNS cholinergic system, peripheral ganglia of the autonomic nervous system, 
parasympathetic effector organs and at the neuromuscular junction.  In addition, 
extraneuronal AChE is found in the lung and on red blood cell (RBC) membranes.  The 
primary function of neuronal AChE is to terminate cholinergic signaling by degrading 
ACh.  The function of extranuronal AChE is unknown, but is likely to clear excess ACh 
since endocrine cholinergic function would be detrimental due to the extensive AChR 
distribution throughout the body.   
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Excess ACh not cleared by AChE that diffuses away from the synaptic cleft can 
stimulate presynaptic nicotinic AChR; by doing so, hyperpolarization of the presynaptic 
neuron results.  Hyperpolarization prevents depolarization, thus halting further ACh 
release.  This negative feedback system prevents overstimulation when excessive ACh is 
released. 
 
Figure 1.3.2.-1. Cholinergic neuronal transmission and ACh synaptic fate 
 
The other ChE isoform is the butyrylcholinesterase (BuChE).  BuChE has no 
known endogenous function, but is thought to serve as a scavenging enzyme for 
xenobiotic and natural alkaloid esters.21  As such, they can be found in barrier organs, 
such as the liver and lung.22  In addition, it is found to a large extent in the plasma and the 
cerebral spinal fluid.  In these organs, it prevents the entry and dissemination of 
potentially harmful ester xenobiotic drugs and endogenous ACh.   
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Importantly for AD, BuChE is also secreted by CNS glial cells where its 
inhibition may further potentiate cholinergic transmission (see figure 1.3.2.-1).  Excessive 
ACh may diffuse away from the synaptic cleft and cause collateral stimulation of other 
AChRs on adjacent neurons.  While theoretically possible, nonselective inhibitors (inhibit 
AChE and BuChE equally) have not been found to be any more efficacious than selective 
inhibitors of AChE. 
1.3.3. Biochemistry of Cholinesterase 
There is a single gene that codes for each AChE and BuChE on human 
chromosome 7 and 3, respectively.23  While several exons in the coding region result in 
alternate splicing, all forms have similar catalytic activities but result in collagen “tails” 
that anchor them to membranes (e.g., post-synaptic neuronal membrane or RBC 
membrane) or to each other to form dimmers and quartets.24, 25  The two enzymes contain 
greater than 50% homology overall, but high homology in the catalytic region, even 
across species.21   
While containing a high degree of homology, AChE and BuChE differ in their 
substrate specificity.  For example, in the 1940s, they were distinguished by the ability of 
BuChE to catalyze butyrylcholine with very little catalysis by AChE.21  On the other 
hand, BuChE is equal in its ability and rate to catalyze ACh as AChE.  More recent 
molecular modeling techniques and x-ray crystallography have shown that the catalytic 
region is deep within a narrow “gorge” for AChE.26  This narrow gorge is responsible for 
the catalytic substrate specificity of AChE.  On the other hand, the gorge is wide for 
BuChE, allowing for a wide assortment of substrates and its low substrate specificity.   
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Adjacent to the catalytic region is a catalytic anionic binding site (ABS) that 
stabilizes the binding of the quaternary amine of ACh, as well as other quaternary and 
protonated tertiary amines.  In addition to this catalytic ABS, at the mouth of the gorge is 
a peripheral ABS where anionic substrates can bind but are not catalytically affected.  
One consequence of this peripheral ABS is substrate inhibition at high substrate 
concentrations.21  Substrate inhibition is thought to be due to low affinity binding of 
substrate to the peripheral ABS which sterically hinders substrate from reaching the 
catalytic region, resulting in decreased activity.  This generally occurs at concentrations 
above physiologic ACh concentrations.  In contrast to AChE, peripheral ABS of BuChE 
is missing the phenylalanine at position 297 which affects binding of ACh.21  Further, 
BuChE does not experience substrate inhibition at high concentrations.  Figure 1.3.3.-1 
shows the theoretical binding of ACh and a hypothetical ChE inhibitor binding to AChE, 
indicating the catalytic ABS and peripheral ABS.27   
Catalytic ABS 
Peripheral ABS 
 
Figure 1.3.3.-1. (From Ref 27) The theoretical binding of ACh and a hypothetical ChE 
inhibitor to AChE.  The catalytic ABS and the peripheral ABS are designated. 
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Degradation of ACh by AChE is very rapid and approaches the diffusion control 
limit.28  The kinetics of AChE and BuChE can be characterized by the Michaelis-Menten 
model.  The general reaction scheme for Michaelis-Menten model is shown in equation 
1.3.3.-1.  The Michaelis-Menten model, which describes this kinetics, is shown in 
equation 1.3.3.-1a. 
The enzyme and substrate binds to form an enzyme-substrate complex.  Km is the 
equilibrium dissociation constant for this binding and characterizes the binding affinity.  
The substrate is then converted to the product while regenerating the enzyme.  vmax is the 
maximum rate the enzymes are able to degradation the substrate to the product.  In 
addition, Km is the concentration at half the maximal rate.  High affinity binding is 
characterized by a low Km and low affinity binding is characterized by a high Km.  Highly 
efficient enzymes or high concentrations of enzymes results in a high vmax. 
PEESSE
MAXm vK +→↔+      <Equation 1.3.3.-1> 
Where : E = Enzyme 
  S = Substrate 
  ES = Enzyme-Substrate complex 
  P = Product 
  Km = Equilibrium dissociation constant, Michaelis constant 
  vmax = Maximum degradation rate 
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1.3.4. Mechanism of Cholinesterase Inhibition 
Given the two binding sites in AChE, there are two proposed mechanisms of 
inhibition, namely competitive and noncompetitive.  Theoretically, competitive inhibitors 
bind to the catalytic region and displace ACh, but are not substrates of ChE.  
Noncompetitive inhibitors bind to the peripheral ABS, preventing the substrate from 
reaching the catalytic region, but not directly; this is similar to the steric hindrance seen 
with substrate inhibition.  Thus, a noncompetitive inhibitor would not bind to the 
catalytic region and would not displace the substrate from the catalytic region.  
Furthermore, if an inhibitor binds to both the catalytic and peripheral ABS, it would be 
considered a mixed competitive-noncompetitive inhibitor.   
Equation 1.3.4.-1 shows the general reaction scheme for a competitive inhibition 
which is observed by an apparent increase in the Michaelis-Menten parameter Km with 
increasing inhibitor concentrations and is described by equation 1.3.4.-1a.  Ki is the 
inhibitor equilibrium dissociation constant and describes the binding affinity of the 
inhibitor.  While the inhibitor is bound to the enzyme, it precludes simultaneous binding 
of the substrate, thus, competing with the substrate for binding to the catalytic site.  While 
the substrate is catalytically converted to the product, the inhibitor is not catalytically 
affected and the concentration of the inhibitor is not affected.  Specifically for ChE, 
competitive inhibitors bind to the catalytic binding site and compete with ACh for 
binding. 
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Where: v = enzyme activity (or reaction velocity) 
  vmax = maximum enzyme activity (or maximum reaction velocity) 
  S = substrate concentration 
  Km = substrate dissociation constant (or Michaelis constant) 
  I = inhibitor concentration 
  Ki = inhibitor dissociation constant  
 
Alternatively the competitive Ki value can be estimated using equation 1.3.4.-1b. 
and c. if only a single substrate concentration is used.  This equation has the advantage of 
not assuming Imax is 100%, while equation 1.3.4.-1a., assumes the maximum inhibition is 
100%. 
IIC
IIvv +−= 50
max
0
*
     <Equation 1.3.4.-1b.> 
m
i
K
S
ICK
+
=
1
50       <Equation 1.3.4.-1c.> 
Where: v0 = the baseline enzyme activity in the absence of any inhibitor 
  Imax = The maximum inhibition from baseline 
  IC50 = The inhibitor concentration to produce 50% inhibition 
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Equation 1.3.4.-2. shows the general reaction scheme for a noncompetitive 
inhibition which is observed by an apparent decrease in the Michaelis-Menten parameter 
vmax with increasing inhibitor concentrations and is described by equation 1.3.4.-2a.  Ki is 
the inhibitor equilibrium dissociation constant and describes the binding affinity of the 
inhibitor.  The inhibitor does not compete for the binding sites, but rather inactivates the 
enzyme while the inhibitor is bound.  A noncompetitive inhibitor does not affect the 
binding of the substrate but the substrate is not converted to the product while the 
inhibitor is also bound.  While the substrate is catalytically converted to the product, the 
inhibitor is not catalytically affected and the concentration of the inhibitor is not affected.  
Specifically for ChE, noncompetitive inhibitors would bind to the peripheral ABS and 
cause steric hinderance of ACh for entering or leaving the gorge.20  By blocking the flow 
of substrate to and from the active site, a noncompetitive inhibitor decreases the activity 
of ChE. 
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Equation 1.3.4.-3. shows the general reaction scheme for a mixed competitive-
noncompetitive inhibitor and is observed by an apparent increase in Km and decrease in 
vmax with increasing inhibitor concentrations, described by equation 1.3.4.-3a.  A mixed 
type inhibitor competes with the substrate for binding to the catalytic region and causes 
decreased activity of the enzyme.  If the inhibitor acts equally as a competitive and 
noncompetitive inhibitor, α is equal to one; if it acts more strongly as a competitive 
inhibitor the α is < 1; and if it acts more strongly as a noncompetitive inhibitor the α is > 
1.  Specifically for ChE, a mixed type inhibitor would bind to both the catalytic bind site 
and the peripheral ABS causing both competition with the substrate for binding to the 
catalytic region and prevents the flow of substrate to the catalytic region. 
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Where: αKm = substrate dissociation constant in the presence of the 
inhibitor(or Michaelis constant) 
  αKi = noncompetitive inhibitor dissociation constant 
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In addition to inhibition by binding to one of these two regions or both, ChE 
inhibitors can act as a suicide inactivator.  Also called mechanism-based inhibitors, 
suicide inactivators are catalytic substrates of the enzyme, but form a stable, covalently 
bound intermediate that persist for a period of time (reversibly) or irreversibly.  While 
this stable intermediate persists, the enzyme is inactive since it covalently occupies the 
amino acids essential to its catalytic activity.  Thus, no amount of substrate would be able 
to overcome the inactivation of the enzyme.  Suicide inactivators show time-dependent 
inhibition and a decrease in activity similar to noncompetitive inhibition at steady-state.29   
Equation 1.3.4-4 shows the general reaction scheme.  The enzyme binds to the 
suicide inactivator to form an enzyme-inactivator complex.  The inactivator catalytically 
reacts with the enzyme to form an intermediate, EI’, where the inactivator is covalently 
bound to the enzyme.  The intermediate complex can release the inhibitor-product to 
regenerate the enzyme or can form a permanent enzyme-inactivator complex, Einact.  The 
rate of inactivation is dependent on the inactivation rate constant, k2.  The rate of 
reactivation is dependent on the reactivation rate constant, k3.  The ratio of k3/k4 is the 
“partition ratio”29.  Very powerful suicide inactivators have a partition ratio of zero and 
leads to irreversible inactivation; weak suicide inactivators have a high partition ratio 
(>>1) and are completely regenerated, but cause a transient reversible inactivation 
through the intermediate EI’. 
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For suicide inactivators, the inactivation rate can be analyzed by the method of Ito 
et al.29  The activity of the enzyme is measured over a period of time after the addition of 
the suicide inactivator.  This is repeated for various inactivator concentrations.  The 
observed time-dependent activity is graphed on a log-linear plot shows a straight line 
relationship, and the slope is the first-order inactivation rate constant, kobs.  As the 
inhibitor concentration increases, the rate of inactivation increases to a maximum 
inactivation rate constant, kinact.  The first-order inactivation rate constant is described by 
equation 1.3.4.-4a and an example is shown in figure 1.3.4.-1. 
0,
0*
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inact
obs +=      <Equation 1.3.4.-4a> 
Where: kinact = maximum inactivation rate constant 
  I0 = initial inhibitor concentration 
Ki,app = inhibitor concentration at half the maximum inactivation 
rate 
 
 
18 
 
Figure 1.3.4.-1. Method to obtain kinetic parameters in-vitro for suicide inactivators 29 
 
1.3.5. Clinical Pharmacokinetics of the Cholinesterase Inhibitors PHYS, PYR, DON 
and GAL 
The PK of the ChE inhibitors are summarized in table 1.3.5.-1.   
 
Table 1.3.5.-1.  PK characteristics of ChE inhibitors 
 PHYS30 PYR§ DON§ GAL§
CLtot (ml/min) 4390 830 163† 300 
Vdss (l) 111 19 900 175 
F 10% 10% ~100% 90% 
1-fu 46% 31 Unk; suspected 
low 
96% 19% to PP 
53% to RBC 
fe 4% 32 15% 54% 20% 
§Prescribing information 
†CL/F 
PP = Plasma Proteins 
 
PHYS has the highest clearance of the ChE inhibitors in this study with a 
clearance that exceeds liver blood flow (1500 ml/min) and renal plasma flow (600 
19 
ml/min) combined.  This high clearance is suggestive of extrahepatic metabolism; it is 
suspected that PHYS is degraded by ChE, in blood and tissues, and accounts for the 
majority of its clearance.  The plasma protein binding of PHYS has been estimated to be 
approximately 46%, however this is suspect since PHYS is degraded in plasma by 
BuChE, thus instability in the binding over time is observed.  The addition of other ChE 
inhibitors, as a preservative to prevent PHYS degradation, potentially could displace 
PHYS binding.  The unbound portion distributes rapidly to tissues, including the CNS.31 
PYR is highly hydrophilic and due to the quaternary amine, has a low volume of 
distribution, despite suspecting to have a low degree of plasma protein binding.  The Vdss 
is more than plasma volume but less than extracellular water volume.  In addition, the 
high hydrophilic nature leads to a urinary clearance similar to the glomerular filtration 
rate (i.e., CLtot * fe = CLren; 830 ml/min * 0.15 = 125 ml/min), indicating filtration but 
little secretion and reabsorption.  The nonrenal clearance is 600 ml/min, approximately 
half of liver blood flow.  One of the factors that may limit hepatic clearance is limited 
intracellular hepatic concentrations due the charged nature of PYR (i.e., diffusion 
limited). 
DON is extensively distributed to tissues, despite its high degree of plasma 
protein binding.  DON also has a relatively low clearance; combined with the high 
volume of distribution leads to a long half-life for DON allowing for once daily dosing.  
The once daily dosing contributes to its popularity in being prescribed; DON is the only 
immediate-release medication approved for AD that is once-daily dosing.  Approximately 
half of the clearance of DON is urinary and the other half is metabolism.  Twenty percent 
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of the metabolism is to desmethyl-DON and is equally potent to inhibit AChE as DON. 
[DON prescribing information] 
GAL has a moderate clearance and volume of distribution compared to the other 
ChE inhibitors.  Approximately 19% is bound to plasma proteins, but 52% is bound to 
RBCs in whole blood.  This leads to an RBC/plasma ratio of 1.2.  The renal clearance of 
GAL is approximately equal to the glomerular filtration rate of free (unbound) GAL in 
whole blood.  This suggests that unbound GAL is freely filtered, but not secreted or 
reabsorbed.  GAL has a half-life of about 7 hours, requiring twice daily dosing. 
1.3.6. Pharmacotherapy of Cholinesterase Inhibitor 
All ChE inhibitors for AD inhibit AChE; DON and GAL are AChE selective 
inhibitors while rivastigmine is a nonselective inhibitor of both AChE and BuChE.  The 
beneficial treatment target is to inhibit CNS AChE, and thus increase cholinergic 
transmission.  By inhibiting AChE, ChE inhibitors increase the intrasynaptic ACh 
concentration and thus are able to increase the amount of cholinergic signaling (see figure 
1.3.2.-1).   
Nonselective agents have the theoretical additional benefit to inhibit BuChE 
released by glial cells.  The ACh not degraded by AChE in the synapse would be 
degraded by this BuChE; however, if also inhibited, the excess ACh may be able to 
diffuse to adjacent cholinergic synapses and cause collateral simulation of additional 
AChR.  Despite this additional theoretical benefit, nonselective ChE inhibitors have not 
been shown to be any more efficacious than AChE selective inhibitors.33 
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While the efficacy is due to inhibition of CNS AChE, excessive inhibition would 
result in several adverse drug reactions such as headaches, dizziness and insomnia.  Thus 
the beneficial inhibition must be balanced with excessive inhibition to prevent these 
adverse drug reactions. 
Given the widespread distribution of the cholinergic system within the human 
body, especially in the peripheral nervous system (PNS), use of ChE inhibitors is 
associated with several adverse effects.  The most severe and dose-limiting toxicities are 
nausea, vomiting and diarrhea due to excessive cholinergic stimulation of the 
gastrointestinal system.  Other common adverse reactions reported are abdominal pain 
and anorexia, which are related to excessive gastrointestinal cholinergic stimulation.33  In 
addition, these toxicities were the most common cause for withdrawal from clinical 
trials.[DON and GAL prescribing information] 
 
1.4. Ex-vivo Sensitivity of Cholinesterase Inhibitors 
A meta-analysis of ex-vivo sensitivity to the ChE inhibition by physostigmine 
(PHYS) was conducted in our lab.  Clinical PK/PD studies with PHYS that 
simultaneously measured PHYS plasma concentrations and ChE activity were included.  
The ChE activity was measured from RBC where AChE is membrane bound, from 
plasma where BuChE is freely soluble or both.  Five studies met this criterion and were 
included in this analysis.30, 34-37  These studies used a variety of dose administrations, age 
groups, as well as disease states.   
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We defined sensitivity to ChE inhibitors as the degree of ex-vivo ChE inhibition 
for a given PHYS plasma concentration change.  Thus, a high sensitivity would be 
observed as a high degree of inhibition for a small increase in PHYS concentration.  
Figure 1.4.-1 and table 1.4.-1. shows the results of this meta-analysis.   
 
Table 1.4.-1. Meta-analysis of sensitivity to 
PHYS 
Transdermal 
patches
Elderly 
Alzheimer65-84 
Levy et al. 
1994 
0.5 mg IV 
injection
Elderly 
Healthy65-76 
Men, et al. 
2004
1.5 mg IV 
injection
Mid/Elderly 
Alzheimer's 52-84
Asthana et 
al. 1995
1 mg/h IV 
injection
Young/Mid 
Healthy28-68
Furey et al. 
2000
18 mg, 24 mg, 
30 mg tablet
Young 
Healthy25-40 
Knapp et al. 
1991
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Figure 1.4.-1.  Meta-analysis of sensitivity 
to PHYS 
 
A general trend was observed, where the studies with the youngest age groups, 
e.g., Knapp et al. 1991, had the highest ex-vivo PHYS sensitivity of 28 %/ng/ml while the 
groups with oldest age groups had the lowest sensitivity, 12 %/ng/ml and 14 %/ng/ml for 
Men 2004 and Levy et al 1994, respectively.  This represented a doubling in sensitivity to 
PHYS for the younger compared to the elderly patients.  This would suggest that young 
adults are more sensitive to the effects of a prototypical cholinesterase inhibitor compared 
to elderly adults.   
In addition, clinical studies that explored the tolerated dose found age-related 
differences in the maximum tolerated dose.  Studies of ChE inhibitors in clinical 
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development typically start with young healthy adults in phase I studies.  When these 
agents continued in clinical drug development they were also tested in healthy elderly 
volunteers.  The young healthy volunteers experienced adverse reactions at a higher rate 
than the elderly volunteers. 38, 39   
For example, epistigmine was a carbamate ChE inhibitor in clinical trials for AD.  
Young adult (n=19) volunteers tested a single 40mg dose experienced adverse effects at a 
40% rate.  The RBC AChE inhibition was ~60%.  The elderly AD patients tested 12, 20 
and 29 mg t.i.d. dosing; of these patients, all completed the study without any serious 
adverse effects.38 
In addition, to AD, ChE inhibitors are used for other indications, most notably, 
myasthenia gravis (MG) and as a prophylactic agent against the chemical warfare agent, 
soman gas.  MG is an autoimmune disorder that attacks the nicotinic ACh receptors 
causing profound weakness.  By using ChE inhibitors, most often PYR, an increase in 
ACh at the neuromuscular juncture.  By doing so, reverse some of the weakness of the 
disease.  If a decrease in sensitivity with age is observed, an increase in dose may be 
required.  
Soman gas is an irreversible ChE inhibitor.  By using a reversible ChE inhibitor, 
such as PYR, before potential exposure, AChE function may be preservation.  Military 
personal are ordered to take PYR if potential exposure is suspected.  By occupying the 
site inactivated by soman, PYR can prevent irreversible inactivation.  Older military 
personnel may require higher doses to achieve the same level for protection. 
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This research study is designed to prospectively study, any age-related differences 
in in-vitro sensitivity to ChE inhibitors.  Due to the limited clinical utility of ChE 
inhibitors, understanding the covariates that can affect efficacy and toxicities to these 
agents may help to improve therapy and may help to better understand the role of ChE 
inhibitors in AD.  If a significant difference were to be found, the results of this research 
would assist in dose optimization trials. 
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Chapter 2  
Research Hypotheses 
 
2.1. Hypotheses 
The research hypotheses that directed this research are: 
1. A young healthy population will be more sensitive to the in-vitro effects of ChE 
inhibitors than an elderly healthy population. 
2. This sensitivity difference will be enzyme specific, e.g., an age-related difference 
in sensitivity will be observed for RBC AChE but not plasma BuChE. 
3. This sensitivity will be compound-specific due to the different mechanism of 
inhibition, i.e., the underlying mechanism of ChE inhibition determines whether 
there is a difference in sensitivity. 
4. There is no gender difference in sensitivity to ChE inhibition. 
 
2.2. Specific Aims 
 The specific aims of this research are to: 
1. Validate a sensitive and selective HPLC method for the quantification of PHYS in 
human plasma. 
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2. Optimize Ellman’s colorimetric method for the measurement of human RBC 
AChE activity, and modify Ellman’s colorimetric method for the measurement of 
human plasma BuChE activity. 
3. Design and perform an in-vitro mechanistic study of PHYS, PYR, DON and GAL 
in human whole blood to study the concentration- and time-dependent inhibition 
of RBC AChE and plasma BuChE as well as time-dependent degradation of 
PHYS in whole blood. 
4. Develop and validate mechanistic PK/PD models of PHYS and PD models of 
PYR, DON and GAL using the mechanistic in-vitro studies. 
5. Conduct a clinical study with young and health volunteers designed to study the 
in-vitro sensitivity to PHYS, PYR, DON and GAL. 
6. Model the inhibition of RBC AChE and plasma BuChE by PHYS, PYR, DON 
and GAL using the validated mechanistic PK and PD models. 
7. Evaluate model-dependent and model-independent methods of assessing in-vitro 
sensitivity to cholinesterase inhibition. 
8. Evaluate any age-related differences in sensitivity statistically. 
 
DON and GAL were chosen due to their approval for AD; they are the most 
widely prescribed ChE inhibitor and both are AChE-selective agents.  PHYS is a 
prototypical nonselective ChE inhibitor of the carbamate class and was at one time under 
clinical study for AD; PHYS was not approved due to the high incidence of adverse drug 
reactions.40  PYR is also a prototypical nonselective ChE inhibitor of the carbamate class, 
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but due to its quaternary amine, does not cross the blood-brain barrier and thus in-vivo 
only has actions in the PNS and at the neuromuscular junction.  As such, PYR is used for 
conditions that require increased cholinergic activity in these systems, but not the CNS, 
e.g., myasthenia gravis.  A specialty use of PYR is by the military for its ability to block 
the target of the warfare nerve agent soman.  One barrier to its effective use is the adverse 
reactions experienced by soldiers. 
Due to the labile nature of PHYS in human blood, the measurement of PHYS 
plasma concentrations are necessary to assess the PK and PD of PHYS.  In addition, the 
measurement of PHYS allows for evaluation of concentration- and time-dependent 
degradation caused by ChE in human blood.  Measurement of simultaneous PHYS 
concentrations and RBC AChE and plasma BuChE activities allows for the development 
of a PK/PD model.  Measurement of RBC AChE and plasma BuChE is achieved by 
Ellman’s colorimetric method, the most widely used method for the measurement of 
ChE.41 
This study was performed in two parts.  The first was an in-vitro pilot study to 
determine the mechanism of inhibition of PHYS, PYR, DON and GAL in human blood 
and to assess candidate PK/PD models; whole blood was collected from a young healthy 
male volunteer.  The RBC AChE and plasma BuChE activity was assessed for inhibition 
by PHYS, PYR, DON and GAL at various inhibitor concentrations.  In addition, the 
degradation of PHYS at various initial concentrations was assessed.  Several PD models 
were assessed including the competitive, noncompetitive, mixed competitive-
noncompetitive inhibition and suicide-inactivation model.  The degradation of PHYS was 
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assessed for linear PK or capacity-limited degradation at physiologic and 
supraphysiologic concentrations. 
The second study was an in-vitro study of young healthy and elderly volunteers 
designed to assess the age-related sensitivity to cholinesterase inhibitors.  Subjects were 
recruited based on age, ten young adults between the ages of 18 to 30 and nine elderly 
adults 65 years of age or older.  After determined to be healthy by a telephone screening, 
a brief inpatient visit and routine laboratory tests, the research subjects were invited to 
donate approximately 170 ml of blood.  This blood was transferred to the VCU PK/PD 
Lab where the sensitivity to PHYS, PYR, DON and GAL was measured for RBC AChE 
and plasma BuChE as well as the degradation of PHYS.  Data were modeled to assess 
sensitivity and compared across the age-groups. 
 
2.3. Significance 
 ChE inhibitors are the first-line agent used in the treatment of AD and are one of 
only two therapeutic options currently approved for use in AD.  ChE inhibitors are able to 
improve the symptoms of AD but unable to alter the course of the disease.1  The 
improvement in symptoms are modest for most patients constituting only a three to six 
month delay in worsening of symptoms over placebo.5   
In addition, ChE inhibitors are known to cause several dose limiting toxicities, 
including nausea, vomiting and diarrhea, related to their mechanism of action.  These 
adverse reactions are also the most frequent cause for withdrawal from controlled clinical 
trials and the most common reported adverse reaction with ChE inhibitors [DON and 
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GAL prescribing information].  Other adverse reactions include headache, syncope, 
dizziness, urinary incontinence and muscle fatigue. 
The efficacy and adverse reactions of ChE inhibitors arise from the underlying 
mechanism of action, i.e., ChE inhibition in the CNS and PNS.  By inhibiting ChE within 
the CNS, a beneficial increase in cholinergic transmission is responsible for the 
symptomatic AD improvement.  However, further excessive increase in CNS cholinergic 
signaling causes the CNS related adverse reactions of dizziness, headache and syncope.  
Conversely, an increase in cholinergic transmission within the PNS results in the dose-
limiting toxicities of nausea, vomiting and diarrhea by stimulation of postsynaptic 
cholinergic neurons in the gastrointestinal tract.  In addition, urinary incontinence and 
muscle fatigue are observed in some patients due to increased cholinergic activity on the 
detrusor urinary muscle and at the neuromuscular junction. 
In addition, to AD, ChE inhibitors are used for other indications, most notably, 
myasthenia gravis (MG) and as a prophylactic agent against the chemical warfare agent, 
soman gas.  MG is an autoimmune disorder that attacks the nicotinic ACh receptors 
causing profound weakness.  By using ChE inhibitors, most often PYR, an increase in 
ACh at the neuromuscular juncture.  By doing so, reverse some of the weakness of the 
disease.  If a decrease in sensitivity with age is observed, an increase in dose may be 
required.  
Soman gas is an irreversible ChE inhibitor.  By using a reversible ChE inhibitor, 
such as PYR, before potential exposure, AChE function may be preservation.  Military 
personal are ordered to take PYR if potential exposure is suspected.  By occupying the 
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site inactivated by soman, PYR can prevent irreversible inactivation.  Older military 
personnel may require higher doses to achieve the same level for protection. 
Those patients that are the most sensitive to the effects of cholinesterase inhibitors 
would be at the most risk for experiencing the adverse reactions associated with ChE 
inhibitors.  Those patients that are the least sensitive would be at the most risk of 
receiving little or limited benefits from ChE inhibitors.  Understanding the covariates that 
make an individual more or less sensitive can help to identify which patients would 
benefit the most and those patients where a slower titration would be warranted to 
prevent adverse reactions.   
While ChE inhibitors have limited clinical utility, they are expected to be the 
mainstay of therapy for years to come due to the continued failure of novel therapeutic 
possibilities.6,42  Thus, improved therapy of currently available modalities is a sensible 
focus of therapy for AD. 
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Chapter 3 
Analytical Method Development for Quantification of Physostigmine 
from Human Plasma 
 
3.1. Introduction – Review and Selection of Analytical Methods 
A sensitive and selective analytical method is required for the quantification of 
PHYS in plasma due to the relatively high inhibitory potencies expected for PHYS, i.e., 
low IC50 concentrations, and to characterize the sensitivity to the effects of PHYS.  This 
section describes reported analytical methods reported and explains the selection of an 
analytical method. 
 The bioanalysis of PHYS in plasma has traditionally been difficult.  One reason is 
due to the two nitrogen atoms’ pKa values of 1.8 and 7.9,19 resulting in a cation below a pH 
of 7.9 and a cation with two charges below a pH of 1.8.  The second reason is base-
catalyzed hydrolysis observed, i.e., instability, at pH values higher than 9.5-10.43, 44  Thus, 
extraction from plasma into an organic phase by liquid-liquid extraction requires a 
relatively high pH to convert PHYS to a neutral state, but subjects PHYS to pH conditions 
where hydrolysis can occur.  This issue, combined with separation problems due to the 
hydrophilic properties of PHYS on column, has made PHYS a difficult quantitative 
analytical problem.  
32 
 In 2004, Zhao et al. published a literature survey of reported bioanalytical 
techniques for PHYS.45  They reported two main extraction methods that have been used, 
liquid-liquid extraction (LLE) and solid-phase extraction (SPE).  The most common 
extraction method has been LLE, all of which have employed alkalization of the extraction 
matrix to precipitate proteins and to convert PHYS into a neutral, i.e., uncharged, state of 
PHYS.  This neutral state facilitates extraction into an organic solvent; however, the degree 
of alkalization affects the rate of hydrolysis.  Whelpton et al.3 and Knapp et al.35 employed 
a pH of 10, however, others used extraction matrix with a higher pH of 12 46 where 
extensive hydrolysis would account for the relatively low extraction recovery of 60% 
observed.  If the internal standard is hydrolytically stable, this could therefore result in 
erroneous values.  Thus, alkalization has been employed to increase recovery, but, if not 
tempered by minimizing base-catalyzed hydrolysis, would result in low recovery. 
 Elsayed et al used a lower extraction pH of 9 coupled with an ion-pairing agent for 
PHYS, picric acid. 47  This resulted in minimal hydrolysis, however, maintained a high 
recovery of more than 92%.   
 The SPE methods reported low extraction recoveries48 of nonhuman matrices with 
low sensitivity49 or used a custom-made radiolabeled internal standard(s),50,51 which would 
make these methods not useful.  Therefore, these methods were not explored as possible 
methods for the bioanalysis of PHYS. 
 Most of the methods described above used addition of cholinesterase inhibitor as a 
preservative to prevent the native ability of plasma matrix to degrade PHYS.  The most 
common inhibitors used were neostigmine and pyridostigmine since they are quaternary 
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amines and their charged state at any pH prevented their extraction from plasma in most 
methods. 
 Men30 validated a method based on the method by Elsayed et al. in the VCU 
PK/PD Laboratory and reported a sensitive and selective method.  This method employed 
a pH of 9 with the ion-pairing agent, picric acid, to extract PHYS from human plasma 
along with the internal standard, tacrine (THA), into methylene chloride and back-
extracted into an acidic ion-pairing reagent tetrabutylammonium (TBA) chloride.  Anionic 
picric acid will ion-pair with cationic PHYS and THA.  By doing so, produces a net neutral 
complex that is able to be extracted into methylene chloride.  In the back extraction step, 
the ion-paring agent, TBA, ion-pairs to picric acid which releases free PHYS and THA.  
PYR was used as the preservative.   
 Separation was achieved by ion-exchange liquid chromatography using 
tetramethylammonium chloride as the counter-ion on a silica column and detected by 
fluorescence.  The novelty of this method was the use of a commercially available internal 
standard, THA.  The current method described here used the method developed by Men 
with minor alterations.   
 Table 3.1.-1. summarizes the methods reviewed for the selection of an appropriate 
sensitive and selective bioanalytical method for the quantification of PHYS in human 
plasma.  The majority of methods only reported the limit of detection (LOD) and not the 
lower limit of quantification (LLOQ).  The LOD was most commonly reported as 25 to 
100 pg/ml, however, the LLOQ was observed to be 2-3 times higher than the LOD. 
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Table 3.1.-1. Summary of bioanalytical methods to analyze PHYS in human plasma 
Reference [ref number] Matrix Extraction Stationary Phase Mobile Phase Detector LOD/LLOQ 
Whelpton. 1983 [43] Plasma  LLE Spherisorb silica (250 mm 
x 4.5 mm, 5 μm) 
Methanol: 0.1 M ammonium 
nitrate (9:1, pH 8.6) 
UV 254; 
ECD 0.8 V 
LOD: 0.5 
ng/ml 
Whelpton et al., 1985 [44] Plasma and 
urine 
LLE Spherisorb silica (150 mm 
x 4.6 mm, 3 μm) 
Methanol: 0.1 M ammonium 
nitrate (9:1, pH 8.9) 
ECD 0.4 V LOD: 0.1 
ng/ml 
Brodie et al. 1987  [52] Plasma LLE Spherisorb silica 5ODS1 
(125 mm x 4.9 mm, 5 μm); 
guard column: ODS 
Acetonitrile: 10 mM sodium 
acetate (95:5) 
FL 254/346 LOD: 0.1 
ng/ml 
Unni et al. 1989 [46] Plasma and 
CSF 
LLE Spherisorb silica (150 mm 
x 4.6 mm, 5 μm); guard 
column: silica 
Methanol: 10mM sodium 
acetate (10:1, pH 4.6) 
ECD 0.95 V LOD: 0.05 
ng/ml  
Knapp et al. 1990 [35] Plasma and 
CSF 
LLE Spherisorb silica (100 mm 
x 4.5 mm, 5 μm) 
Methanol: acetonitrile: 0.1 M 
ammonium nitrate (pH 8.9): 
water (450:450:80:20)   
ECD 0.8 V LOD: 0.025 
ng/ml 
Quinn, et al. 1991 [53] Serum SPE Diol column Aqueous phosphate buffer (pH 
4.0): methanol (80:20) 
FL 243/418 LOD: 2 ng/ml 
Hsigh et al. 1982 [50] Plasma SPE μBoundapak C18 5 mM sodium phosphate (pH 
5.7): methanol (50:50) 
UV 254 LOD: 50 
ng/ml 
Elsayed et al. 1989 [47] Plasma LLE Altex Ultraphere-Si (250 
mm x 4.6 mm, 5 μm); 
guard column: silica 
Acetonitrile: 10 mM sodium 
phosphate buffer, 2.5 mM TMA 
(20:80, pH 3.0) 
FL 240/360 LOD: 0.1 
ng/ml 
Walter et al. 1995 [54] Plasma LLE Nucleosil 100 C18 0.02% phosphoric acid, 2.5 
mg/ml heptanesulphonic acid-
acetonitrile (75:25, pH 4.0) 
FL 255/345 LLOQ: 0.025 
ng/ml 
Asthana et al. 1995 [34] Plasma SPE Applied biosystem narrow-
bore column 
10 mM formic acid: 
acetonitrile: 50 mM tris buffer 
(52:27:21) 
FL 250/345 LOD: 0.055 
ng/ml 
Men. 2004 [30] Plasma LLE Ultrasphere silica (250mm 
x 4.6 mm, 5μm) 
9%Acetonitrile, 91% Buffer (10 
mM phosphate, 2.5 mM 
tetramethylammonium, pH 3.0) 
FL 240/356 LLOQ: 0.25 
ng/ml 
FL, Fluorescence; ECD, Electrochemical detector; LLE liquid-liquid extraction, SPE, solid phase extraction 
Revalidation of the method was attempted as described by Men; however, due to 
failure of revalidation, optimization of PHYS extraction and quantification was 
necessary.  The resultant extraction before optimization showed very little PHYS 
detected chromatographically with a reduced THA peak than expected.   
The extraction procedure is based on ion-pairing principles to maximize the 
extraction of PHYS while reducing the chemical hydrolysis.  The pH of the extraction 
matrix is adjusted to a pH of 9, where approximately 10% of PHYS remains in a cationic 
state.  By using anionic picric acid in the extraction matrix, this allows for ion-paring 
with PHYS.  While ion-paired, the results is a net neutral, PHYS-picric acid complex.  In 
addition to this complex, cationic THA and picric acid may also complex together.  This 
allows for extraction into methylene chloride.  Back extraction takes place into an acidic 
aqueous solution with tetrabutylammonium (TBA) chloride.  The relatively high 
concentrations of cationic TBA will ion-pair with picric acid, and in the process, release 
free cationic PHYS and THA into solution.  Without TBA in the back extraction step, 
picric acid and PHYS will remain complexed and prevents proper chromatographic 
separation. 
The separation is performed by ion-exchange chromatography on a bare silica 
column with tetramethylammonium (TMA) as the counter-ion in the mobile phase.  At 
the mobile phase pH of 3, PHYS and THA exist as cations and the silica on the column 
as an anion.  Cationic PHYS and THA compete for binding to anionic silica with the 
counter ion TMA.  Without TMA, PHYS and THA will remain on the column for an 
extended period of time and makes the chromatography inefficient. 
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Optimization of these conditions are crucial for the extraction and separation of 
PHYS and THA.  Confirmation and identify of physiochemical properties of PHYS was 
performed to optimize the extraction and identify problem areas of extraction.  
Optimization of extraction method, i.e., picric acid and TBA concentrations, pH and time, 
was performed to maximize extraction of PHYS and further identify problem areas of 
extraction.  Finally, optimization of chromatographic conditions, i.e., TMA and 
acetonitrile concentration, was performed.   
This chapter describes the optimization and validation of the quantification of 
PHYS in human plasma. 
 
3.2. Specific Aims 
1. Validate a sensitive and selective HPLC method for the quantification of PHYS in 
human plasma. 
 
3.3. Materials and Reagents 
1. Physostigmine Salicylate (PHYS; Eserine salicylate salt; MWt = 413.47; 
Sigma-Aldrich, St Louise MO) 
2. Tacrine (THA; 9-Amino-1,2,3,4-tetrahydroacridine hydrochloride hydrate; 
MWt = 234.72; Sigma-Aldrich, St Louise MO) 
3. Pyridostigmine bromide (PYR, MW=261.12; Sigma-Aldrich, St. Louis, MO) 
4. Sodium phosphate monobasic (Sodium dihydrogen phosphate; MWt = 
119.98; Sigma-Aldrich, St Louise MO) 
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5. Potassium phosphate dibasic (Dipotassium hydrogen phosphate, reagent 
grade; MWt = 174.18; Sigma-Aldrich, St. Louis, MO) 
6. Phosphoric Acid, 14.8 M (MWt = 98.00; Sigma-Aldrich, St. Louis, MO) 
7. Picric acid 1% by wt. in water (MWt = 229.10; Sigma-Aldrich, St. Louis, 
MO) 
8. Tetramethylammonium chloride (TMA; MWt = 109.60; Sigma,  Sigma-
Alrich, St. Louis, MO) 
9. Tetrabutylammonium hydrogen sulfate (TBA; Tetrabutylammonium bisulfate; 
MWt = 339.53; Sigma, Sigma-Alrich, St. Louis, MO)   
10. Methylene chloride, HPLC grade (Dichloromethane; MWt = 84.93; Burdick 
and Jackson, Morristown, NJ)  
11. Acetonitrile, HPLC grade (MWt = 41.05; Acros Organics, Morris Plains, NJ) 
12. Fasted, non-smoker, drug-free pooled plasma was obtained from BioChemed 
Services (Winchester, VA) 
13. Dulbecco’s Phosphate Buffered Saline (DPBS, Quality Biological Inc, 
Gaithersburg MD) 
 
3.4. Equipment 
1. Shimadzu RF-5301 spectroflorometer (Shimadzu, Columbia, MD) 
2. Shimadzu PharmaSpec UV-1700 Spectrophotometer (Shimadzu, Columbia, 
MD) 
3. Quartz cuvettes (Fisher Scientific, Pittsburgh, PA) 
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4. Corning pH meter 340 (Corning, NY)  
5. Waters 717 Autosampler (Waters Corporation, Milford Massachusetts) 
6. Waters 600 MultiSolvent Delivery Pump and Controller (Waters Corporation, 
Milford Massachusetts) 
7. Waters 2475 Fluorescence Detector (Waters Corporation, Milford 
Massachusetts) 
8. Beckman Coulter Ultrasphere Si, 250x4.6 mm 5 micron silica column 
(Beckman, Fullerton, CA) 
9. IEC Centra GP8 Centrifuge (Thermo Electron Corporation, Waltham, MA). 
10. Single channel variable-volume Pipettes (VWR Signature, West Chester, PA) 
 
3.5. Physiochemical properties of Physostigmine 
The structure of PHYS, THA and PYR are shown in figure 3.5.-1. along with 
reported pKa and log P values.19 
 
 
 
 
Physostigmine 
pKa =1.8, 7.9 
Log P = 1.6 
 
 
 
Tacrine 
pKa = 9.4 
Log P = 3.3 
 
Pyridostigmine 
pKa = n/a 
Log P = -3.7 
Figure 3.5.-1. Chemical structures of PHYS, THA and PYR 
 
PHYS and THA are relatively lipophilic compounds (Log P of 1.6 and 3.3, 
respectively), however, at physiologic pH, they tend to be water soluble due to 
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protonation of the nitrogen atoms.  PYR, in comparison, is very hydrophilic at any pH.  
Due to their conjugated ring systems, both analytes have strong flurophors resulting in 
strong fluorometric signals.   
3.5.1. Fluorescent Spectra of Physostigmine and Tacrine 
Two solutions were prepared in a phosphate buffer at pH 3.0; the first with 100 
ng/ml (0.36 μM) of PHYS and the second with 100 ng/ml (0.43 μM) of THA.  The 
fluorescent spectra of these solutions were determined using a Shimadzu RF-5301, first 
by finding the λmaxexcitation, then holding at the λmaxexcitation for PHYS and scanning for the 
λmaxemission.  The observed λmaxexcitation was 243 nm; the observed λmaxemission was 347 nm.  
The spectra are shown in figure 3.5.1.-1.  THA, for the same concentration, resulted in a 
higher fluorescence, suggesting a stronger flourophor for THA than PHYS. 
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 This study demonstrated the maximum excitation and emission wavelengths for 
PHYS to be 243 and 347 nm, respectively.  This was used as optimized detector 
conditions for the bioanalysis of PHYS. 
3.5.2. Solution Stability of Physostigmine; Effect of pH and Time 
The stability of PHYS over time in different pH solutions of PHYS was explored 
to assess possible factors that may lead to degradation during the extraction and storage 
of samples: PHYS can be hydrolyzed to eseroline which can further be degraded to 
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rubreserine (eserine-red).  Rubreserine can further be degraded to eserine blue and/or to 
eserine brown through condensation reactions.   
Four phosphate buffer solutions at pH values 2, 7, 9 and 12, were prepared with a 
PHYS starting concentration of 22 μg/ml (79.9 μM).  PHYS concentrations of the 
solutions were monitored by UV spectroscopy; samples were taken and UV absorbance 
measured at 243 nm using a Shimadzu UV probe-1700.  The results are shown in figure 
3.5.2.-1.  The concentrations were calculated from the observed UV absorbance using 
Beer’s law; the molar absorptivity for PHYS is 12,302 M-1cm-1.17 
Immediately upon PHYS addition to the 12.2 pH solution, the solution turned red, 
indicating the presents of the degradation product, rubreserine.  Before the first 
measurement could be taken, approximately 30% of the starting PHYS had already been 
degraded.  At the end of 40 minutes, approximately 35% of the PHYS had degraded.  
While part of this absorbance change may have been due to pH related spectral changes, 
the presence of a color changes indicates the presence of degradation product.  This 
product appeared very rapidly after the addition of PHYS. 
For the solutions at pH 2, 7 and 9, no change was observed.   
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Figure 3.5.2.-1. Stability of PHYS in various pH buffer solutions at room temperature 
over 40 minutes (starting concentration 22 μg/ml (79.9 μM)) 
 
This study demonstrated that PHYS is stable at pH 2, 7 and 9 for at least 40 
minutes at room temperature, the approximate time necessary for an extraction.  On the 
other hand, PHYS was unstable at pH 12, with approximately 35% degradation observed 
at the end of 40 minutes.  This information was used to optimize the extraction procedure 
for the bioanalysis of PHYS.  Thus, a pH of 9 or less was used for extraction. 
3.5.3. Aqueous Solubility of Physostigmine 
Due to the lipophilic nature of PHYS, limited solubility may complicate stock 
solution preparation.  Therefore, the solubility of PHYS as a salicylate salt was assessed.  
One mg of PHYS (as 1.5 mg of PHYS salicylate) was placed in 1 ml of deionized water 
and mixed well; this resulted in a suspension, due to incomplete dissolution.  The 
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absorbance of the supernatant was measured and recorded before adding an additional 1 
ml aliquot of water.  The suspension was mixed well and allowed to reequilibrate and the 
absorbance was remeasured.  This was repeated until a linear relationship between 
observed UV spectrophotometric absorbance and nominal concentration was achieved.  
The observed concentration was calculated from the observed absorbance of the 
supernatant using molar absorptivity; the nominal concentration was the known mass (1 
mg) of PHYS per total volume of water added.  Figure 3.5.3.-1. shows the results of this 
experiment for the entire range and figure 3.5.3.-2. shows the results of this experiment in 
the linear range (< 55 μg/ml).  The solubility for PHYS salicylate is determined to be 
approximately 74 μg/ml (268.7 μM). 
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Figure 3.5.3.-1. Determination of aqueous solubility of PHYS salicylate shown on a 
linear scale (left) and log-linear plot (right) 
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Figure 3.5.3.-2. Determination of aqueous solubility of PHYS salicylate, linear range < 
55 μg/ml 
 
This study demonstrated the solubility of PHYS salicylate to be 74 μg/ml.  Below 
55 μg/ml (200 μM), the nominal concentration was linear to the measured concentration 
by UV absorbance (figure 3.5.3.-2). The slope of the line, theoretically, in this plot should 
be one, i.e., for a given increase in nominal concentration, the exact same increase in 
measured concentration should be observed and would confirm the molar absorptivity.  
Therefore, all stock solutions of PHYS were prepared below 55 μg/ml to ensure absolute 
solubility. 
3.5.4. Determination of pKa of PHYS by Spectrophotometery 
As chemicals undergo changes in charge status, they can exhibit a characteristic 
change in absorbance spectra.55  This is also observed for PHYS as the pH is increased 
from 6 to 9 due to the deprotonation of the second amine.  The pKa of PHYS was 
confirmed by spectrophotometric titration.  As PHYS becomes less protonated, a 
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characteristic change in absorbance is observed.  The purpose of this study was to 
determine the pKa of PHYS where it transitions from a singularly protonated to a neutral 
species.   
PHYS salicylate was dissolved in an acetate buffer solution (0.05 M, pH 3.0) at 
an initial concentration of 20 μg/ml (72.6 μM).  Acetate has a pKa of 4.7556 and was 
chosen as the buffer since it should not interfere with titration at the pKas of PHYS, 
expected to be around 1.8 and 7.9.  Phosphate has a pKa at 7.2 and titrations would result 
in an equivalence point near the pKa of interest, making the titration of PHYS difficult at 
the pH of interest.   
Aliquots of NaOH (0.1 M) were added while simultaneously measuring the pH 
and absorbance.  This process was repeated until the pH reached 9.5.  The results are 
shown in figure 3.5.4-1.   
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Figure 3.5.4.-1. Titration of PHYS salicylate with NaOH 
 
The largest absorbance change occurred between a pH of 6 to 9.5, consistent with 
the reported pKa of 7.9.  In addition, a large titration endpoint was observed at pH 4.7 
which is due to the pKa of acetate.  Figure 3.5.4.-2. shows the absorbance decrease as the 
pH is increased.  The pKa is observed when at the steepest decent on the curve.  In order 
to determine the pKa, the first and second derivative on the data is performed, the pKa is 
the point where the first derivative reaches a minimum or where the second derivative 
crosses the x-axis with the largest change. 
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Figure 3.5.4.-2. Determination of PHYS pKa, (top) change in absorbance with pH 
changes, (middle) first derivative and (bottom) second derivative.  The vertical line 
indicates the determined pKa of 7.85. 
 
Using this approach, the pKa of PHYS was determined to be 7.85, very similar to 
the reported value of 7.9.  The confirmation of the pKa was important to maximize the 
extraction while minimizing the base-catalyzed hydrolysis, i.e., maximizing the pH 
assists in the liquid-liquid extraction by maximize the neutral state of PHYS, but pH 
conditions above 9 or 10 cause’s base-catalyzed hydrolysis.  Thus, an extraction pH 
between the pKa but below pH 9 maximizes the extraction while minimizing the degree 
of hydrolysis. 
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3.5.5. Summary of Physiochemical Findings 
The physiochemical properties of PHYS are important for an understanding the 
stability of PHYS and the properties necessary for the successful extraction and 
quantification of PHYS from human plasma. 
The solubility of PHYS salicylate was determined to be 74 μg/ml.  All stock 
solutions of PHYS were prepared below 55 μg/ml, the absolution solubility.   
At room temperature, PHYS was found to be stable in aqueous solutions at pH 
values between 2 and 9.  PHYS was unstable at pH 12 at room temperature.   
The maximum florescent excitation wavelength for PHYS was 243 nm; the 
maximum emission wavelength for PHYS was 347 nm. 
The pKa of PHYS was determined to be 7.85. 
 
3.6. Liquid Chromatographic Separation of Physostigmine and Tacrine 
The purpose of this section was to optimize the chromatographic conditions for 
the separation of PHYS and THA.  The method established by Men30 was optimized for 
the three chromatographic parameters, capacity factor, asymmetry and resolution.   
The capacity factor is the relative retention time of the analyte compared to the 
dead time (the retention time of the solvent front).55  The capacity factor, k’, is calculated 
using equation 3.6.-1.  Higher the capacity factors indicate greater retention of the analyte 
and internal standard of interest.  Under optimized conditions, the capacity factor is 
expected to be between 0.5 and 20 to avoid interference from the solvent front (k’ < 0.5) 
but to avoid peak widening and peak asymmetry at high retention times (k’ > 20).57   
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MMR
t
ttk −='      <Equation 3.6.-1.> 
Where: tR = Retention time of analyte/internal standard 
 tM = Dead time 
Peak asymmetry, AS, is a result of peak broadening, overloading the capacity of 
the column or peak tailing.55  Asymmetric peaks can result in low reproducibility and 
quantification problems.  The peak asymmetry is given by equation 3.6.-2.  The peak is 
bisected at the apex; the front peak width is the width from the front of the peak to the 
bisection at 10% of the peak height; the back peak width is the width from the bisection 
to the back of the peak at 10% of the peak height.  Perfectly symmetric peaks have a peak 
asymmetry of one, peak asymmetry of < 1.5 is acceptable.  
a
bAS =      <Equation 3.6.-2> 
Where: a = Front peak width at 10% of peak height 
 b = Back peak width at 10% of peak height  
Resolution, RS, is a measure of the baseline resolution between two peaks.55  Lack 
of baseline resolution can result in poor estimation of peak area due to inappropriate 
baseline drop.  RS is calculated using equation 3.6.-3.  RS > 1.5 indicate baseline 
resolution between two peaks have been achieved.  
BA
AB
S WW
ttR +
−= )(2      <Equation 3.6.-2> 
Where: tA = retention time of peak A 
 tB = retention time of peak B B
 WA = peak width at baseline for peak A 
 WB = peak width at baseline for peak B 
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Optimization of these parameters is generally established by minimizing the 
capacity factor while maintaining adequate resolution.  This minimizes peak broadening 
and peak asymmetry as well as increase analysis throughput.  
A neat (unextracted) solution of PHYS and THA were separated under a variety 
of chromatographic conditions and the peaks were evaluated for capacity, symmetry and 
resolution.  The initial chromatographic conditions established by Men is shown in table 
3.6.-1.30  The optimized fluorescent detector conditions was λexcitation = 243 nm, λemission = 
347 nm, the measured λmax for PHYS (see section 3.5.1).   
Two conditions were optimized: the concentration of tetramethyl ammonium 
(TMA) in the mobile phase and the percent of acetonitrile in the mobile phase mixture.  
The initial concentration of TMA in the mobile phase (10 mM phosphate, pH 3.0) as 
established by Men was 2.5 mM with 9% of acetonitrile. 
 
Table 3.6.-1. Initial chromatographic conditions30 
 
 
A solution of PHYS (5 ng/ml (0.019 μM)) and THA (0.5 ng/ml) were prepared in 
tetrabutylammonium solution (TBA, 0.001M, pH 1.8).  It was expected this ratio of 
analyte and internal standard would result in a peak height ratio of approximately two.  
This solution was injected onto the HPLC column under various chromatographic 
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conditions shown in table 3.6.-2.  Various concentrations of TMA were explored while 
keeping the ACN composition at 9%; this was followed by exploring various 
compositions of ACN while keeping the TMA concentration at 2.5 mM.  Between 
conditions, the HPLC was allowed to equilibrate for a minimum of 10 column volumes at 
the new condition.  The neat sample was run in triplicate to ensure column equilibration. 
 
Table 3.6.-2. Chromatographic conditions for optimization of separation of PHYS and 
THA 
TMA Conc ACN  TMA Conc ACN 
[mM] [%]  [mM] [%] 
0 9  2.5 5 
0.625 9  2.5 7 
1.25 9  2.5 9 
2.5 9  2.5 11 
3.75 9  2.5 15 
5 9    
 
The resolution, peak asymmetry and resolution was calculated for each condition.  
Figure 3.6.-1 shows the results at various chromatographic conditions.  Increasing 
concentrations of TMA decreased the capacity factor for both PHYS and THA.  TMA 
acts as the ion-pairing chromatography agent and increasing its concentration increases 
the competition with PHYS and THA for adsorption to the column.  Increasing the TMA 
also decreases the resolution between the two peaks.  Peak asymmetry for THA was high 
in the absence of TMA but was relatively insensitive to increasing concentrations.  The 
peak asymmetry for PHYS decreased with increasing TMA concentrations to a minimum 
of 2.0 at 4 mM of TMA; however the resolution was below 1.  Thus, TMA 
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concentrations of 2.5 mM minimized the peak asymmetry while keeping the resolution 
between 1 and 1.5. 
Increasing the acetonitrile decreased the capacity factor and resolution for both 
PHYS and THA.  The peak asymmetry for PHYS was worst at 5% acetonitrile and was 
minimized at 11% acetonitrile.  THA remained relatively insensitive to increasing 
compositions of acetonitrile.  The peak resolution was very sensitive to increasing 
compositions of acetonitrile; acetonitrile concentration 9% and greater resulted in peak 
resolution less than one.  Thus, the acetonitrile composition of 7% resulted in minimized 
peak asymmetry while maintaining the resolution greater than one. 
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Figure 3.6.-1. Effects of chromatographic conditions on capacity factor, peak asymmetry 
and resolution for PHYS and THA 
 
The optimized chromatographic conditions chosen for the separation of PHYS 
and THA in TBA solution was 2.5 mM TMA in 10 mM phosphate buffer at pH 3.0 with 
7% acetonitrile.  These conditions resulted in a capacity factor of 1.1 and 1.4 and a peak 
asymmetry of 2.2 and 2.0 for PHYS and THA, respectively.  The resolution was 1.4 
under these conditions.  Under these conditions, the peak asymmetry was minimized 
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while maximizing the resolution.  Full resolution was not obtained; however, the amount 
of overlap between the two peaks with a resolution of 1.4 is expected to be < 1%.  
Furthermore, the peak heights of PHYS and THA were expected to be used; peak height 
is less sensitive to overlap than peak areas. 
 
3.7. Validation of the Extraction of Physostigmine from human plasma and the 
chromatographic separation and quantification by HPLC-FD 
An optimized HPLC-FD method developed by Men et al.30 was chosen as the 
final assay method to separate and quantify PHYS (see section 3.6).  This method was 
chosen due to its simplicity, sensitivity, selectivity and high throughput.   
3.7.1. Solution Preparation 
1. Phosphate buffer solution (PBS, 0.1M Na2HPO4, pH 7.4).  1.5 g Na2HPO4 was 
weighed into a 100 ml volumetric flask and diluted to the mark with nanopure 
H2O.  The pH was adjusted to 7.4 using phosphoric acid. 
2. Tetrabutylammonium solution (TBA, 1 mM, pH 1.8).  0.034 g 
tetrabutylammonium hydrogen sulfate was weighed into a 100 ml volumetric 
flask and diluted to the mark with nanopure H2O.  The pH was adjusted to 1.8 
using sulfuric acid. 
3. Picric Acid Buffer Solution (PABS, 1.0 mM picric acid, 0.5 M Na2HPO4).  2.3 ml 
of 1% wt/wt picric acid and was added to a 100 ml volumetric flask with 7.1 g 
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Na2HPO4 and dilute to the mark with nanopure water.  The solution was mixed 
until completely dissolved.  The pH of this solution was approximately 8.5. 
4. Mobile Phase (93% Buffer [10 mM NaH2PO4, 2.5 mM TMA, pH 3.0], 7% 
Acetonitrile).  2.4 g of sodium phosphate monobasic and 0.548 g 
tetramethylammonium chloride was placed into a media bottle and dissolved with 
2 liters of nanopure water.  The pH was adjusted to 3.0 using phosphoric acid and 
150 ml acetonitrile added.  The mobile phase was mixed until dissolved and 
sonicated for 10 minutes. 
3.7.2. Stock Standard Preparation 
Note: All PHYS concentrations are given in terms of PHYS free base.  Due to the 
molecular weight difference between PHYS salicylate (413.47 g/mol) and PHYS free base 
(275.35 g/mol) a correction factor of 0.6659 is used to convert the mass of PHYS 
salicylate to PHYS free-base to report the PHYS concentration.   
 
1. PHYS standard solutions 
 PHYS Stock (10 μg/ml).  1.5 mg Eserine Salicylate was weighed into a 100 ml 
volumetric flask and diluted with nanopure H2O to the mark and sonicated 
until all solids dispersed. 
 PHYS Solution A (1.0 μg/ml):  100 μl PHYS Stock is added to 900 μl PBS. 
 PHYS Solution B (100 ng/ml):  100 μl PHYS Solution A is added to 900 μl 
PBS.  
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 PHYS Solution C (10 ng/ml):  100 μl PHYS Solution B is added to 900 μl 
PBS. 
2. THA standard solutions  
 THA Stock (10 μg/ml).  1 mg 9-Amino-1,2,3,4-tetrahydroacridine 
hydrochloride was weighed into a 100 ml volumetric flask and diluted with 
nanopure H2O to the mark. 
 THA Solution A (1.0 μg/ml):  100 μl THA Stock is added to 900 μl PBS. 
 THA Solution B (50 ng/ml):  50 μl THA Stock is added to 950 μl PBS. 
3. PYR Solution (5 mg/ml).  10 mg Pyridostigmine Bromide is weighed in to a 2 ml 
volumetric flask and diluted with nanopure H2O to the mark. 
3.7.3. Plasma Standard/Control Preparation 
The standards in plasma were prepared by addition of PYR solution, THA 
solution B and PHYS solution B or PHYS solution C (see Table 3.7.3.-1. for solution 
volumes).  One ml of blank plasma is added to a 15x150 mm glass tube.  The highest 
concentration point of the calibration curve was 10 ng/ml, and the lowest concentration 
point of the calibration curve was 0.25 ng/ml.  The concentration of THA in the standards 
and controls was 0.5 ng/ml.  Six replicates of each concentration point was prepared 
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Table 3.7.3.-1. Plasma Standard Preparation 
Plasma PHYS 
Concentration 
(ng/ml) 
Volume 
PHYS 
Solution B 
(μl) 
Volume 
PHYS 
Solution 
C (μl) 
Volume 
THA 
Solution 
B (μl) 
Volume 
PYR 
Solution 
(μl) 
Volume 
Plasma 
(μl) 
Total 
Volume 
[μl] 
10.00 100 -- 10 10 1000 1120 
5.00 50 -- 10 10 1000 1070 
2.50 25 -- 10 10 1000 1035 
1.00 -- 100 10 10 1000 1120 
0.50 -- 50 10 10 1000 1070 
0.25 -- 25 10 10 1000 1045 
0.10 -- 10 10 10 1000 1035 
0.00 -- -- 10 10 1000 1010 
blank -- -- -- -- 1000 1000 
 
3.7.4. Extraction Procedure.   
The extraction procedure was started immediately after standard preparation to 
prevent any non-enzymatic degradation of PHYS. The picric acid buffer solution was 
used to denature the proteins in plasma and to act as an ion-paring agent for PHYS and 
THA.  In addition, the choice of pH and buffering capacity maximize the amount of 
PHYS in the neutral state while minimizing the degree of base-catalyzed hydrolysis.  The 
extraction from plasma was performed by liquid-liquid extraction into water-saturated 
methylene chloride and back-extracted into aqueous TBA solution using a low pH to ion 
trap PHYS and THA.  In addition, TBA in the final step ion-pairs with picric acid and, in 
the process, releases PHYS and THA to be free. 
The extraction procedure is shown in figure 3.7.4.-1. 
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 o Rotate the tubes at 60 rpm for 10 min 
o Centrifuge the tubes for 10 min at 2000 rpm 
Decant the organic phase into the second tube (careful 
not to decant the interface or any remaining aqueous) 
and discard the first tube 
o Rotate the tubes at 60 rpm for 10 min 
o Centrifuge the tubes for 10 min at 2000 rpm 
o To a clean second tube (15x150 mm), add 150 
μl TBA (0.001 M) solution 
Add 2 ml more methylene 
chloride to each tube 
Add 10 ml water-saturated 
methylene chloride
1 ml of Plasma 
Add 1 ml PABS
o Vortex for 10 sec 
o Cap the tubes with Teflon lined phenolic caps 
o Rotate the tubes at 60 rpm for 10 min 
o Centrifuge the tubes for 10 min at 2000 rpm
Remove and discard the aqueous 
(top) layer (careful not to remove 
the interface)
Remove at least 115 μl of the aqueous portion to a 
sample vial for HPLC analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7.4.-1. The extraction procedure of PHYS from human plasma 
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3.7.5. Absolute Extraction Recovery 
Neat, unextracted, standards were prepared in TBA solution for determination of 
absolute extraction recovery.  Assuming 100% extraction efficiency, the concentration in 
the TBA solution would be concentrated by a factor of 6.67, i.e., starting with a plasma 
volume of 1 ml, we end with a volume of 150 μl in TBA solution for HPLC analysis 
resulting in a 6.67 fold increase in concentration.  The TBA solution concentrations 
prepared were equivalent to the plasma concentration of 10 ng/ml and 1 ng/ml.   
 The 10 ng/ml sample was prepared by pipetting 910 μL into an auto sampler 
vial with 70 μl PHYS solution A and 70 μL THA solution B and mixing on a 
vortexer.   
 The 1 ng/ml sample was prepared by pipetting 910 μL into an autosampler 
vial with 70 μl PHYS solution B and 70 μL THA solution B and mixing on a 
vortexer.   
These neat standards were analyzed by HPLC-FD in the same manner as the 
extracted samples.  The relative abundance of the extracted standard compared to the 
unextracted neat solution is the absolution extraction recovery. The absolut recovery for 
THA was assessed by the mean of all extracted plasma samples compared to the mean of 
all unextracted standards, excluding blanks. 
3.7.6. HPLC-FD Procedure 
Chromatographic separation was performed using a Beckman Coulter Ultrasphere 
Si, 250x4.6 mm, 5 micron, silica column.  The mobile phase is a phosphate buffer mobile 
phase with 7% acetonitrile and TMA as an ion-pairing reagent.  Analyte detection by FD 
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is performed by exciting at 243 nm and emission at 347 nm.  Table 3.3.8.-1 shows the 
HPLC conditions used in this procedure. 
 
Table 3.7.6.-1. PHYS Assay HPLC-FD conditions 
Column Beckman Coulter Ultrasphere Si, 250x4.6 mm 5 micron silica 
column. 
Mobile Phase 93% Phosphate Buffer (10 mM NaH2PO4, 2.5 mM tetramethyl 
ammonium chloride, adjusted to pH 3.0 with H3PO4) 
7% Acetonitrile 
Flow Rate 1 ml/min (Isocratic) 
Injection 
Volume 
100 μL 
Run Time 13 min 
Excitation λ 243 nm 
Emission λ 347 nm 
Autosampler 
Temperature 
4º C  
 
3.7.7. Data Analysis 
Precision was be assessed by coefficient of variation (COV).  Accuracy was 
assessed by difference from nominal (DFN).   The method was considered accurate and 
precise if the COV and DFN are less then 15% at each concentration level.  A linear 
regression for each of the 6 replicates was performed with and without a weighting factor 
of 1/x2 using JMP version 5.   
3.7.8. Results and Discussion 
Representative chromatograms are shown in figure 3.7.8-1. for a blank standard, 
no PHYS (THA alone), low, medium and high PHYS concentration. 
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 blank
 
0 ng/ml (IS only) 0.25 ng/ml 
 
1 ng/ml 10 ng/ml 
Figure 3.7.8.-1. Representative chromatograms for the blank, 0 ng/ml(internal standard 
only), 0.25 ng/ml, 1 ng/ml and 10 ng/ml 
 
 
The PHYS peak height results of the plasma standard are shown in Table 3.7.8.-1.   
It should be noted that interference was observed in a single blank standard replicate at 
the PHYS retention time (replicate 2).  This interference was relatively large (503 FU), 
and is most likely due to mispipetting during standard preparation.  In addition, PHYS 
could not be detected in a single replicate of the 0.1 ng/ml plasma standard (replicate 5).  
The absence of PHYS in replicate 5 may be due to absence of analyte due to mispipetting 
or may be due to the peak height falling below the LOD.  The overall peak height mean 
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and COV of THA in all nonblank standards was 1258 (±9.97%).  The peak height ratios 
of the six replicates are shown in Table 3.7.8-2. 
 
Table 3.7.8-1. PHYS Peak Height (units: Fluorescence Units) 
Plasma 
Concentration 
Replicate 
1 
Replicate 
2 
Replicate 
3 
Replicate 
4 
Replicate 
5 
Replicate 
6 Mean % COV 
(ng/ml) PHYS PHYS PHYS PHYS PHYS PHYS PHYS 
10.00 7799 7831 7719 6983 6949 7016 7383 (5.9) 
5.00 3863 3663 3843 3315 3089 3457 3538 (8.6) 
2.50 1959 1840 1875 1595 1417 1685 1729 (11.6) 
1.00 824 742 768 669 678 641 720 (9.6) 
0.50 391 315 414 257 347 304 338 (17.2) 
0.25 176 166 166 141 145 151 158 (8.7) 
0.10 98 53 70 62 0 31 52 (64.4) 
0.00 0 0 0 0 0 0 0 (0) 
blank 0 503 0 0 0 0 84 (244) 
 
Table 3.7.8-2. Peak Height Ratio, mean PHR ± %COV 
Plasma Replicate Replicate Replicate Replicate Replicate Replicate   
Concentration 1 2 3 4 5 6 Mean %COV 
(ng/ml) PHR PHR PHR PHR PHR PHR PHR 
10.00 5.342 5.345 5.360 5.677 5.701 5.582 5.501 (3.1) 
5.00 2.740 2.618 2.714 2.863 2.863 2.728 2.754 (3.4) 
2.50 1.425 1.321 1.417 1.474 1.417 1.382 1.406 (3.6) 
1.00 0.596 0.547 0.558 0.588 0.578 0.579 0.574 (3.2) 
0.50 0.286 0.300 0.303 0.233 0.296 0.262 0.280 (9.8) 
0.25 0.121 0.124 0.122 0.124 0.129 0.127 0.125 (2.5) 
0.10 0.072 0.040 0.052 0.052 0.000 0.026 0.036 (61.5) 
0.00 0.000 0.000 0.000 0.000 0.000 0.000 0.004 (0.00 
 
 
The absolute extraction recovery for the low (1 ng/ml) and high (10 ng/ml) PHYS 
concentration was 91.9% (COV ± 4.7%) and 98.1% (± 6.2%), respectively.  The 
extraction recovery of THA is 101% (3.2%). 
The peak height of PHYS was assessed for imprecision and found to be less than 
15% throughout the concentration range between 0.25 ng/ml to 10 ng/ml, with the 
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exception of 0.5 ng/ml.  The peak height at 0.1 ng/ml was not less than 15% due to the 
absence of a detectable peak in replicate 5.  Analysis of peak height alone was found to 
be too imprecise, justifying the use of IS.  The use of the IS reduced variability (i.e., 
COV) to less than 10% between 0.25 ng/ml and 10 ng/ml.  The peak height ratio was 
more precise compared to the peak height. 
Table 3.7.8.-3. shows the parameter estimates for the 6 calibration curves for an 
unweighted regression and a 1/x2 weighted regression.  The intercepts are not statistically 
different from the origin, indicating no systematic bias.  The sensitivity for this method 
ranged between 0.53 and 0.58 PHR/ng/ml, that is, for every 1 ng/ml increase in 
concentration an increase in the PHR between 0.53 and 0.58 was observed. 
 
Table 3.7.8.-3. Unweighted and weighted regression parameter estimates for each of the 
six calibration curves 
Replicate r2 Intercept (SE) Slope (SE) 
    [PHR] [PHR/ng/ml] 
     Unweighted      
Replicate1 0.9996 0.0420 (0.025) 0.533 (0.005) 
Replicate2 0.9998 0.0021 (0.017) 0.532 (0.003) 
Replicate3 0.9998 0.0305 (0.019) 0.535 (0.004) 
Replicate4 0.9997 -0.0017 (0.022) 0.570 (0.004) 
Replicate5 >0.9999 0.0008 (0.006) 0.570 (0.001) 
Replicate6 0.9998 -0.0113 (0.016) 0.557 (0.003) 
     1/x2 Weighting    
Replicate1 0.9952 -0.0153 (0.010) 0.570 (0.019) 
Replicate2 0.9937 -0.0041 (0.011) 0.543 (0.021) 
Replicate3 0.9939 -0.0106 (0.011) 0.563 (0.021) 
Replicate4 0.9946 -0.0262 (0.011) 0.580 (0.021) 
Replicate5 0.9984 -0.0115 (0.006) 0.581 (0.011) 
Replicate6 0.9988 -0.0130 (0.005) 0.561 (0.009) 
 
 
Table 3.7.8-4. shows the %DFN for the weighted and unweighted calibration 
curves.  Using an unweighted regression, the DFN is greater than the 15% in 3 nominal 
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measurements.  Using a weighted regression corrects for the heteroscedacity of the 
residuals results in a more precise calibration curve.  Using the weighted regression, the 
DFN for all curves were less than 15%. 
 
Table 3.7.8.-4. DFN for an unweighted and weighted regression 
Plasma 
Concentration 
Replicate  
1 
Replicate 
2 
Replicate 
3 
Replicate 
4 
Replicate  
5 
Replicate 
6 
 (ng/ml) %DFN %DFN %DFN %DFN %DFN %DFN 
Unweighted calibration curve 
10.00 -0.54 0.42 -0.30 -0.34 -0.06 0.36 
5.00 1.25 -1.66 0.39 0.53 0.36 -1.67 
2.50 3.79 -0.86 3.76 3.59 -0.68 0.03 
1.00 4.01 2.37 -1.38 3.46 1.29 5.84 
0.50 -8.25 12.08 1.88 -17.56 § 3.37 -2.05 
0.25 -40.73 § -8.60 -31.44 § -11.69 -9.84 -0.66 
1/x2 Weighted calibration curve 
10.00 -6.09 -1.56 -4.63 -1.73 -1.66 -0.32 
5.00 -3.41 -3.49 -3.25 -0.45 -1.03 -2.30 
2.50 0.98 -2.47 1.41 3.40 -1.62 -0.55 
1.00 7.20 1.38 0.91 5.80 1.58 5.40 
0.50 5.79 12.04 11.30 -10.61 5.73 -2.12 
0.25 -4.47 -5.90 -5.74 3.58 -3.01 -0.11 
§ DFN > 15% 
 
Using this method, a regression with a 1/x2 weighting scheme is found to be 
preferred over the unweighted regression to determine the calibration curve due to better 
precision.  This method is found to be accurate between 250 pg/ml and 10 ng/ml using a 
1/x2 weighted calibration curve. 
3.7.9. Conclusions 
This analytical method for the quantification of PHYS in human plasma was 
validated; it is sensitive and selective and found to be accurate and precise with a 
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working analytical range between 250 pg/ml and 10 ng/ml.  The method is simple and 
has a relatively high throughput.   
The specificity of this method may be of concern due to a peak observed during 
the retention time of PHYS in a blank sample; however, this was only observed in a 
single replicate out of six, and is not though to be of concern.  In addition, no PHYS 
interference was observed in any of the 0 ng/ml samples. 
 
3.8. Partial Validation of the Quantification of Physostigmine in DPBS 
In addition to the quantification of PHYS in plasma, PHYS was also quantified 
from Dulbecco’s Phosphate Buffered Saline (DPBS, Quality Biological Inc, Gaithersburg 
MD) solution during the preliminary in-vitro studies of PHYS (see section 5.3).   
Three replicates of an abbreviated PHYS calibration curves were prepared 
analogous to section 3.7.3. with the exception of human plasma, DPBS was the matrix of 
interest.  The concentrations of PHYS prepared for this standard curve was 0 (internal 
standard only), 0.25, 1.0, 2.5 and 10 ng/ml.  Table 3.8.-1 shows the concentrations of 
PHYS prepared and the volume of solutions used to prepare the standards. 
Neat standard solutions were prepared to assess absolution extraction recovery.  
The concentration levels to assess recovery was at 1 ng/ml and 10 ng/ml.  These samples 
were prepared as described in section 3.7.5. 
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Table 3.8.-1. DPBS Standard Preparation 
Plasma PHYS 
Concentration 
(ng/ml) 
Volume 
PHYS 
Solution B 
(μl) 
Volume 
PHYS 
Solution 
C (μl) 
Volume 
THA 
Solution 
B (μl) 
Volume 
PYR 
Solution 
(μl) 
DPBS 
(μl) 
Total 
Volume 
[μl] 
10.00 100 -- 10 10 1000 1120 
2.50 25 -- 10 10 1000 1035 
1.00 -- 100 10 10 1000 1120 
0.25 -- 25 10 10 1000 1045 
0.00 -- -- 10 10 1000 1010 
blank -- -- -- -- 1000 1000 
 
The extraction procedure was exactly the same as described in section 3.7.4.  
Table 3.8.-2 shows the peak heights obtained from this study.  The COV was less than 
15% at all levels.  The mean THA peak height was 945 (± 4.3%).  Table 3.8.-3. shows the 
PHR for this analysis.  The %COV for the PHR was less than 15% at all levels.  
Incidentally, the use of internal standard did not improve the analysis of PHYS.  This 
may indicate the extraction variability stems from PHYS rather than THA; however, the 
use of an internal standard is recommended due to the complexity of the extraction 
procedure.  This method was found to be precise with an imprecision less than 12%. 
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Table 3.8.-2. Peak height of PHYS extracted from DPBS 
PHYS Replicate 1 Replicate 2 Replicate 3 Mean(%COV) 
[ng/ml] PHYS PHYS PHYS PHYS 
blank 0 0 0  
10.00 5478 5362 5086 5309 (3.7) 
2.50 1256 1271 1044 1190 (10) 
1.00 500 462 477 480 (3.9) 
0.25 123 101 125 116 (11) 
0 0 0 0 0  
 
Table 3.8.-2. Peak height ratio of PHYS extracted from DPBS 
PHYS 
[ng/ml] Replicate 1 Replicate 2 Replicate 3 
Mean 
(%COV) 
10.00 5.49 5.32 5.10 5.30 (3.7) 
2.50 1.30 1.29 1.07 1.22 (10) 
1.00 0.55 0.49 0.52 0.52 (5.5) 
0.25 0.13 0.11 0.14 0.13 (11) 
0 0 0 0 0  
 
The absolute extraction recovery was 78.3% (± 6.7%) and 82.6% (± 5.7%) for the 
1 ng/ml and10 ng/ml PHYS.  The recovery for THA was 98.1% (± 2.5%). 
The %DFN is shown in table 3.8.-3.  The %DFN was less than 15% at all 
concentration levels in the three replicates.  The inaccuracy was less than 12%. 
 
Table 3.8.-3. %DFN of PHYS extracted from DPBS 
PHYS 
[ng/ml] Replicate 1 Replicate 2 Replicate 3 
10.00 7.07 1.82 6.88 
2.50 1.41 -0.14 -11.89 
1.00 7.15 -2.14 5.13 
0.25 4.15 1.59 -2.09 
 
The purpose of this section was to describe the partial validation of the method for 
the quantification of PHYS in DPBS.  The method was found to be accurate and precise 
in the analytical work range of 0.25 and 10 ng/ml with a LLOQ of 0.25 ng/ml. 
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3.9. Analysis of Study Samples  
The plasma PHYS samples from studies were preserved with PYR solution (50 ng 
for each ml of plasma, i.e., 10 μl of 5 mg/ml PYR solution) and stored at -70°C until 
ready for analysis.   
The analysis of study samples were thawed at room temperature.  To a 15x150 
mm glass tube, add 1 ml of the plasma sample and 10 μl of THA solution B (50 ng/ml).  
The study sample was then extracted and analyzed in a similar manner as the plasma 
standards.  If the study sample concentration was higher than 10 ng/ml, the sample was 
diluted with blank plasma.  This dilution factor is then multiplied to the calculated 
concentration to obtain the concentration per ml.   
For each batch sample analysis, a set of plasma standards are analyzed before the 
study samples.  Interspersed evenly throughout the study samples, two low (1 ng/ml), two 
middle (5 ng/ml) and two high (10 ng/ml) plasma controls were analyzed to ensure stable 
running conditions during the analysis.  No more then 10 study samples were analyzed 
between the plasma standards and controls.  The last sample in the run was a control 
sample.   
A 1/x2 weighted regression is performed for the calibration curve.  The two 
plasma controls and the plasma standard at the low, middle and high concentrations were 
analyzed for precision by calculating the %COV.  The controls were measured for 
accuracy by calculating the %DFN.  A batch sample analysis will be considered valid if 
the %COV and the %DFN is below 20%.   
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3.9.1. Analysis of Intrastudy Quality Control Samples for Preliminary Studies 
The QC samples analyzed during the quantification of clinical samples from the 
preliminary studies (described in chapter 5) were assessed for accuracy and precision.  
Table 3.8.1.-1 shows the results of the calibration curve and the accuracy and precision of 
the low, medium and high quality control samples.  All sample QC samples were 
accurate and precise, i,e,, the DFN and COV were less than 20%. 
 
Table 3.9.1.-1. Summary of QC samples during intrarun analysis 
Study r2 Low
%COV 
QC 
%DFN 
Med
%COV 
QC 
%DFN 
High 
%COV 
QC 
%DFN 
Section 5.3 
Whole blood 
0.9961 4.9 4.8 
3.8 
1.2 -1.0 
-2.3 
1.8 -8.9 
8.3 
Section 5.3 
Plasma 
0.9940 4.3 17.7 
1.4 
2.4 4.6 
5.4 
9.2 10.4 
2.3 
Section 5.3 
RBC 
0.9912 6.1 10.0 
-4.5 
1.4 3.7 
-2.6 
2.9 12.9 
10.4 
Section 5.5 
Subj 1 C0 = 0.73 μM 
0.9772 
 
2.6 
 
-9.7 
-13.4 
6.5 
 
13.1 
0.1 
9.3 
 
-5.8 
1.8 
Section 5.5 
Subj 1 C0 = 0.27 μM 
0.9990 1.5 -1.1 
-1.1 
4.6 9.0 
8.2 
2.3 0.4 
4.3 
Section 5.5 
Subj 1 C0 = 0.018 and 
0.0009; Subj 2 C0 = 0.18 
0.9967 8.5 13.4 
10.4 
3.0 1.3 
-0.9 
2.2 -0.6 
1.7 
Section 5.5 
Subj 2 C0 = 0.018 and 
0.0009 
0.9978 -3.4 3.9 
-0.7 
4.7 -6.4 
-16.9 
8.2 -9.9 
-16.5 
 
3.10. Partial Revalidation of the Analysis of Physostigmine from Human Plasma 
Between the completion of the preliminary studies in Chapter 5 and the in-vitro 
clinical study in Chapter 6, the source for several chemical reagents was no longer 
available or was changed due to increases in procurement cost.  In addition, the HPLC 
system was changed.  With the use the newly sourced picric acid and TBA, detection by 
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HPLC was no longer achieved.  PHYS was no longer detectable in addition to a lower 
than expected THA peak.  For this reason, reoptimization of extraction procedure with 
these two new reagents was performed.  
After optimization, a partial revalidation was performed with four calibration 
curves to test for system suitability.  The newly sourced materials were evaluated for 
suitability for extraction from human plasma and for chromatographic separation. 
3.10.1. Materials and Reagents 
The materials and reagents remained the same as described in section 3.3 with the 
following changes: 
1. Picric Acid, Saturated Solution. ~1.2% (w/v) (MWt = 229.11; BDH Brand 
Chemical, VWR International, West Chester, PA) 
2. Tetrabutylammonium hydrogen sulfate (TBA; Tetrabutylammonium 
bisulfate; MWt = 339.53; Sigma, Sigma-Alrich, St. Louis, MO)   
3.10.2. Equipment 
The equipment remained the same as described in section 3.4 with the following 
change in HPLC system: 
1. Waters Alliance HPLC with 600 Controller (Waters Corporation, Milford 
Massachusetts) 
The identical model of detector was used. 
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3.10.3. Reagent Optimization 
Picric acid and TBA are used as ion-pairing agents and are important for the 
proper extraction of PHYS and THA from plasma.  The sensitivity of extraction to 
varying concentrations of picric acid and TBA was determined.   
Four solutions of PABS (0.5 M Na2HPO4) were prepared with various 
concentrations of picric acid: 0.25 mM, 0.5 mM, 1 mM and 2 mM picric acid.  This 
corresponded to ¼x ½x, 1x and 2x the concentration of picric acid as previously 
validated in section 3.7. 
Four solutions of TBA were prepared with various concentrations of TBA:0.5, 
1.0, 2.0 and 4.0 mM TBA.  This corresponded to ½x, 1x, 2x and 4x the concentration of 
TBA as previously validated in section 3.7   
PHYS standard solution of 5 ng/ml (0.019 μM) was prepared as described in 
section 3.7.3, and placed in 16 glass tubes (15x150 mm).  The extraction procedure was 
carried out as described in section 3.7.4. with the exception of using the PABS and TBA 
solutions described in this section in varying combinations.  A factorial design was 
chosen due to an expected interaction between the two ion-pairing reagents, i.e., picric 
acid allows for extraction, while TBA is required to release the analytes to a free cationic 
form required for chromatographic separation.  Table 3.10.3.-1 shows the concentration 
of picric acid and TBA used in combination with each other during the extraction 
procedure. 
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Table 3.10.3.-1. Concentration of the ion-pairing agents picric acid and TBA for 
optimization of the extraction of PHYS and THA from human plasma 
Tube  PA TBA Tube  PA TBA Tube PA TBA Tube  PA TBA 
 [mM] [mM]  [mM] [mM]  [mM] [mM]  [mM] [mM]
#1 0.25 0.5 #5 0 1 #9 0 2 #13 0 4 
#2 0.5 0.5 #6 0.5 1 #10 0.5 2 #14 0.5 4 
#3 1 0.5 #7 1 1 #11 1 2 #15 1 4 
#4 2 0.5 #8 2 1 #12 2 2 #16 2 4 
 
Table 3.10.3.-2. shows the peak height of PHYS and THA for each of the 
conditions. The maximum peak height of PHYS and THA was observed when using the 
PABS with 2 mM of picric acid and TBA solution at a concentration of 2 mM.  An 
example chromatogram can be seen in figure 3.10.3-1.   
Low concentrations of picric acid resulted in low peak heights of PHYS and 
THA.  This low peak height is presumably due to incomplete ion-pair complexation with 
PHYS and THA resulting in incomplete extraction into methylene choloride.  An 
example chromatogram showing incomplete extraction of PHYS and THA is shown in 
figure 3.10.3-1. 
Low peaks heights with low concentrations of TBA is presumably due to 
inadequate TBA complexation to picric acid.  Incomplete TBA-picric acid complexation 
would result in significant analyte-picric acid complexes.  These complexes will not be 
retained on the column and would elute with the solvent front.  Large solvent front peaks 
were observed at high picric acid and low TBA concentration combinations.  This large 
solvent front peak is presumably due to a high concentration of PHYS-picric acid and 
THA-picric acid complexes.  An example of the large solvent front peak can be observed 
in figure 3.10.3.-1.   
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Table 3.10.3.-2. Peak Height of PHYS and THA under various extraction conditions of 
picric acid and TBA 
       PABS 
         [mM] 
TBA 
[mM] 
2 1 0.5 0.25 
  PHYS   
4 410733 427944 424213 391260 
2 457478 360421 205316 365268 
1 0 3160 0 0 
0.5 0 0 0 0 
  THA   
4 127281 119778 112069 95674 
2 151798 102151 116654 101967 
1 11380 18428 39261 23337 
0.5 4627 5545 3821 4914 
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 Optimized 
conditions:
Small solvent 
front 
 
Large PHYS and 
THA peaks 
Incomplete analyte extraction 
Small solvent  
2 mM PA 
2 mM TBA 
0.5 mM PA 
0.5 mM TBA 
front observed 
Small or no PHYS  
and THA peaks
2 mM PA 
PA-analyte complexation 
Large solvent  
front observed 
Small or no PHYS  
and THA peaks
1 mM TBA 
Figure3.10.3.-1. Chromatograms of PHYS and THA extrated from human plasma under 
various conditions of PA and TBA.  
 
The purpose of this study was to optimize the concentrations of newly sourced 
picric acid and TBA.  The concentrations that resulted in the maximum extraction of 
PHYS and THA was 2 mM of picric acid in the PABS and 2 mM of TBA. 
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3.10.4. System Suitability 
Using the newly optimized concentrations of picric acid and TBA for the 
extraction procedure, four replicates of the PHYS standard curve (see section 3.7.3.)was 
extracted and evaluated for accuracy and precision. 
Table 3.10.4.-1. shows the PHR for the four replicates at each concentration level.  
The %COV was less than 15% at all levels, including the lowest PHYS concentration of 
0.1 ng/ml.  Thus, this method is found to be precise with the imprecision less than 12% 
between the analytical range of 0.1 ng/ml and 10 ng/ml.  The PHR was similar to the 
PHR observed on the previous HPLC system.  Range in PHR was 0.05 to 6.4 in this 
study compared to 0.03 to5.7 in the previously validated method (section 3.7). 
 
Table 3.10.4.-1. Peak height ratio 
PHYS 
Replicate 
1 
Replicate 
2 
Replicate 
3 
Replicate 
4 Mean (%COV) 
[ng/ml] PHR PHR PHR PHR PHR 
10.00 5.352 5.863 6.333 6.362 5.978 (7.9) 
5.00 2.291 2.963 2.953 2.671 2.720 (11) 
2.50 1.345 1.578 1.668 1.653 1.561 (9.5) 
1.00 0.585 0.629 0.705 0.572 0.623 (9.6) 
0.50 0.282 0.260 0.335 0.307 0.296 (11) 
0.25 0.137 0.112 0.147 0.144 0.135 (11) 
0.10 0.052 0.049 0.064 0.051 0.054 (12) 
0.00 0 0 0 0 0.00   
 
Table 3.10.4.-2. shows the %DFN. The %DFN was less than 15% for all 
replicates and concentrations, including 0.1 ng/ml.  This indicates this method is accurate 
with the inaccurately less than 15% between the analytical range of 0.1 ng/ml and 100 
ng/ml.   
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Table 3.10.4.-2. % Difference from nominal 
PHYS 
Replicate 
1 
Replicate 
2 
Replicate 
3 
Replicate 
4 
[ng/ml] %DFN %DFN %DFN %DFN 
10.00 -0.6 -0.4 -1.9 5.4 
5.00 -14.9 0.9 -8.5 -11.4 
2.50 -0.1 7.9 3.4 9.9 
1.00 8.7 8.9 9.4 -4.0 
0.50 4.8 -7.2 4.2 4.5 
0.25 2.0 -14.8 -8.4 0.8 
0.10 -3.0 7.1 1.6 -1.0 
 
The purpose of this study was to revalidate the method for the quantification of 
PHYS from human plasma using the newly sourced materials on a different HPLC 
system.  The method was found to be accurate and precise in the analytical range between 
0.1 ng/ml and 10 ng/ml.  Using this method, the LLOQ was established to be 0.1 ng/ml 
with an analytical working range between 100 pg/ml and 10 ng/ml. 
3.10.5. Intrarun Quality Control Samples for the In-vitro Clinical Study  
The quality control samples for the in-vitro clinical study (chapter 6) were 
analyzed for intra-run accuracy and precision (see section 3.8).  Table 3.10.5.-1. shows 
the results of this analysis.  The inaccuracy and imprecision was less than 20% for all QC 
samples in each of the studies. 
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Table 3.10.5.-1. Summary of QC samples during intrarun analysis 
Study r2 Low
%COV 
QC 
%DFN 
Med
%COV 
QC 
%DFN 
High 
%COV 
QC 
%DFN 
Subject 001, 002, 003, 
011, 012, 013 
0.9942 0.2 -1.2 
-0.1 
5.3 3.4 
-5.5 
18.2 10.2 
11.3 
Subject 004, 005, 006, 
014, 015, 016, 017 
0.9876 5.2 1.9 
2.3 
2.4 -6.7 
17.8 
6.0 8.4 
-9.4 
Subject 007, 008, 009, 
010, 018, 019 
0.9912 8.0 -4.4 
9.0 
3.4 5.3 
-6.8 
9.3 -5.9 
-0.2 
 
3.11. Conclusions 
This chapter describes the validation of the method for the quantification of 
PHYS in human plasma with an inaccuracy and imprecision less than 12%.  The 
analytical working range is 250 pg/ml (0.9 nM) to 10 ng/ml (0.036 μM) with an LLOQ of 
250 pg/ml for the preliminary studies described in Chapter 5.  The analytical working 
range is 100 pg/ml (0.36 nM) to 10 ng/ml with an LLOQ of 100 pg/ml for the in-vitro 
clinical study described in Chapter 6.   
The physiochemical properties of PHYS were explored and found the pKa to be 
7.85, stable in aqueous solutions at pH values between 2 and 9 and the absolute aqueous 
solubility of PHYS salicylate is 55 μg/ml. 
In addition, the method for the quantification of PHYS in DPBS was validated.  
The inaccuracy and imprecision was less than 12% and the analytical work range is 
between 250 pg/ml and 10 ng/ml with a LLOQ of 250 pg/ml. 
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Chapter 4 
Measurement of Acetylcholinesterase and Butyrylcholinesterase 
Activity 
 
4.1. Introduction 
“I added the necessary substrate, enzyme, and DTNB to the spectrophotometer 
while the recorder was going, and, lo and behold, the color began to appear in a 
fantastically linear way that is the delight of every biochemist’s heart.”- George Ellman, 
Ph.D.58 
The most common method to measure ChE activity reported in the literature is 
based on the method first described by Ellman et al in 1961 and has been cited over 
10,400 times to date.41,59  Ellman’s colorimetric method photometrically measures the 
product formation from ChE degradation of a thiocholine substrate.  Other methods have 
quantified ChE activity by measuring the change in pH as acetylcholine is hydrolyzed to 
choline and acetate.60  Production of acetic acid lowers the pH; however, this method 
requires a relatively long measurement time due to the amount of acetate required to 
cause a quantifiable change in pH (generally 20 minutes or longer).  In addition, this 
method requires large sample volumes, increasing the amount of biological samples 
required and large substrate amounts, increasing the cost of the analysis.   
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Another, more recent method measures the ACh concentration directly by 
HPLC.61  The change in concentration at different time points is able to estimate the 
activity of the ChE.  This method is time-consuming and requires more sophisticated 
equipment than a UV/Vis spectrometer or pH meter.  In addition, this method does not 
measure the activity in real-time, but does allow for batch processing. 
Ellman’s colorimetric method, on the other hand, is rapid, namely requiring less 
than 8 minutes; does not require large biological sample volumes or sophisticated 
equipment.  The method can also, and has, be used in a variety of biological matrices, 
including blood, CSF and tissue homogenates, as reported by Ellman et al in the original 
report.41  Furthermore, because the method has been well established for many years, the 
reagents are readily available and inexpensive. 
In this method, AChE hydrolyzes acetylthiocholine (AtCh), an analog substrate of 
ACh, to form thiocholine and acetate.  Ellman’s reagent, 5,5′-dithiobis(2-nitrobenzoic 
acid), also known as DTNB, rapidly reacts with thiols to form a yellow product that can 
be measured spectrophotometrically at 410 nm; the product has an extinction coefficient 
of 13600 M-1cm-1.41  Figure 4.1.-1 shows the reaction of AtCh in the presence of AChE 
and DTNB.  The activity of AChE is measured as the formation rate of TNB. 
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Figure 4.1.-1. Reaction of AtCh in the presence of AChE and DTNB 
 
The activity of BuChE can be measured in the same manner: in this case, an 
alternative substrate (selective for BuChE), such as butyrylthiocholine (BtCh), is used to 
form the products thiocholine and butyrate.  The thiocholine rapidly reacts with the 
DTNB to form the same yellow product (TNB) that can be measured at 410 nm (see 
figure 4.1.-2).  BtCh has the advantage of selective hydrolysis by BuChE over AChE.  
This is because of the inability of BtCh to bind to the acyl-binding pocket of AChE due 
to steric hindrance.21 
 
Figure 4.1.-2. Reaction of BtCh in the presence of BuChE 
 
 A variety of thiocholine ester substrates are available, and have been developed, 
for Ellman’s method; however, AtCh and BtCh remain the most widely used, and 
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available thiocholine esters. 62  Other thiocholine esters include acetyl-β-
methylthiocholine (AβtCh), propionylthiocholine (PtCh) and benzylthiocholine (BztCh).  
Figure 4.1.-1. shows the chemical structures of these thiocholine esters.  AβtCh has been 
reported to be a AChE selective substrate with 95% selectivity even at high substrate 
concentraitons.62  AtCh and PrtCh are nonselctive substrates, i.e., they are able to be 
degraded by both AChE and BuChE about equally.63  BtCh and BztCh are selective 
substrates for BuChE due to the steric hinderance at the acyl-binding pocket of AChE.21 
 
Figure 4.1.-3. Thiocholine ester substrates used with in Ellman’s colorimetric method 
 
 Being esters, AtCh and BtCh are subject to chemical hydrolysis; however, this 
hydrolysis is relatively slow compared to the enzymatic hydrolysis.  Overall, the 
contribution of spontaneous hydrolysis to the total hydrolysis of the substrate in the few 
minutes required for Ellman’s method would contribute very little.63  This can be 
demonstrated by Ellman’s method in the absence of enzyme (substrates only in aqueous 
solution). 
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 4.2. Specific Aims 
1. Optimize Ellman’s colorimetric method for the measurement of human RBC 
AChE activity, and modify Ellman’s colorimetric method for the measurement of 
human plasma BuChE activity. 
 
4.3. Materials and Reagents 
1. Acetylthiocholine Iodide (AtCh; MWt = 289.18; Sigma-Aldrich, St. Louis, MO) 
2. Butytylthiocholine Iodide (BtCh; MWt = 317.23; Sigma-Aldrich, St. Louis, MO) 
3. 5,5’-dithio-bisnitrobenzoic acid (DTNB; MWt = 396.35; Sigma-Aldrich, St. 
Louis, MO) 
4. Potassium phosphate monobasic (KH2PO4; MWt = 174.18; Sigma-Aldrich, St. 
Louis, MO) 
5. Phosphoric Acid, 14.8 M (MWt = 98.00; Sigma-Aldrich, St. Louis, MO) 
6. Acetylcholinesterase from bovine erythrocytes lyophilized powder (0.3 U/mg; 
Sigma-Aldrich, St. Louis, MO) 
7. Butyrylcholinesterase from horse serum lyophilized powder (17 U/mg; Sigma-
Aldrich, St Louis, MO) 
8. Sodium bicarbonate (MWt = 84.01; Sigma-Aldrich, St. Louis, MO) 
9. Gelatin (Sigma-Aldrich, St. Louis, MO) 
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4.4. Equipment 
1. Shimadzu PharmaSpec UV-1700 Spectrophotometer (Shimadzu, Columbia, MD) 
2. Computer equipped with Shimadzu UV-Prob Software (Shimadzu, Columbia, 
MD) 
3. Quartz cuvettes (Fisher Scientific, Pittsburgh, PA) 
4. Eppendorf 5804R, Benchtop Temperature Controlled Centrifuge (Westbury, NY)) 
5. Corning pH meter 340 (Corning, NY) 
6. Single channel variable-volume Pipettes (VWR Signature, West Chester, PA) 
7. Positive displacement pipette, C3-25 μl (Rainin, Woburn, MA) 
 
4.5. Solution Preparation 
1. Phosphate Buffer Solution (PBS, 0.1 M, pH 8.0).  Potassium phosphate dibasic 
8.71 g) was weighed of into a 500 ml volumetric flask and dilute to the mark with 
nanopure water.  The pH was adjusted to 8.0 with phosphoric acid. 
2. Acetylthiocholine solution A (AtCh A, 100 mM).  AtCh A solution was prepared 
by weighing out 289 mg of acetylthiocholine iodide and adding it to 10 ml of 
PBS.  This solution was mixed well until dissolved and stored at -70°C until 
needed for the assay. 
a. Acetylthiocholine solution B (AtCh B, 10 mM).  Pipetted 100 μl AtCh A 
solution into 900 μl PBS and mixed well. 
b. Acetylthiocholine solution C (AtCh C, 1 mM).  Pipetted 100 μl AtCh B 
solution into 900 μl PBS and mixed well. 
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c. Acetylthiocholine solution D (AtCh D, 0.1 mM).  Pipett 100 μl AtCh C 
solution into 900 μl PBS and mixed well. 
3. Butyrylthiocholine solution A (BtCh A, 100 mM).  BtCh A solution was prepared 
by weighing out 317 mg of butytylthiocholine iodide and adding it to 10 ml of 
PBS.  The solution was mixed well until dissolved.  This solution was stored at -
70°C until used for analysis. 
a. Butyrylthiocholine solution B (BtCh B, 10 mM).  Pipetted 100 μl BtCh A 
into 900 μl PBS and mixed well. 
b. Butyrylthiocholine solution C (BtCh C, 1 mM).  Pipetted 100 μl BtCh B 
into 900 μl PBS and mixed well. 
4. DTNB (10 mM).  DTNB solution was prepared by weighing 39.6 mg of 5,5’-
dithio-bisnitrobenzoic acid and 15 mg sodium bicarbonate and added to 10 ml of 
PBS.  The solution was mixed well until dissolved and stored at -70°C until used 
for analysis. 
5. Human blood was collected from healthy volunteers in heparinized tubes.  The 
blood was centrifuged at 5,000 g for 2 min to separate RBC and plasma.   
a. Dilute RBC suspension.  10 μl of packed RBC was pipetted into 600 μl 
PBS using a positive displacement pipette due to the viscosity. 
b. Dilute Plasma solution.  60 μl of plasma was pipetted into 600 μl PBS 
6. Purified AChE suspension (5 U/ml in 1% gelatin solution) was prepared by 
weighing 167 mg of AChE from bovine erythrocytes (0.3 U/mg) and 1 g of 
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gelatin into 100 ml PBS.  The suspension was well mixed until all gelatin was 
dissolved. 
7. Purified BuChE suspension (7.6 U/ml in 1% gelatin solution) was prepared by 
weighing 44.78 mg of BuChE from horse serum (17 U/mg) and 1 g of gelatin into 
100 ml PBS.  The suspension was well mixed until all gelatin was dissolved. 
 
4.6. RBC AChE Activity Measurement 
The product formation, as reported by Ellman et al, was measured for 8 minutes.41  
Men optimized the measurement of RBC AChE activity, under the conditions described 
in this section, which only required 4 minutes, decreasing the measurement time in half to 
increase the analysis throughput.30  Under these conditions, the formation of product was 
observed to be linear at all substrate concentrations for 4 minutes.  The shortened 
measurement time was crucial since the clinical samples were measured throughout the 
study in real time.  Due to the anticipated number of samples and the rapidity of samples 
measurement needed, the shortened analysis time was necessary.   
The measurement of AChE activity was performed at room temperature by the 
following procedure: 
1. Into a 1 ml quartz cuvette, the following was added: 
a. PBS, a sufficient volume to make a total volume of 1 ml, taking into 
account the volume of substrate 
b. 25 ul DTNB solution  
c. 25 μl dilute RBC suspension 
85 
2. To start the reaction, AtCh solution was added to the sample cuvette 
3. The formation of product is observed at 410 nm for 4 minutes by absorbance 
Under these conditions, the final concentration of DTNB was 0.25 mM.  The total 
dilution factor for RBC was 0.000042; i.e., diluted 2400-fold.   
 
4.7. Plasma BuChE Activity Measurement 
The activity of plasma BuChE was optimized using BtCh as the substrate.  The 
concentration of DTNB, dilution of plasma and the time of the measurement were 
optimized for the various concentrations of BtCh necessary to characterize the kinetics of 
plasma BuChE.  The temperature for the measurement of BuChE activity was performed 
at room temperature for all experiments. 
4.7.1. Optimization of Butyrylthiocholine Concentration 
The BtCh concentration dependent activity of purified BuChE suspension was 
assessed.  The activity in the purified BuChE suspension was made to a similar activity as 
observed in human plasma (i.e., 5.10 μmol/min/ml plasma).64  The concentration of 
DTNB and the dilution of plasma chosen for this study was the same as used for RBC 
AChE.  The Km in human plasma was reported to be 171 μM (SD=12) by Cengiz et al.65 
and was reported by Simeon-Rudolf et al.66 to be between 80 and 210 μM, depending on 
the phenotype of the subject.  The concentrations of BtCh in this study ranged from 225 
μM to 10,000 μM.   
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The activity of purified BuChE was determined by the following procedure: 
a. Into a 1 ml quartz cuvette, the following was added: 
i. PBS, a sufficient volume to make a total volume of 1 ml, taking into 
account the volume of substrate 
ii. 25 μl DTNB solution  
iii. 25 μl purified BuChE suspension 
b. To start the reaction, BtCh solution was added to the cuvette 
c. The formation of product is observed at 410 nm for 8 minutes by 
absorbance 
The amount of activity expected in the final mixture is 0.19 U/ml (i.e., 0.19 
μmol/min/ml).  The final concentration of DTNB is 0.25 mM. 
The activity of the purified BuChE was linear over the 8 minutes observed for this 
experiment at all concentrations.  The results are shown in figure 4.7.1.-1 fit by a 
Michaelis-Menten model.  The Km for the purified BuChE suspension was determined to 
be 275 μM (± 15%).  The vmax was determined to be 1.1 μmol/min/U (± 2.5%).  The Km, 
as determined in this study, was higher than reported for human plasma, which may be 
due to species differences.  In addition, this system was a purified enzyme rather than in a 
biological matrix and may account for differences in Km.  A unit of enzyme is defined as 
one μmol/min under ideal conditions.  The vmax value of 1 μmol/min/U is the expected 
activity of the enzyme as defined by the manufacturer and was very close to the results 
observed in this study.   
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We conclude the Km of the purified BuChE suspension was 275 μM and the 
activity conforms to manufactures specifications.   
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Figure 4.7.1.-1. BtCh concentration-dependent activity of the purified BuChE suspension 
 
4.7.2. Optimization of DTNB Concentration 
While DTNB is not important for the activity of plasma BuChE, the presence of 
DTNB is required for the formation of TNB (yellow product).  An adequate amount of 
DTNB to react with the product is required to observe TNB formation over the 8 minute 
reaction time.  The purpose of this study was to determine the optimum concentration of 
DTNB.   
The concentrations of DTNB studied ranged from 0.01 mM to 1 mM.  (The 
concentration optimized for the RBC AChE activity was 0.25 mM.)  The concentration of 
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BtCh used in this study was 2500 μM, approximately 10-fold higher than the Km 
concentration. 
The activity of purified BuChE activity at various DTNB concentrations was 
determined by the following procedure: 
1. Into a 1 ml quartz cuvette, the following was added: 
i. PBS, a sufficient volume to make a total volume of 1 ml, taking into 
account the volume of DTNB 
ii. DTNB ranging from 0.01 mM to 1 mM 
iii. 25 μl purified BuChE suspension 
2. To start the reaction 25 μl of BtCh Solution C was added to the cuvette 
3. The formation of product was observed at 410 nm for 8 minutes by 
absorbance 
The results of this study are shown in figure 4.7.2.-1.  At the lowest 
concentrations of 0.01 and 0.1 mM, DTNB became the limiting reagent in the formation 
of TNB over the 8 minutes.  This is observed by a linear-increase in product formation 
followed by a plateau, resulting in an apparent low activity.  At concentrations of 0.25 
mM and above, DTNB was no longer the limiting reagent and the reaction could proceed 
to completion over an 8 minute reaction time.   
We optimized the concentration of DTNB to be 0.25 mM, the same as used for 
measurement of RBC AChE activity. 
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Figure 4.7.1.-1. Optimization of DTNB concentration 
 
4.7.3. Optimization of Plasma Dilution 
The dilution of plasma was optimized to measure the activity of plasma BuChE.  
The dilution factor of RBC AChE is 0.000042 (i.e., a 2400-fold dilution) and resulted in 
an activity of approximately 0.012 μmol/min at high AtCh concentrations.  A dilution of 
plasma that resulted in similar activities of plasma BuChE and that resulted in a linear 
relationship of enzyme to activity would be optimized. 
Plasma was diluted by the following factors: 0.001250, 0.0025, and 0.005 (i.e. an 
800, 400 and 200-fold dilution, respectively).  The concentration of BtCh was 2500 μM, 
approximately 10-fold higher than the Km of purified BuChE suspension.  The activity 
was measured in triplicate for each plasma dilution factor. 
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The results of this study are shown in figure 4.7.3.-1.  The activities ranged 
between 0.005 and 0.02.  The dilution of 0.0025 resulted in an activity of 0.009 
μmol/min, similar to the activity of RBC AChE at a 0.00083 dilution factor. 
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Figure 4.7.3.-1. Effect of plasma dilution on activity 
 
The optimum dilution factor for plasma was 0.0025, which is a 400-fold dilution.  
This dilution factor resulted in activities similar to RBC AChE at a 2400-fold dilution.  
The dilution was approximately 3-fold less than the dilution used for RBC AChE activity, 
which may indicate the activity for plasma BuChE is less than the RBC AChE. 
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4.7.4. Optimization of Reaction Time 
Using the optimized DTNB concentration (section 4.7.2) and plasma dilution 
(section 4.7.3), the time of reaction was optimized for the shortest time necessary to 
accurately estimate the activity.  The substrate concentrations of BtCh ranged from 100 
μM to 2000 μM in addition to a blank (no BtCh).  The increase in absorbance was 
followed for 8 minutes.  The activity as measured for 8 minutes was compared to the 
activity for 4 minutes.   
Figure 4.7.4 shows the increase in absorbance for 8 minutes.  The activities 
measured at 4 minutes and 8 minutes were correlated with each other with an r2 of 
0.9848.  The difference between the measurements were not statistically different from 
each other (p= 0.9998 by a paired t-test).  Thus the measurement of activity for 4 minutes 
resulted in the same activities as measurement for 8 minutes, but required less time. 
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Figure 4.7.4. The increase in absorbance for 8 minutes for BtCh concentrations of 100 
μM to 2000 μM 
 
In order to minimize the time required and to increase the throughput of this 
method, the time of reaction to measure plasma BuChE activity was optimized to 4 
minutes. 
4.7.5. Summary of Optimization of Plasma BuChE Activity 
The Km of purified BuChE suspension from horse serum was found to be 275 μM.  
The concentration of DTNB was optimized to be 0.25 mM; at this concentration, DTNB 
was not the limiting reactant.  This is the same concentration for the determination of 
RBC AChE activity.  The dilution factor of plasma for the determination of plasma 
BuChE activity was 0.0025 (400-fold dilution); at this dilution factor, similar activities 
were observed for RBC AChE activity and the enzyme to activity relationship was linear.  
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The optimized time of reaction was 4 minutes, and was shortened from 8 minutes to 
increase analysis throughput.   
4.7.6. Measurement of Plasma BuChE Activity 
The measurement of plasma BuChE activity was performed in a similar manner 
as RBC AChE activity.  The measurement of BuChE activity was performed at room 
temperature by the following procedure. 
1. Into a 1 ml quartz cuvette, the following was added: 
a. PBS, a sufficient volume to make a total volume of 1 ml taking into 
account the volume of substrate 
b. 25 ul DTNB solution 
c. 25 μl plasma solution 
2. To start the reaction, BtCh solution was added to the cuvette 
3. The formation of product is observed at 410 nm for 4 minutes by absorbance 
 
4.8. Characterization of AChE and BuChE in RBC and Plasma 
The hydrolysis of AtCh and BtCh by RBC and plasma was characterized.  BtCh, 
being a selective substrate for AtCh, was able to differentiate the presence of AChE and 
BuChE in RBC and plasma.  The ability to hydrolyze the two substrates was measured at 
a range of substrates concentrations and the enzyme kinetics described by an appropriate 
model.  For convention: 
o RBC AChE activity refers to the ability of RBC to hydrolyze AtCh 
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o RBC BuChE activity refers to the ability of RBC to hydrolyze BtCh 
o Plasma AChE activity refers to the ability of plasma to hydrolyze AtCh 
o Plasma BuChE activity refer to the ability of plasma to hydrolyze BtCh 
4.8.1. RBC hydrolysis of AtCh 
Previously, AtCh hydrolysis by RBC has shown an Km of 29.7 ± 8.6 μM by 
Men.30  For this experiment, AtCh concentrations ranged from 10x less to 60x higher 
than the reported Km.  Table 4.8.1.-1 shows the concentration of AtCh, and the volumes 
of each reagent used to measure the activity.  The activity at each concentration was 
measured in triplicate. 
 
Table 4.8.1.-1. Conditions to study AtCh hydrolysis by RBC AChE 
AtCh Conc PBS DTNB 
Dilute RBC 
Suspension AtCh B AtCh C AtCh D 
(μM) (μl) (μl) (μl) (μl) (μl) (μl) 
0.0 950.0 25 25 -- -- -- 
3.0 920.3 25 25 -- -- 29.7 
5.9 890.6 25 25 -- -- 59.4 
8.9 860.9 25 25 -- -- 89.1 
14.9 935.2 25 25 -- 14.9 -- 
29.7 920.3 25 25 -- 29.7 -- 
44.6 905.5 25 25 -- 44.6 -- 
89.1 860.9 25 25 -- 89.1 -- 
148.5 935.2 25 25 14.9 -- -- 
297.0 920.3 25 25 29.7 -- -- 
445.5 905.5 25 25 44.6 -- -- 
594.0 890.6 25 25 59.4 -- -- 
891.0 860.9 25 25 89.1 -- -- 
1188.0 831.2 25 25 118.8 -- -- 
1782.0 771.8 25 25 178.2 -- -- 
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As expected, the hydrolysis of AtCh by RBC AChE followed Michaelis-Menten 
kinetics; the goodness of fit was 0.9830.  Figure 4.8.1.-1 shows the results of this study.  
The Km and vmax values were estimated to be 73.0 μM (13%) and 15.7 μmol/min/ml RBC 
(2.9%), respectively.  The intrinsic clearance for AtCh in RBC was 215.1 ml/min/ml 
RBC. 
The Km in this study matched well with reported Km values in human RBC.  Men 
reported the Km value of 30 μM;30 Froede et al. reported a Km of 290 μM; 67 and Kamal et 
al to be 88 μM.68   
The vmax in this study was higher than reported values, but was within a 5-fold 
range.  Men reported a vmax of 9.2 μmol/min/ml RBC; 30 Wetherell et al reported values 
of 5.0 μmol/min/ml blood;64 and Kamel et al reported a value of 3.7 μM/min/g blood.68 
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Figure 4.8.1.-1. Hydrolysis of AtCh by RBC ChE 
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4.8.2. RBC hydrolysis of BtCh 
Little is known about the ability of RBC to hydrolyze BtCh, other than a high 
selectivity of AChE for ACh and AtCh.  This is thought to be due to the steric hindrance 
at the acyl-binding pocket.21  There are limited reports of the kinetics of this interaction. 
For this experiment, high concentrations of BtCh were required.  The solutions 
were prepared by the following procedure: 
 BtCh stock solution A (300 mM) was prepared by adding 951.7 mg of 
BtCh to 10 ml of PBS.   
 BtCh stock solution B (30 mM) was prepared by adding 100 μl of BtCh 
stock to 900 μl of PBS. 
Table 4.8.2.-1 shows the concentration of BtCh studied and the volumes reagents 
used for the experiment.  The highest concentration of BtCh studied of 22500 μM was 
limited due to limited solubility of BtCh at high concentrations. 
 
Table 4.8.2.-1. Conditions to study BtCh hydrolysis by RBC AChE 
BtCh 
Conc V PBS DTNB 
Dilute RBC 
Suspension
BtCh Stock 
Solution A 
BtCh Stock 
Solution B  
(μM) (μl) (μl) (μl) (μl) (μl) 
3000 850 25 25 -- 100 
7500 925 25 25 25 -- 
15000 900 25 25 50 -- 
30000 850 25 25 100 -- 
75000 700 25 25 250 -- 
150000 450 25 25 500 -- 
225000 200 25 25 750 -- 
 
The hydrolysis of BtCh by RBC AChE followed Michaelis-Menten kinetics; the 
goodness of fit was 0.8810.  The Km and vmax was 130000 μM (39%) and 11.9 
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μmol/min/ml RBC (19%).  Because of the limited solubility of BtCh, the highest 
concentration studied was 225000 μM, less than twice the estimated Km value.  This lead 
to a high correlation between Km and vmax of 0.96; nevertheless, the estimates were 
reasonably well estimated with a COV less than 40%.  The CLint is estimated to be 0.092 
ml/min/ml RBC.  Figure 4.8.2.-1 shows the results of this study. 
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Figure 4.8.2.-1. Hydrolysis of BtCh by RBC ChE 
 
4.8.3. Plasma hydrolysis of BtCh 
Previous measurements of BtCh hydrolysis by plasma BuChE indicated a Km of 
148 μM (± 18) and a vmax of 5.5 μmol/min/ml plasma (± 0.1).69  The concentration of 
BtCh for this study ranged from 10x less to 20x higher than this expected value.  Table 
4.8.3.-1 shows the concentrations and volumes of reagents used in this study. 
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Table 4.8.3.-1. Conditions used to study the hydrolysis of BtCh by plasma BuChE 
BtCh Conc PBS DTNB 
Dilute 
Plasma 
Solution
BtCh 
Solution 
A 
BtCh 
Solution 
B 
BtCh 
Solution 
C 
(μM) (μl) (μl) (μl) (μl) (μl) (μl) 
0 950.0 25 25 -- -- -- 
15 935.0 25 25 -- -- 15.0 
30 920.0 25 25 -- -- 30.0 
45 905.0 25 25 -- -- 45.0 
75 875.0 25 25 -- -- 75.0 
150 935.0 25 25 -- 15.0 -- 
225 927.5 25 25 -- 22.5 -- 
450 905.0 25 25 -- 45.0 -- 
750 875.0 25 25 -- 75.0 -- 
1500 935.0 25 25 15.0 -- -- 
2250 927.5 25 25 22.5 -- -- 
3000 920.0 25 25 30.0 -- -- 
 
The hydrolysis of BtCh by plasma BuChE followed Michaelis-Menten kinetics; 
the goodness of fit was 0.9817.  The Km and vmax were estimated to be 72.45 μM (14%) 
and 4.19 μmol/min/mL plasma (3.1%), respectively, similar to reported values.  The CLint 
was estimated to be 27.3 μmol/min/ml plasma. 
As reported in section 4.8.1.: the Km in human plasma was reported to be 171 μM 
(SD=12) by Cengiz et al.65 and was reported by Simeon-Rudolf et al.66 to be between 80 
and 210 μM, depending on the phenotype of the subject. 
The vmax was reported to be 5.10 μmol/min/ml plasma (SD=0.25) by Wetherell et 
al.64 and was reported by Simeon-Rudolf et al.66 to be between 1.2 and 7.6 μmol/min/ml 
plasma depending on the phenotype of the subject. 
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Figure 4.8.3.-1. Hydrolysis of BtCh by plasma ChE 
 
4.8.4. Plasma hydrolysis of AtCh 
Little information is available for the hydrolysis of AtCh by plasma but it is 
suspected to be similar to the hydrolysis of BtCh by plasma.  Table 4.8.4.-1 shows the 
conditions used to study the hydrolysis of AtCh by BuChE. 
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Table 4.8.4.-1. Conditions used to study the hydrolysis of AtCh by plasma BuChE 
AtCh 
Concentration PBS DTNB 
Dilute 
Plasma 
Solution 
AtCh 
Solution 
A 
AtCh 
Solution 
B 
AtCh 
Solution 
C 
AtCh 
Solution 
D 
(uM) (ul) (ul) (ul) (ul) (ul) (ul) (ul) 
0 950 25 25  --  --  --  -- 
10 850 25 25 -- -- -- 100 
25 925 25 25 -- -- 25 -- 
50 900 25 25 -- -- 50 -- 
100 850 25 25 -- -- 100 -- 
250 925 25 25 -- 25 -- -- 
500 900 25 25 -- 50 -- -- 
1000 850 25 25 -- 100 -- -- 
2500 925 25 25 25 -- -- -- 
5000 900 25 25 50 -- -- -- 
10000 850 25 25 100 -- -- -- 
15000 800 25 25 150 -- -- -- 
20000 750 25 25 200  --  -- --  
 
The hydrolysis of AtCh by plasma BuChE followed Michaelis-Menten kinetics; 
the goodness of fit was 0.9863.  The Km and vmax was estimated to be 117.4 μM (6.3%) 
and 3.2 μmol/min/ml plasma (1.1%), respectively.  The CLint was estimated to be 27.3 
ml/min/ml plasma. The results are shown in figure 4.8.4.-1. 
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Figure 4.8.4.-1. Hydrolysis of AtCh by plasma ChE. 
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 4.8.5. Results and Discussion 
Table 4.8.5.-1 summarizes the results of the measurement of RBC and plasma 
ChE activity by an optimized Ellman’s colorimetric method.  With the exception of RBC 
AChE hydrolysis of BtCh, the COV for the parameter estimates are less then 20%, 
indicating good precision of the estimates. 
Table 4.8.5.-1. Summary of ChE activity in RBC and plasma 
Substrate 
Matrix 
AtCh BtCh AtCh BtCh AtCh BtCh 
 Km (μM) vMAX (μmol/min/ml matrix) CLint (ml/min/ml matrix) 
RBC 73 (13%) 
130000 
(39%) 
15.7 
(2.9%) 
11.9 
(19%) 215.1 0.092 
Plasma 117 (6.3%) 
72 
(14%) 
3.2 
(1.1%) 
4.2 
(3.1%) 27.3 57.8 
RBC Selectivity 1.6 0.0006 4.9 2.9 0.126 628 
 
The results indicate that RBC is very selective towards AtCh relative to BtCh 
with a RBC AChE/plasma AChE Km ratio of 1780.  At very high concentrations, RBC 
has a higher ability to degrade both AtCh and BtCh than plasma.  The vmax of RBC AChE 
is 15.7 μmol/min/ml RBC compared to 3.2 μmol/min/ml plasma for plasma AChE; a 
ratio of 4.9, ie., RBC has nearly a 5-fold higher ability to clear AtCh than plasma at high 
concentrations.  The RBC BuChE vmax was 11.98 μmol/min/ml compared to plasma 
BuChE of 4.2 μmol/min/ml plasma, a ratio of 2.9, i.e., RBC has nearly a 3-fold higher 
ability to clear BtCh than plasma, but requires a very high concentration.   
RBC AChE hydrolysis of AtCh is the most efficient with an CLint of 215.1 
ml/min/ml RBC while the CLint for RBC BuChE is lowest at 0.092 ml/min/ml RBC.  
This is consistent with its function, since AChE is known to be a highly efficient enzyme 
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towards ACh; however, it is also a very selective enzyme for ACh.  At very high 
concentrations of BtCh, RBC is as efficient at hydrolyzing BtCh as AtCh (vmax of 11.9 
compared to 15.7 μmol/min/ml RBC, respectively); however, AtCh experiences substrate 
inhibition at high concentrations due to binding at the peripheral ABS.21  The substrate 
inhibition, presumably, occurs by low affinity binding of AtCh at the mouth of the 
narrow gorge leading into the catalytic binding site, causing steric hindrance of substrate 
into and out of the catalytic binding site (see section 1.3.3.). 
Plasma BuChE is nonselective with less than a two-fold difference in Km towards 
AtCh and BtCh but is slightly more efficient at hydrolyzing BtCh than AtCh with an 
CLint of 57.8 ml/min/ml plasma for BtCh, compared with 27.3 ml/min/ml plasma for 
AtCh.  BuChE is nonselective and degrades the two substrates with similar efficiency. 
AtCh was about eight times more efficient at being cleared by RBC AChE than 
plasma BuChE, indicating that RBC AChE accounts for the majority of the hydrolytic 
activity for AtCh in whole blood.  On the other hand, BtCh is about 630 times more 
efficiently cleared by plasma than RBC, indicating that plasma BuChE accounts for the 
majority of the hydrolytic activity in whole blood. 
Over all, this study shows the majority of the activity in RBC is thought to be due 
to RBC AChE by its selective clearance of AtCh.  This is supported by reports showing 
very little expression of BuChE in RBCs.22  In this study, the activity of plasma cannot be 
proven to be either AChE or BuChE, however, according to literature reports, the 
presents of AChE in plasma is negligible.25  Thus, the predominate ChE on RBC is AChE 
(RBC AChE); and the predominate ChE in plasma is BuChE (plasma BuChE). 
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4.8.6. Comparison of Activities to Other Tissues in Humans 
Other tissues with ChE activity include the brain, muscle, lung, liver and heart.  
The brain mainly contains AChE, mainly localized in certain regions, such as the cortex, 
amygdalae and hippocampus.70  BuChE makes up approximately 5% of the ChE activity 
in the CNS; secreted by glial cells into the CSF, BuChE is distributed evenly throughout 
the CNS.  The skeletal muscles contain a large amount of ChE, which account for 
approximately 75% of the ChE activity in the body.22  The majority of the activity of 
skeletal muscles is AChE associated with the neuromuscular juncture.  The liver 
exclusively expresses BuChE.22  The ChE in the lung consists of approximately 40% of 
BuChE and approximately 60% AChE.71  The ChE activity in the heart is approximately 
95% AChE.22   
The blood ChE activity accounts for approximately 21% of the total ChE activity 
in the body.  The skeletal muscles contain approximately 75%.  Together, blood and 
muscles account for 96% of the total ChE activity in the body.  The brain and liver 
account for 1.8 and 1.3% of the total ChE activity in the body, respectively.22 
4.8.7. Comparison of Blood Activities to Other Species 
Other species also contain ChE activity in blood; however, this activity tends to 
be species specific.  Rat RBC and plasma ChE activity was estimated in our lab by 
Krishnan et al.72  The RBC AChE activity was very small and was difficult to measure 
above baseline (blank samples).  However, the plasma AChE Km was estimated to be 103 
μM and the vmax was 0.4 μmol/min/ml plasma.  The Km was very similar to humans, 
however, the vmax was 8-fold less.  The plasma BuChE Km was 162 μM and the vmax was 
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0.14 μmol/min/ml plasma.  The Km was similar to humans but the vmax was 
approximately 30-fold lower.  The activity in rat plasma was estimated to be 
approximately 50% AChE and 50% BuChE. 
In addition to plasma AChE and BuChE activity, there was a large amount of 
nonselective esterase activity, presumably carboxyesterase, in rat RBC and plasma.73  
This nonselective activity was only observed at high concentrations with a Km of 
>100,000 μM. 
Tecles et al. measure the ChE activity with AtCh and BtCh in whole blood, RBC 
and plasma in several species.74  The AtCh and BtCh concentrations used in the study 
was 1,000 μM, concentrations that are expected to result in activities near the vmax.  For 
AChE, this concentration would be relatively selective for AtCh.  The results are shown 
in table 4.8.7.-1.  The RBC AChE selectivity was relatively similar across the species, 
with RBC BuChE activity being approximately 10% of the RBC AChE activity.  The 
RBC AChE activity ranged from 1.23 μmol/min/ml in cats to 4.24umol/min/ml in cows.  
The plasma BuChE activity was generally higher than the plasma AChE activity, as was 
observed in humans, but this was not consistent across all species.  The activity of RBC 
and plasma AChE activity was generally equal in RBC and plasma, as was observed in 
humans, with the exception of cows, goats, sheep and pigs.  For these later species, the 
RBC activity accounted for the majority of the activity with the plasma activity 
approximately 10% of the RBC activity. 
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Table 4.8.7.-1. ChE activity in whole blood, RBC and plasma from several species74 
 
Many mammalian species exhibit AChE and BuChE activity in blood.  For most 
species the RBC contains mainly AChE.  Most species have approximately 50% AChE 
and BuChE in the plasma, but ranges from nearly exclusively BuChE in humans to only 
10% of ChE activity in cows, goats and sheep.  Some species, such as rats, show very 
little specific blood ChE activity, but instead exhibit nonselective esterase activity, 
presumably carboxyesterase. 
 
4.9. Analysis of Study Samples 
The purpose of the preliminary studies (described in Chapter 5) and the in-vitro 
clinical study (described in Chapter 6) was to characterize the inhibition of AChE and 
BuChE by the cholinesterase inhibitors PHYS, PYR, DON and GAL.  In these studies, 
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the inhibition of RBC AChE activity is measured using AtCh as the substrate; the 
inhibition of plasma BuChE is measured using BtCh as the substrate.   
The activity was measured in real-time, during the course of the study due to the 
instability of PHYS in blood, plasma and RBC.  Storage of samples created the concern 
of changes in PHYS concentrations, leading to variability in ChE activity.  While rapid 
analysis of samples was necessary, this eliminated the concern for stability of inhibitors 
and effects of freeze-thaw.  Optimization of this method included shortening the analysis 
time and assisted in rapid analysis of samples during the course of the experiments. 
At the beginning of each study, quality control enzyme activities were measured.  
These QC sample ensured interday consistency in activity measurements.  See section 
4.9.1 for the procedure the QC samples were measured and section 4.9.2 for the analysis 
of the QC samples 
Blood was collected during the course of the study.  The blood was centrifuged at 
5,000 rpm for 2 minutes to separate RBC and plasma.  The plasma (60 μl) was placed in 
600 μl of PBS and vortexed for 10 seconds to make a diluted plasma solution.  The RBC 
(10 μl) was pipetted with a positive displacement pipette (due to its viscosity) into 600 μl 
of PBS and vortexed for 10 seconds to make a dilute RBC suspension.  The measurement 
of RBC AChE was performed as described in section 4.6 and plasma BuChE was 
performed as described in section 4.7.6.  Depending on the type of inhibition, various 
substrate concentrations were used. 
107 
4.9.1 Quality Control Enzyme Activity 
The activity of the standard bovine AChE suspension with a standard 
concentration of AtCh and BtCh was measured for each study.  This activity was used to 
establish interday consistency in the measurement of activity.  Measured approximately 
at the Km concentration for AtCh (Km=109 μM) 72 and BtCh (Km=12,566 μM) 72, the 
activity is dependent on the substrate concentration, and is able to establish consistent 
substrate concentrations at the start of each study.  Thus, inconsistency in the interday 
standard activity would be able to detect substrate concentration variability, such as by 
degradation.  The activity was measured in duplicate and the activity must have been 
within 20% of the prespecified criteria.   
All standard enzyme activity was measured at room temperature.  The 
measurement was made in duplicate by the following procedure: 
• Standard AtCh activity (100 μM AtCh, Bovine AChE 0.05 U/ml) 
1. Into a cuvette, add:  
o 865 μl of PBS was added to a cuvette  
o 25 μl DTNB 
o 10 μl Bovine AChE suspension 
2 To start the reaction, add: 
o 100 μl AtCh C 
3 Autozero the absorbance and start recording the change in absorbance. 
4 The formation of product is observed at 410 nm for 4 minutes 
• Standard BtCh activity (10,000 μM BtCh, Bovine AChE 0.25 U/ml) 
108 
1. Into a cuvette, add:  
o 825 μl of PBS was added to a cuvette  
o 25 μl DTNB 
o 50 μl Bovine AChE suspension 
2 To start the reaction, add: 
o 100 μl BtCh A 
3 Autozero the absorbance and start recording the change in absorbance. 
4 The formation of product is observed at 410 nm for 4 minutes 
4.9.2 Interstudy Quality Control Enzyme Activity 
The prespecified activity for AtCh was 0.011 μmol/min ± 20% (i.e., 0.0088 to 
0.013 μmol/min); the prespecified activity for BtCh was 0.0035 μmol/min ± 20% (0.0028 
to 0.0042 μmol/min).  The mean control AtCh activity for the preliminary studies 
(chapter 5) was 0.012 μmol/min (8.7%); the mean control BtCh activity was 0.0039 
(11%).  The QC activity for each study can be seen in figure 4.9.2.-1.   
The mean control AtCh activity for the in-vitro clinical study (chapter 6) was 
0.011 μmol/min (11%); the mean control BtCh activity was 0.0032 μmol/min (9.1%).  
The QC activity for each subject can be seen in figure 4.9.2.-2. 
The activity of a standard enzyme control at a fixed substrate concentration was 
consistent across all of the studies, demonstrating consistent substrate concentrations and 
low interday/interstudy variability in activity measurement. 
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Figure 4.9.2.-1.  QC activities for the preliminary studies described in Chapter 5 
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Figure 4.9.2.-2.  QC activities for the each study subject described in Chapter 6 
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4.10. Conclusions 
This chapter describes the method and optimization for the measurement of RBC 
and plasma ChE activity.  The method was simple, with improved throughput due to a 
decreased analysis time.   
The RBC activity is highly selective for AtCh with very little activity for BtCh, 
except at very high concentrations.  Plasma is able to hydrolyze AtCh and BtCh with 
similar activities.  This is thought to be due to the nonselective nature of BuChE in 
plasma.   
The RBC AChE and plasma BuChE activity was used to measure the inhibition 
by PHYS, PYR, DON and GAL.  The interstudy consistency was demonstrated with QC 
samples using a standard enzyme and concentration solution.  The samples were analyzed 
in real-time, during the course of the study.  This was necessary due to PHYS instability 
in blood, plasma and RBC, but eliminated the concern for effects of a freeze-thaw cycle.  
The total analysis time was approximately 6 minutes, including centrifugation to separate 
RBC and plasma. 
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Chapter 5 
Mechanistic Inhibition Studies of Human RBC AChE and Plasma 
BuChE by PHYS, PYR, DON and GAL 
 
5.1. Introduction 
Understanding the mechanism of inhibition of ChE inhibitors will be helpful in 
understanding the sensitivity of AChE and BuChE.  As discussed in Chapter 1, there are 
three possible mechanisms of inhibition proposed for ChE inhibitors; they include:27 
1. Competitive inhibition, if the inhibitor binds to the catalytic region of the 
catalytic ABS of ChE 
2. Noncompetitive inhibition, if the inhibitor binds to the peripheral ABS of 
ChE 
3. Suicide-inactivator, if the inhibitor acts as an alternate substrate and, 
transiently, covalently binds to the catalytically active region of ChE 
In addition, an agent may act as a mixed competitive-noncompetitive inhibitor if 
the inhibitor binds to both the catalytic ABS and the peripheral ABS (see section 1.3.4.).  
Determination of the mechanism of inhibition will assist in the full characterization of 
sensitivity to each of the inhibitors.  For example, full characterization of the inhibition 
mechanism allows for comparison of how the inhibitor affects the ChE across a range of 
conditions, such as time, inhibitor and substrate concentrations.  The purpose of the study 
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described in this chapter was to characterize the mechanism of inhibition of PHYS, PYR, 
DON and GAL on human RBC AChE and plasma BuChE.  In addition, the purpose of 
this study was to characterize the degradation of PHYS in human whole blood and 
determine the relative contribution of RBC and plasma to its enzymatic degradation.  
This was studied in several experiments; 
1. An in-vitro study of PHYS in human whole blood, RBC suspension and 
plasma to assess the degradation of PHYS, the relative contribution of 
RBC and plasma to whole blood clearance and to assess the time-
dependent and concentration-dependent inhibition of RBC AChE and 
plasma BuChE at a single initial PHYS concentration 
2. A preliminary in-vitro inhibition study of PYR, DON and GAL in human 
whole blood at steady-state using a competitive inhibition model 
(assessing for steady-state concentration dependent inhibition). 
3. A mechanistic study of PHYS in human whole blood to assess for time- 
and concentration-dependent inhibition for several initial PHYS 
concentrations and the degradation of PHYS in human whole blood 
4. A mechanistic study of PYR, DON and GAL in human whole blood to 
assess for time- and concentration-dependent inhibition at several initial 
inhibitor concentrations.  
The results of this study were used to design the laboratory procedure of a clinical 
study to assess age-related difference in sensitivity to the ChE inhibitors. 
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5.2. Specific Aims 
1. Design and perform an in-vitro mechanistic study of PHYS, PYR, DON and GAL 
in human whole blood to study the concentration- and time-dependent inhibition 
of RBC AChE and plasma BuChE as well as time-dependent degradation of 
PHYS in whole blood. 
2. Develop and validate mechanistic PK/PD models of PHYS and PD models of 
PYR, DON and GAL using the mechanistic in-vitro studies. 
 
5.3. Materials and Reagents 
The materials and regents were previously described in Chapter 3 and Chapter 4 
with the following additions: 
Donepezil (DON as free base; MWt = 379.50; Bosche Scientific, New Brunswick 
NJ) 
Galantamine hydrogen bromide (GAL; MWt = 374.31; Bosche Scientific; New 
Brunswick NJ) 
 
5.4. Equipment  
The equipment was the same as described in Chapter 3 and 4. 
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5.5. Solution Preparation   
The solution preparation was the same as described in Chapter 3 and 4 with the 
following additions: 
PYR preservative solution (5 mg/ml; 18.2 mM) was prepared by weighing 5 mg 
of PYR bromide into 1 ml of PBS. 
PHYS stock solution (3.63 mM; 1mg/ml) was prepared by weighing 1.5 mg of 
PHYS salicylate into 1 ml PBS.   
PHYS solution A (36.3 μM; 10 μg.ml) was prepared by pipetting 10 μl of PHYS 
stock solution into 990 μl of PBS. 
PYR Stock (100 mM) was prepared by weighing 261.1 mg PYR Br into 10 ml 
PBS 
PYR Solution A (1,000 μM) was prepared by pipetting 10 μl of PYR Stock into 
990 μl of PBS 
PYR Solution B (100 μM) was prepared by pipetting 10 μl into of PYR Solution 
A into 990 μl of PBS 
DON Stock (167,000 μM) was prepared by weighing 189.75 mg DON into 2.8 ml 
nanopure water with 200 μl phosphoric acid (total volume of 3 ml). 
DON Solution A (1,670 μM) was prepared by pipetting 10 μl of DON Stock into 
990 μl PBS 
GAL Stock (100,000 μM) was prepared by weighing 36.8 mg of GAL HBr into 1 
ml PBS 
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GAL Solution A (1,000 μM) was prepared by pipetting 10 μl of GAL Stock into 
990 μl PBS 
 
5.6. In-vitro PK/PD studies of PHYS in human whole blood, plasma and RBC 
suspensions 
 A PK/PD study of PHYS in human whole blood, plasma and RBC suspension 
was performed to study the inhibition of RBC AChE and plasma BuChE by PHYS and to 
assess the relative contribution of plasma and RBC to the total degradation of PHYS in 
human whole blood.  Blood was collected from a young healthy male volunteer recruited 
for this study (Subject 1).   
Plasma and RBC were separated by centrifuging whole blood at 5,000 g for 10 
min.  The plasma was removed and stored at 4 °C until studied.  The packed RBCs were 
washed by adding Dulbecco’s Phosphate Buffered Saline (DPBS, Quality Biological Inc, 
Gaithersburg MD) at a 1:1 ratio, vortexed and centrifuged again.  This was repeated twice 
more for a total of three washings.  The RBCs were suspended at a 1:1 ratio of DPBS.  
This would result in a suspension with an approximate 50% hematocrit. 
The whole blood, RBC suspension and plasma were placed in an oscillating water 
bath set to 37°C and 70 rpm and allowed to equilibrate.  Baseline activity of RBC AChE 
was measured for both whole blood and the RBC suspension; baseline activity of plasma 
BuChE was measured for both whole blood and the plasma.  The substrate concentration 
to assess ChE activity was 1,000 μM of AtCh for AChE and 1,000 μM of BtCh for 
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BuChE.  This concentration is approximately 15-fold Km for both enzymes; at 15-fold Km 
the enzyme activity is expected to be near vmax. 
PHYS was added to whole blood, RBC suspension and plasma for an initial 
concentration of 0.18 μM (50 ng/ml).  At prespecified time points after the addition of 
PHYS, samples were taken to measure the PHYS concentration in plasma (whole blood, 
plasma) or buffer (RBC suspension) as well as AChE activity (whole blood, RBC 
suspension) and/or the BuChE activity (whole blood, plasma) until the ChE activity had 
returned to baseline. 
Figure 5.6.-1. shows the resulting PHYS concentration and ChE activity-time 
profiles in whole blood, RBC suspension and plasma.  The PHYS degradation in plasma 
and buffer was fit by a Michaelis-Menten kinetic model shown in equation 5.6.-1.  The 
Michaelis-Menten kinetic model parameter estimates are shown in table 5.6.-1.  The CLint 
is the ability of the enzyme to degrade PHYS at low concentrations and is calculated 
using equation 5.6.-2.  The ChE activity-concentration profile was fit by a pseudo-steady-
state noncompetitive inhibition model (see equation 1.3.4.-2a). 
 
CK
Cv
dt
dC
m +
−= *max       <Equation 5.6.-1> 
Where: C = Concentration in plasma or buffer 
 vmax = Maximum rate of degradation 
 Km = Equilibrium dissociation constant, the concentration at half the 
maximum rate of degradation; Michaelis constant  
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mK
vCL maxint =        <Equation 5.6.-2.> 
 
Time-dependent ChE inhibition was observed; the lag-time of the maximum 
inhibition was observed at approximately 30 minutes.  This time-dependent inhibition is 
suggestive of suicide-inactivation; however, more initial PHYS concentrations would 
need to be explored to assess the concentration-dependent inactivation-rate constant 
relationship observed for a suicide inactivator.   
Figure 5.6.-2. shows the inhibition of AChE and BuChE in whole blood, RBC 
suspension and plasma fit by a noncompetitive inhibition model.  Due to an observed lag 
time, the pseudo-steady-state inhibition was used for the inhibition analysis.  Pseudo-
steady-state inhibition is the time when the ChE activity is recovering (increasing), while 
the concentration of PHYS is declining.  Pseudo-steady-state inhibition is observed after 
the lag-time.  For this analysis, the first 30 minutes was excluded from the pseudo-steady-
state noncompetitive inhibition model, i.e., the time before lag-time was excluded.  The 
parameter fits are shown in table 5.6.-2. 
The coefficient of determination for the kinetics of PHYS in whole blood, RBC 
suspension and plasma was 0.98 or above; however, the parameter estimates were not 
well estimated for RBC suspension kinetics with a COV >30% for both Km and vmax.  
The coefficient of determination for the inhibition in whole blood and plasma was above 
0.9, but was only 0.71 for RBC suspension.  This was due to a high degree of variability 
in RBC AChE activity. 
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Figure 5.6.-1. PK/PD-time profile of PHYS in human whole blood (left), RBC 
suspension (center) and plasma (right), symbols indicate observations while lines are 
model predictions.  PHYS concentrations were fit by a Michaelis-Menten kinetics model 
and ChE inhibition was fit by a pseudo-steady-state competitive inhibition model (note: 
concentrations are on a log scale) 
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Figure 5.6.-2. Inhibition of RBC AChE (left graphs, squares) and plasma BuChE (right 
graphs, triangles) by PHYS in human whole blood (top graphs), RBC suspension 
(bottom-left) and plasma (bottom-right) fit by a pseudo-steady-state competitive 
inhibition model 
 
 
Table 5.6.-1. In-vitro PK of PHYS in human whole blood, RBC suspension and plasma 
fit by a Michaelis-Menten kinetic model 
 r2 Km (%COV) vmax (%COV) CLint
  [μM] [nmol/min/ml]† [ml/min/ml] 
Whole Blood >0.99 0.021 (10) 0.00125 (6) 0.058 
RBC Suspension 0.98 0.046 (36) 0.00079 (56) 0.017 
Plasma >0.99 0.047 (13) 0.00103 (23) 0.022 
† Units of vmax is nmol of PHYS degraded per minute for each ml of plasma (whole blood, plasma) 
or nmol of PHYS degraded per minute for each ml of buffer (RBC suspension) 
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Table 5.6.-2. In-vitro PD of PHYS in human whole blood, RBC suspension and plasma 
fit by a pseudo-steady-state inhibition model 
Matrix – Substrate r2 v0 %COV Imax %COV Imax Ki  %COV
  [μmol/min/ml] ‡ [μmol/min/ml]‡ [%] [μM] 
Whole Blood – AtCh 0.94 12.7 (4) 7.5 (8) 59 0.0049 (45) 
Whole Blood – BtCh 0.98 2.6 (3) 2.2 (5) 82 0.0058 (26) 
RBC Suspension – AtCh 0.71 11.5 (12) 9.0 (16) 79 0.0056 (64) 
Plasma – BtCh >0.99 4.2 (1) 4.3 (3) 103 0.0437 (10) 
‡ Units of Imax and v0 is μmol of AtCh degraded per minute for each ml of RBC or μmol of BtCh 
degraded per minute for each ml of plasma 
 
 
PHYS was least rapidly degraded in the RBC suspension and most rapidly 
degraded in whole blood.  The vmax, the maximum degradation rate, was highest in whole 
blood, followed by plasma and lowest for RBC suspension.  The CLint, indicating the 
ability to clear PHYS at low PHYS concentrations, was highest for whole blood, 
followed by plasma and lowest for RBC suspension.  The sum of vmax by RBC 
suspension (0.00079 nmol/min/ml buffer) and one-half of plasma vmax (0.00052 
nmol/min/ml plasma) would predict the whole blood vmax (0.00131 compared to 0.00125 
nmol/min/ml plasma), i.e., whole blood degradation would consist of the RBCs at the 
same ratio as the RBC suspension, since it is already diluted to approximately the same 
proportion as whole blood (approximately 50% hematocrit), and half of the plasma (1-
hematocrit).  Comparing the relative contribution to vmax, RBCs are predicted to 
contribute approximately 60% and plasma contributes40% to the whole blood clearance 
of PHYS. 
The Km was similar in whole blood, RBC suspension and plasma.  The Km was 
approximately double in RBC suspension (0.046 μM) and plasma (0.047 μM) compared 
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to whole blood (0.021 μM), but was not statistically different from each other, suggesting 
similar affinity of PHYS for plasma BuChE and RBC AChE.   
PHYS inhibition potency for AChE was the same, regardless of the matrix.  The 
Ki values ranged from 0.0049 μM in whole blood to 0.0056 μM in RBC suspension.  
Inhibitory potency for BuChE was 10-fold lower in plasma alone compared to whole 
blood.  The Ki ranged from 0.0058 μM in whole blood to 0.044 μM in plasma.  The 
maximum inhibition was higher for AChE than for BuChE regardless or the matrix, 
whole blood, RBC suspension or plasma.  The maximum inhibition was less in whole 
blood compared to RBC suspension or plasma.  This may be due to the larger amount of 
enzymes to inhibit in the whole blood than in RBC suspension and plasma alone.   
This study shows that plasma and RBCs degrade PHYS enzymatically, following 
Michaelis-Menten kinetics and contribute approximately 60% and 40%, respectively, to 
the degradation of 0.18 μM of PHYS in whole blood.  PHYS has a similar inhibitory 
potency for RBC AChE and plasma BuChE in whole blood.  RBC AChE is inhibited 
equally potent in suspension than in whole blood, but plasma BuChE had a higher 
inhibitory potency in whole blood than plasma alone.  Inhibition was greater in RBC 
suspension and plasma compared to whole blood.  Overall, PHYS inhibited both RBC 
AChE and plasma BuChE nonselectively, with low inhibitory Ki.   
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5.7. Preliminary in-vitro Inhibition Studies of PYR, DON and GAL 
In-vitro inhibition studies in human whole blood were performed with PYR, DON 
and GAL.  The purpose of this experiment was to establish the inhibitory potency (Ki) 
assuming a competitive inhibition model.   
Whole blood was collected from the same young healthy male volunteer recruited 
in the study described in section 5.6 (Subject 1).  Whole blood was placed in an 
oscillating water bath set to 37°C and 70 rpm, and various concentrations of the inhibitors 
was added.  Table 5.7.-1 shows the in-vitro whole blood concentrations for each 
inhibitor.  These concentrations were chosen from literature values.30, 75-79  Higher DON 
concentrations were explored due to insufficient inhibition at concentrations 10-fold 
higher than the reported Ki.  For each inhibitor concentration, the activity of RBC AChE 
and plasma BuChE was measured after 30 minutes, but no more than after 60 minutes, 
after the addition of each inhibitor to ensure steady-state inhibition.  The activity was 
measured at the approximate Km substrate concentration of 75 μM for both AChE and 
BuChE.  The Km substrate concentration was chosen to decrease the amount of inhibitor 
required to over the substrate concentration.  In addition, using Km as the substrate 
concentration makes the conversion of IC50 to Ki simple, a 2:1 ratio.  The inhibition was 
fit by a steady-state competitive inhibition model using equations 1.3.4.-1b. and c. 
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Table 5.7.-1. In-vitro whole blood inhibitor concentration for the preliminary inhibition 
studies 
Initial PYR Whole Blood 
Concentrations (μM) 
Initial DON Whole Blood 
Concentrations (μM) 
Initial GAL Whole Blood 
Concentrations (μM) 
0.0010 
0.0091 
0.018 
0.091 
0.46 
0.91 
1.5 
3.0 
0.0010 
0.0057 
0.029 
0.71 
7.1 
71 
100 
1,000 
5,000 
10,000 
0.10 
0.36 
3.6 
19 
190 
850 
1,500 
4,400 
 
 
In addition to whole blood, PYR, DON and GAL were also studied in plasma, 
where the plasma BuChE inhibition was measured.  Any difference in plasma and whole 
blood inhibition may be due to RBC distribution, i.e., if whole blood requires a much 
higher concentration to achieve the same inhibition, this might indicate the inhibitor 
distributed mainly to the cytosol/membrane of RBCs.  On the other hand, if whole blood 
required a lower concentration than plasma, this would indicate the inhibitor did not 
distribute within the RBC cytosol and remained in the plasma.   
The ratio of plasma BuChE Ki to whole blood BuChE Ki would indicate the 
degree of RBC distribution.  Ratios of one indicate an even distribution between plasma 
and RBCs.  A ratio of two indicates only plasma distribution and no distribution to the 
RBCs.  Ratios less than one indicate more RBC distribution than plasma.  Very low ratios 
would indicate most of the inhibitor is located within the RBCs.   
The inhibition for RBC AChE and plasma BuChE, fit by a competitive inhibition 
model (equations 1.3.4.-1b. and c.), is shown in figure 5.7.-1.  The hashed line shows the 
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model fit for whole blood BuChE for comparison.  The model parameter fits are shown in 
table 5.7.-2. 
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Figure 5.7.-1. Results of preliminary inhibition study fit by a steady-state competitive 
inhibition model.  Hashed line is the whole blood BuChE model fit for comparison. 
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Table 5.7.-2. Results of preliminary inhibition study fit by a competitive inhibition model 
 r2  v0 (%COV) Imax (%COV) Imax Ki (%COV) 
  [μmol/min/ml] [μmol/min/ml] [%] [μM] 
   Whole Blood AChE    
PYR 0.88 5.68 (5) 4.69 (9) 82 0.07 (44) 
DON 0.9434 4.16 (3) 3.79 (6) 91 8.11 (30) 
GAL 0.8973 3.10 (3) 2.46 (9) 79 137.74 (40) 
   Whole Blood BuChE   
PYR 0.9819 2.31 (2) 2.46 (4) 107 0.20 (16) 
DON 0.9843 1.89 (1) 1.73 (3) 92 420.24 (15) 
GAL 0.9843 1.86 (1) 1.84 (5) 99 509.50 (14) 
   Plasma BuChE    
PYR 0.9877 2.24 (2) 2.45 (5) 109 0.40 (18) 
DON 0.9830 1.91 (2) 1.80 (3) 94 525.54 (13) 
GAL 0.9885 1.76 (1) 1.73 (4) 98 470.47 (11) 
 
This study showed that PYR was the most potent ChE inhibitor, but was 
nonselective.  DON was the most selective inhibitor for AChE, showing about a 50-fold 
selectivity.  GAL was moderately selective with about a 3.5-fold selectivity for AChE, 
but was the least potent inhibitor for both AChE and BuChE.   
Each of the inhibitors was able to achieve similar, almost complete maximal 
inhibition; approximately 80-90% for AChE and approximately 90-100% for BuChE.  
Even at high concentrations, the remaining residual activity in RBC was approximately 
10% to 20%.  Presumably, the residual activity in RBC is most likely due to nonspecific 
esterases in RBCs such as Esterase D.80  The residual activity in plasma was less than 
10%, indicating that plasma BuChE was able to be inhibited completely or nearly 
completely with virtually no remaining residual activity.   
Esterase D is a carboxylesterase with no known endogenous function, but has 
some activity against medications such as phenobarbital.81, 82  While classified as a 
carboxylesterase, esterase D has a similar structurally AChE, including the catalytic triad.  
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In esterase D, the Ser and His in the catalytic triad are the same as AChE, but replaces 
Glu with the Asp.  The arrangement of the catalytic triad in both enzymes are also very 
similar.83  While the Glu in AChE does not bind directly with ACh, it does stabilize the 
binding to the catalytic binding site.  Thus replacement of Glu with Asp is expected to 
decrease the affinity of ACh.  Due to similar structures, carboxylesterases and ChEs share 
similar substrate specificities.83   
Comparatively, PHYS was a nonselective inhibitor with a higher inhibitory 
potency than PYR, DON and GAL (Ki =0.005 μM for AChE and 0.006 μM for BuChE).   
The plasma BuChE Ki to whole blood BuChE Ki ratio indicate the degree of RBC 
distribution.  The Ki ratio was highest for PYR with a ratio of 2.0 indicating no RBC 
distribution.  Given that PYR is a quaternary amine, intracellular diffusion would be 
limited, thus the ratio of two is expected.  The DON ratio was 1.2 and indicates that DON 
distributes about equally within the RBC and in plasma with a slight preference for 
plasma.  The GAL ratio was 0.9 also indicating equal distribution and only slight 
preference for RBCs.   
The results of this study were used to design the mechanism of inhibition study by 
PHYS, PYR DON and GAL of RBC AChE and plasma BuChE. 
 
5.8. Full Mechanistic Inhibition Study Design  
This study was an in-vitro study in human whole blood.  Whole blood was 
collected from Subject 1 also recruited for the studies in section 5.6 and 5.7.  The whole 
blood was placed in an oscillating water bath set to 37°C and 70 rpm and various 
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concentrations of the inhibitors were added.  At various time points, the inhibition of 
AChE and BuChE was measured.   
Time-dependent inhibition, for ChE inhibitors, strongly indicate the mechanism 
of inhibition is by suicide inactivation.84  While there are other possible mechanisms for 
time-dependent inhibition, transient covalently bound intermediates to ChE are known 
and are strongly suggestive of suicide-inactivators, rather than other mechanisms.  The 
concentration-dependent rate of inactivation will be assessed as well as the steady-state 
inactivation model. 
The lack of time-dependency indicates the mechanism of inhibition is either by 
competitive inhibition, noncompetitive inhibition or mixed type.  The inhibitor- and 
substrate-concentration dependent activity will be studied to differentiate the type of 
inhibition. 
5.8.1. Mechanism of Inhibition by PHYS Study Design 
This study examined the PK/PD of PHYS at various starting concentrations to 
assess the concentration-dependent degradation of PHYS and the time- and 
concentration- dependent inhibition.  An additional young healthy male adult, Subject 2, 
was recruited for this study to assess interindividual variability.   
PHYS was added to whole blood at the start of the experiment at different starting 
concentrations of PHYS.  The concentrations are shown in Table 5.8.1-1. Blood samples 
were taken at pre-specified time points to measure RBC AChE activity, plasma BuChE 
activity and plasma PHYS concentrations until the ChE activity returned to baseline 
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levels.  Time-dependence was studied implicitly due to PHYS degradation over time as 
observed in section 5.6. 
 
Table 5.8.1-1. Initial concentrations of PHYS studied in human whole blood 
Initial PHYS Whole Blood 
Concentrations (μM) 
 
Subject 1 
Initial PHYS Whole Blood 
Concentrations (μM) 
 
Subject 2 
0.018 
0.091 
0.18 
0.27 
0.73 
0.018 
0.091 
0.18 
 
5.8.2. Mechanism of Inhibition by PYR, DON and GAL 
This study examined the concentration- and time-dependent ChE inhibition by 
PYR, DON and GAL in human whole blood.  The initial whole blood concentrations of 
PYR, DON and GAL are shown in table 5.8.2.-1.  The RBC AChE and plasma BuChE 
activities were measured at baseline, 0.5, 5, 35, 70 and 1000 min after the addition of the 
inhibitors.  The activity was measured at the following substrate concentrations for both 
AtCh and BtCh: 19, 75 and 7500 μM; corresponding to ¼x Km, 1x Km, and 100x Km, 
respectively. 
 
Table 5.8.2.-1 Whole blood concentrations of PYR, DON and GAL 
PYR Whole Blood 
Concentrations (μM) 
DON Whole Blood 
Concentrations (μM) 
GAL Whole Blood 
Concentrations (μM) 
0.00383 
0.0383 
0.383 
2.19 
25.5 
383 
1 
10 
100 
1,000 
10,000 
4 
40 
400 
4,000 
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 5.9. Results of PHYS Mechanism of Inhibition Study and In-vitro whole blood PK   
At the highest PHYS concentration of 0.73 μM, recovery of ChE activity was not 
observed within 600 minutes and a significant concentration of PHYS was remaining at 
600 minutes (0.11 μM).  Thus, the highest concentration was excluded from the PK 
analysis.  The degradation of PHYS over time in human whole blood is shown in figure 
5.9.-1.  The PHYS concentration-time profile was fit by a Michaelis-Menten PK model 
across all concentrations and the parameter estimates are shown in table 5.9.-1. 
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Figure 5.9.-1. Concentration-time profile of PHYS in human whole blood fit by a 
Michaelis-Menten kinetic model. 
 
Table 5.9.-1. Parameter estimates of Michaelis-Menten kinetic model 
  r2 vmax (%COV) Km (%COV) CLint
    [nmol/min/ml plasma] [uM] [ml/min/ml plasma] 
Subject 1 0.99 0.00134 (6) 0.021 (26) 0.0650 
Subject 2 0.97 0.00091 (8) 0.010 (14) 0.0869 
 
The two subjects showed similar kinetics.  The vmax ranged from 0.0013 to 
0.00091 nmol of PHYS degraded per minute for each ml of plasma and the Km ranged 
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from 0.021 to 0.010 μM for Subject 1 and 2, respectively.  In addition, the CLint was 
similar across the two subjects, ranging from 0.065 to 0.087 ml/min for each ml of 
plasma.  The kinetics was similar to that observed in the preliminary PK/PD described in 
section 5.6.  The Km and vmax was similar to the results in section 5.6 using a single initial 
PHYS concentration of 0.18 μM, i.e., 0.021 μM and 0.00125 nmol/min/ml plasma, 
respectively. 
Using total plasma volume in an average human (3000 ml) as a scaling factor, the 
above in-vitro clearance can be used to predict the in-vivo whole blood clearance.  Using 
this method, the in-vivo blood CLint is predicted to be 195 ml/min for Subject 1 and 261 
ml/min for Subject 2.  Comparing this to the observed plasma CLtot in humans, 
approximately 4500 ml/min, 30 whole blood seems to be responsible for only little of the 
total body clearance, approximately, 4.3% in Subject 1 and 5.8% in Subject 2; this 
suggests that PHYS is degraded in body tissues as well as hepatic metabolism.  The 
concentrations in this study are much higher than the concentrations in the in-vivo study 
where linear pharmacokinetics is observed. 
Time-dependent ChE inhibition was observed, and the lag-time to maximum 
inhibition occurred approximately 30 minutes after the addition of PHYS.  Time-
dependent inhibition suggests that the mechanism of inhibition may be by suicide 
inactivation (see Chapter 1 and equation 1.3.4.-4.29  The initial first-order inactivation 
rate constant, kobs, was estimated for each of the PHYS concentrations for the first 5-10 
minutes (i.e., the log-linear slope of the activity-time profile) and is shown in table 5.8.-2.  
The inactivation rate constant-concentration plot is shown in figure 5.8.-2.  The 
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inactivation-rate constant was fit by the suicide inactivation model to describe the 
concentration-inactivation rate relationship (equation 1.3.4.-4a.).  Due to a lack of 
sufficiently high PHYS concentrations, the inactivation model could not be fit to Subject 
2; however, the inactivation rate constants were similar to Subject 1.   
The maximum inactivation rate, kinact, for RBC AChE is 0.30 min-1 (21%) and 
0.21 min-1 (38%) for plasma BuChE.  The concentration at half of the maximum 
inactivation rate, Ki,app, for RBC AChE is 0.21 μM (52%)and 0.099 μM (126%)for 
plasma BuChE.  PHYS inhibited both AChE and BuChE rapidly and at approximately 
the same rate. 
 
Table 5.8.-2. PHYS first-order inactivation rate constants 
PHYS C0 AChE kobs BuChE kobs
[uM] [min-1] [min-1] 
  Subject 1   
0.726 0.218 0.142 
0.272 0.200 0.223 
0.182 0.119 0.159 
0.091 0.089 0.058 
0.018 0.000 0.014 
  Subject 2   
0.182 0.123 0.099 
0.091 0.057 0.077 
0.018 0.008 0.018 
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Figure 5.8.-2. PHYS concentration-dependent inactivation rate constant fit by a suicide 
inactivation rate model.  Subject 1 (left) and Subject 2 (right) 
 
After inactivation achieved pseudo-steady-state, inhibition was assessed, i.e., after 
maximum inhibition was reached.  Observed ChE inhibition and corresponding plasma 
PHYS concentrations were paired over time and plotted.  The inhibition followed a 
noncompetitive inhibition model under pseudo-steady-state conditions.  Figure 5.8.-3 
shows the inhibition fit by a pseudo-steady-state noncompetitive inhibition model and 
table 5.8.-3. shows the model parameter fits. 
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Figure 5.8.-3. PHYS pseudo-steady-state inactivation fit by a pseudo-steady-state 
noncompetitive inactivation model.  Subject 1 (top) and Subject 2 (bottom) 
 
Table 5.8.-3. PHYS pseudo-steady-state inactivation fit by a pseudo-steady-state 
noncompetitive inactivation model 
  r2  v0 (%COV) Imax (%COV) Imax Ki (%COV) 
    [μmol/min/ml] [μmol/min/ml] [%] [μM] 
        AChE         
Subject 1 0.8605 12.2 (3) 9.6 (6) 79 0.011 (27) 
Subject 2 0.8712 12.8 (3) 9.9 (10) 78 0.011 (36) 
        BuChE        
Subject 1 0.8255 3.3 (4) 3.3 (6) 99 0.023 (30) 
Subject 2 0.8303 4.4 (3) 2.9 (11) 66 0.008 (42) 
 
The PHYS induced ChE inhibition was similar between the two subjects.  PHYS 
was found to be a nonselective reversible inactivator of RBC AChE and BuChE.  The Ki 
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for AChE was 0.011 for both subjects and ranged from 0.023 to 0.008 in Subject 1 and 2, 
respectively, for BuChE.  AChE was inhibited approximately 80% for both subjects.  The 
residual activity that remained was similar to what was observed at high concentrations 
of PYR, DON and GAL.  BuChE was inhibited completely in Subject 1, similar to what 
was observed for PYR, DON and GAL, but was only inhibited maximally to 66% in 
Subject 2, indicating that a higher initial concentration may have been needed to inhibit 
BuChE completely in this subject.  The highest initial concentration in Subject 1 was 0.73 
μM while the highest initial concentration in Subject 2 was 0.18 μM. 
In conclusion, the mechanism of action for PHYS is by suicide inactivation, 
inhibiting both AChE and BuChE rapidly and with similar inhibitory potencies.  PHYS is 
able to inhibit plasma BuChE completely, but RBC AChE to only about 80%.  The 
remaining residual activity may to be due to the nonspecific esterase D found in the RBC 
cytosol.80  PHYS is rapidly degraded in human whole blood, however, this blood 
clearance only accounts for about 4-6% of the total body clearance.  The blood clearance 
follows Michaelis-Menten kinetics, however, at therapeutic concentrations, the 
concentrations are at or below the Km concentration.30, 35, 36, 43  Thus, in-vivo, only first-
order pharmacokinetics is observed for PHYS.  In addition, the pseudo-steady-state 
inhibition at physiologic concentrations is at or below the Ki concentration and thus the 
inhibition in-vivo is a linear relationship with concentration and less than 50%.30   
The results of this study matched well with in-vivo studies with PHYS.  The mean 
maximum concentration in the study by Men, where 6.7 μg/kg PHYS was given by 30 
minute IV infusion to healthy elderly adults, was 0.012 μM which resulted in an RBC 
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AChE mean maximum inhibition of approximately 20%.30  At a similar initial PHYS 
concentration, the maximum inhibition in this study was 14%.  The mean initial activity 
of ex-vivo RBC AChE was 9.3 μmol/min, compared to the in-vitro RBC AChE activity of 
12.2 to 12.8 μmol/min/ml RBC for this study.  A counter-clockwise hysteresis was 
observed for the ex-vivo inhibition of RBC AChE, indicating very little effect early in the 
study even at high concentrations followed by more effect for the same concentration.  
Inhibition by a suicide inactivator would show this kind of clockwise hysteresis since the 
maximum inhibition did not occur until about 30 minutes later, i.e., high concentrations 
initially, resulted in little effect until the lag-time was reached. 
The study by Knapp et al.35, where PHYS was given by oral sustained release 
dose to six young healthy males, achieved a Cmax of 0.004 μM which resulted in a 35% 
inhibition, after oral dosing.  A clockwise hysteresis was also reported.  This was 
explained as concentration-dependent binding to plasma proteins that they called “protein 
pools”, where high concentrations results in little binding to BuChE followed by more 
binding to BuChE at lower concentrations.  The reported concentration-dependent 
binding is probably due to time-dependent concentration changes (degradation) observed 
in the plasma protein binding experiments rather than a true concentration dependent 
binding.  The clockwise hysteresis is more satisfactorily explained by a suicide 
inactivator. 
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5.9. Results of the PYR Mechanism of Inhibition Study 
PYR showed time-dependent inhibition of both RBC AChE and plasma BuChE, 
i.e., the inhibition was not instantaneous and required a period of time to reach a steady-
state inhibition.  The inactivation was very rapid, occurring within a few minutes after the 
addition of PYR.  Figure 5.9.-1. shows the affect of PYR at different time points fit by a 
noncompetitive inhibition model for the highest  substrate concentration (7500 μM).  
Similar curves were observed at the other substrate concentrations where a proportional 
decrease in activity was observed.   
A general trend of increasing inhibition was observed.  The greatest inhibition 
was observed after 115 minutes.  This difference in inhibition is most readily observed in 
plasma, where a pronounced difference from 0.5 min to 35 min can be seen. 
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Figure 5.9.-1. PYR fit to a noncompetitive inhibition mode at different incubation times.  
Top solid line = 0.5 min; hashed middle line = 35 min; solid middle line = 70 min; 
bottom hashed line = 115 min. 
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The first-order inactivation rate constants, kobs, were estimated from the baseline 
and 0.5 min activities.  Because the inactivation rate constant is independent of the 
substrate concentration, for each PYR concentration, the rate constant at the three 
substrate concentrations (19, 75 and 7500 μM) was estimated and pooled.  Figure 5.9.-2. 
shows the PYR concentration-dependent inactivation rate constant fit by the suicide 
inactivation model (equation 1.3.4.-4a.).  Table 5.9.-1 shows the model parameter 
estimates for the suicide inactivation model.  At low concentrations, AChE is inhibited 
more rapidly than BuChE as indicated by a lower Ki,app of 0.12 μM, but at high 
concentrations, BuChE is able to inhibit more rapidly with a kinact of 6.8 min-1.  The 
inactivation-rate constant for PYR was higher than for PHYS; 4.0 min-1 compared to 0.30 
min-1 for RBC AChE, respectively, and 6.8 min-1 compared to 0.21 min-1 for plasma 
BuChE, respectively.  The difference may be due to the estimation methods of the 
inactivation rate.  Estimation of the inactivation rates for PHYS used the first 5 or10 min, 
while estimation for PYR only used the first 30 seconds.  Further, PHYS experienced 
degradation over time, while there was no evidence of degradation for PYR. 
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Figure 5.9.-2. The first-order inactivation rate constant-concentration profile fit by a 
suicide inactivation model 
 
Table 5.9.-1. PYR first-order inactivation rate constant fit by a suicide inactivation model 
 r2 kinact   Ki,app   
    [min-1] [μM] 
RBC AChE 0.83 4.0 (6.8) 0.12 (48) 
Plasma BuChE 0.95 6.8 (5.0) 4.10 (25) 
 
Steady-state inactivation was achieved within 70 minutes after the addition of 
PYR.  The percent inactivation from baseline activity for each of the three substrate 
concentrations was calculated.  The percent inactivation was fit by a steady-state EMAX 
model, where EMAX is the maximum inactivation and Ki,noncomp is the concentration at half 
maximal inactivation.  Figure 5.9.-3. shows the steady-state inactivation and table 5.9.-2. 
shows the corresponding model parameter estimates. 
For this model, Emax is analogous to Imax in the inhibition models.  PYR is a 
potent, nonselective inhibitor of both AChE and BuChE with a Ki of 0.0643 μM and 
0.036 μM, respectively.  PYR is able to inhibit plasma BuChE completely but was only 
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able to inhibit RBC AChE to about 88.3%, similar to what has been observed for the 
other inhibitors. 
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Figure 5.9.-3. PYR percent inactivation fit by an Emax model 
 
Table 5.9.-2. PYR inactivation fit by an Emax model 
 r2 Emax (%COV) Ki,noncomp (%COV) 
   [%] [μM] 
RBC AChE 0.7031 88.3 (7) 0.063 (50) 
Plasma BuChE 0.9913 95.4 (1) 0.036 (8) 
 
The results of this study shows that PYR is a suicide inactivator with rapid 
inhibition.  The inactivation rate is faster for RBC AChE at low concentrations, but faster 
for plasma BuChE at higher concentrations.  This is due to the relatively lower Ki,app for 
AChE and higher kinact for BuChE.  The first order inactivation rate for PYR was higher 
than for PHYS; however, this may be due to the availability (or lack thereof) of the early 
data points.  Steady-state inactivation is achieved rapidly and was nearly complete by 35 
minutes.  At steady-state, PYR was a nonselective inactivator for both AChE and BuChE.  
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BuChE was completely inhibited at high PYR concentrations, however, residual activity 
for RBC AChE was observed, similar to what is observed for other ChE inhibitors. 
 
5.10. Results of the DON Mechanism of Inhibition Study 
No time-dependency was observed in the inhibition of RBC AChE and plasma 
BuChE by DON, i.e., inhibition was achieved nearly instantaneous, and the inhibition 
observed at 0.5 minutes was stable for 1,000 minutes.  To assess the type of inhibition, 
the inhibitor-concentration and substrate-concentration relationship on activity was 
explored in three different inhibitor models; competitive, noncompetitive and mixed-
competitive-noncompetitive.  The model that was best able to describe the data was the 
mixed-competitive-noncompetitive inhibition model.  Figure 5.10.-1. shows the 
inhibition by DON fit by a mixed inhibition model. 
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Figure 5.10.-1. DON inhibition fit by a mixed competitive-noncompetitive inhibitor 
model 
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Table 5.10.-1. DON inhibition fit by a mixed competitive-noncompetitive inhibitor model 
  r2 Km (%COV) vmax (%COV) KIcomp (%COV) KInoncomp (%COV) 
  [μM substrate] [μmol/min/ml] [μM DON] [μM DON] 
AChE 0.91 65.8 (11) 9.0 (3) 869 (264) 119 (21) 
BuChE 0.97 99.9 (7) 4.6 (2) 995 (16) 17,000 (18) 
 
The Km and vmax in this study was similar to those measured in previous studies 
(see Chapter 4).  DON has a similar Kicomp for RBC AChE and plasma BuChE, but the 
Kinoncomp is much higher for BuChE than for AChE.  The Kinoncomp for BuChE is 
approximately 17-fold higher than for Kicomp, indicating that DON acts only very weakly 
as a noncompetitive inhibitor on BuChE.  For AChE, the Kinoncomp is approximately 7-
fold lower than the Kicomp, indicating that DON primarily acts as a competitive inhibitor 
on AChE.  At physiologic concentrations, DON is expected to primarily act as a 
noncompetitive inhibitor on AChE but a competitive inhibitor for BuChE.78, 79  This 
difference in mechanism of inhibition is what lends to DON being a selective inhibitor. 
While the models were able to adequately describe the data (r2>0.9), problems 
with the model fits and parameters were observed.  The competitive Ki for AChE was not 
well estimated with a COV of 264%.  This may be due to overparameterization of the 
model, however, the parameters were not highly correlated with each other.  Another 
problem is with the noncompetitive Ki for BuChE.  The estimate of 17,000 μM is higher 
than the highest concentration of DON studied.  Because the parameter estimate is 
beyond the concentration range studied, there is little confidence in this estimate.   
Because of the lack of confidence in the competitive Ki value for AChE and the 
noncompetitive Ki for BuChE, the full model was reduced to a noncompetitive inhibitor 
model for AChE and competitive inhibitor model for BuChE.  The model parameter fits 
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for the respective reduced models are shown in table 5.10.-2.  For AChE, the Ki,noncomp 
changed very little but for BuChE, the Ki,comp was reduced approximately 4-fold to 213 
μM.  The r2 for both fits were similar to the full models. 
 
Table 5.10.-2. DON inhibition fit by a competitive or noncompetitive inhibitor model 
  r2 Km (%COV) vmax (%COV) KIcomp (%COV) KInoncomp (%COV) 
  [μM substrate] [μmol/min/ml] [μM DON] [μM DON] 
AChE 0.9069 66.7 (11) 9.1 (3.1) -- -- 113.9 (18) 
BuChE 0.9542 91.6 (8.1) 4.5 (1.9) 212.6 (17) -- -- 
 
This study validates that DON showed no time-dependent inhibition.  Inhibition 
by DON followed a mixed-competitive-noncompetitive inhibition model.  However, due 
to a lack of confidence with this model, the models were reduced to a noncompetitive 
inhibition model for AChE and competitive inhibition model for BuChE.  While the 
relative binding affinities to AChE and BuChE are quite similar, the selective inhibition 
for AChE is due to the difference in mechanisms.  Acting as a noncompetitive inhibitor 
on AChE produces a reduced activity, regardless of the substrate concentrations.  High 
substrate concentrations are not able to overcome the inhibition by a noncompetitive 
inhibitor.  On the other hand, the degree of inhibition by a competitive inhibitor is also 
dependent on the substrate concentrations, and high substrate concentrations are able to 
overcome the inhibition by a competitive inhibitor. 
The mechanism of inhibition suggests that DON binds to both the catalytic 
binding site on ChE.  This binding has been described by molecular docking studies that 
show that DON spans from the peripheral ABS to the catalytic ABS.85  Binding to the 
peripheral ABS blocks ACh from reaching the catalytic binding site by steric blockage.20  
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In addition, spanning to the catalytic ABS blocks ACh binding to the catalytic site.  
Comparing the AChE noncompetitive and competitive Kis indicates that DON may bind 
more strongly to the peripheral ABS.  Due to the wider gorge on BuChE, binding to the 
peripheral ABS, presumably, would not lead to the steric blockade of ACh.  This may 
explain the very high noncompetitive Ki for BuChE.  Furthermore, the relatively weak 
binding to the catalytic binding site leads to weak inhibition by DON on BuChE.   
 
5.11. Results of the GAL Mechanism of Inhibition Study 
No time-dependency was observed for GAL; the inhibition was nearly 
instantaneous and was stable for up to 1,000 minutes.  In order to differentiate the 
mechanism of inhibition as competitive, noncompetitive or mixed, the inhibitor and 
substrate concentration dependency was explored in these three inhibitor models.  The 
model that best described the inhibition was a competitive inhibitor model for both RBC 
AChE and plasma BuChE.  Figure 5.11.-1 shows the inhibition fit by a competitive 
inhibitor model.  Table 5.11. shows the model parameter estimates for this model. 
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Figure 5.11.-1. GAL inhibition fit by a competitive inhibitor model 
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Table 5.11.-1. GAL inhibition fit by a competitive inhibitor model 
  r2 Km % CV vmax %CV KI %CV 
    [μM substrate] [μmol/min/ml] [μM GAL] 
AChE 0.8521 31.3 (18) 7.9 (4) 66.2 (37) 
BuChE 0.9871 91.0 (5) 4.7 (1) 358.1 (15) 
 
 
The Km and vmax in this study was similar to other studies (see section 5.10 and 
chapter 4).  The Ki for GAL in this study was estimated to be 66 μM for AChE and 358 
μM for BuChE.  GAL has a relatively low selectivity for AChE of 5.4-fold, indicating 
that GAL is only a modest selective inhibitor.  The competitive Ki in this study was 
similar to the Ki found in the preliminary study (Section 5.7), assuming a competitive 
inhibitor model; 138 μM compared to 66.2 μM for AChE and 510 μM compared to 358 
μM for BuChE.  Thus, this study, using various substrate concentrations, was able to 
confirm the results obtained in the preliminary study using a single substrate 
concentration.   
This study demonstrates that GAL is a competitive inhibitor for both RBC AChE 
and plasma BuChE.  The selectivity is modest, having approximately a 4 to 5 fold 
selectivity for AChE.  For BuChE, the competitive Ki for GAL is similar to DON.   
The mechanism of action demonstrated in this study suggests that GAL binds to 
the catalytic bind site and not to the peripheral ABS.  Molecular docking studies of GAL 
on AChE show binding to the catalytic binding site.86-88  On the other hand, GAL showed 
little affinity to the peripheral binding site in these docking studies.  Because of the well 
conserved protein structure of the catalytic regions between AChE and BuChE, binding 
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to this area may explain the low degree of selectivity, i.e., the structural similarities of the 
binding sites prevent a high degree of selectivity for AChE.   
 
5.12. Discussion of Mechanistic studies 
These studies demonstrate that PHYS was rapidly degraded in human whole 
blood; the degradation followed Michaelis-Menten kinetics.  The degradation in human 
whole blood, when scaled to total plasma volume was estimated to contribute only about 
4-6% of the total in-vivo CLtot  in humans.  The minor contribution of blood clearance to 
the total body clearance in-vivo suggests other extrahepatic metabolic pathways, 
presumably esterases in other tissues, such as the muscle, lung, heart and brain.  The 
relative contribution of RBC and plasma whole blood clearance was approximately 60% 
and 40%, respectively.  This is in line with the nonselective inhibition by PHYS and the 
mechanism of inhibition by PHYS, i.e., inhibition is due to the stable, but transient and 
reversible, intermediate formed during in the degradation process of PHYS. 
The mechanism of ChE inhibition for PHYS was suicide inactivation.  The 
inhibition requires the catalytic conversion of PHYS to a stable, covalently bound, 
intermediate, the carbamolyated enzyme complex.84  Formation of this carbamolyate-
enzyme complex is time-dependent, but rapid.  ChE is inactive while carbamolyated and 
cannot degrade further bind substrate or PHYS.  Recovery of ChE by decarbamolyation 
on the enzyme is relatively rapid, and occurs rapidly enough to be observed in this study 
(see figure 5.3.-1.). 
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The mechanism of inhibition for PYR was also suicide inactivation.  PYR forms a 
stable carbamolyate-enzyme complex84 that is time-dependent but very rapid, and more 
rapid than PHYS, however, decarbamoylation occurs relatively slow for PYR and even 
after 1,000 minutes, recovery of ChE activity is not observed.  This indicates that the 
decarbamolyation/recovery of ChE is sufficiently slow that the concentration of PYR is 
not affected significantly enough to change the degree of inactivation after 1,000 minutes 
in-vitro. 
Inhibition by DON is by noncompetitive inhibition for RBC AChE and 
competitive inhibition for plasma BuChE.  Presumably, inhibition of RBC AChE is due 
to binding to the peripheral ABS, causing steric hindrance for the substrate to reach the 
catalytic region; inhibition of plasma BuChE is due to binding to the catalytic ABS and 
competing with substrate for binding.  This type of interaction is speculative, however, is 
supported by molecular docking studies that confirm this type of interaction.20, 85  These 
molecular docking studies where performed with murine AChE structures and may 
confound the results, but the structure is expected to be close enough to be extrapolated to 
human AChE. 
Inhibition by GAL is by competitive inhibition for both RBC AChE and plasma 
BuChE.  Presumably, inhibition is due to competition of GAL and the substrate for 
binding to the catalytic region.  This type of interaction is supported by the molecular 
docking studies that show the binding of GAL to AChE.  The molecular docking studies 
were performed with torpedo californica (pacific electric ray) AChE structure.86-88  There 
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is greater difference between t. californica and human AChE than there is murine AChE 
but the catalytic binding site is expected to be similar enough to generalize to humans. 
The results of these studies were used to design a laboratory experiment for the 
effects of age on sensitivity to these ChE inhibitors.  By understanding the mechanism of 
inhibition for each of the inhibitors, the study design should be able to differentiate a 
mechanism-based sensitivity difference. 
148 
 
 
 
 
Chapter 6 
Age-related Differences in In-vitro Sensitivity to Cholinesterase 
Inhibition 
 
6.1. Introduction 
The objective of this clinical study was to evaluate any age-related differences in 
sensitivity to the inhibition of human RBC AChE and plasma BuChE by PHYS, PYR, 
DON and GAL.  A group of healthy young and elderly volunteers were recruited for 
participation into this study.  The volunteers were asked to donate blood.  The whole 
blood was exposed to various concentrations of each inhibitor, and the in-vitro inhibition 
of RBC AChE and plasma BuChE was measured.  The inhibition was fit by various 
models, as discussed in chapter 5.  Using the models, the sensitivity to each inhibitor was 
compared between the two age groups.   
Two markers of in-vitro sensitivity were used: The Ki values, namely the inhibitor 
concentration that inhibits ChE by 50%, and a linear sensitivity model.  High Ki values 
indicate a high concentration is required to inhibition to 50% (low sensitivity), while a 
low Ki value indicates a low concentration is required to inhibit to the same extent (high 
sensitivity). The IC50 and Ki values as a marker of sensitivity has some precedent in 
AChE inhibition by carbamates and organophosphates.89, 90  This marker as also been 
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used in other pharmacological agents and represents a left or right shift in the effect 
curves. 
The linear sensitivity model was the original model that suggested an age-related 
difference in PHYS sensitivity during the meta-analysis (see Chapter 1).  The linear 
sensitivity model was used in this study as a marker for sensitivity to PHYS.  This model 
is an observational, less model-dependent and arguably, a more direct measurement of 
sensitivity.  In this model, the change in inhibition for an accompanying inhibitor 
concentration change was used as a measure of sensitivity and was estimated by slope of 
inhibition and concentration.  For this model, concentrations below the Ki value were 
used, since this is the expected linear sensitivity range; inhibitor concentrations above Ki 
are expected to result in a hyperbolic inhibition relationship.  This model was used in the 
study by Men30 and in Chapter 1; in this study a comparison to both is made. 
 
6.2. Specific Aims 
The specific aims of this study were to: 
1. Conduct a clinical study with young and health volunteers designed to study the 
in-vitro sensitivity to PHYS, PYR, DON and GAL. 
2. Model the inhibition of RBC AChE and plasma BuChE by PHYS, PYR, DON 
and GAL using the validated mechanistic PK and PD models. 
3. Evaluate model-dependent and model-independent methods of assessing in-vitro 
sensitivity to cholinesterase inhibition. 
4. Evaluate any age-related differences in sensitivity statistically. 
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 6.3. Study Design 
This study was a prospective clinical study with healthy young and elderly 
volunteers to evaluate the age-related differences in in-vitro sensitivity of RBC AChE 
and plasma BuChE to inhibition to PHYS, PYR, DON and GAL.   
Potential volunteers underwent a telephone health screening to assess their 
possible inclusion to the study.  Each potential volunteer had to be free of any major 
illness, such as cancer or infectious diseases.  Chronic health conditions, such as 
hypertension, must have been controlled by life-style modification or by medications not 
thought to affect ChE activity.  To qualify as young, the potential volunteer had to be at 
least 18 years old but not more than 30 years old; to qualify as elderly, the potential 
volunteer had to be at least 65 years old, no upper age limit was placed.  The gender in 
each age group was balanced (5M/5F).  The potential volunteer was invited to an out-
patient screening visit if found to meet these qualifications. 
The outpatient screening visit including evaluation of clinical labs, (i.e., serum 
electrolytes, liver metabolic panel, urinalysis for drugs of abuse, if of child bearing 
potential, urine pregnancy test) medical history, Mini-Mental State Examination and vital 
signs.  All tests must be considered clinically normal, and females had to be non-
pregnant.  If all tests were within acceptable criteria, the eligible volunteer was invited to 
participate in the study. 
On the day of the second visit, each eligible volunteer was asked to fast, other 
than water, at least four hours before visit.  If not possible, the subject was asked to limit 
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the food intake.  On the day of the visit, the subject was administered an entry probe 
questionnaire to assess for any changes in health status and medications and the vital 
signs for each subject was taken.  Each subject donated approximately 170 ml blood by 
venous puncture of the antecubital vein.  The blood was collected in seventeen 10 ml 
sodium heparin vacutainer tubes.  The tube were immediately placed on ice and stored at 
4°C until studied.   
All subjects were discharged after allowed to rest and have a light snack, juice, 
coffee or tea.  All subjects could ambulate without assistance and had no signs and 
symptoms of hypotension (e.g., dizziness, lightheadedness). 
 
6.4. Study Subjects  
Although this was a pilot study, a power analysis was performed to prospectively 
estimate the number of subjects required to show a meaningful difference in in-vitro ChE 
inhibitor senstivity.  The observed sensitivity in the healthy young study by Knapp et al. 
was estimated as 27 %/(ng/ml)35 while the observed sensitivity in the healthy elderly 
study by Men was estimated as 12 %/(ng/ml)30.  The sample size necessary to detect a 
similar difference (α = 0.05, β = 0.20, σ = 75% COV, δ = 12 %/(ng/ml) for a two-sided 
test) is at least ten (10) for each group.  Thus, ten young and ten elderly subjects were 
planned for recruitment. 
Volunteers were recruited from the greater Richmond metropolitan area by 
advertisements on bulletin boards and by an advertisement in the Mature Life newsletter, 
a newsletter by the nonprofit organization Senior Connections.  A total of twenty 
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volunteers were screened at an out-patient visit; one young volunteer was removed from 
the study due to obesity.  Nineteen subjects completed the study, including ten young 
subjects (five males, five females) and nine elderly subjects (four males, five females).  
Table 6.4.-1. shows the demographics and basic health and medication information of the 
subjects included in the study.  Subject numbers 001-010 were healthy young adults; 
numbers 011-019 were healthy elderly adults.  Table 6.4.-2 shows the clinical and 
laboratory findings for each subject. 
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Table 6.4.-1. Demographic and Basic Health and Medical Information 
Subject  Age  Sex Race Age Weight Height 
No. of 
Medications/ Current Medical 
  Group      [years] [kg] [cm] last 30 days Conditions 
001 Young F White 28 60.0 164 1 n/r 
002 Young M Black 18 66.6 174 0 n/r 
003 Young M White 22 77.8 185 1 n/r 
004 Young M Asian 27 92.5 178 0 n/r 
005 Young M White 30 76.9 168 0 n/r 
006 Young F Black 19 70.0 170 2 n/r 
007 Young F White 25 88.8 175 2 n/r 
008 Young F Asian 26 57.0 157 1 n/r 
009 Young F White 22 68.6 174 2 ADHD 
010 Young M White 26 76.9 183 2 n/r 
Mean     24 73.5 173 1.1  
SD   3.9 11.4 8.5 0.9  
25% Quartile   22 67.1 169 0  
Median   26 73.5 174 1  
75% Quartile     27 77.6 177 2  
011 Elderly M White 66 82.1 178 1 n/r 
012 Elderly M White 82 92.1 174 1 CVD, BPH, glaucoma 
013 Elderly F White 70 93.0 187 3 RA, OP 
014 Elderly F White 76 58.5 162 6 CVD, OP, UI 
015 Elderly F White 72 75.2 162 1 CVD 
016 Elderly M White 67 110.7 176 3 CVD 
017 Elderly F White 66 77.3 168 4 CVD, Depression 
018 Elderly F White 66 74.5 166 4 CVD, BPH, Hypothyroid 
019 Elderly M White 68 80.7 176 3 Depression, RA 
Mean     70 82.7 172 2.9   
SD   5.5 14.7 8.3 1.7  
25% Quartile   66 75.2 166 1  
Median   68 80.7 174 3  
75% Quartile     72 92.1 176 4   
CVD, Cardiovascular Disease; BPH, Benin Prostatic Hypertrophy; RA, Rheumatoid Arthritis; OP, 
Osteopenia/Osteoperosis; UI, Urinary Incontinence; ADHD, Attention Deficient Hyperactivity 
Disorder; n/r, none reported 
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Table 6.4.-2. Clinical and Laboratory Findings 
Subject  MMSE SBP Avg HCT ALBU BUN Cr CLCr AST ALT 
    [mm Hg] [%] [mg/dl] [mg/dl] [mg/dl] [ml/min] [U/l] [U/l] 
1 30 109 37.8 4.2 17 0.7 117 16 12 
2 26 111 45.6 4.5 12 1.1 107 38 36 
3 30 118 44.2 4.8 17 1.1 115 19 16 
4 29 123 40.2 4.2 10 0.8 150 26 36 
5 30 138 42.4 4.7 12 1.0 117 23 34 
6 26 121 37.1 4.5 12 0.8 123 28 17 
7 30 125 35.3 4.0 13 0.8 150 24 25 
8 27 109 39.7 4.3 12 0.7 105 18 15 
9 30 110 34.1 3.8 13 0.8 124 22 21 
10 30 127 43.5 4.2 14 0.9 135 21 16 
Mean 29 119 40.0 4.3 13 0.9 129 24 23 
SD 1.8 9.5 3.9 0.3 2.3 0.1 25.6 6.3 9.3 
25% Quartile 28 110 37.3 4.2 12 0.8 115 20 16 
Median 30 119 40.0 4.3 13 0.8 120 23 19 
75% Quartile 30 124 43.2 4.5 14 1.0 132 26 32 
11 28 141 41.7 4.1 21 1.0 89 22 19 
12 29 160 42.5 4.5 18 1.1 70 14 14 
13 30 143 39.2 4.1 20 0.7 105 69 49 
14 30 143 34.7 4.1 25 1.0 44 29 27 
15 29 130 39.8 4.6 22 0.9 67 34 34 
16 30 161 40.5 4.8 23 0.9 121 33 42 
17 30 154 38.0 4.4 15 0.8 84 20 23 
18 27 136 42.7 4.3 19 0.7 89 19 24 
19 28 120 37.4 3.9 13 0.8 102 21 21 
Mean 29 143 39.6 4.3 20 0.9 85.8 29 28 
SD 1.1 13.6 2.6 0.3 3.8 0.1 23.0 16.4 11.4 
25% Quartile 28 136 38.0 4.1 18 0.8 70.0 20 21 
Median 29 143 39.8 4.3 20 0.9 88.8 22 24 
75% Quartile 30 154 41.7 4.5 22 1.0 102.2 33 34 
MMSE = Mini-Mental State Exam 
SBP = Systolic Blood Pressure; averaged from the two first visits 
HCT = Hematocrit 
ALBU = Serum albumin  
BUN = Blood urea nitrogen 
Cr = Creatinine 
CLCr = Creatinine clearance, calculated by the Cockroft-Gault equation 
AST = Aspartate Aminiotransferase 
ALT = Alanine Aminotransferase 
 
 
The various laboratory tests demonstrate different aspects of the volunteer’s 
health status.  The systolic blood pressure (SBP) was measured by brachial arterial 
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pressure by automated electronic sphygmomanometer and indicates the degree of cardiac 
disease.  The HCT is measured by capillary centrifugation and is measured as the percent 
of packed RBC in whole blood.  Albumin (ALBU) is measured by spectrophotometry 
and is decreased in poor nutritional states and severe liver disease.  Blood urea nitrogen 
(BUN) is determined enzymatically and is produced in the liver and eliminated by the 
kidney, thus can indicate renal disease and severe liver disease.  Creatinine is measured 
enzymatically and is produced by muscles and eliminated by the kidney, thus, indicates 
renal disease but can be lower due to lower muscle mass.  The creatinine clearance (CLCr) 
esimates the glomaular filtration rate, is a measure of renal function and is calculated 
from the Cockroft-Gault equation shown below: 
Cr
WeightAgeCLCr *72
*)140( −=  
AST and ALT are intracellular enzymes and are shown measured by their 
activity.  AST and ALT are indicative of hepatic damage but are nonspecific, however, 
ALT is a more selective hepatic enzyme than AST. 
A statistical analysis of the demographic and clinical findings was performed, and 
the result shown in table 6.4.-3.  The males subjects had a statistically higher weight and 
height than the females.  The elderly subjects had a higher systolic blood pressure.  There 
was also a gender difference in the hematocrit; females had a statistically lower 
hematocrit than males.  A group interaction was also observed for hematocrit; when 
further analyzed by Tukey’s HSD, the difference was observed to be between the young 
males (46%) and young females (37%).  The elderly males and females showed no 
statistical difference in hematocrit and the elderly and young groups were not statistically 
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different.  The BUN and CLCr was statistically different for the two age groups.  
Creatinine was statistically lower for females compared to males.  All of these differences 
were expected, reflecting physiologic differences between the genders or physiologic 
changes due to age.   
The two age groups were not statistically different by weight, height, and 
hematocrit.   
 
Table 6.4.-3. Statistical analysis of demographic and clinical findings 
Demographic p-value* 
Weight S p=0.0384 
Height S p=0.0307 
SBP A p=0.0005 
Hct S p=0.0023, S*A p=0.0469 
Album NS 
BUN A p=0.0008 
Cr S p=0.0048 
CLCr A p=0.0022 
AST NS 
ALT NS 
MMSE NS 
*A, p-value for differences in Age groups; S, p-value for differences in gender; S*A p-value for an 
interaction between the factors; NS, not significant 
 
6.5. Adverse Effects  
No subject experienced AEs severe enough to withdraw from the study.  The most 
common AE experienced was pain associated with the blood draw.  One subject reported 
bruising of the IV sampling site during a follow up call. 
One young subject became dizzy during the course of the blood draw; the blood 
draw was stopped and the subject was allowed to rest.  The draw was continued with no 
further complaints.   
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Three subjects, two young and one elderly, required a second venous puncture to 
complete the blood draw. 
Other than bruising, no other AE was reported upon a telephone or e-mail follow 
up approximately one week after the second visit. 
 
6.5. Laboratory Protocol  
Immediately upon blood draw, the laboratory procedures for the in-vitro ChE 
inhibition sensitivity testing were started.  Until ready to be studied, the blood was stored 
at 4°C.  Each inhibitor exhibited different in-vitro inhibitor properties.  The laboratory 
protocols were designed to explore these properties to test for sensitivity differences.  All 
in-vitro studies were finished within 72 hours after the blood collection. 
6.5.1. Materials and Regents  
The materials and regents were previously described in Chapter 3 and Chapter 4 
with the following additions: 
Donepezil (DON as free base; MW = 379.50 D; Bosche Scientific, New 
Brunswick NJ) 
Galantamine hydrogen bromide (GAL; MW = 374.31 D; Bosche Scientific; New 
Brunswick NJ) 
6.5.2. Equipment  
The equipment was the same as described in Chapter 3 and 4. 
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6.5.3. Solution Preparation   
The solution preparation was the same as described in Chapters 3 and 4 with the 
following additions: 
PYR preservative solution (5 mg/ml; 18.2 mM) was prepared by weighing 5 mg 
of PYR bromide into 1 ml of PBS. 
PHYS stock solution (3.63 mM; 1mg/ml) was prepared by weighing 1.5 mg of 
PHYS salicylate into 1 ml PBS.   
PHYS solution A (36.3 μM; 10 μg.ml) was prepared by pipetting 10 μl of PHYS 
stock solution into 990 μl of PBS. 
PYR Stock (100 mM) was prepared by weighing 261.1 mg PYR Br into 10 ml 
PBS 
PYR Solution A (1,000 μM) was prepared by pipetting 10 μl of PYR Stock into 
990 μl of PBS 
PYR Solution B (100 μM) was prepared by pipetting 10 μl into of PYR Solution 
A into 990 μl of PBS 
DON Stock (167,000 μM) was prepared by weighing 189.75 mg DON into 2.8 ml 
nanopure water with 200 μl phosphoric acid (total volume of 3 ml). 
DON Solution A (1,670 μM) was prepared by pipetting 10 μl of DON Stock into 
990 μl PBS 
GAL Stock (100,000 μM) was prepared by weighing 36.8 mg of GAL HBr into 1 
ml PBS 
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GAL Solution A (1,000 μM) was prepared by pipetting 10 μl of GAL Stock into 
990 μl PBS 
6.5.4. Cholinesterase Inhibitor Registry 
During the informed consent process, permission was sought from each subject to 
participate in a ChE Inhibitor Registry.  Participation in the registry allowed for a portion 
of the blood collected to be used for future studies associated with AD or ChE inhibitors.   
All subjects agreed to participate, however, several subjects requested to be 
contacted before inclusion in such studies. 
At least 10 ml of blood was centrifuged at 5,000 rpm for 10 minutes.  The plasma 
was removed to a second tube and both tubes were labeled with the study title, subject 
number, gender and age.  The samples were immediately placed in the -70°C freezer.  
Access to registry samples was limited to IRB-trained, approved study personnel only. 
6.5.5. RBC AChE Kinetics in Human RBC and Plasma BuChE Kinetics in Human 
Plasma; Determination of Subject Specific Km and vmax
The RBC AChE and plasma BuChE activity profiles were determined for each 
subject.  This was used to determine if there were baseline differences in activity and 
kinetics between the groups.  In addition, several studies require the determination of Km 
for the calculation of Ki from IC50 values.  The initial reaction velocity of RBC AChE 
and plasma BuChE was measured, in triplicate, as described in chapter 4.  The 
concentrations of AtCh and BtCh were: 10, 30, 100, 300, 1000, 3000 μM; additional 
concentrations were tested, if necessary to characterize the activity profile.   
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Whole blood (1 ml) was centrifuged at 5,000 rpm for 3 minutes.  Plasma (60 μl) 
was placed in 600 μl of PBS and vortexed for 10 seconds to make a dilute plasma 
solution; RBC (10 μl) was pipetted with a positive displacement pipette into 600 μl of 
PBS and vortexed for 10 seconds to make a dilute RBC suspension. 
Table 6.5.5.-1. shows the volume of AtCh and BtCh solution and PBS solution 
that should be added to each 1 ml cuvette to achieve the desired concentration.  The 
reagents are added in the following order:  
1) PBS,  
2) 25 μl DTNB,  
3) 25 μl of dilute RBC suspension or dilute plasma solution 
4) AtCh or BtCh solution to start the reaction 
5) Record the increase in product formation at 410 nm for 4 minutes 
 
Table 6.5.5.-1. Conditions for determination of subject specific Km and vmax  
Final AtCh or BtCh 
Concentration 
[μM] 
AtCh A or  
BtCh A 
[μl] 
AtCh B or  
BtCh B 
[μl] 
AtCh C or  
BtCh C 
[μl] 
PBS 
[μl] 
10,000* 100*   850 
3,000 30 - - 920 
1,000 - 100 - 850 
300 - 30 - 920 
100 - - 100 850 
30 - - 30 920 
10 - - 10 940 
*BtCh only (AtCh caused substrate inhibition) 
 
The activity is estimated by the slope of the absorbance-time profile (units: 
Abs/sec).  Using equation 6.5.5.-1. converts the units to μmol/min/ml RBC or plasma. 
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DFml
cmMAbs
Absslopeactivity *
min
sec60*1000*
*13600
sec]/[
11 −−=  <Equation 6.5.5.-1.> 
The dilution factor (DF) is for 2400 for RBC 
The dilution factor is 400 for plasma 
The activities for this study was fit by a Michaelis-Menten model to estimate the 
subject specific Km and vmax (see equation 1.3.3.-1a.). 
The model-estimated parameters were compared using a two-factor ANOVA 
using age group and gender as factors to assess for baseline differences.  Statistical 
significance was determined at p < 0.05. 
6.5.6. Inhibition of RBC AChE and Plasma BuChE by Physostigmine 
As determined in Chapter 5, PHYS is a suicide inactivator that is unstable in 
whole blood.  This procedure simultaneously measures the plasma concentration of 
PHYS, RBC AChE activity and plasma BuChE activity for approximately 360 minutes.  
The initial PHYS concentration was 0.363 μM (100 ng/ml).  At this concentration, PHYS 
would be able to maximally inhibit both RBC AChE and BuChE, but allowed for 
recovery within approximately 400 minutes. 
Whole blood (80 ml) was placed in a flask on an oscillating water bath at 37°C at 
100 rpm and allowed to equilibrate.  A 5 ml baseline sample was taken for measurement 
of plasma PHYS concentration, RBC AChE activity and plasma BuChE activity by the 
following procedure: 
1. 5 ml of blood were centrifuged at 5,000 rpm for 2 minutes 
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2. 60 μl of plasma was placed in 600 ml PBS to make a dilute plasma 
solution 
3. The remaining plasma was transferred to a 15 ml polypropylene tube 
with 25 μl of PYR preservative solution and placed at -70°C for future 
analysis of PHYS concentration. 
4. 10 μl of packed RBC was placed in 600 ml of PBS to make a dilute RBC 
suspension 
5. RBC AChE and plasma BuChE activity was measured using 1,000 μM 
AtCh and 10,000 BtCh, respectively.    
To start the study, PHYS solution A (750 μl, 36.3 μM) was added to the blood (75 
ml remaining after taking the baseline sample) and mixed well.  At the following time 
points, 5 ml of blood was taken to measure plasma PHYS, RBC AChE activity, plasma 
BuChE activity by the procedure outlined for the baseline measurement outlined above: 
0.5, 5, 10, 30, 60, 105, 150, 195, 240, 300, 360 and 420 minutes.  The RBC AChE and 
plasma BuChE activity was measured in real-time, i.e., within 5 minutes after the sample 
collection; the plasma PHYS was stored at -70°C for future analysis. 
Additional samples may have been taken at hourly intervals, as necessary if the 
ChE activity had not returned to within 10% of baseline activity. 
The plasma PHYS concentrations vs time profiles were fit by a Michaelis-Menten 
kinetic model.  The pseudo-steady-state ChE activity was fit by a noncompetitive 
inhibition model.   
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In addition, a linear sensitivity model was used to estimate in-vitro sensitivity.  
The activity and concentrations below the model estimated Ki,pss values was used to 
estimate a slope.  This slope is the sensitivity to PHYS with units of activity (i.e., 
μmol/min/ml RBC or plasma) per concentration (i.e., ng/ml) and estimates the change in 
activity for a change in concentration.  This was divided by the baseline activity to 
convert the activity to %/ng/ml.   
The model-estimated parameters (vmax, Km, CLint, v0, Ki,pss, Imax and duration of 
inhibition) and the linear sensitivity model were compared using a two-factor ANOVA 
using age group and gender as factors.  Statistical significance was determined at p < 
0.05. 
6.5.7. Inhibition of RBC AChE and Plasma BuChE by Pyridostigmine 
PYR is a suicide inactivator that is stable in human blood.  PYR concentrations 
between 0.1 to 100 μM was evaluated for the rate of inactivation and the degree of 
steady-state inactivation.   
The following procedure was followed: 
1. 3.6 ml of blood was placed in a 15 ml tube and placed in a water bath 
(37°C, 100 rpm) and allowed to equilibrate 
2. 600 μl of blood was take to measure baseline activity of RBC AChE and 
plasma BuChE at the Km concentration for the subject 
3. PYR was added to the blood 
a. 0.1 μM PYR concentration was prepared by pipetting 30 μl PYR B 
into the 3 ml of blood 
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b. 1 μM PYR concentration was prepared by pipetting 300 μl PYR B 
into the 3 ml of blood 
c. 10 μM PYR concentration was prepared by  pipetting 30 μl PYR A 
into the 3 ml of blood 
d. 100 μM PYR concentration was prepared by pipetting 300 μl PYR 
A into the 3 ml of blood 
4. At the following time points, 600 μl of blood was collected to measure the 
RBC AChE and plasma BuChE activity at the Km concentration for the 
subject: 0.5, 5, 10 and >180 minutes. 
The first-order inactivation rate constant was estimated for the 10 minutes for 
PYR concentrations of 0.1 to 10 μM, and 5 minutes for the PYR concentration of 100 
μM.  The inactivation rate constant was fit by a suicide inactivator model.  
The steady-state inactivation, i.e., the inhibition after at least 180 minutes, was fit 
by a noncompetitive inhibition model. 
The model-estimated parameters (kinact, Ki,app, Imax,Ki,ss)  were compared using a 
two-factor ANOVA using age group and gender as factors.  Statistical significance was 
determined at p < 0.05. 
6.5.8. Inhibition of RBC AChE and Plasma BuChE by Donepezil 
DON is a noncompetitive inhibitor for RBC AChE and a competitive inhibitor for 
plasma BuChE activity.  The substrate and inhibitor concentration dependency was 
studied.  
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Five 1 ml aliquots of blood were placed into tubes.  Into each tube DON was 
added for various concentrations ranging from 50 μM to 30,000 μM: 
a. 50 μM was prepared by 30 μl DON solution A to 1 ml blood 
b. 100 μM was prepared by adding 60 μl DON solution A to 1 ml blood 
c. 1,000 μM was prepared by adding 6 μl DON stock to 1 ml blood 
d. 10,000 μM was prepared by adding 60 μl DON stock to 1 ml blood 
e. 30,000 μM was prepared by adding 180 μl DON stock to 1 ml blood 
The blood samples were placed in the oscillating water bath (37°C, 100 rpm) until 
equilibrated.  The blood samples were analyzed for RBC AChE activity and plasma 
BuChE activity at various substrate concentrations ranging from 20 to 15,000 μM.  At the 
lowest DON concentration, 50 μM, only AChE activities were measured and at the 
highest concentration, 30,000 μM, only BuChE activities were analyzed.  The activity 
was measured by the procedure described in section 6.5.4; table 6.5.8.-1. shows the 
preparation of each concentration in addition to the 25 μl DTNB and 25 μl of dilute RBC 
suspension or dilute plasma solution. 
 
Table 6.5.8.-1. Measurement of RBC AChE and plasma BuChE activity in the presence 
of DON  
Final AtCh 
or BtCh 
[μM] 
AtCh A or 
BtCh A 
[μl] 
AtCh B or 
BtCh B 
[μl] 
AtCh C or 
BtCh C 
[μl] 
PBS 
[μl] 
15,000 150 - - 800 
7,500 75 - - 875 
750 - 75 - 875 
75 - - 75 875 
20 - - 20 930 
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The RBC AChE activity for the inhibitor and substrate concentrations were fit by 
a noncompetitive inhibition model; the plasma BuChE activity for the inhibitor and 
substrate concentrations was fit by a competitive inhibition model. 
The model-estimated parameters (Ki,comp, Ki,noncomp, Km, Imax)were compared using 
a two-factor ANOVA using age group and gender as factors.  Statistical significance was 
determined at p < 0.05. 
6.5.9. Inhibition of RBC AChE and Plasma BuChE by Galantamine 
GAL is a competitive inhibitor for both RBC AChE and plasma BuChE.  The 
inhibition was measured at a single substrate concentration, the Km concentration for each 
subject. 
Four 1 ml aliquots of blood were placed in tubes and equilibrated on a waterbath 
(37°C, 100 rpm).  Into each tube, GAL was added to each for various GAL 
concentrations ranging from 10 to 10,000 μM.   
a. 10 μM was prepared by 10 μl GAL Solution A to 1 ml blood 
b. 100 μM was prepared by adding 100 μl GAL Solution A to 1 ml blood 
c. 1,000 μM was prepared by adding 10 μl GAL Stock to 1 ml blood 
d. 10,000 μM was prepared by adding 100 μl GAL Stock to 1 ml blood 
The RBC AChE and plasma BuChE activity was measured in triplicate at the Km 
concentration for the subject.  The activity was fit by a competitive Imax inhibition model. 
The model-estimated parameters (v0, Imax, Ki,comp) were compared using a two-
factor ANOVA using age group and gender as factors.  Statistical significance was 
determined at p < 0.05. 
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 6.6. Results 
6.6.1. RBC AChE Kinetics in Human RBC and Plasma BuChE Kinetics in Human 
Plasma – Km and vmax  
Figure 6.6.1.-1 shows the kinetics of RBC AChE in human blood from a 
representative individual, fit by a Michaelis-Menten model.  The parameter fits for each 
individual is shown in table 6.6.1.-1.  In this table, the geometric mean, standard 
deviation, median and 25th and 75th quartile for each group is also shown.   
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Figure 6.6.1.-1. RBC AChE kinetics fit by a Michaelis-Menten model from a 
representative subject (Subject 001) 
 
168 
Table 6.6.1.-1. RBC AChE kinetics fit by a Michaelis-Menten model  
Subject r2 vmax (%CV) Km (%CV) CLint
    [μmol/min/ml] [μM] [μl/min/ml plasma] 
      AChE      
001 0.89 12.1 (5) 60.3 (22) 201 
002 0.87 12.6 (5) 46.2 (24) 273 
003 0.92 9.5 (6) 119.8 (23) 79 
004 0.93 10.2 (5) 159.8 (21) 64 
005 0.92 10.8 (6) 62.7 (14) 172 
006 0.91 11.3 (5) 110.5 (24) 102 
007 0.98 10.8 (2) 59.9 (10) 181 
008 0.87 9.4 (5) 45.3 (23) 207 
009 0.98 10.2 (2) 71.8 (10) 142 
010 0.94 10.3 (3) 55.4 (16) 187 
Geo Mean   10.7   72.5   147 
Geo SD   1.10  1.53  1.6 
25% Quartile  10.2  56.5  112 
Median  10.6  61.5  176 
75% Quartile   11.2   100.8   197 
011 0.89 11.1 (6) 91.8 (25) 121 
012 0.99 13.1 (2) 78.5 (9) 166 
013 0.89 11.2 (5) 66.7 (24) 167 
014 0.97 11.0 (3) 63.3 (11) 174 
015 0.92 10.2 (5) 113.2 (21) 90 
016 0.96 9.6 (3) 84.4 (15) 114 
017 0.98 12.1 (2) 52.0 (10) 233 
018 0.88 10.1 (8) 62.5 (29) 162 
019 0.91 12.7 (5) 61.2 (21) 204 
Geo Mean   11.2   75.2   157 
Geo SD   1.10  1.28  1.3 
25% Quartile  10.4  62.7  131 
Median  11.1  72.6  167 
75% Quartile   11.9   90.0   192 
 
The goodness of fits were 0.87 or above.  There was no statistical difference in 
Km, vmax, and CLint between the two age groups and genders.  The geometric mean for 
vmax in the young group was 10.7 μmol/min/ml RBC (± 10%) and was 11.2 μmol/min/ml 
RBC (± 10%) for the elderly group.  The vmax ranged from 9.4 to 13.1 μmol/min/ml RBC, 
only approximately a 30% difference in the entire range.  The geometric mean for Km in 
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the young group was 72.5 μM (± 53%) and 75.2 (± 28%) μM in the elderly group.  The 
Km ranged form 45.3 to 160 μM, approximately a 3.5-fold range.  The CLint geometric 
mean for the young and elderly groups was 147 (± 59%) and 157 μl/min/ml RBC (± 
34%), respectively, and ranged from 64 to 273 μl/min/ml RBC, about a four-fold range. 
The vmax showed very little difference across all subjects.  This suggests that RBC 
AChE activity is very well conserved across the patients in this study.  Little 
polymorphisms have been reported for AChE, due to its vital function to life.91  The 
known polymorphisms resulted in phenotypically conservative substitutions. 
Figure 6.6.1.-2 shows the kinetics of RBC AChE in human blood from a 
representative individual fit by a Michaelis-Menten model.  The parameter fits for each 
individual is shown in table 6.6.1.-2.  In this table, the geometric mean, standard 
deviation, median and 25th and 75th quartile for each group is also shown.   
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Figure 6.6.1.-2. Plasma BuChE kinetics fit by a Michaelis-Menten model from a 
representative subject (Subject 001) 
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Table 6.6.1.-2. Plasma BuChE kinetics fit by a Michaelis-Menten model  
Subject r2 vmax (%CV) Km (%CV) CLint
    [μmol/min/ml] [μM] [μl/min/ml plasma] 
   BuChE    
001 0.95 3.8 (3) 106 (15) 35.9 
002 0.83 4.3 (5) 113 (21) 37.9 
003 0.83 4.4 (5) 95 (29) 46.3 
004 0.93 5.7 (3) 140 (18) 40.7 
005 0.92 5.7 (4) 141 (26) 40.1 
006 0.89 3.1 (4) 116 (24) 26.7 
007 0.90 3.5 (3) 78 (19) 44.5 
008 0.86 3.9 (4) 114 (24) 33.9 
009 0.92 4.3 (3) 147 (18) 29.6 
010 0.95 7.6 (3) 180 (16) 42.2 
Geo Mean   4.5   120.0   37.3 
Geo SD   1.31  1.27  1.19 
25% Quartile  3.8  108  34.4 
Median  4.3  115  39.0 
75% Quartile   5.3   141   41.8 
011 0.92 5.4 (3) 119 (18) 45.1 
012 0.97 4.3 (3) 247 (13) 17.5 
013 0.93 4.2 (3) 125 (18) 33.4 
014 0.95 6.4 (2) 112 (14) 57.5 
015 0.92 5.8 (3) 113 (18) 51.4 
016 0.94 5.8 (3) 143 (16) 40.5 
017 0.89 6.9 (4) 143 (22) 48.3 
018 0.85 4.7 (5) 129 (26) 36.4 
019 0.90 3.6 (4) 122 (20) 29.5 
Geo Mean   5.1   136   38.3 
Geo SD   1.23  1.26  1.41 
25% Quartile  4.4  120  34.2 
Median  5.4  127  41.2 
75% Quartile   5.8   142   47.5 
 
The coefficient of determination was 0.82 or above.  There were no statistical 
difference in Km between the two groups; the geometric mean for the young and elderly 
subjects was 120 μM (± 27%) and 136 μM (± 26%), respectively and ranged from 78.5 to 
247 μM, about a three-fold range.  There were no statistical difference in vmax between 
the two groups but there was a group interaction (p = 0.010); the vmax for the young 
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females were statistically lower (3.7 μmol/min/ml plasma (± 9%)) than young males and 
elderly females (5.4 (± 9%) and 5.5 μmol/min/ml (± 9%)).  The vmax for the elderly males 
were not statistically different from any other group (4.7 μmol/min/ml (± 10%)).  The 
vmax ranged from 3.1 to 7.6, approximately a two-fold range.   
A study of males and females across a range of ages showed similar differences.92  
The study consisted of 443 males and 258 females, 70 of which were taking oral 
contraceptives, across a wide variety of ages.  The RBC AChE and plasma BuChE 
activity was measured and the activity in various age groups was compared.  Women less 
than 30 years old showed lower BuChE activity than men less than 30 years old (3.6 (± 
0.9) compared to 4.2 (± 0.9) μmol/min/ml plasma).  In addition, women less than 30 
years old showed lower activity to women 60 and over (3.6 (± 0.9) compared to 5.1 (± 
1.2) μmol/min/ml plasma).  Further, women taking oral contraceptives had lower plasma 
BuChE activity compared to women not taking oral contraceptives.  In this study, three of 
the five young females were taking oral contraceptives.   The mean vmax for plasma 
BuChE in women (n=3) on oral contraceptives in this study was 3.9 (± 11%) 
μmol/min/ml plasma (subjects 001, 007, 009); mean vmax for plasma BuChE of women 
(n=2) not on oral contraceptives was 3.5 (± 16%) μmol/min/ml plasma (subjects 006, 
008), not a statistical difference due to the low sample size but in total, lower than the 
other groups.  This difference was suggested to be due to hormonal suppression of 
hepatic BuChE production.  Women on oral contraceptives were the lowest, followed by 
young women and post-menopausal women had the highest BuChE activity. 
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No statistical difference between the two groups was observed for CLint, but a 
group interaction was observed (p = 0.027); when further analyzed by Tukey’s HSD, no 
group was different from each other.  The CLint ranged from 17.5 to 57.5 μl/min/ml 
plasma, an approximately three-fold range.  
The vmax for plasma BuChE showed little variability between all the subjects, only 
a two-three fold range, but the vmax showed a wider range than RBC AChE which only 
showed about a 30% difference between the highest and lowest activity.  BuChE is 
known to display over thirty genetic polymorphisms; many of the polymorphisms affect 
the activity, some even abolishing activity.66  The wide variability in activity is not 
uncommon in other studies (see discussion in Chapter 4).66   
6.6.2. In-vitro PK of Physostigmine in Human Blood 
The in-vitro  PK of PHYS in human blood followed the Michaelis-Menten kinetic 
model using a 1/y2 weighting factor for this chapter only.  Figure 6.6.2.-1. shows the 
concentration-time profile for a representative subject.  Table 6.6.2.-1. shows the 
Michaelis-Menten parameters and the goodness of fit. 
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Figure 6.6.2.-1. PHYS concentration profile in human blood –representative plot (Subject 
001) 
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Table 6.6.2.-1. In-vitro  PK of PHYS in human blood fit by a Michaelis-Menten kinetic 
model  
Subject r2 Km (%COV) vmax (%COV) CLint
    [μM] [μmol/min/ml plasma] [μl/min/ml plasma] 
001 0.99 0.074 (21) 2.1 (14) 28.0 
002 0.97 0.183 (57) 3.5 (45) 19.3 
003 1.00 0.045 (27) 1.7 (14) 37.9 
004 0.99 0.070 (75) 2.5 (21) 35.8 
005 0.99 0.034 (98) 1.9 (17) 55.5 
006 1.00 0.133 (45) 2.3 (17) 17.5 
007 0.98 0.049 (13) 1.6 (35) 33.4 
008 0.99 0.187 (88) 3.3 (43) 17.9 
009 1.00 0.030 (25) 1.4 (10) 46.0 
010 1.00 0.040 (46) 2.3 (9.3) 57.2 
Geo Mean  0.068  2.2  32.0 
Geo SD  1.98  1.35  1.56 
25% quartile  0.041  1.8  21.4 
Median  0.060  2.2  34.6 
75% Quartile   0.118   2.5   44.0 
011 1.00 0.048 (8.0) 2.1 (5.2) 43.1 
012 1.00 0.106 (25) 2.5 (13) 23.6 
013 1.00 0.059 (23) 1.7 (14) 29.5 
014 0.99 0.103 (87) 3.0 (31) 29.3 
015 0.99 0.084 (85) 2.6 (27) 30.7 
016 0.99 0.126 (76) 2.6 (30) 20.5 
017 0.98 0.141 (11) 3.2 (53) 22.7 
018 0.90 0.219 (23) 2.5 (13) 11.4 
019 0.96 0.049 (18) 2.0 (35) 40.8 
Geo Mean  0.092  2.4  26.2 
Geo SD  1.67  1.22  1.49 
25% quartile  0.059  2.1  22.7 
Median  0.103  2.5  29.3 
75% Quartile   0.126   2.6   30.7 
 
The coefficient of determination for all subjects was acceptable with an r2 of 0.90 
or greater; however, the parameter estimates were not well estimated for several subjects.  
Nevertheless, the Km, vmax and CLint were not statistically different between the two 
groups.  The geometric mean for Km was 0.068 μM (± 98%) for the young group and 
0.092 μM (± 67%) for the elderly group and ranged from 0.03 to 0.22 μM, more than a 
seven-fold range.  The geometric mean for vmax in the young and elderly groups was 2.2 
176 
(± 35%) and 2.4 μmol/min/ml plasma (± 22%), respectively, and ranged from 1.4 to 3.5 
μmol/min/ml plasma, a two-fold range.  The geometric mean for CLint in the young and 
elderly group was 32 (± 56%) and 26 (± 49%) μl/min/ml plasma, respectively; the CLint 
ranged from 11 to 57 μl/min/ml plasma, a five-fold range.   
PHYS kinetics showed no difference between the groups.  PHYS is thought to be 
degraded by RBC AChE and plasma BuChE with approximately equal contributions (see 
Chapter 5); plasma BuChE showed a two-fold range in vmax, similar to what is observed 
for PHYS.   
6.6.4. In-vitro Inhibition of RBC AChE and Plasma BuChE by Physostigmine in 
Human Blood 
A lag time in maximum inhibition was observed relative to the addition of PHYS, 
occurring approximately 30 minutes after the addition of PHYS.  The onset of inhibition 
was rapid, at least 10% inhibition was observed within 0.5 min for most subjects.  Figure 
6.6.4.-1. shows the time course of RBC AChE and plasma BuChE inhibition for a 
representative subject.  Table 6.6.4.-1a. and b. shows the model-independent PD 
inhibition parameters.  The duration of inhibition was defined as the time where activity 
was less than 10% of baseline activity.  The observed v0 is the baseline activity at the 
start of the study.   
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Figure 6.6.4.-1. ChE activity-time profile of RBC AChE and plasma BuChE inhibited by 
PHYS in human blood from a representative subject (Subject 001) 
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Table 6.6.4.-1a.  Model independent PD of PHYS inhibition of RBC AChE 
Subject 
Onset of 
inhibition Observed v0
Duration of 
inhibition 
Maximum 
inhibition 
  [min] [μmol/min/ml] [min] [%] 
    AChE    
001 0.5 11.4 540 74 
002 0.5 11.4 420 84 
003 0.5 9.1 420 77 
004 0.5 9.8 360 93 
005 0.5 10.2 360 90 
006 0.5 10.8 480 85 
007 0.5 10.0 360 81 
008 0.5 8.9 360 78 
009 5.0 9.7 355 81 
010 5.0 9.3 300 81 
Geo Mean 0.8 10.0 390 82 
Geo SD 2.64 1.09 1.19 1 
25% Quartile 0.5 9.4 360 79 
Median 0.5 9.9 360 81 
75% Quartile 0.5 10.7 420 85 
011 0.5 11.6 300 81 
012 0.5 11.8 360 76 
013 5.0 10.5 295 85 
014 5.0 10.7 190 79 
015 0.5 8.6 300 93 
016 0.5 9.5 360 82 
017 5.0 11.5 240 85 
018 5.0 9.3 360 93 
019 0.5 7.3 480 78 
Geo Mean 1.4 10.0 311 83 
Geo SD 3.37 1.17 1.31 1.07 
25% Quartile 0.5 9.3 295 79.3 
Median 0.5 10.5 300 81.7 
75% Quartile 5.0 11.5 360 85.2 
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Table 6.6.4.-1b.  Model independent PD of PHYS inhibition of plasma BuChE 
Subject 
Onset of 
inhibition Observed v0
Duration of 
inhibition 
Maximum 
inhibition 
  [min] [umol/min/ml] [min] [%] 
    BuChE    
001 0.5 3.8 420 89 
002 0.5 4.3 420 90 
003 0.5 5.2 420 91 
004 0.5 5.8 300 90 
005 0.5 5.4 360 91 
006 0.5 3.6 480 87 
007 0.5 4.0 360 88 
008 0.5 4.6 420 91 
009 0.5 4.7 420 87 
010 0.5 8.0 300 89 
Geo Mean 0.5 4.8 385 89 
Geo SD 1.00 1.27 1.17 1.02 
25% Quartile 0.5 4.1 360 88 
Median 0.5 4.7 420 90 
75% Quartile 0.5 5.4 420 91 
011 0.5 5.2 300 85 
012 0.5 4.5 360 88 
013 0.5 4.6 360 85 
014 0.5 6.5 300 86 
015 0.5 6.3 300 88 
016 0.5 6.3 360 88 
017 0.5 7.7 300 97 
018 0.5 5.4 420 88 
019 0.5 4.0 420 88 
Geo Mean 0.5 5.5 343 88 
Geo SD 1.00 1.23 1.15 1.04 
25% Quartile 0.5 4.6 300 86 
Median 0.5 5.4 360 88 
75% Quartile 0.5 6.3 360 88 
 
The duration of inhibition of RBC AChE was statistically different between the 
two age groups (p = 0.048).  The geometric mean duration of inhibition of young and 
elderly groups was 390 (± 19%) and 311 minutes (± 31%), respectively, and ranged from 
190 to 540 minutes.  In addition, a group interaction was observed (p = 0.040) with the 
young females showing a longer duration of inhibition than elderly females (277 (± 9%) 
180 
minutes compared to 419 minutes (± 9%)).  The duration of RBC AChE inhibition for the 
males was not different from each other or the female subjects.   
The plasma BuChE duration of inhibition was not statistically different from each 
other.  The geometric mean duration of plasma BuChE inhibition for the young and 
elderly groups were 385 (± 17%) and 343 (± 15%) minutes, respectively.   
No difference between the two groups, was observed for initial activity, v0, nor 
the maximum inhibition for both RBC AChE and plasma BuChE. 
The ChE inhibition vs PHYS concentration was fit by a pseudo-steady-state 
inhibition model, which excluded the first 30 minutes.  Figure 6.6.4.-2. shows the 
inhibitor concentration-activity profile for a representative subject.  Table 6.6.4.-2a. 
shows the parameter estimates for RBC AChE and table 6.6.4.-2b. shows the parameter 
estimates for plasma BuChE.  The coefficient of determination was acceptable with an r2 
of 0.7 or greater for RBC AChE and 0.9 or greater for plasma BuChE.  The parameters 
were well estimated with a COV less than 30% with the exception of a few subjects; most 
notably, subject 016.  This was most likely due to a significant PHYS concentration 
(0.012 μM) at the end of the experiment.  This was higher than the estimated Ki,pss value 
(0.0028 μM) and was unable to precisely estimate Ki,pss. 
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Figure 6.6.4.-2. Concentration-activity profile of RBC AChE and plasma BuChE 
inhibited by PHYS in human blood from a representative subject (Subject 001) 
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Table 6.6.4.-2a.  Inhibition of RBC AChE by PHYS fit by a pseudo-steady-state 
noncompetitive inhibition model 
Subject r2 Model v0 %COV Imax %COV Imax Ki,pss %COV 
    [μmol/min/ml] [μmol/min/ml] [%] [μM] 
   AChE     
001 0.88 9.7 (7) 5.7 (12) 59 0.003 (68) 
002 0.93 10.3 (9) 8.1 (11) 79 0.012 (61) 
003 0.83 7.7 (7) 4.3 (16) 56 0.010 (102) 
004 0.94 7.6 (8) 6.4 (10) 84 0.014 (51) 
005 0.95 8.1 (6) 6.6 (10) 81 0.012 (55) 
006 0.93 10.7 (9) 8.8 (10) 82 0.019 (48) 
007 0.91 11.6 (10) 9.5 (14) 82 0.016 (62) 
008 0.93 10.1 (7) 7.7 (12) 76 0.015 (52) 
009 0.97 10.7 (5) 9.4 (7) 88 0.032 (33) 
010 0.87 9.6 (12) 6.5 (19) 67 0.002 (85) 
Geo Mean   9.5   7.1   75 0.010   
Geo SD  1.16  1.28  1.17 2.33  
25% quartile  8.5  6.4  70 0.010  
Median  9.9  7.1  80 0.013  
75% Quartile   10.6   8.6   82 0.016   
011 0.98 11.5 (4) 9.1 (7) 79 0.0228 (32) 
012 0.96 14.5 (6) 11.0 (9) 76 0.0113 (37) 
013 0.96 10.7 (6) 9.4 (9) 88 0.0599 (38) 
014 0.80 11.6 (19) 8.0 (28) 69 0.0065 (11) 
015 0.99 9.4 (3) 8.8 (4) 94 0.0204 (19) 
016 0.97 40.7 (110) 38.7 (115) 95 0.0028 (14) 
017 0.80 11.7 (19) 9.3 (25) 80 0.0214 (11) 
018 0.70 8.7 (18) 8.9 (33) 102 0.0861 (11) 
019 0.87 10.9 (10) 7.2 (15) 66 0.0037 (79) 
Geo Mean   12.7   10.5   82 0.015   
Geo SD  1.58  1.65  1.16 3.22  
25% quartile  10.7  8.8  76 0.007  
Median  11.5  9.1  80 0.020  
75% Quartile   11.7   9.4   94 0.023   
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Table 6.6.4.-2b.  Inhibition of plasma BuChE by PHYS fit by a pseudo-steady-state 
noncompetitive inhibition model 
Subject r2 Model v0 %COV Imax %COV Imax Ki,pss %COV 
    [μmol/min/ml] [μmol/min/ml] [%] [μM] 
    BuChE         
001 0.98 4.3 (5) 3.7 (6) 85 0.0035 (27) 
002 0.98 7.2 (19) 6.5 (20) 91 0.0015 (51) 
003 0.97 5.1 (5) 4.5 (6) 89 0.0069 (35) 
004 0.99 6.6 (3) 5.8 (4) 89 0.0029 (16) 
005 0.97 5.9 (6) 5.0 (8) 85 0.0016 (42) 
006 1.00 3.7 (2) 3.3 (2) 91 0.0124 (10) 
007 0.99 4.3 (4) 3.8 (5) 89 0.0116 (23) 
008 0.96 3.9 (6) 3.6 (9) 92 0.0124 (41) 
009 0.99 5.0 (4) 4.3 (5) 86 0.0063 (20) 
010 0.99 8.4 (5) 7.2 (6) 86 0.0048 (28) 
Geo Mean   5.2   4.6   88 0.005   
Geo SD  1.32  1.31  1.03 2.21  
25% quartile  4.3  3.7  86 0.003  
Median  5.1  4.4  89 0.006  
75% Quartile   6.4   5.6   90 0.010   
011 0.99 5.7 (3) 4.9 (4) 85 0.0086 (19) 
012 1.00 4.8 (0.4) 4.5 (1) 93 0.0174 (2) 
013 1.00 4.9 (2) 4.5 (2) 90 0.0177 (8) 
014 0.99 7.1 (5) 6.1 (6) 85 0.0101 (26) 
015 1.00 6.2 (2) 5.5 (3) 88 0.0078 (12) 
016 0.99 15.0 (22) 14.3 (23) 95 0.0061 (35) 
017 0.93 7.7 (12) 7.0 (14) 92 0.0092 (49) 
018 0.91 5.1 (10) 5.0 (12) 99 0.0292 (45) 
019 0.94 4.6 (8) 3.9 (10) 85 0.0042 (51) 
Geo Mean  6.3  5.7  90 0.010  
Geo SD  1.45  1.47  1.05 1.82  
25% quartile  4.9  4.5  85 0.008  
Median  5.7  5.0  90 0.009  
75% Quartile   7.1   6.1   93 0.017   
 
A statistically significant difference in initial activity of RBC AChE was observed 
between the two age groups (p = 0.0343).  The geometric mean RBC AChE v0 for the 
young and elderly group was 9.5 (± 16%) and 12.7 μmol/min/ml RBC (± 58%), 
respectively.  In addition a group interaction was observed (p = 0.026); when further 
examined by Tukey’s HSD, the young males RBC AChE initial activity was significantly 
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lower than for elderly males (8.6 (± 14%) compared to 16.5 μmol/min/ml RBC (±16%)).  
It should be noted that the model v0 is limited to observation after the first 30 minutes and 
excludes the baseline activities.  The vmax for RBC AChE kinetics showed no difference 
between the age groups or gender nor did the observed baseline activity (see table 6.6.4.-
1.; model independent PD).  Thus, this difference is most likely an anomaly of the data 
rather than a true difference in baseline activity.  Sampling more at the later time points 
would most likely have abolished this difference. 
More importantly, a gender difference was observed for the RBC AChE Ki,pss; the 
mean Ki,pss for males was 0.008 μM (± 35%) and the mean for females was 0.020 μM (± 
32%), nearly a three-fold difference; however, gender and age were only able to account 
for 33% of the variance in Ki,pss.   
The RBC AChE Imax was not statistically different between the groups.  The Imax 
ranged from 59% to 102%.   
The PHYS Ki,pss for plasma BuChE was statistically different between age groups 
(p = 0.033) and gender (p = 0.023); the geometric mean for the young and elderly group 
was 0.005 (± 21%) and 0.010 μM (± 81%) a two-fold difference between the two groups.  
The mean for the males and females was 0.005 (± 23%) and 0.099 μM (± 22%), a two-
fold difference between males and females.  Age and gender were able to account for 
48% of the variance in Ki,pss. 
The plasma BuChE Imax was not statistically different between the groups, and 
ranged from 85% to 99%. 
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Ki is defined as the concentration where 50% inhibition is observed and has been 
used as a marker of sensitivity.  Thus, a higher Ki indicates a low sensitivity, i.e., a higher 
concentration is required to inhibit 50%.  For both enzymes, the Ki,pss was statistically 
lower, by 2-3 fold, for the male subjects compared to the female subjects.  This shows 
that the males in this study were 2-3 times more sensitive to inhibition by PHYS than 
females.   
Plasma BuChE in elderly subjects were less sensitive by 2-fold, to inhibition by 
PHYS in than young subjects.  The RBC AChE did not show any difference in sensitivity 
between the young and elderly subjects.   
The linear sensitivity model was estimated for each subject, and the result is 
shown in table 6.6.4.-3.  There was no difference in RBC AChE sensitivity between the 
age groups, but a group interaction was found (p=0.046).  When analyzed by Tukey’s 
HSD, no difference in the groups was found.  When the sensitivity was analyzed taking 
into account the baseline activity, i.e., in units of %/(ng/ml), no difference was found 
between the groups.   
There was an age-related difference in plasma BuChE sensitivity using the units 
of (μmol/min/ml)/(ng/ml) (p = 0.008); in addition, a difference in gender was observed 
(p=0.042).  The geometric mean for the young and elderly subjects was -1.87 (± 135%) 
and -0.76 (μmol/min/ml)/(ng/ml) (± 75%), respectively, i.e., for an increase in 1 ng/ml 
concentration of PHYS, the activity of PHYS decrease by 1.87 μmol/min/ml in the young 
group and decreased by only 0.76 μmol/min/ml in the elderly group, nearly a 2.5-fold 
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difference.  The mean for the male and female subjects was -1.66 (± 23%) and -0.87 
(μmol/min/ml)/(ng/ml) (22%), respectively.   
The sensitivity, taking into account baseline activity, showed similar results; an 
age-related difference (p=0.002) and gender difference (p=0.039) was observed.  The 
geometric mean in the young group was 42 %/ng/ml (± 121%) and 14 %/ng/ml (± 80%) 
in the elderly group, a three-fold difference.  The geometric mean for males was 33.8 
%/ng/ml (± 23%) and 17.5 %/ng/ml (± 22%) for the female subjects, nearly a two-fold 
difference. 
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Table 6.6.4.-3.  Linear sensitivity model of RBC AChE and plasma BuChE sensitivity to 
PHYS  
Subject AChE Sensitivity BuChE Sensitivity 
  [(μmol/min/ml)/(ng/ml)] [%/ng/ml] [(μmol/min/ml)/(ng/ml)] [%/ng/ml]
001 -1.17 10.8 -2.64 68.3 
002 -0.57 5.0 -4.62 108.7 
003 -0.91 10.1 -1.73 66.9 
004 -1.34 13.8 -1.88 32.3 
005 -0.73 7.2 -5.94 110.0 
006 -2.30 21.4 -0.76 21.4 
007 -3.33 33.3 -1.09 28.3 
008 -0.61 6.9 -0.38 8.3 
009 -0.49 5.1 -1.76 37.1 
010 -0.69 7.4 -4.05 50.8 
Geo Mean -1.00 10.0 -1.87 41.9 
Geo SD 1.87 1.85 2.35 2.21 
25% Quartile -0.63 7.0 -1.25 29.3 
Median -0.82 8.7 -1.82 44.0 
75% Quartile -1.30 13.0 -3.70 67.9 
011 -1.32 11.4 -1.19 22.9 
012 -1.52 12.8 -0.51 11.5 
013 -0.36 3.4 -0.55 12.1 
014 -1.31 12.2 -1.57 24.2 
015 -0.88 10.2 -0.87 13.7 
016 -1.16 12.2 -0.59 9.4 
017 -1.15 9.9 -0.83 10.8 
018 -0.47 5.1 -0.27 5.0 
019 -2.26 19.4 -1.41 35.3 
Geo Mean -1.02 9.7 -0.76 13.9 
Geo SD 1.78 1.69 1.75 1.80 
25% Quartile -0.88 9.9 -0.55 10.8 
Median -1.16 11.4 -0.83 12.1 
75% Quartile -1.32 12.2 -1.19 22.9 
 
The study by Men estimated the ex-vivo sensitivity of RBC AChE to PHYS in a 
group of healthy elderly subjects (n=8).30  After a 30 minute IV infusion (6.7 μg/kg), the 
mean Cmax was 3.3 ng/ml (0.012 μM) (± 41%) and the RBC AChE experienced 
approximately 20% inhibition (± 28%).  The mean sensitivity for all subjects was -0.96 
(μmol/min)/(ng/ml), the mean sensitivity for the male and female subjects was -1.00 (± 
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52%) and -0.93 (μmol/min)/(ng/ml) (± 120%), respectively.  When the base line was 
taken into account, the mean sensitivity was 12 %/(ng/ml) (SD not reported).   
In the current study, the sensitivity for the elderly subjects was -1.02 
(μmol/min/ml)/(ng/ml) or 9.7 %/ng/ml (± 69%).  The elderly males in this study had a 
sensitivity of -1.5 (μmol/min/ml)/(ng/ml) (± 32%).  The elderly females in this study had 
a sensitivity of -0.74 (μmol/min/ml)/(ng/ml) (± 28%).  The RBC AChE sensitivity in this 
study was similar to the sensitivity observed in the study by Men.  Table 6.6.4.-4. 
summarizes the results from the current study and the study by Men. 
 
Table 6.6.4.-4.  Comparison of RBC AChE sensitivity between the elderly subjects in the 
current study and the study by Men30  
             Current Study (in-vitro)                     Men30 (ex-vivo) 
 (μmol/min/ml)/(ng/ml) %/ng/ml (μmol/min/ml)/(ng/ml) %/ng/ml 
Elderly Male -1.5 (± 32%) 13.6 -1.00 (± 52%) n/r 
Elderly Female -0.7 (± 28%) 7.3 -0.9 (± 120%) n/r 
Total -1.0 (69%) 9.7 -1.0 (± 90%) 12 
 
 
The ex-vivo sensitivity of plasma BuChE to PHYS was estimated from the study 
by Knapp et al.  In this study, six (6) young healthy male subjects were administered 
extended release PHYS tablets, 9, 12 and 15 mg, twice a day, and the plasma BuChE was 
measured along with PHYS plasma concentrations.  The mean Cmax was 0.004 μM and 
the subjects experienced a mean maximum plasma BuChE activity inhibition of 35% and 
the ex-vivo sensitivity was 28%/ng/ml.  In the plasma BuChE in-vitro sensitivity for the 
young males in the current study was 33 %/ng/ml (± 32%).  Table 6.6.4.-5. summarizes 
the results from the current study and the study by Knapp et al. 
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Table 6.6.4.-5.  Comparison of plasma BuChE sensitivity between the young male 
subjects in the current study and the study by Knapp et al35  
             Current Study (in-vitro)                     Knapp et al.35 (ex-vivo)
 (μmol/min/ml)/(ng/ml) %/ng/ml (μmol/min/ml)/(ng/ml) %/ng/ml 
Young Male -3.2 (± 33%) 33 (± 32%) n/r 28 
 
The in-vitro sensitivity in this study was similar to the ex-vivo sensitivity in the 
meta-analysis of PHYS sensitivity explored in Chapter 1 (section 1.4).  In the studies 
included in the meta-analysis, the sensitivity ranged from 28 %/ng/ml (Knapp et al35) to 
12 %/ng/ml (Men30).  For the current study, the overall RBC AChE sensitivity was 10 
and 9.7 %/ng/ml for the young and elderly subjects, respectively; the overall plasma 
BuChE sensitivity was 42 and 13.9 %/ng/ml, for the young and elderly subjects, 
respectively.  This was similar to the values observed for the meta-analysis.   
The study by Knapp, used plasma sensitivity to PHYS and resulted in a sensitivity 
of 28 %/ng/ml in a young male population.  The young male population in this study had 
a mean plasma BuChE sensitivity of 33 %/ng/ml.   
The study by Men, used RBC AChE sensitivity to PHYS in an elderly population 
balanced for gender and resulted in a sensitivity of 12 %/ng/ml.  The elderly population 
in this study had a mean RBC AChE sensitivity of 10 %/ng/ml. 
This study showed that PHYS inhibition of RBC AChE and plasma BuChE was 
similar between the groups.  The RBC AChE duration of inhibition was longer for young 
subjects compared to the elderly subject.  This difference was mainly observed for the 
females.  The plasma BuChE showed no difference in duration.  RCB AChE and plasma 
BuChE was inhibited maximally to the same extent between the two groups.   
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RBC AChE and plasma BuChE sensitivity to PHYS was evaluated in two ways.  
First by Ki,pss, which measures the concentrations where 50% inhibition is observed; 
second by an estimation of sensitivity by a linear model at low concentrations.  There is a 
gender difference in sensitivity for both enzyme and an age-related difference in 
sensitivity for plasma BuChE for the inhibition by PHYS, as measured by Ki,pss.  Males 
are more sensitive than females by 2-3 fold in both enzymes and young subjects are about 
2-fold more sensitive to plasma BuChE inhibition by PHYS. 
The in-vitro sensitivity measured in this study matched very well to the ex-vivo 
sensitivity as compared by the studies by Men and Knapp et al and demonstrates 
measurement of in-vitro sensitivity is a suitable marker for ex-vivo sensitivity.   
Comparison by the linear sensitivity model confirmed that RBC AChE showed no 
age-related difference in sensitivity; no gender difference was observed.  The linear 
sensitivity model also confirmed an age-related and gender difference in plasma BuChE 
sensitivity.  The magnitude of the difference was similar to the difference in Ki,pss, 
approximately a three-fold higher sensitivity in the young subjects compared to the 
elderly subjects and the male subjects were two-fold more sensitive than the female 
subjects. 
6.6.5. In-vitro Inhibition of RBC AChE and Plasma BuChE by Pyridostigmine in 
Human Blood 
The log-linear activity of RBC AChE and plasma BuChE for the first 10 minutes 
after the addition of PYR for a representative subject is shown in figure 6.6.5.-1.  The 
first-order inactivation rate constant, kobs, was estimated for 10 minutes for initial PYR 
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concentrations of 0.1 to 10 μM, and for 5 minutes at the highest concentration of 100 μM.  
At the highest concentration, the inhibition reached a steady-state by 5 minutes. 
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Figure 6.6.5.-1. Log-linear Inhibition of RBC AChE (left) and plasma BuChE (right) for 
the first 10 minutes (Subject 004) 
 
The first-order inactivation rate constant vs PYR concentration was fit by a 
suicide inactivation model.  Figure 6.6.5.-2. shows the inactivation rate constant fit by the 
suicide inactivation model for a representative subject.  Table 6.6.5.-1a. and b. shows the 
model parameter estimates for RBC AChE and plasma BuChE, respectively.  The 
coeffiecient of determination for RBC AChE fit by the suicide inactivation model was 0.8 
or greater, with the exception of several subjects with a coeffiecient of determination less 
than 0.6.  The lack of goodness of fit was most likely due to very rapid inactivation in a 
few subjects, even at low concentrations, that lead to difficulty estimating the first-order 
inactivation rate constant.  The goodness of fit for plasma BuChE was 0.99 or greater for 
all subjects.   
In addition to a lack of goodness of fit for some subjects for RBC AChE, there 
was a lack of precision in the parameter estimates with a COV of 50% or greater in 
192 
several subjects.  The parameter estimates were well estimated for plasma BuChE with 
COV of 30% or less. 
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Figure 6.6.5.-2. The first-order inactivation rate constant fit by a suicide inactivation 
model for RBC AChE (left) and plasma BuChE (right) 
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Table 6.6.5.-1a. Model parameters of first-order inactivation rate constant fit by fit by a 
suicide inactivation model for RBC AChE 
Subject r2 kinact (%CV) Ki,app (%CV) 
    [min-1] [μM] 
    AChE      
001 0.95 0.11 (7) 0.6 (42) 
002 0.79 0.21 (15) 0.2 (98) 
003 0.85 0.46 (39) 31.5 (120) 
004 0.84 0.25 (16) 1.9 (84) 
005 0.84 0.15 (14) 0.6 (83) 
006 0.97 1.38 (56) 92.4 (11) 
007 0.94 0.44 (19) 19.9 (64) 
008 0.79 0.25 (22) 1.1 (11) 
009 0.49 0.22 (35) 2.4 (17) 
010 0.42 0.37 (45) 9.6 (17) 
Geo Mean   0.29   3.37   
Geo SD  2.03  7.37  
25% Quartile  0.21  0.73  
Median  0.25  2.14  
75% Quartile   0.42   17.34   
011 0.93 0.24 (11) 0.6 (66) 
012 >0.99 1.14 (8) 61.3 (20) 
013 >0.99 5.77 (51) 419.3 (64) 
014 0.58 0.14 (30) 0.4 (18) 
015 0.97 0.88 (22) 37.6 (65) 
016 0.91 0.29 (16) 5.4 (70) 
017 0.95 0.23 (8) 0.4 (53) 
018 0.93 0.45 (17) 12.6 (61) 
019 0.99 0.41 (4) 3.5 (21) 
Geo Mean   0.51   6.68   
Geo SD  3.07  11.14  
25% Quartile  0.24  0.58  
Median  0.41  5.38  
75% Quartile   0.88   37.58   
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Table 6.6.5.-1b. Model Parameters of first-order inactivation rate constant fit by a suicide 
inactivation model plasma for BuChE 
Subject r2 kinact (%CV) Ki,app (%CV) 
    [min-1] [μM] 
  BuChE    
001 >0.99 0.43 (4) 14.1 (16) 
002 >0.99 0.56 (2) 16.4 (7) 
003 >0.99 0.70 (2) 22.2 (7) 
004 >0.99 0.66 (1) 24.7 (5) 
005 >0.99 0.75 (1) 25.5 (3) 
006 >0.99 0.80 (2) 28.0 (7) 
007 >0.99 0.84 (0.7) 28.3 (2) 
008 >0.99 0.64 (0.7) 23.8 (2) 
009 >0.99 0.87 (2) 41.1 (5) 
010 >0.99 0.75 (0.7) 24.8 (2) 
Geo Mean   0.69   23.9   
Geo SD  1.24  1.34  
25% Quartile 0.64  22.6  
Median  0.73  24.7  
75% Quartile  0.79  27.4  
011 >0.99 0.73 (4) 23.2 (14) 
012 0.99 0.61 (7) 5.3 (31) 
013 >0.99 0.79 (4) 34.9 (13) 
014 >0.99 0.85 (2) 46.8 (6) 
015 >0.99 1.04 (7) 69.8 (17) 
016 >0.99 0.39 (1) 13.8 (4) 
017 >0.99 0.74 (2) 19.9 (8) 
018 >0.99 0.75 (0.9) 21.2 (3) 
019 >0.99 0.67 (1) 23.6 (4) 
Geo Mean   0.71   23.2   
Geo SD  1.31  2.09  
25% Quartile  0.67  19.9  
Median  0.74  23.2  
75% Quartile   0.79   34.9   
 
There was no difference in RCB AChE Ki,app or kinact between the groups; the 
geometric mean in the young group was 0.29 μM (± 103%) and 3.37 min-1 (± 634%), 
respectively, and 0.51 μM (± 207) and 6.68 min-1 (± 1014%), respectively, for the elderly 
group.  There was considerable interindividual variability; the Ki,app ranged from 0.11 to 
5.77 μM and the kinact ranged from 0.2 to 419.3 min-1.   
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The plasma BuChE Ki,app showed a gender difference (p=0.033) but no age-
related difference; the Ki,app for the male and female subjects was 29.7 (± 17%) and 17.8 
μM (16%), respectively.  There was considerable interindividual variability in kinact but 
not for Ki,app; kinact ranged from 5.3 to 69.8 min-1, a 13-fold difference, while Ki,app ranged 
from 0.39 to 1.04 μM, a 2.5-fold difference. 
The Ki,app was higher for plasma BuChE than for RBC AChE but kinact was higher 
for RBC AChE than for plasma BuChE.  At low concentrations, RBC AChE is inhibited 
more rapidly, but at higher concentrations plasma BuChE is inhibited more rapidly.  This 
is similar to what was observed during the mechanistic studies (Chapter 5).  The 
preliminary studies used the baseline activity and the inhibition at 0.5 minutes to estimate 
the first-order inactivation model while the current study used the first 5-10 minutes.  
There was concern that the mechanistic study would have overestimated the inactivation 
rate constant since only very early observations were used.  The results from the 
preliminary study compared to the young subjects in the current study are shown in table 
6.6.5.-2.  The RBC AChE compared very well to the preliminary study; however, the 
Ki,app for plasma BuChE may have been overestimated and was higher than any subject in 
this study; the kinact may have been underestimated, but was within the range of this 
study.   
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Table 6.6.5.-2. The steady-state inactivation fit by a noncompetitive inactivation model 
for RBC AChE 
 Current Study Mechanistic Study
 Ki,app kinact Ki,app kinact
 [μM] [min-1] [μM] [min-1] 
RBC AChE 0.29 3.4 0.12 4.0 
Plasma BuChE 0.69 23.9 4.10 6.8 
 
The steady-state inactivation vs PYR concentration was fit by a noncompetitive 
inhibition model.  Figure 6.6.5.-3. shows the steady-state inactivation for a representative 
subject.  Table 6.6.5.-3a. and b. shows the model parameter estimates for RBC AChE and 
plasma BuChE, respectively.  The goodness of fit was 0.8 or greater for all subjects and 
for both enzymes; however, the RBC AChE parameters were not well estimated for a few 
subjects with a COV of 50% of greater.  The plasma BuChE parameters were well 
estimated with a COV less than 35% for all subjects. 
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Figure 6.6.5.-3. The steady-state inactivation fit by a noncompetitive inactivation model 
for a representative subject (Subject 004) 
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Table 6.6.5.-3a. The steady-state inactivation fit by a noncompetitive inactivation model 
for RBC AChE 
Subject r2 v0 (%CV) Imax (%CV) Imax Ki,ss (%CV) 
    [μmol/min/ml] [μmol/min/ml] [%] [μM] 
        AChE         
001 >0.99 8.83 (0.2) 7.41 (0.3) 83.9 0.07 (1) 
002 0.97 4.55 (11) 4.48 (13) 98.4 0.20 (58) 
003 0.83 2.79 (16) 1.68 (31) 60.1 0.05 (138) 
004 0.99 4.13 (6) 3.48 (8) 84.1 0.10 (34) 
005 0.99 3.38 (6.3) 3.12 (7) 92.2 0.14 (33) 
006 0.81 5.03 (22) 3.98 (33) 79.1 0.37 (160) 
007 0.97 4.98 (9) 4.61 (12) 92.5 0.38 (60) 
008 0.99 4.19 (4) 3.72 (6) 88.9 0.15 (26) 
009 >0.99 5.59 (3) 5.24 (4) 93.7 0.10 (17) 
010 >0.99 4.72 (1) 4.15 (1) 87.9 0.04 (8) 
Geo Mean   4.61   3.94   85.4 0.12   
Geo SD  1.36  1.47  1.15 2.16  
25% Quartile  4.15  3.54  84.0 0.08  
Median  4.63  4.06  88.4 0.12  
75% Quartile   5.02   4.57   92.4 0.19   
011 >0.99 4.87 (3) 4.86 (3.7) 99.8 0.34 (17) 
012 0.87 5.42 (16) 4.02 (26) 74.1 0.47 (127) 
013 0.96 4.81 (9) 3.70 (14) 76.9 0.28 (66) 
014 0.89 4.82 (17) 3.92 (25) 81.4 0.22 (116) 
015 0.97 5.05 (9) 4.35 (12) 86.0 0.27 (59) 
016 0.99 4.46 (5) 3.89 (7) 87.2 0.44 (36) 
017 >0.99 6.00 (2) 5.37 (3.3) 89.5 0.07 (13) 
018 0.93 3.36 (12) 2.50 (19) 74.3 0.23 (89) 
019 >0.99 4.39 (1) 3.92 (1) 89.2 0.23 (7) 
Geo Mean   4.75   3.98   83.9 0.25   
Geo SD  1.17  1.24  1.10 1.72 
25% Quartile  4.46  3.89  76.9 0.23 
Median  4.82  3.92  86.0 0.27 
75% Quartile   5.05   4.35   89.2 0.34  
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Table 6.6.5.-3b. The steady-state inactivation fit by a noncompetitive inactivation model 
for plasma BuChE 
Subject r2 v0 (%CV) Imax (%CV) Imax Ki,ss (%CV) 
    [μmol/min/ml] [μmol/min/ml] [%] [μM] 
       BuChE        
001 >0.99 4.17 (1) 3.89 (1) 93.3 0.25 (7) 
002 >0.99 2.16 (1) 2.12 (2) 97.9 0.22 (9) 
003 >0.99 2.29 (1) 2.23 (1) 97.4 0.21 (6) 
004 >0.99 2.83 (2) 2.81 (3) 99.3 0.46 (15) 
005 >0.99 2.66 (1) 2.63 (1) 98.5 0.31 (7) 
006 >0.99 1.73 (3) 1.69 (3) 98.1 0.39 (18) 
007 0.99 3.00 (6) 2.92 (7) 97.6 0.19 (31) 
008 0.99 2.00 (6) 1.98 (7) 99.3 0.34 (34) 
009 >0.99 2.20 (1) 2.17 (1) 98.7 0.44 (9) 
010 >0.9999 4.14 (0.2) 4.04 (0.2) 97.5 0.35 (1) 
Geo Mean   2.61   2.55   97.8 0.30   
Geo SD  1.34  1.33  1.02 1.37  
25% Quartile  2.17  2.13  97.6 0.23  
Median  2.48  2.43  98.0 0.32  
75% Quartile   2.96   2.90   98.7 0.38   
011 0.99 2.84 (5) 2.78 (6) 98.1 0.21 (28) 
012 0.99 3.00 (6) 2.92 (7) 97.6 0.19 (31) 
013 >0.99 2.24 (3) 2.22 (4) 99.3 0.17 (18) 
014 >0.99 3.45 (3) 3.40 (4) 98.5 0.27 (21) 
015 >0.99 2.85 (2) 2.76 (2) 97.0 0.25 (13) 
016 0.99 3.11 (5) 3.06 (6) 98.5 0.37 (30) 
017 >0.99 4.01 (2) 3.97 (2) 99.0 0.26 (11) 
018 >0.99 2.38 (3) 2.32 (3) 97.4 0.31 (18) 
019 >0.99 1.93 (2) 1.88 (3) 97.4 0.46 (15) 
Geo Mean   2.80   2.75   98.1 0.27   
Geo SD  1.25  1.26  1.01 1.36  
25% Quartile  2.38  2.32  97.4 0.21  
Median  2.85  2.78  98.1 0.26  
75% Quartile   3.11   3.06   98.5 0.31   
 
An age-related difference was observed for RBC AChE Ki,ss (p=0.019); the 
geometric mean for the young and elderly subjects was 0.12 and 0.25 μM, a two-fold 
difference.  A group interaction was also observed (p=0.048); when further analyzed by 
Tukey’s HSD, the Ki,ss for the young males was statistically lower than elderly males 
(0.044 μM (± 33%) compared to 0.18 μM (± 37%), respectively, a four-fold difference).  
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The female subjects were not statistically different from each other or from the male 
subjects.  For all subject, the RBC AChE Ki,ss ranged from 0.04 to 0.47 μM, about a 12-
fold difference.   
The Ki,ss indicates that the elderly subjects are less sensitive to inhibition by PYR; 
the age-related difference is mainly observed for the males where young males require a 
four-fold higher concentration to inhibit to 50% compared to the elderly males. 
The Imax and v0 were not statistically different from each other for RBC AChE. 
The Ki,ss, Imax and v0 for plasma BuChE was not statistically different each other.  
For all subjects the plasma BuChE Ki,ss ranged from 0.17 to 0.46 μM, less than a three-
fold difference. 
The Ki,ss for RBC AChE and plasma BuChE was similar indicating that PYR is a 
nonselective inhibitor.  The Imax for RBC AChE was less than for plasma BuChE, which 
was nearly completely inhibited.  The residual RBC AChE, approximately 15-20%, is 
presumably due to Esterase D and is similar to what was observed in the preliminary 
studies in Chapter 5.80  
This study shows that at low concentrations, RBC AChE is inactivated more 
rapidly but at higher concentrations, plasma is more rapidly inactivated.  The plasma 
BuChE Ki,app, the concentration at half the maximum rate of inactivation, for the male 
was two-fold higher than for female subjects.  That is, males required twice the 
concentration of PYR to inhibit plasma BuChE at the same rate as females.   
At steady-state, PYR is a nonselective inactivator of RBC AChE and plasma 
BuChE.  The RBC AChE displayed an age-related difference in sensitivity; young 
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subjects were twice as sensitive to PYR as the elderly subjects and the young males were 
four-fold more sensitive to PYR than elderly males. 
The plasma BuChE showed no age-related difference in sensitivity to PYR. 
6.6.6. In-vitro Inhibition of RBC AChE and Plasma BuChE by Donepezil in Human 
Blood 
The inhibition of RBC AChE was fit by a noncompetitive inhibition model and 
the inhibition of plasma BuChE by DON was fit by a competitive inhibition model.  
Figure 6.6.6.-1. shows the inhibition fit by the two models for a representative subject.  
Table 6.6.6.-1a. shows the model parameter fits.  The RBC AChE coefficient of 
determination was 0.79 or above with the exception for a few subjects.  The plasma 
BuChE goodness of fit was 0.88 or above for all subjects.  The parameter estimates were 
not precisely estimated and COV greater than 50% was not uncommon for RBC AChE 
and is greater than 30% for several subjects.   
 
201 
02
4
6
8
10
12
14
10 100 1000 10000
AtCh Concentration [μM]
R
B
C
 A
C
hE
 A
ct
iv
ity
[ μm
ol
/m
in
/m
l]
0 uM
100 uM
1,000 uM
10,000 uM
30,000 uM
0
0.5
1
1.5
2
2.5
3
3.5
4
10 100 1000 10000
BtCh Concentration [μM]
Pl
as
m
a 
B
uC
hE
 A
ct
iv
ity
[ μm
ol
/m
in
/m
l]
0 uM
100 uM
1,000 uM
10,000 uM
30,000 uM
 
Figure 6.6.6.-1. Inhibition by DON fit by a noncompetitive inhibition for RBC AChE and 
a competitive inhibition model for plasma BuChE for a representative subject (Subject 
001) 
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Table 6.6.6.-1a. Inhibition by DON fit by a noncompetitive inhibition for RBC AChE  
Subject r2 Km (%CV) vmax (%CV) Ki,noncomp (%CV) 
    [μM] [μmol/min/ml] [μM] 
      AChE         
001 0.92 77 (19) 12.2 (4) 44 (34) 
002 0.91 56 (21) 12.7 (4) 37 (33) 
003 0.93 137 (19) 9.5 (4) 57 (30) 
004 0.92 145 (19) 9.9 (4) 52 (32) 
005 0.90 44 (23) 9.2 (4) 28 (49) 
006 0.79 147 (34) 10.8 (8) 16 (106) 
007 0.65 76 (57) 11.0 (13) 38 (40) 
008 0.87 76 (30) 10.0 (7) 141 (28) 
009 0.81 140 (40) 11.2 (10) 74 (29) 
010 0.82 113 (38) 11.1 (12) 73 (29) 
Geo Mean   93   10.7   48   
Geo SD  1.54  1.11  1.81  
25% Quartile  76  9.9  37  
Median  95  10.9  48  
75% Quartile   139   11.2   69   
011 0.79 155 (44) 11.9 (11) 50 (31) 
012 0.92 95 (28) 13.4 (6) 25 (27) 
013 0.95 77 (21) 11.4 (5) 36 (14) 
014 0.93 74 (24) 11.2 (5) 39 (18) 
015 0.84 176 (36) 10.8 (10) 77 (27) 
016 0.92 89 (27) 9.7 (6) 40 (20) 
017 0.81 103 (40) 13.1 (10) 69 (29) 
018 0.73 115 (47) 11.3 (15) 59 (33) 
019 0.89 76 (31) 12.8 (7) 41 (20) 
Geo Mean   102   11.7   46   
Geo SD  1.37  1.11  1.42  
25% Quartile  77  11.2  39  
Median  95  11.4  41  
75% Quartile   115   12.8   59   
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Table 6.6.6.-1b. Inhibition by DON fit by a competitive inhibition for plasma BuChE  
Subject r2 Km (%CV) vmax (%CV) Ki,comp (%CV) 
    [μM] [μmol/min/ml] [μM] 
      BuChE         
001 0.95 95 (13) 3.6 (2) 192 (22) 
002 0.91 109 (14) 4.3 (3) 190 (24) 
003 0.90 96 (18) 4.4 (3) 147 (28) 
004 0.95 126 (13) 5.7 (2) 213 (19) 
005 0.94 138 (14) 5.7 (2) 309 (22) 
006 0.92 129 (17) 3.2 (3) 29 (28) 
007 0.88 77 (37) 3.5 (7) 0.6 (55) 
008 0.91 169 (30) 4.5 (4) 245 (36) 
009 0.94 164 (24) 4.6 (4) 197 (29) 
010 0.94 215 (26) 8.4 (4) 186 (31) 
Geo Mean   126   4.6   94   
Geo SD  1.37  1.33  6.72  
25% Quartile  99  3.8  157  
Median  127  4.4  191  
75% Quartile   157   5.4   209   
011 0.95 98 (23) 5.2 (3) 182 (28) 
012 0.93 257 (27) 4.8 (4) 408 (32) 
013 0.94 154 (24) 4.5 (3) 271 (29) 
014 0.93 133 (27) 7.1 (4) 170 (33) 
015 0.91 138 (31) 6.3 (5) 132 (37) 
016 0.94 153 (25) 6.0 (4) 186 (30) 
017 0.94 180 (25) 7.5 (4) 182 (30) 
018 0.89 139 (35) 5.1 (5) 123 (42) 
019 0.94 121 (25) 3.8 (3) 174 (30) 
Geo Mean   147   5.5   190   
Geo SD  1.31  1.25  1.44  
25% Quartile  133  4.8  170  
Median  139  5.2  182  
75% Quartile   154   6.3   186   
 
The inhibition of RBC AChE and plasma BuChE by DON was not statistically 
different from each other.  The RBC AChE Ki,noncomp geometric mean for the elderly and 
young subjects was 47.8 and 45.8 μM, respectively.  The plasma BuChE Ki,comp 
geometric mean for the elderly and young subjects was 93.8 and 190.4 μM, respectively.  
There was a nominal two-fold difference in plasma BuChE Ki,comp, similar to what was 
observed for PHYS, but this difference was nonsignificant.  This may be due to the high 
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interindividual variability; the Ki,comp ranged from 0.6 to 408 μM and the young subjects 
had a large geometric SD of 6.7.   
The Km and vmax for this study, i.e., in the presence of DON, was the same as the 
Km and vmax estimated in section 6.6.1.  The values were associated with each other with 
a correlation of at least 0.7. 
6.6.7. In-vitro Inhibition of RBC AChE and Plasma BuChE by Galantamine in 
Human Blood 
The inhibition of RBC AChE and plasma BuChE was fit by a competitive 
inhibition model and is shown in figure 6.6.7.-1; table 6.6.7.-1a. and b. shows the model 
parameter fits for RBC AChE and plasma BuChE, respectively.  The coefficient of 
determination for the RBC AChE was 0.83 or greater with the exception for one subject.  
The goodness of fit for the plasma BuChE was 0.91 or greater for all subjects.  The v0 
and Imax were estimated precisely for both enzymes but Ki,comp was less precisely 
estimated with COV of over 50% for several subjects. 
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Figure 6.6.7.-1. Inhibition by GAL fit by a competitive inhibition for RBC AChE and 
plasma BuChE for a representative subject 
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Table 6.6.7.-1a. Inhibition by GAL fit by a competitive inhibition model for RBC AChE  
Subject r2 v0 (%CV) Imax (%CV) Imax IC50 (%CV) Ki,comp
    [μmol/min/ml] [μmol/min/ml] [%] [μM] [μM] 
        AChE           
001 0.92 5.4 (5) 5.0 (7) 94 553 (40) 276 
002 0.94 3.2 (4) 3.0 (6) 94 620 (31) 310 
003 0.95 3.9 (3) 3.7 (7) 96 447 (33) 224 
004 0.88 3.4 (5) 3.9 (13) 116 1765 (52) 883 
005 0.88 3.4 (7) 3.1 (10) 90 89 (48) 44 
006 0.98 5.1 (2) 5.6 (5) 110 945 (20) 473 
007 0.96 5.4 (3) 4.9 (5) 90 312 (28) 156 
008 0.92 3.9 (4) 3.8 (8) 98 453 (41) 227 
009 0.88 5.7 (5) 5.6 (12) 99 765 (50) 383 
010 0.95 4.1 (3) 3.9 (6) 95 447 (31) 224 
Geo Mean   4.3   4.2   98 506   253 
Geo SD   1.24  1.25  1.09 2.18  2.18 
25% Quartile  3.5  3.8  94 447  224 
Median  4.0  3.9  95 503  251 
75% Quartile   5.3   5.0   99 729   365 
011 0.94 6.1 (3) 5.8 (7) 95 747 (33) 373 
012 0.64 5.1 (9) 4.1 (24) 81 780 (100) 390 
013 0.83 4.6 (6) 4.6 (15) 100 1178 (59) 589 
014 0.94 4.4 (3) 4.1 (8) 94 736 (33) 368 
015 0.97 4.9 (2) 4.7 (5) 97 814 (23) 407 
016 0.89 3.9 (5) 3.7 (11) 95 943 (47) 472 
017 0.87 4.7 (5) 4.3 (12) 92 556 (54) 278 
018 0.95 3.6 (3) 3.4 (6) 93 334 (32) 167 
019 0.96 4.1 (3) 4.0 (6) 98 487 (27) 243 
Geo Mean   4.5   4.3   94 693   344 
Geo SD   1.17  1.17  1.06 1.43  1.46 
25% Quartile  4.1  4.0  93 599  278 
Median  4.6  4.1  95 741  373 
75% Quartile  4.9  4.6  97 806  407 
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Table 6.6.7.-1b. Inhibition by GAL fit by a competitive inhibition model for plasma 
BuChE and selectivity for AChE 
Subject r2 v0 (%CV) Imax (%CV) Imax IC50 (%CV) Ki,comp AChE 
    [μmol/min/ml] [μmol/min/ml] [%] [μM] [μM] Selectivity
        BuChE            
001 0.97 1.7 (2) 1.7 (4) 100 2175 (24) 1088 3.9 
002 0.98 2.2 (2) 2.1 (4) 97 1103 (19) 552 1.8 
003 0.98 2.0 (1) 2.0 (5) 100 1514 (19) 757 3.4 
004 0.98 2.9 (2) 2.9 (3) 101 1744 (18) 872 1.0 
005 0.97 2.4 (2) 2.3 (6) 97 1522 (25) 761 17.2 
006 0.95 1.6 (3) 1.5 (7) 95 881 (29) 441 0.9 
007 0.97 1.9 (2) 1.8 (5) 97 756 (23) 378 2.4 
008 0.97 1.9 (2) 1.8 (6) 98 1327 (23) 663 2.9 
009 0.94 2.1 (3) 1.9 (8) 93 822 (33) 411 1.1 
010 0.98 3.9 (1) 4.0 (4) 101 1861 (18) 931 4.2 
Geo Mean   2.2   2.1   98 1293   646 2.6 
Geo SD   1.31  1.33  1.03 1.44  1.44 2.4 
25% Quartile  1.9  1.8  97 937  468 1.2 
Median  2.0  2.0  98 1420  710 2.7 
75% Quartile   2.3   2.3   100 1688   844 3.8 
011 0.97 2.7 (2) 2.5 (6) 93 1052 (24) 526 1.4 
012 0.93 3.2 (4) 3.0 (9) 92 828 (37) 414 1.1 
013 0.95 2.1 (3) 2.1 (8) 100 1560 (31) 780 1.3 
014 0.97 3.1 (2) 3.1 (6) 100 1468 (23) 734 2.0 
015 0.98 2.7 (1) 2.9 (5) 105 1869 (19) 934 2.3 
016 0.92 2.7 (4) 2.7 (1) 97 1509 (40) 755 1.6 
017 0.93 3.5 (3) 3.4 (9) 96 1253 (35) 627 2.3 
018 0.95 2.1 (3) 2.1 (8) 99 1314 (31) 657 3.9 
019 0.95 1.7 (3) 1.7 (8) 99 1387 (31) 694 2.8 
Geo Mean   2.6   2.5   98 1360   664 1.9 
Geo SD   1.26  1.25  1.04 1.27  1.27 1.5 
25% Quartile  2.1  2.1  96 1268  627 1.4 
Median  2.7  2.7  99 1428  694 2.0 
75% Quartile   3.1   3.0   100 1547   755 2.3 
 
The v0, the initial activity, for RBC AChE showed a group interaction (p=0.008); 
when further analyzed by Tukey’s HSD, the initial activity for young males was 
statistically lower then young females (3.6 (± 7%) compared to 5.0 μmol/min/ml (± 7%)).  
The Imax and Ki,comp was not statistically different among the groups.  The geometric mean 
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RBC AChE Ki,comp for the elderly and young subjects was 253 (± 118%)and 344 μM (± 
46%) respectively.   
The v0 for plasma BuChE was not statistically different among the groups.  The 
plasma BuChE Imax showed a group interaction (p=0.012), but when examined by 
Tukey’s HSD, no group was found to be statistically different from each other.  The 
plasma BuChE Ki,comp showed a group interaction (p=0.049), but when further analyzed 
by Tukey’s HSD, no difference between the groups was found.  The geometric mean 
plasma BuChE Ki,comp for the elderly and young subjects was 646 (± 44%) and 664 μM 
(27%), respectively. 
Inhibition of RBC AChE and plasma BuChE by GAL showed no age-related 
difference.  The young males showed lower RBC AChE activity compared to young 
females.   
In this study, GAL was only found to be about two-times more selective for RBC 
AChE than plasma BuChE.  Compared to the preliminary study, GAL was found to be 4-
5-fold more selective.  In addition the Ki,comp in this study was higher than the preliminary 
study; the Ki,comp for AChE was found to be 66 μM compared to 253 in this study; Ki,comp 
for plasma BuChE was found to be 358 μM compared to 646 μM in this study.  However, 
the values in the preliminary study were in, or close, to the range for this study.   
6.6.8. Statistical Summary of Results 
The mean model parameters for the kinetics of RBC AChE, plasma BuChE and 
PHYS in whole blood is shown in table 6.6.8.-1.  Table 6.6.8 -2 shows the p=value and r2 
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if a statistical difference was found.  If a group interaction was found, a post-hoc test by 
Tukey’s HSD was used to determine where the difference was. 
 
Table 6.6.8.-1. Summary of kinetics of RBC AChE, plasma BuChE and PHYS in whole 
blood 
 Km (%COV) vmax (%COV) CLint (%COV) 
 [μM] [μmol/min/ml] [μl/min/ml] 
  Young  
RBC AChE 72.5 (53) 10.7 (10) 147 (59) 
Plasma BuChE 120 (27) 4.5 (31) 37 (19) 
PHYS 0.068 (98) 2.2 (35) 32 (56) 
  Elderly  
RBC AChE 75.2 (28) 11.2 (10) 157 (34) 
Plasma BuChE 135.6 (26) 5.2 (23) 38 (41) 
PHYS 0.092 (67) 2.4 (22) 26 (49) 
 
Table 6.6.8.-2. Significance table of RBC AChE, plasma BuChE and PHYS in whole 
blood 
 Km  vmax CLint
RBC AChE NS NS NS 
Plasma BuChE NS G*A p=0.010 r2 =0.46 
G*A p=0.027 
r2 =0.29 
PHYS NS NS NS 
A, p-value for an Age difference;  
G, p-value for a difference based on Gender;  
G*A, value for a group interaction between Gender and Age groups 
 
Posthoc Analysis by Tukey’s HSD: 
Plasma BuChE vmax ; Elderly female (5.5)= young males (5.4) > young females (3.7) 
Plasma BuChE CLint; No difference 
 
Table 6.6.8.-3. shows the summary of the inhibition models for PHYR, PYR, 
DON and GAL.  Table 6.6.8.-4. shows the p=value and r2 if a statistical difference for an 
interaction, if observed. 
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Table 6.6.8.-3. Summary of inhibition of RBC AChE and plasma BuChE by PHYS, 
PYR, DON and GAL: [mean (%COV)] 
 v0‡ Imax Ki,comp Ki,noncomp † Ki,app kinact
 [μmol/min/ml] [%] [μM] [μM] [μM] [min-1] 
  RBC AChE – Young   
PHYS 9.5 (16) 75 (17) -- 0.01 (133) -- -- 
PYR 4.61 (36) 85 (15) -- 0.12 (16) 3.37 (637) 0.29 (103) 
DON -- -- -- 47.8 (81) -- -- 
GAL 4.26 (24) 98 (9) 253 (118) -- -- -- 
  RBC AChE – Elderly   
PHYS 12.7 (58) 82 (16) -- 0.015 (122) -- -- 
PYR 4.75 (17) 84 (10) -- 0.25 (72) 6.68 (1014) 0.51 () 
DON -- -- -- 45.8 (42) -- -- 
GAL 4.55 (17) 94 (6) 344 (46) -- -- -- 
    Plasma BuChE - Young      
PHYS 5.2 (32) 88 (3) -- 0.005 (121) -- -- 
PYR 2.61 (34) 98 (1) -- 0.3 (37) 23.9 (34) 0.69 (24) 
DON -- -- 93.8 (572) -- -- -- 
GAL 2.17 (31) 98 (3) 646 (44) -- -- -- 
  Plasma BuChE – Elderly   
PHYS 6.3 (45) 90 (5) -- 0.01 (82) -- -- 
PYR 2.8 (25) 98 (1) -- 0.27 (36) 23.2 (109) 0.71 (31) 
DON -- -- 190.4 (44) -- -- -- 
GAL 2.6 (26) 98 (4) 664 (27) -- -- -- 
†Ki,noncomp is measured at pseudo-steady-state for PHYS and steady-state for PYR 
‡Measured at vMAX for PHYS; measured at Km for PYR and GAL 
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Table 6.6.8.-4. Significance table of RBC AChE, plasma BuChE inhibition by PHYS, 
PYR, DON and GAL 
 v0 Imax Ki,comp Ki,noncomp Ki,app kinact
 [μmol/min/ml] [%] [μM] [μM] [μM] [min-1] 
  RBC AChE   
PHYS 
A p=0.034 
G*A p=0.030 
r2=0.43 
NS -- G p=0.034 r2=0.33 -- -- 
PYR NS NS -- 
A p=0.019 
G*A p=0.048 
r2=0.42 
NS NS 
DON -- -- -- NS -- -- 
GAL G*A p=0.008 r2=0.50 -- NS -- -- -- 
  Plasma BuChE   
PHYS NS NS -- 
A p=0.033 
G p=0.023 
r2=0.48 
-- -- 
PYR NS NS -- NS G p=0.033 r^2=0.35 NS 
DON -- -- NS -- -- -- 
GAL NS G*A p=0.012 r2=0.37 
G*A p=0.049 
r2=0.24 -- -- -- 
A, p-value for an Age difference;  
G, p-value for a difference based on Gender;  
G*A, value for a group interaction between Gender and Age groups 
 
Posthoc Analysis by Tukey’s HSD: 
RBC AChE PHYS v0 ; Elderly male (16.5) > young males (8.6)  
RBC AChE PYR Ki,noncomp; Elderly males (0.17) >> young males (0.04) 
RBC AChE GAL v0; Young female (5.0) > young males (3.6) 
Plasma BuChE GAL Imax; No difference 
Plasma BuChE GAL Ki,comp; No difference 
 
Table 6.6.8.-5. shows the summary of the PHYS linear sensitivity models RBC 
AChE and plasma BuChE.  Table 6.6.8.-6. shows the p=value and r2 if a statistical 
difference for an interaction is observed. 
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 Table 6.6.8.-5. Summary of sensitivity of RBC AChE and plasma BuChE to PHYS 
inhibition 
 
Sensitivity to PHYS 
[(μmol/min/ml)/(ng/ml)]
Sensitivity to PHYS 
[%/ng/ml] 
 Young  
RBC AChE -1.00 (87) 10.0 (85) 
Plasma BuChE -1.87 (135) 41.9 (121) 
 Elderly  
RBC AChE -1.02 (78) 9.7 (69) 
Plasma BuChE -0.76 (75) 13.9 (80) 
 
Table 6.6.8.-6. Significance table of sensitivity of RBC AChE and plasma BuChE to 
PHYS inhibition 
 
Sensitivity to PHYS 
[(μmol/min/ml)/(ng/ml)]
Sensitivity to PHYS 
[%/ng/ml] 
RBC AChE G*A p=0.046 r=0.25 NS 
Plasma 
BuChE 
A p=0.008 
G p=0.042 
r2=0.54 
A p=0.002 
G p=0.039 
r2=0.63 
A, p-value for an Age difference;  
G, p-value for a difference based on Gender;  
G*A, value for a group interaction between Gender and Age groups 
 
Posthoc Analysis by Tukey’s HSD: 
RBC AChE PHYS Sensitivity [(μmol/min/ml)/(ng/ml)]; No difference  
 
Correlation between the Ki values and PHYS sensitivity was explored to assess 
the generalizability in sensitivity results.  If two measures of sensitivity were significantly 
correlated (p-value<0. 05), the two values also had to be associated with a correlation 
coefficient of 0.5 or greater for the measures to be considered highly correlated.  The 
correlation matrix is shown in table 6.6.8.-7. and the correlation scatter plots are shown in 
figure 6.6.8.-1a. and b.   
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For RBC AChE, the DON Ki,comp was significantly negatively correlated with 
PYR Ki,ss.  The RBC AChE PYR Ki,ss showed an age-related difference in sensitivity; 
DON RBC AChE Ki,noncomp showed a negative correlation, which would suggest that 
elderly subjects were more sensitive to the effects of DON than young subjects.   
For plasma BuChE, DON Ki,comp was significantly positively correlated with GAL 
Ki,comp.  DON and GAL Ki,comp for plasma BuChE was correlated, but neither shows an 
age-related difference in sensitivity.  While significant, the correlation for both was not a 
strong correlation with a coefficient of 0.49 and 0.46, respectively.   
Also for plasma BuChE, PHYS Ki,pss and PHYS sensitivity was significantly 
negatively correlated.  This correlation was strong with an association of -0.83.  Both 
were found to exhibit an age-related difference in sensitivity.  They are expected to be 
negatively correlated, i.e., a decrease in Ki,pss indicates more sensitivity and an increase in 
PHYS sensitivity indicates more sensitivity. 
 
Table 6.6.8.-7. Correlation matrix for measures of sensitivity 
 DON  
ln(Ki) 
GAL  
ln(Ki,comp)
PYR  
ln(Ki,ss) 
PHYS  
ln(Ki,pss) 
PHYS  
ln(Sensitivity)
   AChE   
DON ln(Ki,noncomp) 1.0000 -0.0112 -0.4896 0.0480 -0.3538 
GAL ln(Ki,comp) -0.0112 1.0000 0.1842 0.0739 0.0453 
PYR ln(Ki,ss) -0.4896† 0.1842 1.0000 0.3037 0.2936 
PHYS ln(Ki,pss) 0.0480 0.0739 0.3037 1.0000 -0.3628 
PHYS ln(Sensitivity) -0.3538 0.0453 0.2936 -0.3628 1.0000 
   BuChE   
DON ln(Ki,comp) 1.0000 0.4593 0.1798 -0.2207 -0.0070 
GAL ln(Ki,comp) 0.4593† 1.0000 0.1706 -0.3438 0.1406 
PYR ln(Ki,ss) 0.1798 0.1706 1.0000 -0.2864 0.0486 
PHYS ln(Ki,pss) -0.2207 -0.3438 -0.2864 1.0000 -0.8306 
PHYS ln(Sensitivity) -0.0070 0.1406 0.0486 -0.8306† 1.0000 
† Correlation p-value < 0.05 
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Figure 6.6.8.-1a. RBC AChE correlation scatter plot of measures of sensitivity  
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Figure 6.6.8.-1b. Plasma BuChE correlation scatter plot of measures of sensitivity 
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 6.6.9. Covariate Analysis 
The sensitivity endpoints that had shown a statistically significant age-related 
difference were also tested for the effects of other potential covariates.  In particular, 
chronological age (in years) and clinical laboratory values, such as creatinine, estimated 
creatinine clearance, hematocrit, albumin, blood urea nitrogen, AST and ALT, (see tables 
6.4.-1. and 6.4.-2.) were tested for significant correlations with RBC AChE Ki,ss for PYR 
and plasma Ki,pss for PHYS and linear sensitivity for BuChE to PHYS.  In order to be 
considered a significant covariate, the p-value must have been less than 0.05 and the r2 
greater than 0.3.  Age was significantly correlated with PHYS sensitivity (%/(ng/ml)) 
with a p-value of 0.005 and an r2 of 0.38.  The regression plot is shown in figure 6.6.9.-1.  
This indicates that age (years) was able to account for 38% of the variability in linear 
sensitivity.  The slope of the regression line was 0.98 %/(ng/ml)/year and indicates that 
for each decade of life, plasma BuChE becomes 9.8 %/(ng/ml) less sensitive to the 
inhibition by PHYS.   
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Figure 6.6.9.-1. Regression plot of linear sensitivity  for PHYS to BuChE by Age (years); 
circles = female, square = male 
 
 
To assess similar effects, the ANOVA (p-value = 0.002), using age and gender as 
factors, was able to account for 63% of the variability in linear BuChE sensitivity to 
PHYS (see table 6.6.8.-6.).  Thus, age and gender (as nominal variables) were able to 
account for more of the variability than age alone as a continuous variable. 
No other clinical laboratory value showed any significant correlation.   
 
6.6.10. Summary of Age-Related Sensitivity Measurements 
The endpoints that showed an age-related difference in sensitivity are summarized 
in table 6.6.10.-1.  If age, in years, was found to be significantly correlated with the 
endpoint, the regression r2 is also reported. 
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Table 6.6.10.-1. Summary of age-related as differences in endpoints of sensitivity 
ChE Inhibitor Endpoint r
2
ANOVA 
r2
Regression 
PHYS Plasma BuChE Ki,pss 0.48 -- 
PHYS Linear Plasma BuChE Sensitivity (%/ng/ml) 0.63 0.38 
PYR RBC AChE Ki,ss 0.42 -- 
 
6.6.11. Conclusions 
The results of study demonstrate conclusively that there is indeed an age-related 
difference in in-vitro ChE inhibition sensitivity to two of the ChE inhibitors studied, 
namely PHYS and PYR, both of which are carbamates.   
For PHYS, the difference was observed only for plasma BuChE, but not for RBC 
AChE.  The Ki,pss, the concentration where 50% inhibition is observed, was two-fold 
higher for elderly subjects than for the young subjects; an age-related decrease in 
sensitivity of BuChE to PHYS was also found in the regression analysis.  This indicates 
that the elderly subjects may require a doubling in the ChE inhibitor concentration to 
attain the same inhibition as the young subjects.   
Furthermore, the inhibition at low concentrations was fit by a linear sensitivity 
model.  As suggested by the meta-analysis (see section 1.4.), for PHYS, the sensitivity 
slope showed a three-fold higher sensitivity in plasma BuChE for the young subjects 
compared to the elderly subjects; i.e., they showed three-fold higher percentage inhibition 
for the same increase in PHYS concentration.  The ANOVA was able to account for 63% 
of the variance in sensitivity by age and gender, depending on which units of sensitivity 
were used.   
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The ANOVA was able to account for as much as 63% of the variance in Ki,pss by 
age and gender, while the regression of linear sensitivity to PHYS as a function of age 
accounted for 38%, both indicating the importance of age in carbamate ChE inhibition. 
A statistically significant, age-related sensitivity difference for PYR was observed 
only for RBC AChE and not for plasma BuChE.  This difference was observed as two-
fold higher Ki,ss value for the elderly subjects compared to the young subjects.  This 
difference was mainly observed in the male subjects, where the Ki,ss for the elderly males 
were four-fold higher than for the young males.  Overall, the ANOVA was able to 
account for 42% of the variance in Ki,ss by age and gender   
No other potential clinical covariates were found to be significantly correlated 
with measures of sensitivity for PHYS and PYR. 
There was a gender difference in sensitivity for RBC AChE inhibition by PHYS, 
where males were twice as sensitive than females, however, the strength of the 
relationship was small and was only able to account for 33% in the variance in Ki,pss. 
The other two ChE inhibitors, DON and GAL, did not show any age-related 
differences in sensitivity.   
 
6.7. Discussion 
Using IC50 or Ki as a marker of sensitivity has precedent with AChE inhibitors 
and other pharmacologic agents.89, 90  The two ChE inhibitors that showed a 2-3-fold 
difference in in-vitro sensitivity in this study were PYR inhibition of RBC AChE and 
PHYS inhibition of plasma BuChE.  These findings could not be generalized to all ChE 
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inhibitors and were limited to these specific interactions, e.g., PYR only showed an age-
related difference in RBC AChE and not plasma BuChE, and vice versa for PHYS.   
As discussed in Chapter 1, the original meta-analysis of in-vivo human clinical 
studies with PHYS showed an apparent two-fold difference in sensitivity between a 
young group and an older group (see table 1.4.-1.).  This meta-analysis used reported ex-
vivo inhibition of both RBC AChE and plasma BuChE.  The study with young male 
subjects (Knapp et al)35 in the meta-analysis measured ex-vivo plasma BuChE activity, 
while the study with the older group (Men)30 measured ex-vivo RBC AChE activity.  The 
observed in-vitro sensitivity to PHYS in this current study matched well with the reported  
ex-vivo sensitivity in the studies included in the meta-analysis (see tables 6.6.4.-4 and 
6.6.4.-5); however, a difference in-in-vitro sensitivity to PHYS between young and older 
subjects was found only for plasma BuChE, while age and gender were able to account 
for 54% to 63% of the variance in sensitivity.   
The following mechanism may explain the decrease in ChE sensitivity with age: 
Carbamates, such as PHYS and PYR, cause inhibition by acting as reversible 
suicide inactivators, resulting in a transient and reversible inactivation of ChE.84  
Equation 1.3.4.-4 (shown below) shows the general reaction scheme for suicide 
inactivators.  Carbamate inhibitors (I) bind to ChE (E) to form the enzyme-inhibitor 
complex (EI) in a noncovalent fashion, characterized by the rate constants, k1 and k-1.  
The ChE then catalytically degrades the carbamate, causing release of a hydrolyzed 
product (I’) and formation of an inactive carbamoyl-enzyme complex (EI’).  This step is 
the carbamoylation step, characterized by the rate constant k2; the hydrolyzed product is 
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the noncarbamate portion (the leaving group) of the carbamate inhibitor. This EI’ 
complex is enzymatically inactive since the carbamoyl group covalently occupies the 
catalytic site.  Gradually, the carbamoyl group (I’’) is released from the enzyme to 
regenerate the free enzyme (E).  This step is the decarbamoylation step, characterized by 
the rate constant k3.  For carbamates, the carbamoylated ChE completely regenerates to 
the active enzyme, i.e., no irreversibly inactive ChE, Einact, is formed. 84 
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Other ChE inhibitors, such as organophosphates (insecticides and certain 
chemical warfare nerve agents), are irreversible suicide inactivators which interact with 
E, form an EI complex, followed by phosphorylation to EI’.  After an “aging” process, 
characterized by the rate constant k4, where rearrangement of the phosphate groups results 
in a phosphate product (the leaving group; I’’’) and formation of an irreversibly inactive 
phosphorylated ChE (Einact).84  The ratio of enzyme regeneration, k3, to irreversible 
inactivation, k4, is referred to as the “partition coefficient”.29  Strong irreversible 
inactivators, such as soman nerve gas, have a high partition coefficient, but carbamates 
have a partition approaching zero, i.e., virtually no irreversible inactivation.  Weaker 
irreversible inactivators, such as insecticides, have a lower partition coefficient.29   
The rate of enzyme inactivation/carbamoylation (k2) occurs very rapidly and can 
be observed as time-dependent inhibition by PHYS and PYR, characterized by the 
apparent first-order inactivation rate constant, kobs.  In equation 1.3.4.-4., kobs is described 
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empirically by a saturable function of initial ChE inhibitor concentration, where kinact is 
the maximum inactivation rate, Ki,app  is the concentration at half the maximum rate of 
inactivation and I0 is the initial inhibitor concentration. 
0,
0*
IK
Ik
k
appi
inact
obs +=      <Equation 1.3.4.-4a.> 
This equation describes the rate of inactivation and is determined by the initial E 
and I interaction, i.e., it characterizes the reaction scheme up to the formation of the 
inactive EI’ enzyme-inhibitor complex during the initial first 5-10 minutes.  Thus, in this 
scheme, Ki,app reflects the binding affinity of E and I, and kinact, the maximum rate of 
carbamoylation reflects k2.  Table 6.7.-1. shows the values for Ki,app and kinact for PHYS 
(section 5.9) and PYR (tables 6.6.5.-1a. and b.).  PHYS and PYR have similar affinities 
for both enzymes, ranging from 0.10 to 0.69 μM.  The inactivation rate constant (kinact) 
for PHYS is slower than for PYR, indicating that PYR is a rapid inactivator compared to 
PHYS. 
 
Table 6.7.-1. Summary of rate of inactivation described by the suicide inactivator model 
ChE Inhibitor -Enzyme Ki,app (%COV) [μM] 
kinact (%COV) 
[min-1] 
PHYS-RBC AChE † 0.21 (52) 0.30 (21) 
PHYS-Plasma BuChE † 0.099 (126) 0.21 (38) 
PYR-RBC AChE ‡ 0.29 (103) 3.4 (637) 
PYR-Plasma BuChE ‡ 0.69 (24) 23.9 (34) 
† the reported %COV is for the model imprecision 
‡ the reported %COV is the interindividual variability (n=19) 
 
On the other hand, the decarbamoylation rate is important for the estimation of 
Ki,pss:  Rapid decarbamoylation would result in a low degree of inhibition and is 
manifested by a high Ki,pss.  Slow decarbamoylation would result in persistent inhibition 
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and would be manifested by a low Ki,pss value.  For an illustration, see figure 6.7.-1 that 
shows a simulation of PHYS concentration-time profile in whole blood and the 
corresponding RBC AChE activity-time profile for three conditions, namely a rapid, 
intermediate and slow rate of recovery (excluding the first 30 minutes).  The model used 
in the simulation was the noncompetitive inhibition model (see equation 1.3.4.-1b).  The 
Ki,pss is defined as the PHYS concentration when 50% of the activity has recovered.  For 
rapid ChE recovery, the corresponding PHYS concentration would be higher (less time 
for PHYS to be degraded), resulting in a higher Ki,pss value.  For slow ChE recovery, a 
low corresponding PHYS concentration would be observed (more time for PHYS to be 
degraded), resulting in a lower Ki,pss value.  This means that the Ki,pss values, estimated 
from the observed data, are inversely related to the rate of recovery (k3 in model 1.3.4.-4). 
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Figure 6.7.-1. Simulation of the effect of rapid, intermediate and slow rates of ChE 
recovery on PHYS Ki,pss  
 
 
Therefore, since elderly subjects showed higher Ki,pss values for BuChE than 
younger subjects, the plasma BuChE in elderly subjects experienced rapid 
decarbamoylation while younger subjects experienced slow decarbamoylation.  The 
slower decarbamoylation rate/slower recovery may have also resulted in longer duration 
of inhibition in the younger subjects, however, this difference was not statistically 
significant, (see table 6.6.4.-1a and b; duration of RBC AChE inhibition for young = 390 
min (± 19%) and elderly = 311 min (± 31%); duration of plasma BuChE inhibition for 
young = 385 min (± 17%) and elderly = 343 min (± 15%)).  Nevertheless, the direction of 
the difference in duration (i.e., younger > elderly) was as expected. 
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For PYR, the magnitude of steady-state inhibition (EI’) is dependent on the ratio 
of k2/k3, i.e., the ratio of the rate of decarbamoylation to the rate of carbamoylation.  
Subjects with high sensitivity have a higher k2/k3 ratio, i.e., a low rate of 
decarbamoylation and/or a high rate of carbamoylation.  The rate of carbamoylation (k2, 
estimated by kobs) did not show a statistically significant difference between the two age 
groups.  However, lower Ki,ss for RBC AChE suggests that the decarbamoylation rate (k3) 
is slower for young subjects than for elderly.  Again, the age-related difference in Ki,ss for 
AChE with PYR seems to reflect kinetic differences in decarbamoylation rates across age 
groups, similar to what was observed for Ki,pss for BuChE with PHYS. 
For both PHYS and PYR, the (pseudo-)steady-state inhibition is dependent on the 
relative inactivation/carbamoylation rate (k2) and the rate of 
reactivation/decarbamoylation (k3).  The Ki,pss and Ki,ss for both AChE and BuChE are 
shown in table 6.7.-2.  The Ki,pss for PHYS is approximately 10-fold higher than the Ki,ss 
for PYR, but are not statistically different from each other due to the variability.  The 
Ki,pss is measured during the recovery of the enzymes by PHYS, and the Ki,ss is 
determined by the steady-state inactivation by PYR. 
 
Table 6.7.-2. Summary of (pseudo-)steady-state inactivation potency 
ChE Inhibitor –Enzyme Ki,
pss (%COV) 
[μM] 
Ki,ss  (%COV) 
[μM] 
PHYS-RBC AChE 0.01 (133) -- 
PHYS-Plasma BuChE 0.005 (121) -- 
PYR-RBC AChE -- 0.12 (16) 
PYR-Plasma BuChE -- 0.30 (72) 
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For carbamates, the rate of decarbamoylation (k3) occurs at a relatively slow rate, 
compared to carbamoylation (k2).  In addition, the decarbamoylation rate for PHYS is 
expected to be more rapid than for PYR.  Rapid decarbamoylation/reactivation, would 
allow for rapid degradation of the carbamate inhibitor, such as what is observed for 
PHYS, and would allow for complete recovery of in-vitro ChE activity.  On the other 
hand, ChE activity showed no appreciable recovery within 1,000 minutes after the 
addition of PYR, suggesting very slow decarbamoylation/reactivation.93   
This indicates that, for PHYS, the decarbamoylation/reactivation rate (k3) is rapid 
enough to allow for degradation of PHYS.  In other words, after inactivation by PHYS 
(and in the process, degradation of PHYS), the reactivation to free/active enzyme occurs 
rapidly, rapidly enough to then degrade further PHYS.  In this manner, PHYS is degraded 
over time.  On the other hand, the decarbamoylation/reactivation rate (k3) of ChE by PYR 
inhibition is slow.  This decarbamoylation rate is sufficiently slow to prevent further 
degradation of PYR.  This explains why PHYS degrades and why PYR inhibition persists 
for a very long time. 
The slower decarbamoylation for PYR is reported to be due to the N,N-dimethyl 
carbamate structure, while PHYS is an N-methyl carbamate.93  The dimethyl carbamate 
structure allows for more stabilizing resonance structures than methyl carbamates.  
However, the dimethyl carbamate structure also allows for more rapid inactivation, since 
they act as electron withdrawing groups to facilitate hydrolysis.93  This would also 
explain the more rapid maximum inactivation rate constant (kinact) by PYR than PHYS 
that was observed (see table 6.7.-1.). 
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The degradation of PHYS in plasma and a RBC suspension was characterized by 
an apparent Michaelis-Menten model.  The Km in plasma and RBC suspension was 
estimated as 0.046 μM (± 13%) and 0.047 μM (± 36%), respectively.  This Km 
characterizes the affinity of PHYS for the ChE, i.e., the E and I interaction.  However, 
this interaction is also characterized by Ki,app, obtained from the initial enzyme 
inactivation rates (kobs).  Thus, while measured independently from two different 
endpoints and estimated by two different models, the affinity of I for E is reflected by 
both the Ki,app in the suicide inactivator model and the Km of the degradation of PHYS in 
the Michaelis-Menten model.  Table 6.7.-3 summarizes the Ki and Km values for PHYS 
and PYR.  The Km and Ki,app values are similar to each other, within a 5-fold range, 
supporting the notion that they reflect the same process by two different, independent 
models.  On the other hand, the Ki,app values for PHYS are approximately 20-fold higher 
than Ki,pss, and the Ki,app values for PYR are approximately 2-fold higher than Ki,ss.  
Based on Ki,ss and Ki,app, both carbamate inhibitors appear more potent than based on 
Ki,app, since the former measures the slow decarbamoylation rate rather than the 
interaction of the E and I.  This means that PHYS and PYR are potent inhibitors, not 
because of their higher affinity with the enzyme (E+I), but rather because they cause 
strong inactivation of the enzyme (EI’) with slow reactivation.  The inactivation is more 
rapid for PYR (kinact), but the reactivation is very slow (k3).  For PHYS, the inactivation is 
slower (kinact), but the reactivation is more rapid (k3). 
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Table 6.7.-3. Summary of Ki values for PHYS and PYR, [Mean (%COV)] 
ChE Inhibitor -Enzyme Km  [μM]] 
Ki,app
[μM]] 
Ki,pss  
[μM] 
Ki,ss
[μM] 
PHYS-RBC AChE 0.046 (36) 0.21 (52) 0.01 (133) -- 
PHYS-Plasma BuChE 0.047 (13) 0.099 (126) 0.005 (121) -- 
PYR-RBC AChE -- 0.29 (103) -- 0.12 (16) 
PYR-Plasma BuChE -- 0.69 (24) -- 0.30 (72) 
 
In summary, the age-related difference in sensitivity for PYR was observed in 
RBC AChE while, for PHYS, it was observed for plasma BuChE.  While it is unclear 
why the difference was not generalizable to both RBC AChE and plasma BuChE, both 
PHYS and PYR share similar properties.  They are: 
o Reversible suicide inactivation mechanism of inhibition 
o Similar affinity with the enzyme (Ki,app) 
o Rate-limiting decarbamoylation/reactivation (k3) for recovery from 
inactivation (long duration of action) 
o Similar (pseudo)-steady-state inhibitory potencies, which is a function of 
the their inaction with the enzyme, inactivation and reactivation. 
However, they also have differences in their enzyme inhibitory properties: 
o Rate of inactivation (PYR >> PHYS), which is a function of k2PYR >> 
k2PHYS and kinactPYR >> kinactPHYS 
o Duration of action (PYR >> PHYS), which is a function of k3PYR << 
k3PHYS 
 
6.8. Clinical Implications 
The results of this study may have several implications as discussed below: 
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6.8.1. Extrapolation of in-vivo Inhibition/Cognitive Effects of Physostigmine  
Using the linear sensitivity model, the magnitude of in-vitro inhibition of RBC 
AChE and plasma BuChE by PHYS in the current study, matched well with ex-vivo 
measurements of inhibition (see section 6.6.5).  This indicates that ex-vivo inhibition of 
RBC AChE and plasma BuChE can be well predicted by in-vitro studies, at least at low 
concentrations of PHYS. 
Several studies explored in-vitro and in-vivo CNS inhibition versus whole blood 
inhibition for PHYS:   
In an in-vivo study, 0.5 to 2 mg of PHYS every two hours, six times per day for 
ten days, was administered orally to healthy (n=11 male, 7 female) and supranuclear 
palsy patients (n=5 male, 4 female) with a mean age of 65 years.94  A cerebrospinal fluid 
(CSF) sample was taken 30-minutes after the second dose of the day on the 10th day from 
both patient populations.  The PHYS CSF concentrations were reported to range between 
0.0003 and 0.0013 μM and resulted in an average of 10% inhibition for both CSF AChE 
and BuChE.  In addition to measuring ex-vivo CSF inhibition, the in-vitro CSF IC50 value 
(details of experiment not given) of AChE and BuChE was reported to range from 0.030 
to 0.040 μM.   
The 10% inhibition of CSF AChE and BuChE activity by PHYS concentration of 
0.0003 μM – 0.0013 μM is consistent with the results of this study:  Using in-vitro RBC 
AChE linear slope values in the elderly population from table 6.6.4.-3. ranging from 5.0 
to 35.3%/(ng/ml), the reported CSF concentrations would be predicted to result in RBC 
AChE inhibition ranging from 0.5% to 13%, similar to the reported 10% inhibition. 
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The reported IC50 values for for CSF AChE and BuChE inhibition (i.e., 0.03 – 
0.04 μM) are similar to the in-vitro RBC AChE Ki,pss (0.015 (± 122%)) and Ki,pss values 
for plasma BuChE (0.010 μM (± 82%)) (see tables 6.6.4-2a. and b.). 
The inhibition of AChE in postmortem human brain tissue and RBC by PHYS has 
previously been determined in-vitro.95  Brain tissue was obtained from 7 normal males 
and 4 normal females, aged between 56 and 87 years; tissue was dissected 5-28 hours 
after death.  Tetraisopropylpyrophosphoramide (iso-OMPA) was added to selectively 
inhibit BuChE.  The activity of AChE was measured using a radiolabeled ACh at pH 7.4 
and 25°C.  The results are summarized in table 6.8.1.-1.   
 
Table 6.8.1.-1.  Reported inhibition IC50 of PHYS in human brain tissue and RBC95 
PHYS IC50 [μM] (%COV) 
Frontal Cortex95 0.015 
Hippocampus95 0.014 
RBC95 0.027 
RBC AChE Ki,pss 
(current study) 0.015 (122) 
 
The reported IC50 values are similar to the RBC AChE Ki,pss values observed in 
the current study, 0.015 μM..  This suggests that the in-vitro measures of PHYS 
inhibition in RBC are similar to in-vitro inhibition of human brain tissue.   
These studies also allow to relate inhibition of AChE and BuChE in the CNS to 
the inhibition of RBC/plasma in the current study.  The IC50 values for inhibition of ex-
vivo human CSF AChE and BuChE (0.03 to 0.04 μM) were similar to the in-vitro values 
for inhibition in human brain tissue (frontal cortex, 0.015 μM; hippocampus, 0.014 μM) 
and similar to the in-vitro RBC AChE Ki,pss (0.015 μM) from the current study.  Thus, 
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AChE inhibition by PHYS appears to be similar in these different human tissues, 
regardless of ex-vivo or in-vitro conditions. 
In the study by Men,30 6.7 μg/kg of PHYS as a 30 minute IV infusion was used to 
reverse the effects of 6.7 μg/kg of scopolamine IV bolus, administered 60 minutes prior 
to PHYS.  The plasma PHYS Cmax was reported 0.012 μM (± 41%) and resulted in ex-
vivo RBC AChE inhibition of 20% (± 28%) in the elderly males (n=8) and females (n=8).  
The ability of PHYS to reverse the CNS and PNS effects of scopolamine was estimated 
for four PD endpoints, two peripheral endpoints, namely, heart rate (HR) and salivary 
flow (SF), and two CNS endpoints, namely, simple reaction time (SRT) and numerical 
working memory (NWM).  The reported values for potency of scopolamine (EC50) and 
the reversal potency (IC50) of PHYS are shown in table 6.8.1.-2.  For comparison sake, 
the Ki value for PHYS was calculated using one-half of the scopolamine plasma 
concentration predicted one hour after scopolamine administration (the start of the PHYS 
infusion), i.e., 0.0011 μM.  This concentration was chosen to predict the scopolamine 
concentrations in the CNS at the start of the PHYS infusion. 
 
Table 6.8.1.-2. EC50 of Scopolamine and reversal IC50 by PHYS (μM (± %COV))30 
  HR SF SRT NWM 
Reported Scopolamine EC50  0.0038 (100) 0.0003 (82) 0.0029 (96) 0.0046 (101) 
Reported PHYS IC50 0.0068 (232) 0.0182 (78) 0.0006 (2553) 0.0037 (325) 
Estimated PHYS Ki  0.0052 0.0033 0.0004 0.0030 
Current Study: PHYS RBC AChE Ki,pss = 0.015 (± 122%) 
 
Comparison of functional Ki values to the enzyme inhibitory Ki,pss values can be 
made:  The values of Ki for NWM, was similar to the Ki,pss indicating that the inhibition 
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of AChE and reversal of cognitive deficits by scopolamine are very similar.  The CNS 
measure of SRT was approximately 34-fold lower than RBC AChE Ki,pss and indicates 
that PHYS was able to reverse the effects of scopolamine very easily, more easily than 
PHYS can inhibit RBC AChE.  The Ki, of the two PNS measurements, HR and SF, was 
similar to the RBC AChE Ki,pss (3-fold lower and 5-fold lower, respectively).   
There are several limitations to this study:  The high EC50 values for scopolamine 
was most likely due to both estimation errors (of a biophase model for the effect) and 
interindividual variability.  In addition, the high variability in IC50 values for PHYS was 
likely due to the small reversal of effect by PHYS, especially for SF.  Finally, model 
misspecification for the interaction may have contributed to the overall variability; a 
competitive inhibition model was used, while it is known that PHYS does not compete 
directly with scopolamine for muscarinic receptors, but rather indirectly rises ACh 
synaptic concentrations by inhibition of postsynaptic AChE.  Nevertheless, the in-vivo 
functional Ki values of PHYS (characterized the reversal of scopolamine inducted 
anticholinergic effects) are similar to the in-vitro RBC AChE Ki,pss value in this study.  
In summary, these studies suggest that for PHYS:  
1. in-vitro RBC AChE inhibition was similar to ex-vivo AChE inhibition 
2. in-vitro RBC AChE inhibition is similar to ex-vivo and in-vitro CNS ChE 
inhibition 
3. in-vitro RBC AChE  inhibition appears to predicted the ability to reverse 
scopolamine-induced cognitive impairment of NWM and peripheral 
effects of HR and SF.  
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6.8.2. Epistigmine Maximum Tolerated Dose 
Epistigmine is a tertiary amine carbamate ChE inhibitor, similar to PHYS.  It was 
investigated as potential oral treatment of AD patients but never approved.38  During an 
early development phase I dose escalation study, the maximum tolerated dose in young 
healthy male subjects (n=19; age not specified) was 40 mg single dose.38  Forty percent 
of the subjects experienced moderate to severe adverse reactions, such as GI symptoms 
(nausea the most common), headache and fatigue.  However, during a dose escalation 
“bridge” trial, in AD patients (n=20; aged 57-84), these patients were able to tolerate the 
maximum dose in the trial, 90 mg/day, with no severe adverse effects. 38  Thus, this 
appears to indicate that young subjects were at least two-fold more sensitive to the 
(mechanism-related) adverse effects of epistigmine than older subjects.  This two-fold 
increased sensitivity to peripheral GI effects of a carbamate inhibitor is consistent with 
the observed 2-3- fold increase in in-vitro sensitivity for RBC AChE from this current 
study. 
6.8.3. Protection against Soman Nerve Gas by Pyridostigmine 
In the use of PYR for prophylaxis of nerve gas poisoning by soman, the 
recommended dosing regimen is 30 mg p.o. every eight hours. 96  Under this dosing 
regimen, men (n=30) and women (n=30) between 18 and 45 years old were recruited for 
a 21-day study to assess for the PK and ex-vivo PD (RBC AChE inhibition).96  In this 
study, the approximate Cmax in plasma (by visual inspection) in males and females was 25 
ng/ml (0.14 μM) (SD not reported) and 21.5 ng/ml (0.12 μM) (SD not reported), 
respectively.  Mean baseline RBC AChE activity was 10.4 μmol/min/ml (± 10), similar to 
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results of the current study, (10.7 μmol/min/ml (± 10%) (see table 6.6.1.-1)).  The mean 
peak inhibition (by visual inspection) observed for males and females was 2.6 and 2.3 
μmol/min/ml (SD not reported), respectively, or 24% and 21% inhibition.  The mean 
trough inhibition RBC AChE inhibition was reported to be between 10 and 15%.   
Using the results of the current study (RBC Ki,ss, 0.12 μM, for young males and 
females; see table 6.6.4-2a.), RBC AChE inhibition at the Cmax and trough (~6 ng/ml) 
PYR levels, is predicted to be 31% and 10%, respectively, in young subjects.   
The observed ex-vivo RBC AChE inhibition in the in-vivo study and the predicted 
RBC AChE inhibition, using the results of the current study, are shown in table 6.8.3.-1.  
For the prediction range, the AChE Ki,ss ranged from 0.04 μM (subject 010) to 0.38 μM 
(subject 007).  The observed mean ex-vivo RBC AChE from the in-vivo study was well 
within the range predicted using the results of the in-vitro inhibition from the young 
subjects in.  Thus, this in-vitro study was able to predict the inhibition observed in the in-
vivo study. 
 
Table 6.8.3.-1. Predictions of ex-vivo inhibition using the results of the current in-vitro 
study  
Condition Observed mean Cmax 
[μM] 96 
Observed ex-vivo RBC 
AChE inhibition 96 
[%] 
Predicted range of in-vitro RBC 
AChE inhibition 
[%] 
Peak 0.12-0.14 24-21 20-66 
Trough 0.033 10-15 7-40 
 
The in-vivo PYR study modeled ex-vivo inhibition by an Emax-model.  Due to the 
noncompetitive nature of PYR at steady-state, the EC50 estimated would be comparable 
to the Ki,ss estimated in the current study.  The Emax model assumed the maximum 
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inhibition to be 100%, while the model in the current study did not make this assumption.  
In fact, there was generally a 15-20% residual RBC AChE activity.  Despite the model 
difference, comparison of the EC50 and Ki,ss can be made to compare the ex-vivo and in-
vitro inhibition by PYR.  The ex-vivo EC50 was estimated to be 0.38 μM (± 22.2%); the 
in-vitro Ki,ss estimated for the young subjects was 0.12 μM (± 120%).  The ex-vivo EC50 
was estimated from plasma PYR concentrations, while the Ki,ss in the current study was 
estimated from nominal in-vitro whole blood PYR concentrations.  In order to estimate 
the corresponding plasma Ki,ss concentration, we assume PYR distributes only within the 
plasma of whole blood (quaternary amine and indirect evidence in chapter 5, see section 
5.7).  Thus, assuming a 50% hematocrit, the plasma Ki,ss value would be estimated to be 
0.24 μM, very similar to the EC50 value (0.38 μM) reported in the in-vivo PYR study, 
further supporting evidence that in-vitro measurement of sensitivity is a good marker for 
ex-vivo sensitivity of PYR.   
In summary, for PYR, the in-vitro RBC AChE inhibition predicted ex-vivo RBC 
AChE inhibition.  There is no information on CNS inhibition but PYR is not expected to 
cause appreciable CNS inhibition (quaternary amine).  There is also no published 
quantitative information about PYR effects on PNS inhibition (e.g., salivary flow, heart 
rate, etc.) 
6.8.4. Predictions of In-vivo Cholinesterase Inhibition by Donepezil 
In therapeutic doses (5 or 10 mg tablet, once a day), DON is reported to inhibit 
RBC AChE between 30 and 80% in AD patients.97  In this, large multi-center study, 
plasma DON concentrations were measured along with ex-vivo RBC AChE inhibition 
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and cognitive measurements, at monthly follow up visits, for up to 6 months.  The plasma 
DON concentrations and the percent inhibition was fit by an Emax-model.  The ex-vivo 
plasma EC50 was reported to be 0.04 μM (± 9%) and the mean Cmax in plasma was 0.13 
μM (± 4).97, 98  This is much lower than the in-vitro whole blood Ki,noncomp found in the 
current study (48 to 94 μM).  The discrepancy may be due to the presence of several 
accumulating metabolites of DON that are pharmacologically active, of which, 6-O-
desmethyl-DON is known to have a similar inhibitory potency to DON [DON prescribing 
information].  DON undergoes extensive metabolism and these metabolites are expected 
to contribute to RBC AChE inhibition in-vivo, which would lower the apparent EC50.  An 
in-vitro study, such as the current study, would not be able to capture this discrepancy, 
unless the metabolites are studied separately as well. 
In a bioequivalence study of DON, 24 healthy males and females were 
administered a 10 mg DON tablet.99  Concentrations of DON and the major metabolite, 
6-O-desmethyl-DON, were measured.  The plasma concentration of the metabolite was 
much lower than the concentrations of unchanged DON; however, the elimination of the 
metabolite was much lower than for the parent compound.  Given the long half-life of 
443 hr, significant accumulation of the metabolite can be expected to occur.  Under daily 
dosing conditions, and assuming linear PK, only about 3% of desmethyl-DON would be 
eliminated within the dosing interval.  This would result in significant accumulation and 
may be able to account for the discrepancy between ex-vivo and in-vitro inhibition. 
This discrepancy prevents predictions of the current results to in-vivo 
observations; however, an in-vivo observations have been made.  Under therapeutic 
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conditions, the CSF inhibition of AChE ranged from 10% to up to 49% inhibition.100  
RBC AChE inhibition ranged from 30% to 80% under the same conditions.  Thus, for 
DON the reported inhibition in the blood is 2-3 times higher than the observed inhibition 
in CSF. 
6.8.5. Predictions of In-vivo Galantamine Inhibition 
In a single dose PK/PD study with eight young healthy males receiving 10 mg 
GAL tablet, GAL concentrations and ex-vivo RBC AChE inhibition were measured.  The 
reported plasma Cmax was 0.17 μM (range: 0.1 to 0.2 μM).101  The IC50 and value from 
ex-vivo inhibition study was 0.42 μM and the mean ex-vivo AChE inhibition was 
approximately 40%.  In the current study, the Ki,comp of RBC AChE inhibition for GAL in 
the young subjects was 253 μM (± 118), and the predicted inhibition in the concentration 
range of 0.1 and 0.2 μM would be less than 1%  This in-vitro study severely 
underpredicts the inhibition observed in an in-vivo study.   
GAL is reported to have an active metabolite, O-desmethyl GAL, however, its 
plasma concentration levels at therapeutic doses are low and not expected to contribute to 
inhibition.102   
The inhibition of AChE in postmortem human brain tissue and RBC was 
determined in-vitro, described in section 6.8.1 for PHYS.95  The results are shown in 
table 6.8.5.-1.  The reported IC50 values were 100- to 1,000-fold lower than the RBC 
AChE Ki,comp found in the current study (ranging from 506 to 693 μM).  This discrepancy 
may be due to differing methodologies:  The brain tissue studies used radiolabled ACh, 
which may have affected the activity compared to the current study which used AtCh as 
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the substrate.  In addition, to inhibit BuChE, iso-OMPA was used as a selective inhibitor.  
While reported to be a selective inhibitor, its selectivity is concentration-dependent, and 
concentrations used in this study may not be completely selective.  Nonselective 
inhibition of AChE by iso-OMPA would potentiate the inhibition by GAL and lower the 
apparent IC50 values determined in the study.   
 
Table 6.8.5.-1.  Inhibition of brain tissue AChE and RBC AChE by GAL 
PHYS IC50 [μM] (%COV) 
Frontal Cortex 2.75 
Hippocampus 3.24 
RBC 0.36 
RBC AChE Ki,comp 253 (118) 
 
In addition, the current study was performed in whole blood, and the Ki,comp is 
reported as nominal whole blood GAL concentrations.  GAL has a high log P value and 
partitions significantly to RBCs (53%) and binds to plasma proteins (19%) [GAL 
prescribing information].  This may suggest that the nominal whole blood concentrations 
may not be the best measurement of actual potency.  If there is significant GAL 
accumulation in RBC, using plasma Cmax values would lead to underprediction of 
inhibition, and RBC concentrations may be more relevant. 
In AD patients, GAL inhibition of CNS AChE assessed by positron emission 
tomography imaging was estimated to be 30 to 36%.103  These AD patients were taking 
16-24 mg/day in two divided doses for 3 months.  This CNS inhibition is similar to the 
reported ex-vivo RBC AChE inhibition of 40% (described above). 
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In summary, the reported ex-vivo GAL RBC AChE inhibition in healthy young 
subjects matched well to in-vivo CNS AChE inhibition in AD patients on therapeutic 
doses; however, the current in-vitro results underpredict ex-vivo RBC AChE severely for 
reasons not fully understood. 
 
In order to make a generalized observation of the CNS inhibition required for a 
therapeutic effect, the estimated or predicted ex-vivo CNS inhibition for DON, GAL and 
PHYS are shown in table 6.8.5.-2.  The measured inhibition of CNS AChE for the 
treatment of AD by DON and GAL was 10-49% for DON and 30-36% for GAL.  The 
predicted PHYS inhibition to reverse the cognitive effects of scopolamine was 37% 
(assuming Cmax of 0.012 μM (± 0.005)30 and Ki,pss of 0.012 μM (± 113%)).  The degree of 
inhibition in the CNS for these three agents are similar and would suggest the required 
inhibition of CNS AChE for a cognitive benefit is in this range.  The inhibition necessary 
for a cognitive benefit, either in AD or in elderly subjects with scopolamine induced 
cognitive deficient, was in the range of approximately 30-40%.  This may suggest the 
goal of CSF CNS inhibition associated with clinically significant cognitive benefit is in 
this range. 
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 Table 6.8.5.-2. Predicted/observed CNS ChE inhibition for PHYS, DON and GAL  
 Patient Dose Cmax  
[μM] 
Ki used in 
prediction or 
“Observed” 
CNS AChE 
Inhibition 
Predicted PHYS CNS 
Inhibition101,30
Elderly, 
scopolamine 
induced cognitive 
6.7 μg/kg IV 
infusion 
0.012 0.015 μM 37% 
Observed DON CSF 
Inhibition100, 101 
AD 5 or 10 mg 
tablet 
0.13 Observed 10-49% 
Observed GAL CNS 
Inhibition103 
AD 16 or 24 
mg/day tablet 
0.18,  Observed 30-36% 
 
 
6.9. Limitation of Current Study 
This study had several limitations: 
This study was an in-vitro rather than an in-vivo study.  While this allowed us to 
study higher concentrations and inhibition than allowed in-vivo, extrapolation to in-vivo 
conditions may not always successful, especially for DON and GAL (see discussion in 
section 6.8.).   
This study was a 2-group study, with groups of young and older adults.  While an 
age-related difference in sensitivity was found, the particular age range when this 
difference occurs is unknown.  A 3-group study with young, middle-aged and older-aged 
adults may have been able to distinguish at what age this difference may occur.  In 
addition, a more physiologic model of age-related sensitivity may have been able to be 
developed. 
This study was a cross-sectional design.  A longitudinal study would be able to 
follow the effect of age in a single individual.  This limitation is due to time constraints 
for the project. 
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The older adults in this study were active and did not include anyone over the age 
of 85.  This limited age range prevents us from understanding the effects in the frail and 
the very old. 
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Chapter 7 
Conclusions 
 
The research project investigated the mechanism of action of the in-vitro RBC 
AChE and plasma BuChE for four structurally diverse ChE inhibitors (PHYS, PYR, 
DON and GAL), and it included a clinical study to assess any age- and gender-related 
differences in in-vitro sensitivity to ChE inhibition in healthy young and aged volunteers.   
Table 7-1. summarizes the findings of this study. 
 
Table 7.1. Summary of sensitivity findings 
Inhibitor Enzyme MOA 
Ki Young (±COV) 
Ki, Elderly (±COV)
[μM] 
Selectivity Age-related sensitivity 
AChE Suicide inactivation 
0.010 (130%) 
0.015 (220%) None PHYS 
BuChE Suicide inactivation 
0.005 (110%) 
0.010 (82%) 
None Young 2-3-fold more 
sensitive 
AChE Suicide inactivation 
0.12 (120%) 
0.25 (72%) 
Young 2-fold more 
sensitive, primarily in 
males PYR 
BuChE Suicide inactivation 
0.30 (37%) 
0.27 (36%) 
None 
None 
AChE Noncompetitive 48 (81%) 94 (42%) None DON 
BuChE Competitive 94 (570%) 190 (44%) 
AChE  
(>40-fold)† None 
AChE Competitive 253 (120%) 344 (46%) None GAL 
BuChE Competitive 646 (44%) 664 (27%) 
AChE 
(2.2-fold) None 
† Calculated from the ratio of the degree of inhibition at the Km concentration of substrate 
and Ki concentration of inhibitor 
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The conclusions from these finding are as follows: 
1. In-vitro RBC AChE and plasma BuChE activity followed Michaelis-Menten 
kinetics, with respect to their substrates, AtCh and BtCh.  The baseline kinetics of 
RBC AChE, using AtCh as the model substrate, (Km, vmax; young – 72.5 μM, 10.7 
μmol/min/ml RBC; elderly – 75.2 μM, 11.2 μmol/min/ml RBC) showed no age-
related differences; the baseline vmax of plasma BuChE, using BtCh as model 
substrate, showed that young females had a 40% lower activity (3.7 μmol/min/ml 
plasma) compared to young males and elderly females (5.4 and 5.5 μmol/min/ml 
plasma, respectively), which may be due to sexual dimorphism and effects of oral 
contraceptives on hepatic expression of BuChE; Km values were similar across all 
age groups (young - 120 μM; elderly – 136 μM). 
2. AtCh was found to be a nonselective, but high affinity substrate (RBC AChE Km 
= 73 μM; plasma BuChE Km = 117 μM).  BtCh was found to be a selective 
substrate for plasma BuChE (RBC AChE Km = 130,000 μM; plasma BuChE Km = 
72 μM).   
3. PHYS degradation by human whole blood, RBC suspension and plasma was 
described by a Michaelis-Menten model.  The vmax, Km and CLint in human whole 
blood was 0.0013 nmol/min/ml plasma, 0.021 μM 0.058 ml/min/ml plasma, 
respectively, in a 50% RBC suspension was 0.00079 nmol/min/ml buffer, 0.046 
μM and 0.017 ml/min/ml buffer, respectively; in human plasma was 0.00103 
nmol/min/ml plasma, 0.047 μM and 0.022 ml/min/ml plasma, respectively. 
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4. The human whole blood degradation clearance of PHYS, scaled up using human 
plasma volume, ranged from 195 to 261 ml/min, accounting for only about 4-6% 
of the reported in-vivo total clearance (CLtot: 4500 ml/min).30  Clearance by RBC, 
presumably by AChE, was estimated to be responsible for 60% of the whole 
blood clearance; plasma clearance, presumably by BuChE, was estimated to be 
responsible for 40% of the whole blood clearance.   
5. PHYS was found to be a potent, nonselective, reversible suicide inactivator of 
ChEs.  For a starting concentration of 0.36 μM, maximum inhibition of both RBC 
AChE and plasma BuChE was observed at approximately 30 minutes after the 
addition of PHYS, and inhibition recovered to baseline in 390 minutes in the 
young subjects and 311 minutes in the elderly subjects.  The Ki,pss values for RBC 
AChE in the young and elderly were 0.010 and 0.015 μM, respectively; for 
plasma BuChE in the young and elderly were 0.005 and 0.010 μM (p<0.05 for the 
latter). 
6. PHYS showed an age-related difference in sensitivity to inhibition of plasma 
BuChE, as measured as the slope of percent inhibition per PHYS concentration 
relation at low concentrations.  Young subjects were approximately 2-3 fold more 
sensitive to plasma BuChE inhibition by PHYS (42 compared to 14 %/(ng/ml))  
The difference in sensitivity may be due to a slower decarbamoylation rate in the 
young subjects.   
7. The in-vitro sensitivity values in this study matched well with other clinical ex-
vivo studies of PHYS (Men (2004)30, elderly males and females RBC AChE - 12 
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%/(ng/ml); Knapp et al. (1991)35 young male plasma BuChE - 27 %(ng/ml)).  
This suggests that in-vitro sensitivity is a good marker for ex-vivo sensitivity.  
Using in-vitro ChE sensitivity is a safer alternative to ex-vivo measurements, since 
the ChE inhibitor does not need to be administered to study subjects. 
8. PYR was also found to be a potent, nonselective, suicide inactivator of ChE, but 
compared to PHYS, it is stable in-vitro in human blood over the experimental 
time period of 1,000 minutes.  ChE inactivation by PYR was more rapid than 
PHYS.  The inactivation of RBC AChE was more rapid than plasma BuChE at 
low concentration (PYR concentrations of ~3.4 to 6.7 μM), but was more rapid 
for plasma BuChE at higher concentrations (> 23 μM).  There was no difference 
in inactivation rates between RBC AChE and plasma BuChE, the RBC AChE 
Ki,ss in the young and elderly adults was 0.12 and 0.25 μM respectively; plasma 
BuChE Ki,ss in the young and elderly was 0.30 and 0.27 μM, respectively.  The 
Ki,ss of PYR was approximately 10-fold higher than the Ki,pss of PHYS for both 
enzymes.  The inactivation by PYR was more rapid than PHYS; the maximal 
inactivation rate constant of PYR were 3.4 min-1 and 23.9 min-1 for RBC AChE 
and plasma BuChE, respectively; for PHYS, the maximal inactivation rate 
constants were only 0.30 min-1 and 0.21 min-1, respectively. 
9. PYR showed an age-related difference in in-vitro sensitivity to inhibition of RBC 
AChE as measured by Ki,ss.  Young subjects were approximately two-fold more 
sensitive to RBC AChE inhibition by PYR (0.12 vs. 0.25 μM).  The difference in 
245 
in-vitro sensitivity is, presumably, due to a slower decarbamoylation rate in the 
young subjects, as was observed for PHYS in plasma. 
10. The high potency of PHYS and PYR, both carbamate ChE inhibitors, is likely due 
to their suicide inactivation mechanism with slow decarbamoylation rates 
(recovery rates) rather than differences in binding affinity to the enzyme.  It 
appears that decarbamoylation rates may decrease with old age, leading to the 
observed decrease in in-vitro ChE sensitivity. 
11. DON was found to be a selective inhibitor of AChE, with noncompetitive 
inhibition of RBC AChE compared to competitive inhibition of plasma BuChE.  
The RBC AChE Ki,noncomp for the young and elderly subjects was 48 and 94 μM, 
respectively; the plasma BuChE Ki,comp was 94 and 190 μM, respectively.  No 
age-related differences in sensitivity were observed.  Its mechanism of action 
involves presumably binding to the peripheral ABS on AChE, causing steric 
hindrance of ACh (and AtCh) entering and leaving the narrow gorge, leading to 
noncompetitive inhibition while binding to the catalytic ABS on BuChE, causing 
competitive binding with AtCh (and BtCh).  While DON may also bind to the 
peripheral ABS of BuChE, this is not expected to lead to inhibition.  The observed 
kinetic mechanism is findings are consistent with molecular modeling studies, 
suggesting this type of interaction. 
12. GAL was found to be a competitive inhibitor with moderate selectivity for AChE 
(only about 2-fold selective).  GAL was the least potent inhibitor for both AChE 
and BuChE (RBC AChE Ki,comp; young, 253 μM; elderly, 344 μM - plasma 
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BuChE Ki,comp; young, 646 μM; elderly, 664 μM).  No age-related difference in 
sensitivity was observed.  This type of inhibition suggests the mechanism of 
inhibition is by binding to the catalytic ABS.  This type of interaction is also 
consistent with molecular modeling studies. 
13. Overall, this research suggests suicide inactivators, such as carbamates, show an 
age-related difference in in-vitro sensitivity, while competitive and 
noncompetitive inhibitors do not.  The age-related difference in in-vitro 
sensitivity may be due to the kinetics of inactivation/recovery, rather than a 
difference in binding affinity of ChE inhibitors.  Thus, competitive and 
noncompetitive inhibitors did not show an age-related difference in sensitivity.   
14. For PHYS and PYR, in-vitro ChE inhibition is similar to ex-vivo ChE inhibition; 
DON and GAL, probably due to active metabolite (DON) and/or due to RBC 
accumulation (GAL), the reported ex-vivo inhibition was greater than predicted 
in-vitro inhibition.  In-vitro inhibition is a good marker of in-vivo inhibition as 
long as possible contribution of pharmacologically active metabolites or RBC 
partitioning are considered. 
15. For PHYS, in-vitro RBC AChE inhibition is similar to in-vitro and ex-vivo CNS 
(postmortem brain tissue, CSF) ChE inhibition, most likely since brain 
concentrations are similar to blood concentrations.  This suggests that CNS ChE 
enzymes behave similarly to RBC AChE and plasma BuChE enzymes.  For other 
CNS-active ChE inhibitors (DON and GAL), this could not be evaluated due to 
the lack of an apparent in-vitro-in-vivo correlation of ChE inhibition.. 
247 
16. For PHYS, in-vitro and in-vivo/ex-vivo inhibition predicts CNS/PNS effects 
(scopolamine reversal) of clinically relevant cognitive effects.  For other ChE 
inhibitors, cognitive effects in AD patients seem to be associated with in-vitro/ex-
vivo blood AChE inhibition of 30-40% 
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Appendix B 
Informed Consent Form 
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Appendix C 
Scientist ® PK/PD Models 
1. Michaelis-Menten Kinetic Model (PHYS) 
 
// Michaelis-Menten kinetics 
// DSL/JV 2007 
IndVars: T, D 
DepVars: C 
Params: VMAX, KM, V 
C'=-VMAX*C/(KM+C) 
// Initial conditions 
T=0 
C=D/V 
*** 
 
 
2. Michaelis-Menten Model (RBC AChE and plasma BuChE) 
 
// Michaelis-Menten Model 
// DSL/JV 2007 
IndVars: C 
DepVars: v 
Params: VMAX, KM 
v=VMAX*C/(KM+C) 
*** 
 
 
3. Mixed Competitive-noncompetitive Inhibition Model (DON) 
 
// Mixed Competitive-noncompetitive Inhibition Model 
// DSL/JV 2007 
IndVars: S, I 
DepVars: V 
Params: Vmax, Km, Knc, Kc 
v=(Vmax/(1+I/Knc))*S/(Km*(1+I/Kc)+S) 
*** 
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4. Competitive Inhibition Model (DON) 
 
// Competitive Inhibition Model 
// Multiple substrate concentrations, S. 
// DSL/JV 2007 
IndVars: S, I 
DepVars: V 
Params: Vmax, Km, Ki 
v=(Vmax/(1+I/Ki))*S/(Km+S) 
*** 
 
 
5. Noncompetitive Inhibition Model (DON) 
 
// Noncompetitive Inhibition Model 
// DSL/JV 2007 
IndVars: S, I 
DepVars: V 
Params: Vmax, Km, Kc 
v=Vmax*S/(Km*(1+I/Kc)+S) 
*** 
 
 
6. Competitive Imax  Model (GAL) and Noncompetitive/Steady-State/Pseudo-Steady-
State Inhibition Model (PYR and PHYS) 
 
// Competitive Inhibition Model  
// Single substrate concentration 
// DSL/JV 2007 
IndVars: I 
DepVars: v 
Parameters: Imax, IC50, v0  
v=v0-Imax*I/(IC50+I) 
// 
// Competitive: KI,comp = IC50/(1+S/KM) 
// Noncompetitive: IC50 = KI, noncomp 
*** 
 
 
7. Suicide Inactivation Model (PYR) 
 
// Suicide Inactivation Model (Ito et al. Pharmacol Rev 1998; 50:387-412) 
// DSL 2008 
IndVars: I 
DepVars: kobs 
Params: kinact, Kiapp 
kobs=kinact*I/(Kiapp+I) 
*** 
 
272 
Appendix D 
RBC AChE and Plasma BuChE Kinetics 
1. RBC AChE and Plasma BuChE kinetics 
2. Table of Substrate concentration, RBC AChE and Plasma BuChE activity 
Subject 001 
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AtCh or BtCh Concentration RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
1000 -- 3.754 
1000 -- 3.885 
1000 -- 4.004 
3000 11.029 4.028 
3000 11.206 3.582 
3000 11.144 3.770 
1000 10.813 3.234 
1000 12.146 3.221 
1000 14.537 2.944 
300 10.690 2.463 
300 9.997 2.792 
300 9.360 2.546 
100 6.126 1.806 
100 6.701 1.829 
100 6.928 1.803 
30 4.147 1.189 
30 6.291 1.436 
30 3.683 1.276 
10 0.492 -0.002 
10 3.984 -0.010 
10 1.302 0.018 
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AtCh or BtCh Concentration RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 -- 4.451 
10000 -- 4.173 
10000 -- 5.310 
3000 10.799 4.541 
3000 11.241 4.387 
3000 10.716 4.340 
1000 12.222 3.722 
1000 13.028 3.391 
1000 15.717 3.231 
300 10.732 1.978 
300 10.287 1.971 
300 12.342 2.346 
100 8.447 2.029 
100 7.295 2.277 
100 9.154 2.186 
30 7.502 2.041 
30 6.068 1.890 
30 3.143 2.004 
10 0.654 1.720 
10 2.302 1.737 
10 1.062 1.479 
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AtCh or BtCh Concentration RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 -- 3.908 
10000 -- 3.471 
10000 -- 3.072 
3000 7.486 5.135 
3000 8.259 5.166 
3000 8.619 4.398 
1000 10.597 4.967 
1000 8.280 5.154 
1000 8.738 4.799 
300 8.231 2.603 
300 7.139 2.636 
300 7.983 2.745 
100 3.368 2.127 
100 4.534 2.202 
100 3.036 2.131 
30 0.632 1.438 
30 1.329 1.481 
30 2.995 1.453 
10 0.110 0.346 
10 0.452 0.590 
10 0.446 0.609 
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AtCh or BtCh Concentration RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 -- 6.459 
10000 -- 6.320 
10000 -- 6.345 
3000 8.397 5.393 
3000 8.882 5.807 
3000 10.986 4.781 
1000 10.455 4.408 
1000 9.008 4.565 
1000 8.346 4.449 
300 5.990 3.439 
300 5.385 3.961 
300 7.564 3.031 
100 3.054 2.725 
100 2.766 2.676 
100 5.285 2.515 
30 2.362 1.867 
30 2.258 1.547 
30 1.620 1.426 
10 1.121 0.487 
10 0.605 0.408 
10 0.805 0.300 
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AtCh or BtCh Concentration RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 -- 5.864 
10000 -- 6.295 
10000 -- 6.284 
3000 7.518 5.452 
3000 7.604 5.573 
3000 5.832 5.785 
1000 10.364 4.114 
1000 9.243 4.294 
1000 10.519 4.380 
300 9.937 3.174 
300 9.121 3.277 
300 9.471 3.346 
100 5.619 2.555 
100 5.810 2.576 
100 5.005 2.702 
30 3.548 1.661 
30 4.165 1.721 
30 5.977 1.752 
10 1.318 0.685 
10 0.539 0.640 
10 1.453 0.664 
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AtCh or BtCh Concentration RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 -- 3.641 
10000 -- 3.600 
10000 -- 3.353 
3000 9.542 2.840 
3000 12.557 3.019 
3000 11.772 2.916 
1000 10.696 2.304 
1000 10.856 2.471 
1000 9.656 2.520 
300 7.413 1.781 
300 7.132 1.911 
300 6.189 1.957 
100 4.960 1.406 
100 6.732 1.517 
100 5.041 1.499 
30 4.094 1.006 
30 3.015 1.069 
30 1.629 1.074 
10 1.811 0.476 
10 2.192 0.496 
10 1.839 0.511 
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AtCh or BtCh Concentration RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 -- 3.828 
10000 -- 4.117 
10000 -- 3.561 
3000 10.361 3.337 
3000 9.474 3.659 
3000 10.840 3.674 
1000 9.780 2.869 
1000 10.225 3.006 
1000 11.053 3.069 
300 10.010 2.249 
300 8.862 2.342 
300 9.488 2.361 
100 6.651 1.749 
100 6.357 1.823 
100 7.095 1.823 
30 3.748 1.563 
30 3.451 1.368 
30 3.430 1.563 
10 1.811 0.560 
10 1.376 0.580 
10 0.836 0.557 
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AtCh or BtCh Concentration RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 -- 4.691 
10000 -- 4.494 
10000 -- 4.499 
3000 9.836 3.711 
3000 9.050 3.262 
3000 7.454 3.721 
1000 8.583 3.097 
1000 9.633 3.189 
1000 8.378 2.890 
300 7.426 2.425 
300 10.228 2.357 
300 9.651 2.107 
100 4.233 1.898 
100 7.020 1.913 
100 6.814 1.916 
30 2.792 1.287 
30 4.353 1.266 
30 3.661 1.424 
10 1.533 0.617 
10 3.017 0.559 
10 0.937 0.864 
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AtCh or BtCh Concentration RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 -- 4.554 
10000 -- 4.821 
10000 -- 4.844 
3000 9.126 3.970 
3000 9.938 4.302 
3000 9.916 4.046 
1000 9.215 3.247 
1000 9.565 3.572 
1000 10.248 3.504 
300 8.151 2.333 
300 7.872 2.486 
300 8.861 2.503 
100 6.581 1.764 
100 5.702 1.941 
100 6.319 1.954 
30 2.850 1.288 
30 2.750 1.321 
30 1.897 1.385 
10 1.329 0.621 
10 0.950 0.641 
10 1.966 0.635 
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AtCh or BtCh Concentration RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 -- 8.169 
10000 -- 7.639 
10000 -- 8.117 
3000 10.661 7.515 
3000 9.276 7.482 
3000 10.125 7.238 
1000 9.313 5.695 
1000 9.253 5.306 
1000 9.477 5.711 
300 9.500 4.177 
300 8.555 4.289 
300 10.040 4.421 
100 7.689 2.873 
100 7.119 3.103 
100 6.712 3.355 
30 2.090 1.167 
30 2.715 2.615 
30 2.694 1.784 
10 2.224 0.541 
10 1.612 0.525 
10 2.801 0.609 
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AtCh or BtCh Concentration RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 -- 5.612 
10000 -- 5.696 
10000 -- 5.760 
3000 13.711 5.117 
3000 10.059 5.540 
3000 9.146 5.613 
1000 10.685 4.163 
1000 7.142 4.251 
1000 10.246 4.447 
300 9.756 3.235 
300 10.527 3.486 
300 8.288 3.398 
100 4.538 2.249 
100 6.580 2.605 
100 5.143 2.235 
30 2.217 1.488 
30 2.807 2.001 
30 2.516 1.892 
10 2.435 0.690 
10 0.889 1.092 
10 0.250 0.924 
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AtCh or BtCh Concentration RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 -- 4.565 
10000 -- 4.369 
10000 -- 4.439 
3000 12.925 3.201 
3000 13.327 3.936 
3000 13.626 4.332 
1000 11.890 3.149 
1000 11.788 3.466 
1000 11.520 3.355 
300 9.661 2.265 
300 9.813 2.639 
300 10.285 2.729 
100 7.059 1.107 
100 7.288 0.945 
100 7.787 1.091 
30 3.371 0.788 
30 4.812 0.815 
30 4.095 0.720 
10 1.261 0.218 
10 0.988 0.220 
10 1.292 0.239 
 
284 
Subject 013 
0
2
4
6
8
10
12
10 100 1000 10000
AtCh [μM]
R
B
C
 A
C
hE
 A
ct
iv
ity
[ μm
ol
/m
in
/m
l]
0
1
2
3
4
5
10 100 1000 10000
BtCh [μM]
P
la
sm
a 
B
uC
hE
 A
ct
iv
ity
[ μm
ol
/m
in
/m
l]
 
 
AtCh or BtCh Concentration RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 -- 4.753 
10000 -- 4.572 
10000 -- 4.449 
3000 10.815 4.076 
3000 10.374 4.204 
3000 9.359 4.058 
1000 11.099 3.286 
1000 9.900 3.285 
1000 10.443 3.315 
300 10.023 2.406 
300 10.900 2.567 
300 10.838 2.418 
100 7.880 2.121 
100 6.113 2.026 
100 3.460 2.009 
30 5.461 1.167 
30 3.458 1.399 
30 3.049 1.380 
10 0.691 0.360 
10 0.312 0.494 
10 0.646 0.475 
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AtCh or BtCh Concentration RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 -- 6.391 
10000 -- 6.252 
10000 -- 6.809 
3000 10.225 5.939 
3000 10.250 6.336 
3000 10.380 6.654 
1000 10.838 5.791 
1000 10.686 5.990 
1000 10.683 6.237 
300 9.465 3.718 
300 9.167 3.891 
300 9.598 4.004 
100 6.774 2.935 
100 6.028 3.058 
100 7.466 3.032 
30 2.554 2.053 
30 3.747 2.098 
30 4.169 2.119 
10 0.875 0.819 
10 2.416 0.781 
10 0.252 0.806 
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AtCh or BtCh Concentration RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 -- 6.514 
10000 -- 6.155 
10000 -- 6.351 
3000 9.608 5.422 
3000 9.485 5.831 
3000 10.622 5.913 
1000 9.193 4.415 
1000 8.896 4.813 
1000 7.831 4.770 
300 6.979 3.426 
300 9.405 3.565 
300 8.111 3.643 
100 2.555 2.654 
100 3.508 2.783 
100 5.900 2.939 
30 2.867 1.936 
30 1.877 2.002 
30 2.640 1.986 
10 0.762 0.826 
10 0.836 0.820 
10 1.578 0.826 
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AtCh or BtCh Concentration RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 -- 6.460 
10000 -- 6.118 
10000 -- 6.355 
3000 9.025 5.448 
3000 8.532 5.480 
3000 7.867 5.670 
1000 9.159 4.492 
1000 10.232 4.622 
1000 9.006 4.387 
300 8.255 3.250 
300 7.793 3.544 
300 8.022 3.427 
100 5.338 2.366 
100 5.624 2.729 
100 4.693 2.667 
30 1.638 1.873 
30 2.709 1.669 
30 2.159 1.601 
10 0.586 0.589 
10 0.213 0.550 
10 0.772 0.584 
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AtCh or BtCh Concentration RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 -- 8.012 
10000 -- 7.637 
10000 -- 7.425 
3000 11.974 6.479 
3000 11.303 6.538 
3000 12.833 7.196 
1000 10.812 5.315 
1000 11.518 4.036 
1000 12.290 5.585 
300 10.119 3.788 
300 9.432 4.322 
300 10.425 4.058 
100 8.859 3.245 
100 8.570 3.325 
100 7.228 3.048 
30 4.553 2.106 
30 3.710 2.003 
30 4.338 2.011 
10 2.739 0.835 
10 1.732 0.822 
10 2.163 0.793 
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AtCh or BtCh Concentration RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 -- 5.581 
10000 -- 5.701 
10000 -- 4.979 
3000 7.691 4.068 
3000 8.655 4.777 
3000 5.972 4.919 
1000 9.313 3.015 
1000 10.657 3.623 
1000 7.928 2.873 
300 7.621 2.847 
300 6.749 3.062 
300 10.203 3.271 
100 7.337 2.174 
100 5.957 1.880 
100 8.853 2.277 
30 2.430 1.207 
30 2.974 2.001 
30 2.013 1.489 
10 0.610 0.549 
10 1.060 0.578 
10 1.189 0.544 
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AtCh or BtCh Concentration RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 -- 3.975 
10000 -- 4.032 
10000 -- 4.007 
3000 10.602 3.449 
3000 13.829 3.473 
3000 9.743 3.652 
1000 11.292 2.820 
1000 11.031 2.677 
1000 12.611 2.964 
300 12.506 2.054 
300 11.595 2.227 
300 10.992 2.186 
100 8.949 1.578 
100 7.762 1.827 
100 6.778 1.702 
30 4.759 1.091 
30 2.244 1.165 
30 2.625 1.183 
10 2.314 0.501 
10 1.337 0.979 
10 1.694 0.454 
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Appendix E 
PHYS in Human Whole Blood 
1. PHYS concentration-time profile fit by a Michaelis-Menten kinetic model with 
RBC AChE and plasma BuChE activity-time profile 
2. PHYS inhibition of RBC AChE and Plasma BuChE fit by a pseudo-steady-state 
noncompetitive inhibition model 
3. Table of Time, PHYS concentration, RBC AChE and Plasma BuChE 
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  Plasma PHYS RBC AChE Plasma BuChE 
Time Concentration Activity Activity 
[min] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0  Baseline 10.00 3.97 
0.5 0.3032 7.65 1.44 
5 0.2898 2.57 0.77 
10 0.2901 1.93 0.46 
30 0.2160 3.00 0.52 
60 0.2441 1.88 0.64 
105 0.1464 2.34 0.74 
150 0.1075 4.41 0.89 
195 0.0429 4.31 1.30 
240 0.0298 6.97 1.81 
300 0.0049 7.86 2.88 
360 <LLOQ 12.39 4.36 
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  Plasma PHYS RBC AChE Plasma BuChE 
Time Concentration Activity Activity 
[min] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 Baseline 11.42 4.25 
0.5 0.3679 7.35 0.99 
5 0.3419 4.47 0.56 
10 0.3716 3.53 0.42 
30 0.3629 1.79 0.42 
60 0.2778 3.46 0.47 
105 0.2308 2.96 0.55 
150 0.1389 2.17 0.57 
195 0.0527 2.89 0.76 
240 0.0730 3.55 0.96 
300 0.0245 5.73 1.70 
360 0.0023 8.10 3.11 
420 0.0011 9.32 4.33 
480 0.0008 10.49 5.16 
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  Plasma PHYS RBC AChE Plasma BuChE 
Time Concentration Activity Activity 
[min] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 Baseline 9.05 5.17 
0.5 0.4130 5.47 1.43 
5 0.4510 2.05 0.55 
10 0.4276 2.89 0.67 
30 0.3932 3.53 0.51 
60 0.3097 4.97 0.48 
105 0.2540 3.87 0.64 
150 0.1261 2.63 0.76 
195 0.1045 2.83 0.87 
240 0.0684 3.35 1.11 
300 0.0231 5.73 1.99 
360 0.0025 6.43 3.50 
420 <LLOQ 7.06 4.71 
480 <LLOQ 7.55 5.66 
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  Plasma PHYS RBC AChE Plasma BuChE 
Time Concentration Activity Activity 
[min] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 Baseline 9.75 5.82 
0.5 0.3803 2.04 1.41 
5 0.3648 1.60 0.78 
10 0.3628 1.53 0.58 
30 0.3197 1.25 0.61 
60 0.2848 1.64 0.66 
105 0.1899 0.69 0.78 
150 0.1166 3.07 1.13 
195 0.0228 3.90 1.58 
240 0.0069 5.16 2.62 
300 0.0010 6.87 4.93 
360 <LLOQ 8.05 6.71 
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  Plasma PHYS RBC AChE Plasma BuChE 
Time Concentration Activity Activity 
[min] [ng/ml] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 Baseline 10.16 5.41 
0.5 0.3612 3.44 1.51 
5 0.3353 2.00 0.75 
10 0.3614 1.01 0.60 
30 0.3382 1.21 0.51 
60 0.2760 1.06 0.63 
105 0.1758 1.85 0.69 
150 0.1216 3.13 0.92 
195 0.0590 3.46 1.22 
240 0.0195 3.83 2.16 
300 0.0014 6.96 3.36 
360 <LLOQ 8.20 5.63 
420 <LLOQ 8.62 6.23 
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  Plasma PHYS RBC AChE Plasma BuChE 
Time Concentration Activity Activity 
[min] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 Baseline 10.78 3.62 
0.5 0.4489 5.52 1.38 
5 0.4420 3.60 0.75 
10 0.4305 3.62 0.54 
30 0.3891 2.16 0.44 
60 0.3482 2.19 0.45 
105 0.2434 1.62 0.47 
150 0.2331 3.96 0.55 
195 0.1390 2.99 0.62 
240 0.0936 3.57 0.70 
300 0.0437 3.61 1.00 
360 0.0260 6.83 1.55 
420 0.0049 8.15 2.65 
480 0.0007 10.78 3.52 
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  Plasma PHYS RBC AChE Plasma BuChE 
Time Concentration Activity Activity 
[min] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0   10.00 3.97 
0.5 0.3032 7.65 1.44 
5 0.2898 2.57 0.77 
10 0.2901 1.93 0.46 
30 0.2160 3.00 0.52 
60 0.2441 1.88 0.64 
105 0.1464 2.34 0.74 
150 0.1075 4.41 0.89 
195 0.0429 4.31 1.30 
240 0.0298 6.97 1.81 
300 0.0049 7.86 2.88 
360 <LLOQ 12.39 4.36 
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  Plasma PHYS RBC AChE Plasma BuChE 
Time Concentration Activity Activity 
[min] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 Baseline 8.86 4.56 
0.5 0.3605 6.96 1.57 
5 0.3627 1.95 0.67 
10 0.3829 3.47 0.77 
30 0.3338 2.42 0.41 
60 0.2803 2.68 0.52 
105 0.1499 2.50 0.66 
150 0.1121 4.39 0.77 
195 0.0660 5.06 0.78 
240 0.0376 3.21 1.09 
300 0.0204 6.98 1.82 
360 <LLOQ 10.41 3.40 
420 <LLOQ 9.81 4.47 
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  Plasma PHYS RBC AChE Plasma BuChE 
Time Concentration Activity Activity 
[min] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 Baseline 9.68 4.74 
0.5 0.4025 9.08 2.20 
5 0.3943 5.44 1.00 
10 0.3877 5.18 0.72 
30 0.3677 2.92 0.64 
60 0.3254 1.97 0.70 
105 0.1850 2.14 0.71 
150 0.1842 1.82 0.84 
195 0.1187 4.00 0.96 
240 0.0780 3.88 1.14 
300 0.0328 6.06 1.73 
360 0.0040 9.66 3.16 
420 <LLOQ 10.69 5.07 
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  Plasma PHYS RBC AChE Plasma BuChE 
Time Concentration Activity Activity 
[min] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 Baseline 9.35 7.98 
0.5 0.3481 7.65 2.59 
5 0.3527 4.23 1.27 
10 0.3270 3.61 1.02 
30 0.2934 3.76 0.89 
60 0.2429 1.73 1.01 
105 0.1456 2.90 1.96 
150 0.0667 3.24 1.76 
195 0.0246 5.30 2.83 
240 0.0027 5.53 5.84 
300 <LLOQ 9.68 8.51 
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  Plasma PHYS RBC AChE Plasma BuChE 
Time Concentration Activity Activity 
[min] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 Baseline 11.63 3.45 
0.5 0.3334 8.48 2.34 
5 0.3291 4.75 1.27 
10 0.3089 4.74 0.91 
30 0.2722 2.22 0.79 
60 0.2077 3.62 0.99 
105 0.1451 4.53 1.10 
150 0.0685 4.66 1.59 
195 0.0338 6.24 2.03 
240 0.0072 9.06 3.37 
300 0.0006 11.17 5.19 
360 <LLOQ 11.88 5.90 
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  Plasma PHYS RBC AChE Plasma BuChE 
Time Concentration Activity Activity 
[min] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 Baseline 11.84 2.98 
0.5 0.4087 6.08 1.74 
5 0.4077 3.74 0.82 
10 0.4081 2.82 0.53 
30 0.3752 4.28 0.53 
60 0.2919 3.48 0.63 
105 0.2402 5.09 0.68 
150 0.1238 2.98 0.88 
195 0.0894 4.93 1.07 
240 0.0512 5.63 1.51 
300 0.0142 8.57 2.82 
360 <LLOQ 14.50 4.82 
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  Plasma PHYS RBC AChE Plasma BuChE 
Time Concentration Activity Activity 
[min] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 Baseline 10.48 4.59 
0.5 0.4838 10.00 1.93 
5 0.4686 4.81 1.21 
10 0.4434 5.68 0.93 
30 0.4418 2.36 0.66 
60 0.3302 1.57 0.68 
105 0.2707 3.98 0.75 
150 0.1496 4.56 0.87 
195 0.1144 4.91 1.20 
240 0.0743 5.25 1.29 
300 0.0415 6.59 1.87 
360 0.0104 9.06 3.26 
420 0.0014 10.79 4.63 
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  Plasma PHYS RBC AChE Plasma BuChE 
Time Concentration Activity Activity 
[min] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 Baseline 10.74 6.48 
0.5 0.4204 8.07 2.73 
5 0.3765 4.58 1.54 
10 0.3430 2.22 1.05 
30 0.3084 4.36 0.91 
60 0.2321 2.81 1.21 
105 0.1780 3.68 1.38 
150 0.0984 6.29 1.87 
195 0.0283 3.04 2.89 
240 0.0060 8.75 4.53 
300 0.0006 10.69 6.85 
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  Plasma PHYS RBC AChE Plasma BuChE 
Time Concentration Activity Activity 
[min] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 Baseline 8.64 6.34 
0.5 0.3705 6.68 2.51 
5 0.3628 3.88 1.06 
10 0.3330 2.13 0.78 
30 0.3200 0.62 0.74 
60 0.2782 1.88 0.83 
105 0.1614 1.30 1.02 
150 0.1133 1.81 1.23 
195 0.0160 5.48 2.48 
240 0.0133 5.95 2.90 
300 0.0009 9.03 5.43 
360 <LLOQ 9.31 6.40 
 
306 
Subject 016 
0.0001
0.001
0.01
0.1
1
0 200 400 600
Time (min)
Pl
as
m
a 
PH
YS
 C
on
c 
[ μM
]
0
2
4
6
8
10
12
14
16
C
hE
 A
ct
iv
ity
 [ μ
m
ol
/m
in
/m
l]
0
2
4
6
8
10
12
14
16
0.0001 0.001 0.01 0.1 1
Plasma PHYS Conc [μM]
C
hE
 A
ct
iv
ity
 [ μ
m
ol
/m
in
/m
l]
 
  Plasma PHYS RBC AChE Plasma BuChE 
Time Concentration Activity Activity 
[min] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 Baseline 9.47 6.31 
0.5 0.3861 6.29 3.22 
5 0.3581 4.00 1.46 
10 0.3894 2.62 1.03 
30 0.3412 2.31 0.76 
60 0.2959 2.32 0.95 
105 0.1754 1.74 1.22 
150 0.1557 3.36 1.42 
195 0.0725 3.81 1.82 
240 0.0405 4.58 2.41 
300 0.0230 6.10 3.77 
360 0.0116 9.75 5.63 
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  Plasma PHYS RBC AChE Plasma BuChE 
Time Concentration Activity Activity 
[min] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 Baseline 11.54 7.69 
0.5 0.3531 9.50 2.76 
5 0.3511 5.16 1.28 
10 0.2945 4.01 1.13 
30 0.3041 2.06 0.23 
60 0.2488 1.71 0.86 
105 0.1421 5.22 1.19 
150 0.1023 5.42 1.74 
195 0.0115 5.91 2.75 
240 0.0132 9.70 4.41 
300 0.0006 11.98 7.30 
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  Plasma PHYS RBC AChE Plasma BuChE 
Time Concentration Activity Activity 
[min] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 Baseline 9.30 5.42 
0.5 0.2857 9.51 2.06 
5 0.3460 4.18 0.92 
10 0.2713 1.82 0.68 
30 0.2993 0.64 0.67 
60 0.3026 1.27 0.73 
105 0.1201 4.27 0.76 
150 0.1427 6.00 0.88 
195 0.0721 3.59 1.09 
240 0.0992 3.91 1.25 
300 0.0246 4.28 2.22 
360 0.0277 7.49 3.64 
420 <LLOQ 9.60 5.03 
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  Plasma PHYS RBC AChE Plasma BuChE 
Time Concentration Activity Activity 
[min] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 Baseline 11.64 4.00 
0.5 0.3797 6.42 1.54 
5 0.4829 2.58 0.75 
10 0.4581 4.31 0.56 
30 0.4514 4.56 0.49 
60 0.4284 3.61 0.55 
105 0.2454 3.57 0.66 
150 0.2099 2.58 0.67 
195 0.1194 4.27 0.98 
240 0.0729 5.17 1.08 
300 0.0326 3.60 1.41 
360 0.0052 7.36 2.48 
420 0.0004 8.45 3.49 
480 <LLOQ 12.09 5.16 
 
310 
Appendix F
PYR in Human Whole Blood 
1. Ln(RBC AChE activity) and ln(Plasma BuChE activity)-time profile for the first 
10 minutes fit by a straight line that estimates the first order inactivation rate 
constant 
2. Concentration-dependent first-order inactivation rate constants fit by a suicide 
inactivation model 
3. Steady-state inactivation fit by a steady-state noncompetitive inactivation model 
4. Table of Time, RBC AChE and Plasma BuChE activity for each PYR 
concentration 
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    RBC AChE Activity   Plasma BuChE Activity 
Time 
C0
100 μM 
C0
10 μM 
C0
1 μM 
C0
0.1 μM 
C0
100 μM 
C0
10 μM 
C0
1 μM 
C0
0.1 μM 
0 8.83 8.83 8.83 8.83 4.15 4.15 4.15 4.15 
0.5 1.25 2.17 4.70 6.98 0.65 2.76 3.53 3.98 
5 2.23 2.83 4.07 5.82 0.32 1.21 3.09 3.44 
10 2.25 1.86 3.57 6.47 0.30 0.65 2.70 3.47 
180 1.41 1.48 1.94 4.54 0.32 0.37 1.00 3.09 
kobs 0.115 0.093 0.066 0.024 0.375 0.175 0.037 0.018 
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    RBC AChE Activity     Plasma BuChE Activity 
Time 
C0
100 μM 
C0
10 μM 
C0
1 μM 
C0
0.1 μM 
C0
100 μM 
C0
10 μM 
C0
1 μM 
C0
0.1 μM 
0 4.75 4.98 5.43 4.31 2.05 2.08 2.27 2.21 
0.5 0.72 0.00 2.58 4.11 0.24 1.44 1.74 2.34 
5 0.91 0.28 0.07 3.41 0.08 0.45 1.67 2.10 
10 0.58 0.65 0.71 2.94 0.05 0.24 1.37 2.04 
180 0.00 0.24 0.69 2.45 0.06 0.10 0.38 1.53 
kobs 0.180 0.210 0.227 0.037 0.483 0.211 0.039 0.011 
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    RBC AChE Activity     Plasma BuChE Activity 
Time 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0  
0.1 μM 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0  
0.1 μM 
0 2.76 2.76 3.24 2.44 2.55 2.27 2.19 2.12 
0.5 0.33 0.63 2.04 2.55 0.36 1.56 1.72 2.00 
5 0.21 0.20 0.85 1.96 0.07 0.54 1.47 1.99 
10 0.54 0.73 1.08 1.88 0.05 0.24 1.32 2.02 
180 0.62 1.37 1.52 1.63 0.05 0.13 0.42 1.58 
kobs 0.349 0.094 0.102 0.030 0.576 0.216 0.041 0.003 
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    RBC AChE Activity     Plasma BuChE Activity 
Time 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0  
0.1 μM 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0  
0.1 μM 
0 5.22 3.51 3.78 3.96 2.99 2.89 2.87 2.77 
0.5 -0.02 1.00 1.80 5.13 0.25 1.97 2.54 2.84 
5 1.07 0.68 1.46 3.38 0.08 0.84 2.31 2.88 
10 0.01 -0.44 1.05 2.52 0.08 0.38 2.28 2.73 
180 0.56 0.95 0.77 2.46 0.04 0.11 0.97 2.25 
kobs 0.274 0.175 0.098 0.058 0.529 0.191 0.019 0.002 
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    RBC AChE Activity     Plasma BuChE Activity 
Time 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0  
0.1 μM 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0  
0.1 μM 
0 3.00 3.83 3.07 3.60 2.64 2.53 2.62 2.82 
0.5 0.37 0.24 1.48 2.38 0.50 1.81 2.22 2.69 
5 0.53 0.08 1.24 2.72 0.07 0.58 2.14 2.76 
10 -0.97 0.50 0.89 2.12 -0.08 0.29 1.93 2.72 
180 0.48 0.09 0.63 2.11 0.07 0.11 0.64 2.05 
kobs 0.177 0.114 0.094 0.033 0.598 0.212 0.023 0.001 
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    RBC AChE Activity     Plasma BuChE Activity 
Time 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0 
 0.1 μM 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0 
 0.1 μM 
0 6.14 4.87 6.55 5.89 1.77 1.72 1.64 1.64 
0.5 1.85 3.36 5.52 5.26 0.26 1.01 1.48 1.66 
5 0.12 2.52 3.81 5.42 0.04 0.39 1.32 1.58 
10 -0.19 1.22 2.17 6.44 0.05 0.18 1.31 1.48 
180 0.52 2.04 2.46 3.16 0.06 0.10 0.47 1.44 
kobs 0.716 0.123 0.104 0.007 0.625 0.212 0.019 0.011 
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    RBC AChE Activity   Plasma BuChE Activity 
Time 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0  
0.1 μM 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0
0.1 μM 
0 4.87 5.20 4.67 5.55 2.09 2.09 2.12 1.96 
0.5 1.41 0.52 3.84 3.68 0.38 1.45 1.66 1.76 
5 0.50 0.85 3.53 3.34 0.04 0.48 1.66 2.07 
10 0.90 0.50 1.88 3.84 0.05 0.22 1.47 2.03 
180 0.78 -0.06 1.88 3.85 0.05 0.08 0.46 1.65 
kobs 0.368 0.133 0.080 0.022 0.652 0.219 0.026 -0.010 
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    RBC AChE Activity    Plasma BuChE Activity 
Time 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0
0.1 μM 
C0 
 100 μM 
C0  
10 μM 
C0  
1 μM 
C0  
0.1 μM 
0 3.64 5.00 4.06 4.02 1.98 1.95 1.99 1.82 
0.5 0.85 1.33 4.49 4.52 0.40 1.47 1.62 2.05 
5 0.48 1.04 1.92 4.57 0.09 0.61 1.50 1.94 
10 0.11 0.64 1.04 3.90 0.03 0.28 1.45 2.01 
180 0.32 0.75 0.86 2.73 0.05 0.11 0.40 1.66 
kobs 0.296 0.151 0.146 0.007 0.515 0.189 0.024 -0.004 
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    RBC AChE Activity   Plasma BuChE Activity 
Time 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0 
 0.1 μM 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0  
0.1 μM 
0 5.27 5.46 5.53 6.10 2.10 2.28 2.11 2.23 
0.5 0.70 0.48 4.31 5.00 0.41 1.40 1.80 2.17 
5 0.72 0.08 1.76 4.79 0.05 0.40 1.68 2.16 
10 0.59 0.99 1.25 4.59 0.05 0.40 1.50 2.13 
180 0.19 0.61 0.78 2.98 0.07 0.10 0.68 1.83 
kobs 0.238 0.106 0.147 0.021 0.618 0.170 0.028 0.003 
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    RBC AChE Activity   Plasma BuChE Activity 
Time 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0  
0.1 μM 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0  
0.1 μM 
0 4.03 4.55 5.63 4.67 4.25 4.23 4.08 4.01 
0.5 0.45 0.56 2.52 5.34 0.83 2.90 3.40 3.77 
5 0.29 0.29 1.46 3.55 0.12 1.06 3.22 4.04 
10 0.47 0.61 0.59 3.41 0.11 0.44 2.75 3.96 
180 0.64 0.53 0.70 1.67 0.11 0.23 1.15 3.23 
kobs 0.355 0.128 0.194 0.041 0.603 0.216 0.032 -0.002 
 
330 
Subject 011 
-6
-5
-4
-3
-2
-1
0
1
2
3
0 5 10
Time [min]
  l
n 
(A
C
hE
 A
ct
iv
ity
)
-3
-2
-1
0
1
2
0 5
Time [min]
ln
 (B
uC
hE
 A
ct
iv
ity
)
10
 
 
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.01 1 100 10000
PYR [μM]
ko
bs
 [m
in
-1
]
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.01 1 100 10000
PYR [μM]
ko
bs
 [m
in
-1
]
 
331 
 0
1
2
3
4
5
6
0.001 0.1 10 1000
PYR Blood Concentration [μM]
R
B
C
 A
C
hE
 A
ct
iv
ity
 [ μ
m
ol
/m
in
/m
l]
0
0.5
1
1.5
2
2.5
3
0.001 0.1 10 1000
PYR Blood Concentration [μM]
Pl
as
m
a 
B
uC
hE
 A
ct
iv
ity
 [ μ
m
ol
/m
in
/m
l]
 
 
    RBC AChE Activity   Plasma BuChE Activity 
Time 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0  
0.1 μM 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0  
0.1 μM 
0 4.08 5.04 6.25 4.00 2.78 2.73 2.77 2.84 
0.5 0.49 2.01 3.83 5.90 0.37 1.91 2.31 2.92 
5 0.60 0.00 1.59 4.65 0.07 0.67 2.13 2.68 
10 0.43 0.00 1.04 4.09 0.06 0.29 1.77 2.26 
180 0.18 0.00 1.24 3.78 0.09 0.19 0.37 2.05 
kobs 0.215 0.257 0.167 0.003 0.593 0.218 0.037 0.024 
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    RBC AChE Activity   Plasma BuChE Activity 
Time 
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100 μM 
C0  
10 μM 
C0  
1 μM 
C0  
0.1 μM 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0  
0.1 μM 
0 4.97 4.49 4.44 5.45 2.58 3.22 2.98 2.99 
0.5 1.89 1.21 4.41 5.52 0.37 1.69 2.48 3.03 
5 0.11 1.80 2.66 4.22 0.08 0.05 2.49 2.53 
10 0.81 0.48 3.51 4.68 0.06 0.00 1.59 2.71 
180 1.35 1.98 1.97 5.66 0.08 0.25 0.36 2.10 
kobs 0.706 0.158 0.031 0.019 0.563 0.423 0.053 0.013 
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RBC AChE 
Activity     Plasma BuChE Activity 
Time 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0  
0.1 μM 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0  
0.1 μM 
0 6.04 4.91 4.39 4.63 2.21 2.26 2.25 2.17 
0.5 1.02 1.85 2.48 4.22 0.51 1.59 1.82 2.05 
5 0.01 1.73 1.73 3.82 0.07 0.79 1.74 2.16 
10 1.55 2.64 2.69 4.13 0.05 0.36 1.39 2.07 
180 0.81 2.59 2.32 3.47 0.04 0.09 0.25 1.47 
kobs 1.112 0.132 0.033 0.009 0.584 0.172 0.039 0.002 
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    RBC AChE Activity   Plasma BuChE Activity 
Time 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0  
0.1 μM 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0  
0.1 μM 
0 4.92 4.88 5.21 4.77 3.46 3.48 3.34 3.31 
0.5 0.37 1.21 4.57 5.53 0.74 2.71 2.76 3.33 
5 0.67 0.85 3.00 3.41 0.11 1.42 2.93 3.37 
10 0.84 1.44 1.64 4.50 0.10 0.73 2.36 3.28 
180 0.00 1.70 1.94 3.29 0.15 0.11 0.64 2.62 
kobs 0.188 0.072 0.112 0.019 0.582 0.149 0.025 0.001 
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    RBC AChE Activity   Plasma BuChE Activity 
Time 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0  
0.1 μM 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0  
0.1 μM 
0 5.73 4.77 4.33 4.65 2.86 2.65 2.93 2.85 
0.5 1.34 2.69 3.47 4.91 0.59 2.29 2.51 2.87 
5 0.14 0.65 2.12 4.52 0.08 1.23 2.29 2.75 
10 0.28 0.81 1.44 3.55 0.07 0.71 2.06 2.80 
180 0.76 1.07 1.14 4.26 0.10 0.19 0.58 2.12 
kobs 0.643 0.172 0.105 0.029 0.615 0.129 0.029 0.003 
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    RBC AChE Activity   Plasma BuChE Activity 
Time 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0  
0.1 μM 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0  
0.1 μM 
0 4.58 4.04 4.38 4.82 2.72 3.00 3.29 3.06 
0.5 0.94 3.36 3.70 4.32 0.20 2.31 2.70 3.02 
5 0.61 0.99 2.64 2.21 0.17 1.21 2.63 2.95 
10 1.03 0.76 2.21 2.94 0.18 0.52 2.40 3.06 
180 0.35 1.02 1.70 3.75 0.09 0.19 0.72 2.61 
kobs 0.282 0.172 0.064 0.054 0.346 0.167 0.023 0.000 
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    RBC AChE Activity   Plasma BuChE Activity 
Time 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0  
0.1 μM 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0  
0.1 μM 
0 4.96 7.83 6.03 5.18 3.95 4.08 3.92 3.97 
0.5 1.28 2.96 5.52 5.59 0.61 2.99 3.16 3.03 
5 0.90 0.59 1.66 4.38 0.10 0.92 2.84 3.79 
10 1.49 0.79 1.02 4.80 0.10 0.32 2.90 3.77 
180 0.77 0.50 1.04 2.90 0.09 0.15 0.76 2.97 
kobs 0.236 0.210 0.184 0.014 0.613 0.249 0.023 -0.008 
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    RBC AChE Activity   Plasma BuChE Activity 
Time 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0  
0.1 μM 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0  
0.1 μM 
0 3.46 3.38 3.31 3.46 2.46 2.36 2.37 2.23 
0.5 0.21 1.29 2.82 4.03 0.31 1.53 1.99 2.13 
5 0.15 0.63 1.64 4.02 0.05 0.50 1.69 2.26 
10 0.53 0.39 1.33 2.26 0.05 0.19 1.54 2.27 
180 1.20 0.45 1.52 2.51 0.05 0.19 0.55 1.88 
kobs 0.407 0.182 0.090 0.045 0.618 0.239 0.037 -0.004 
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    RBC AChE Activity   Plasma BuChE Activity 
Time 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0  
0.1 μM 
C0  
100 μM 
C0  
10 μM 
C0  
1 μM 
C0  
0.1 μM 
0 3.91 4.36 4.46 4.78 1.95 1.98 1.95 1.70 
0.5 0.43 0.62 3.30 4.64 0.46 1.37 1.76 1.91 
5 0.23 0.03 1.49 4.04 0.08 0.55 1.49 1.87 
10 1.25 0.16 1.64 3.40 0.08 0.25 1.40 1.83 
180 0.54 0.54 1.15 3.24 0.09 0.12 0.61 1.64 
kobs 0.401 0.295 0.097 0.033 0.539 0.198 0.030 -0.002 
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Appendix G 
DON in Human Whole Blood 
1. RBC AChE and plasma BuChE kinetics in the presents of DON 
2. Table of substrate concentrations, DON concentrations, RBC AChE activity and 
plasma BuChE activity 
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AtCh Concentration [μM]
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AtCh or BtCh Concentration DON RBC AChE Activity Plasma BuChE Activity 
[μM] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
7500 0   3.662 
750 0 10.376 2.668 
75 0 4.080 1.581 
20 0 0.272 0.940 
7500 100 4.864 0.343 
750 100 1.932 3.432 
75 100 1.212 2.439 
20 100 1.535 1.373 
7500 1000 2.107 0.735 
750 1000 0.401 3.172 
75 1000 0.166 1.621 
20 1000 0.726 0.744 
7500 10000 2.445 0.536 
750 10000 0.897 2.332 
75 10000 0.357 0.608 
20 10000 0.000 0.138 
7500 30000 1.236 0.113 
750 30000 0.000 1.210 
75 30000 0.231 0.241 
20 30000 0.082 0.062 
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AtCh Concentration [μM]
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AtCh or BtCh Concentration DON RBC AChE Activity Plasma BuChE Activity 
[μM] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
15000 0   4.671 
7500 0  4.663 
750 0 11.284 3.384 
75 0 4.221 1.923 
20 0 2.934 0.992 
15000 100 4.582 3.867 
7500 100 4.342 4.110 
750 100 1.164 2.907 
75 100 0.444 1.773 
20 100 0.267 0.724 
15000 1000 2.623 4.182 
7500 1000 1.981 4.152 
750 1000 0.610 2.093 
75 1000 0.000 0.979 
20 1000 0.000 0.541 
15000 10000 2.216 3.187 
7500 10000 1.909 2.477 
750 10000 0.095 0.751 
75 10000 0.000 0.225 
20 10000 0.657 0.107 
15000 30000  1.637 
7500 30000 2.364 1.054 
750 30000 0.488 0.241 
75 30000 0.482 0.098 
20 30000 0.000 0.038 
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AtCh Concentration [μM]
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AtCh or BtCh Concentration DON RBC AChE Activity Plasma BuChE Activity 
[μM] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
15000 0   4.788 
7500 0  4.647 
750 0 6.905 3.124 
75 0 2.160 2.016 
20 0 0.292 1.068 
15000 100 0.000 4.344 
7500 100 4.379 4.299 
750 100 1.449 2.750 
75 100 0.768 1.609 
20 100 0.474 0.967 
15000 1000 0.986 4.528 
7500 1000 1.461 4.387 
750 1000 0.439 2.213 
75 1000 0.193 1.031 
20 1000 0.270 0.568 
15000 10000 1.046 3.041 
7500 10000 1.121 2.124 
750 10000 1.210 0.464 
75 10000 0.000 0.172 
20 10000 0.047 0.094 
15000 30000  1.866 
7500 30000 0.612 1.212 
750 30000 0.666 0.252 
75 30000 0.302 0.112 
20 30000 0.000 0.115 
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AtCh or BtCh Concentration DON RBC AChE Activity Plasma BuChE Activity 
[μM] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
15000 0   5.738 
7500 0  6.295 
750 0 7.815 4.637 
75 0 3.794 2.412 
20 0 1.883 1.334 
15000 100 0.000 5.146 
7500 100 3.816 5.307 
750 100 1.719 3.648 
75 100 0.903 2.029 
20 100 0.000 0.965 
15000 1000 1.533 5.380 
7500 1000 1.233 5.552 
750 1000 0.691 2.728 
75 1000 0.135 1.284 
20 1000 0.912 0.634 
15000 10000 1.633 3.967 
7500 10000 1.757 3.399 
750 10000 0.433 0.799 
75 10000 0.126 0.338 
20 10000 1.015 0.135 
15000 30000 2.777 2.275 
7500 30000 1.501 1.452 
750 30000 0.395 0.311 
75 30000 0.000 0.111 
20 30000 0.106 0.020 
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AtCh Concentration [μM]
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AtCh or BtCh Concentration DON RBC AChE Activity Plasma BuChE Activity 
[μM] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
15000 0   6.028 
7500 0  6.202 
750 0 9.161 4.114 
75 0 4.704 2.569 
20 0 2.717 1.419 
15000 100   5.533 
7500 100 3.524 5.630 
750 100 0.970 3.399 
75 100 0.000 2.029 
20 100 0.443 1.115 
15000 1000  5.917 
7500 1000 1.399 5.725 
750 1000 0.000 2.862 
75 1000 0.000 1.449 
20 1000 0.080 0.765 
15000 10000 1.907 4.605 
7500 10000 1.218 3.619 
750 10000 0.426 0.877 
75 10000 0.000 0.357 
20 10000 0.000 0.170 
15000 30000 0.018 2.751 
7500 30000 1.474 1.813 
750 30000 0.015 0.365 
75 30000 0.057 0.139 
20 30000 0.037 0.000 
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AtCh Concentration [μM]
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BtCh Concentration [μM]
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0 uM
100 uM
1,000 uM
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AtCh or BtCh Concentration DON RBC AChE Activity Plasma BuChE Activity 
[μM] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
15000 0   3.234 
7500 0  3.271 
750 0 2.083 2.205 
75 0 0.367 1.223 
20 0 0.489 0.734 
15000 100   3.855 
7500 100 1.547 3.183 
750 100 0.607 1.736 
75 100 0.085 0.818 
20 100 0.000 0.443 
15000 1000 2.789 2.108 
7500 1000 1.667 1.482 
750 1000 0.207 0.505 
75 1000 0.335 0.077 
20 1000 0.000 0.089 
15000 10000 2.483 1.123 
7500 10000 1.504 0.694 
750 10000 0.682 0.223 
75 10000 0.168 0.082 
20 10000 0.000 0.029 
15000 30000 NM NM 
7500 30000 NM NM 
750 30000 NM NM 
75 30000 NM NM 
20 30000 NM NM 
NM = Not Measured 
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AtCh or BtCh Concentration DON RBC AChE Activity Plasma BuChE Activity 
[μM] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 0   3.835 
3000 0 10.225 3.557 
1000 0 10.352 2.981 
300 0 9.453 2.317 
100 0 6.701 1.798 
30 0 3.543 1.498 
10 0 1.341 0.566 
15000 50  NM 
7500 50 4.708 NM 
750 50 1.579 NM 
75 50 0.119 NM 
20 50 1.335 NM 
15000 100 7.776 1.828 
7500 100 1.012 1.241 
750 100 2.508 0.183 
75 100 1.626 0.019 
20 100 0.484 0.005 
15000 1000 3.839 0.349 
7500 1000 5.102 0.184 
750 1000 2.237 0.019 
75 1000 0.000 0.002 
20 1000 2.592 0.001 
15000 10000 1.456 0.038 
7500 10000 1.118 0.019 
750 10000 0.997 0.002 
75 10000 0.188 0.000 
20 10000 0.418 0.000 
15000 30000 NM 0.013 
7500 30000 NM 0.006 
750 30000 NM 0.001 
75 30000 NM 0.000 
20 30000 NM 0.000 
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AtCh or BtCh Concentration DON RBC AChE Activity Plasma BuChE Activity 
[μM] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 0   4.561 
3000 0 8.780 3.565 
1000 0 8.864 3.059 
300 0 9.102 2.296 
100 0 6.022 1.909 
30 0 3.602 1.326 
10 0 1.829 0.680 
15000 50  NM 
7500 50 8.116 NM 
750 50 7.802 NM 
75 50 2.946 NM 
20 50 2.005 NM 
15000 100 5.235 4.390 
7500 100 6.478 4.322 
750 100 2.859 3.385 
75 100 1.056 1.068 
20 100 0.641 0.346 
15000 1000 3.541 4.218 
7500 1000 1.956 4.001 
750 1000 1.275 2.079 
75 1000 1.132 0.358 
20 1000 -0.593 0.102 
15000 10000 2.604 3.032 
7500 10000 1.081 2.296 
750 10000 1.180 0.428 
75 10000 0.332 0.047 
20 10000 0.481 0.013 
15000 30000 NM 1.866 
7500 30000 NM 1.179 
750 30000 NM 0.155 
75 30000 NM 0.016 
20 30000 NM 0.004 
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AtCh or BtCh Concentration DON RBC AChE Activity Plasma BuChE Activity 
[μM] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 0   4.740 
3000 0 9.660 4.106 
1000 0 9.676 3.441 
300 0 8.294 2.441 
100 0 6.200 1.886 
30 0 2.499 1.332 
10 0 1.415 0.632 
15000 50 8.382 NM 
7500 50 7.161 NM 
750 50 3.597 NM 
75 50 1.317 NM 
20 50 0.948 NM 
15000 100 6.229 4.501 
7500 100 4.920 4.430 
750 100 0.817 3.443 
75 100 0.430 1.067 
20 100 0.430 0.343 
15000 1000 3.869 4.291 
7500 1000 1.737 4.040 
750 1000 0.219 1.968 
75 1000 -0.021 0.321 
20 1000 0.138 0.090 
15000 10000 2.752 2.925 
7500 10000 1.862 2.150 
750 10000 0.960 0.373 
75 10000 -0.011 0.040 
20 10000 0.139 0.011 
15000 30000 NM 1.713 
7500 30000 NM 1.054 
750 30000 NM 0.133 
75 30000 NM 0.014 
20 30000 NM 0.004 
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AtCh or BtCh Concentration DON RBC AChE Activity Plasma BuChE Activity 
[μM] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 0   7.975 
3000 0 7.439 7.412 
1000 0 9.299 5.571 
300 0 8.191 4.295 
100 0 7.383 3.110 
30 0 2.472 1.855 
10 0 0.953 0.558 
15000 50 7.435 NM 
7500 50 5.782 NM 
750 50 4.441 NM 
75 50 0.934 NM 
20 50 0.371 NM 
15000 100 6.152 8.198 
7500 100 5.295 8.025 
750 100 2.467 5.813 
75 100 0.926 1.547 
20 100 0.480 0.477 
15000 1000 3.123 7.676 
7500 1000 2.121 7.081 
750 1000 1.163 2.958 
75 1000 1.163 0.434 
20 1000 0.641 0.120 
15000 10000 2.440 4.688 
7500 10000 1.696 3.255 
750 10000 0.628 0.500 
75 10000 0.627 0.053 
20 10000 0.110 0.014 
15000 30000 NM 2.514 
7500 30000 NM 1.479 
750 30000 NM 0.176 
75 30000 NM 0.018 
20 30000 NM 0.005 
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AtCh or BtCh Concentration DON RBC AChE Activity Plasma BuChE Activity 
[μM] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 0   5.690 
3000 0 10.972 5.424 
1000 0 9.358 4.287 
300 0 9.524 3.373 
100 0 5.420 2.363 
30 0 2.514 1.794 
10 0 1.191 0.902 
15000 50  NM 
7500 50 6.505 NM 
750 50 1.080 NM 
75 50 0.200 NM 
20 50 0.200 NM 
15000 100 5.270 5.106 
7500 100 6.442 5.055 
750 100 2.203 4.287 
75 100 0.610 1.701 
20 100 0.375 0.598 
15000 1000 2.032 4.947 
7500 1000 1.802 4.754 
750 1000 0.869 2.787 
75 1000 0.768 0.543 
20 1000 0.117 0.157 
15000 10000 4.017 3.775 
7500 10000 1.368 2.977 
750 10000 0.355 0.619 
75 10000 0.000 0.069 
20 10000 0.354 0.019 
15000 30000 NM 2.473 
7500 30000 NM 1.626 
750 30000 NM 0.227 
75 30000 NM 0.024 
20 30000 NM 0.006 
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AtCh or BtCh Concentration DON RBC AChE Activity Plasma BuChE Activity 
[μM] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 0   4.458 
3000 0 13.293 3.823 
1000 0 11.733 3.323 
300 0 9.920 2.545 
100 0 7.378 1.047 
30 0 4.093 0.774 
10 0 1.180 0.226 
15000 50  NM 
7500 50  NM 
750 50 2.966 NM 
75 50 0.836 NM 
20 50 0.000 NM 
15000 100  4.746 
7500 100 4.967 4.649 
750 100 1.647 3.399 
75 100 0.704 0.921 
20 100 0.000 0.285 
15000 1000 3.021 4.577 
7500 1000 1.319 4.335 
750 1000 1.011 2.222 
75 1000 0.000 0.378 
20 1000 0.639 0.107 
15000 10000 1.781 3.374 
7500 10000 0.922 2.587 
750 10000 1.334 0.498 
75 10000 0.007 0.055 
20 10000 0.509 0.015 
15000 30000 NM 2.129 
7500 30000 NM 1.364 
750 30000 NM 0.183 
75 30000 NM 0.019 
20 30000 NM 0.005 
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AtCh or BtCh Concentration DON RBC AChE Activity Plasma BuChE Activity 
[μM] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 0   4.592 
3000 0 10.183 4.113 
1000 0 10.481 3.295 
300 0 10.587 2.464 
100 0 5.818 2.052 
30 0 3.989 1.315 
10 0 0.550 0.443 
15000 50  NM 
7500 50 4.583 NM 
750 50 4.612 NM 
75 50 1.363 NM 
20 50 0.988 NM 
15000 100 2.855 4.454 
7500 100 3.514 4.394 
750 100 2.895 3.528 
75 100 0.382 1.188 
20 100 0.526 0.393 
15000 1000 0.960 4.310 
7500 1000 1.573 4.122 
750 1000 0.325 2.306 
75 1000 0.138 0.426 
20 1000 0.000 0.122 
15000 10000  3.256 
7500 10000 1.680 2.545 
750 10000 0.436 0.516 
75 10000 0.344 0.058 
20 10000 0.000 0.015 
15000 30000 NM 2.109 
7500 30000 NM 1.376 
750 30000 NM 0.189 
75 30000 NM 0.020 
20 30000 NM 0.005 
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AtCh or BtCh Concentration DON RBC AChE Activity Plasma BuChE Activity 
[μM] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 0   6.484 
3000 0 10.285 6.310 
1000 0 10.736 6.006 
300 0 9.410 3.871 
100 0 6.756 3.009 
30 0 3.490 2.090 
10 0 1.181 0.802 
15000 50  NM 
7500 50 5.228 NM 
750 50 2.799 NM 
75 50 1.969 NM 
20 50 0.534 NM 
15000 100  6.968 
7500 100 4.798 6.872 
750 100 2.889 5.512 
75 100 0.441 1.851 
20 100 1.455 0.611 
15000 1000 1.375 6.660 
7500 1000 1.671 6.298 
750 1000 0.795 3.183 
75 1000 0.394 0.535 
20 1000 0.838 0.151 
15000 10000 1.386 4.619 
7500 10000 1.234 3.430 
750 10000 0.847 0.609 
75 10000 0.000 0.066 
20 10000 0.416 0.018 
15000 30000 NM 2.747 
7500 30000 NM 1.705 
750 30000 NM 0.218 
75 30000 NM 0.022 
20 30000 NM 0.006 
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AtCh or BtCh Concentration DON RBC AChE Activity Plasma BuChE Activity 
[μM] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 0   6.340 
3000 0 9.905 5.722 
1000 0 8.640 4.666 
300 0 8.165 3.545 
100 0 3.988 2.792 
30 0 2.461 1.975 
10 0 1.059 0.824 
15000 50  NM 
7500 50 7.496 NM 
750 50 3.768 NM 
75 50 1.496 NM 
20 50 0.926 NM 
15000 100  6.186 
7500 100 4.286 6.090 
750 100 1.749 4.753 
75 100 0.575 1.488 
20 100 0.113 0.480 
15000 1000 2.911 5.828 
7500 1000 2.390 5.432 
750 1000 1.068 2.445 
75 1000 0.392 0.376 
20 1000 0.679 0.105 
15000 10000 3.291 3.691 
7500 10000 1.195 2.613 
750 10000 0.053 0.417 
75 10000 0.036 0.044 
20 10000 0.089 0.012 
15000 30000 NM 2.034 
7500 30000 NM 1.213 
750 30000 NM 0.147 
75 30000 NM 0.015 
20 30000 NM 0.004 
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AtCh or BtCh Concentration DON RBC AChE Activity Plasma BuChE Activity 
[μM] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 0   6.311 
3000 0 8.475 5.532 
1000 0 9.466 4.500 
300 0 8.024 3.407 
100 0 5.219 2.587 
30 0 2.169 1.714 
10 0 0.524 0.574 
15000 50  NM 
7500 50 4.595 NM 
750 50 3.553 NM 
75 50 1.797 NM 
20 50 0.780 NM 
15000 100  5.913 
7500 100 3.411 5.823 
750 100 1.584 4.569 
75 100 0.929 1.449 
20 100 0.764 0.470 
15000 1000 0.304 5.639 
7500 1000 0.859 5.314 
750 1000 0.727 2.608 
75 1000 0.759 0.428 
20 1000 0.765 0.120 
15000 10000 2.158 3.851 
7500 10000 2.195 2.834 
750 10000 0.516 0.493 
75 10000 0.583 0.053 
20 10000 0.101 0.014 
15000 30000 NM 2.259 
7500 30000 NM 1.391 
750 30000 NM 0.176 
75 30000 NM 0.018 
20 30000 NM 0.005 
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AtCh or BtCh Concentration DON RBC AChE Activity Plasma BuChE Activity 
[μM] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 0   7.691 
3000 0 12.037 6.738 
1000 0 11.540 4.979 
300 0 9.992 4.056 
100 0 8.219 3.206 
30 0 4.200 2.040 
10 0 2.211 0.817 
15000 50  NM 
7500 50 9.645 NM 
750 50 3.059 NM 
75 50 1.920 NM 
20 50 0.003 NM 
15000 100  7.390 
7500 100 6.392 7.257 
750 100 2.236 5.486 
75 100 1.099 1.595 
20 100 0.000 0.504 
15000 1000 3.870 6.982 
7500 1000 2.282 6.511 
750 1000 0.410 2.940 
75 1000 0.359 0.453 
20 1000 0.578 0.126 
15000 10000 3.388 4.501 
7500 10000 1.752 3.210 
750 10000 0.458 0.521 
75 10000 0.654 0.056 
20 10000 0.384 0.015 
15000 30000 NM 2.515 
7500 30000 NM 1.510 
750 30000 NM 0.184 
75 30000 NM 0.019 
20 30000 NM 0.005 
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AtCh or BtCh Concentration DON RBC AChE Activity Plasma BuChE Activity 
[μM] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 0   5.420 
3000 0 7.439 4.588 
1000 0 9.299 3.170 
300 0 8.191 3.060 
100 0 7.383 2.110 
30 0 2.472 1.566 
10 0 0.953 0.557 
15000 50 7.294 NM 
7500 50 6.292 NM 
750 50 3.453 NM 
75 50 1.087 NM 
20 50 0.992 NM 
15000 100 5.154 4.983 
7500 100 4.432 4.902 
750 100 1.973 3.792 
75 100 0.099 1.162 
20 100 0.467 0.372 
15000 1000 4.663 4.672 
7500 1000 2.431 4.333 
750 1000 1.099 1.881 
75 1000 0.196 0.283 
20 1000 0.570 0.079 
15000 10000 3.173 2.874 
7500 10000 1.971 2.006 
750 10000 0.133 0.312 
75 10000 0.217 0.033 
20 10000 0.255 0.009 
15000 30000 NM 1.549 
7500 30000 NM 0.914 
750 30000 NM 0.109 
75 30000 NM 0.011 
20 30000 NM 0.003 
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AtCh or BtCh Concentration DON RBC AChE Activity Plasma BuChE Activity 
[μM] [μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
10000 0   4.005 
3000 0 11.391 3.525 
1000 0 11.645 2.821 
300 0 11.698 2.156 
100 0 7.829 1.703 
30 0 3.209 1.147 
10 0 1.782 0.645 
15000 50 6.150 NM 
7500 50 7.190 NM 
750 50 1.942 NM 
75 50 1.754 NM 
20 50 2.203 NM 
15000 100 4.185 3.715 
7500 100 5.615 3.669 
750 100 2.815 3.001 
75 100 0.625 1.065 
20 100 0.196 0.358 
15000 1000 1.433 3.568 
7500 1000 1.270 3.393 
750 1000 0.169 1.803 
75 1000 0.188 0.317 
20 1000 0.211 0.090 
15000 10000 2.954 2.557 
7500 10000 1.308 1.937 
750 10000 0.601 0.361 
75 10000 -0.012 0.040 
20 10000 0.179 0.011 
15000 30000 NM 1.569 
7500 30000 NM 0.992 
750 30000 NM 0.130 
75 30000 NM 0.013 
20 30000 NM 0.004 
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Appendix H 
GAL  in Human Whole Blood 
3. Inhibition of RBC AChE and plasma BuChE activity by GAL 
4. Table of GAL concentration and RBC AChE activity and plasma BuChE activity 
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GAL RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
1 5.966 1.760 
1 6.920 1.761 
1 5.798 1.778 
10 4.765 1.571 
10 4.853 1.787 
10 4.713 2.080 
100 3.390 1.464 
100 4.281 1.481 
100 4.413 1.635 
1000 1.795 1.221 
1000 3.003 1.214 
1000 2.602 1.226 
10000 1.263 0.297 
10000 0.633 0.307 
10000 0.438 0.274 
30000 0.166 0.117 
30000 0.012 0.135 
30000 0.136 0.103 
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GAL RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 3.578 2.356 
0 3.805 2.164 
0 2.779 2.231 
10 2.841 2.133 
10 3.074 2.122 
10 3.139 2.128 
100 3.094 1.665 
100 3.056 1.730 
100 2.379 2.247 
1000 0.965 1.192 
1000 1.370 1.126 
1000 1.818 1.237 
10000 0.259 0.301 
10000 0.262 0.294 
10000 0.171 0.295 
30000 0.589 0.129 
30000 0.401 0.084 
30000 0.161 0.085 
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l]
 
 
GAL RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 4.279 2.168 
0 3.777 2.129 
0 3.356 2.052 
10 4.695 2.071 
10 3.813 2.069 
10 3.697 2.069 
100 2.912 1.743 
100 2.860 1.757 
100 3.207 1.693 
1000 1.445 1.254 
1000 1.560 1.279 
1000 1.415 1.277 
10000 0.464 0.262 
10000 0.163 0.268 
10000 0.163 0.261 
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l]
 
 
GAL RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 3.701 3.200 
0 2.953 2.732 
0 3.240 2.728 
10 3.878 2.874 
10 3.105 3.002 
10 4.521 3.015 
100 2.616 2.391 
100 2.317 2.539 
100 3.069 2.470 
1000 2.488 1.840 
1000 2.119 1.920 
1000 1.587 1.952 
10000 0.082 0.440 
10000 0.000 0.421 
10000 0.000 0.411 
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l]
 
 
GAL RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 3.081 2.626 
0 3.574 2.544 
0 3.968 2.462 
10 2.998 2.378 
10 2.744 2.417 
10 3.202 2.474 
100 1.320 2.026 
100 1.513 1.986 
100 2.309 1.989 
1000 0.833 1.465 
1000 0.553 1.461 
1000 1.867 1.682 
10000 0.000 0.381 
10000 0.000 0.361 
10000 0.000 0.348 
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GAL RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 5.538 1.583 
0 4.719 1.666 
0 4.664 1.616 
10 5.273 1.608 
10 5.003 1.616 
10 4.801 1.647 
100 4.100 1.157 
100 5.205 1.241 
100 4.636 1.171 
1000 2.366 0.866 
1000 2.258 0.816 
1000 1.878 0.857 
10000 0.000 0.152 
10000 0.000 0.177 
10000 0.000 0.167 
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l]
 
 
GAL RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 5.616 1.931 
0 6.131 1.904 
0 5.505 2.199 
10 5.287 1.938 
10 5.048 1.928 
10 4.477 1.817 
100 4.149 1.472 
100 3.967 1.592 
100 4.372 1.532 
1000 2.441 0.956 
1000 1.743 0.915 
1000 1.364 0.926 
10000 0.904 0.153 
10000 0.561 0.171 
10000 0.392 0.181 
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GAL RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 4.022 1.994 
0 4.056 1.947 
0 3.643 1.983 
10 4.147 1.870 
10 3.894 1.912 
10 4.363 1.858 
100 2.923 1.680 
100 2.739 1.475 
100 2.156 1.529 
1000 1.548 1.217 
1000 1.403 1.042 
1000 2.016 1.133 
10000 0.000 0.246 
10000 0.109 0.233 
10000 0.000 0.242 
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GAL RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 5.528 2.229 
0 5.461 2.110 
0 5.275 2.276 
10 6.265 2.146 
10 4.844 2.016 
10 4.888 2.121 
100 6.275 1.487 
100 7.013 1.857 
100 4.459 1.422 
1000 2.813 1.147 
1000 2.038 1.114 
1000 1.586 1.107 
10000 0.445 0.256 
10000 0.454 0.252 
10000 0.891 0.251 
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GAL RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 4.666 4.080 
0 4.553 4.232 
0 4.029 4.254 
10 3.792 3.833 
10 3.633 3.720 
10 4.193 3.840 
100 3.180 3.505 
100 3.845 3.532 
100 2.695 3.504 
1000 1.541 2.674 
1000 1.590 2.512 
1000 1.654 2.574 
10000 0.471 0.601 
10000 0.188 0.551 
10000 0.288 0.560 
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GAL RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 5.592 2.769 
0 6.212 2.823 
0 6.237 2.740 
10 6.133 2.776 
10 6.607 2.732 
10 6.882 2.730 
100 4.649 2.174 
100 4.422 2.083 
100 5.444 2.185 
1000 3.170 1.547 
1000 3.489 1.560 
1000 2.423 1.567 
10000 0.162 0.399 
10000 0.703 0.402 
10000 1.016 0.404 
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GAL RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 4.160 3.804 
0 4.123 3.675 
0 6.072 3.551 
10 7.847 2.937 
10 4.609 3.087 
10 5.072 2.946 
100 2.337 2.554 
100 5.576 2.500 
100 3.781 2.469 
1000 3.003 1.870 
1000 2.860 1.658 
1000 3.291 1.782 
10000 1.801 0.519 
10000 0.582 0.335 
10000 1.186 0.409 
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GAL RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 5.483 2.075 
0 4.577 2.061 
0 5.846 2.119 
10 2.840 2.247 
10 3.375 2.265 
10 4.852 2.353 
100 3.880 1.692 
100 4.783 1.730 
100 4.535 1.634 
1000 2.711 1.330 
1000 2.275 1.344 
1000 2.384 1.325 
10000 0.074 0.256 
10000 0.732 0.264 
10000 0.630 0.277 
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GAL RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 4.286 3.196 
0 5.186 3.303 
0 4.681 3.276 
10 3.558 3.132 
10 4.287 3.226 
10 3.974 3.211 
100 4.039 2.753 
100 4.026 2.378 
100 3.757 2.710 
1000 1.853 1.944 
1000 1.757 1.887 
1000 2.425 1.972 
10000 0.995 0.392 
10000 0.222 0.384 
10000 0.436 0.385 
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GAL RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 4.655 2.851 
0 4.770 2.650 
0 5.467 2.857 
10 4.234 2.952 
10 5.082 2.815 
10 4.911 2.777 
100 3.946 2.534 
100 4.554 2.369 
100 4.569 2.318 
1000 2.284 1.693 
1000 2.354 1.850 
1000 2.188 1.817 
10000 0.652 0.329 
10000 0.103 0.316 
10000 0.733 0.314 
 
382 
Subject 016 
0
1
2
3
4
5
6
1 100 10000 1000000
GAL Blood Concentration [μM]
R
B
C
 A
C
hE
 A
ct
iv
ity
[ μm
ol
/m
in
/m
l]
0
1
2
3
4
1 100 10000 1000000
GAL Blood Concentration [μM]
Pl
as
m
a 
B
uC
hE
 A
ct
iv
ity
[ μm
ol
/m
in
/m
l]
 
 
GAL RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 4.823 3.058 
0 4.379 3.292 
0 4.038 3.003 
10 4.024 2.693 
10 3.012 2.735 
10 3.784 2.598 
100 2.741 2.256 
100 3.807 2.095 
100 3.075 2.098 
1000 2.596 1.827 
1000 1.967 1.770 
1000 1.853 1.782 
10000 0.533 0.410 
10000 0.147 0.385 
10000 0.726 0.415 
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GAL RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 5.184 3.967 
0 6.030 3.922 
0 4.959 4.083 
10 2.989 3.670 
10 4.140 3.378 
10 4.627 3.308 
100 3.697 2.812 
100 3.883 2.778 
100 4.242 2.825 
1000 1.448 2.174 
1000 2.466 2.174 
1000 2.113 2.225 
10000 0.533 0.522 
10000 0.211 0.480 
10000 0.861 0.472 
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GAL RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 3.313 2.366 
0 3.379 2.360 
0 3.458 2.457 
10 3.696 2.060 
10 4.410 2.116 
10 3.420 1.940 
100 3.061 1.737 
100 2.870 1.713 
100 2.520 1.814 
1000 0.986 1.299 
1000 0.971 1.283 
1000 1.290 1.300 
10000 0.565 0.244 
10000 0.319 0.249 
10000 0.185 0.265 
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GAL RBC AChE Activity Plasma BuChE Activity 
[μM] [μmol/min/ml RBC] [μmol/min/ml plasma] 
0 4.779 1.704 
0 3.906 1.947 
0 4.357 1.978 
10 4.056 1.771 
10 3.628 1.726 
10 3.817 1.640 
100 3.476 1.439 
100 3.391 1.412 
100 2.977 1.383 
1000 1.524 0.970 
1000 1.437 1.085 
1000 1.570 1.150 
10000 -0.120 0.227 
10000 0.146 0.219 
10000 0.643 0.215 
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David S. Lee was born in Tifton, GA on 30-March-1977 and is an American 
citizen.  He graduated from Tift County High School in 1995 with honors.  He received a 
Bachelors of Science in Chemistry with a specialization in Biochemistry from the 
Georgia Institute of Technology in Atlanta, Georgia in December 1999.  From 2000 to 
2001, he worked for Virginia Polytechnic Institute and State University’s Agricultural 
Research and Extension Center in Suffolk, Virginia as a chemist and from 2002-2003 at 
Wyeth Consumer Healthcare in Richmond, Virginia as an analytical chemist and a 
formulation scientist.   
He joined the Doctor of Pharmacy degree program at the Virginia Commonwealth 
University School of Pharmacy in 2002 and the Doctor of Philosophy program in the 
Pharmaceutical Sciences in 2003 where his research was performed in the 
Pharmacokinetics and Pharmacodynamics Research Laboratory in the Department of 
Pharmaceutics.  During his time at VCU, he served as pharmacy class vice president from 
2002-2003, pharmacy class president from 2003-2004, Department of Pharmaceutics 
Graduate Student Association President from 2005-2006 and the Chair of the VCU 
Student Chapter of the American Association of Pharmaceutical Sciences from 2006-
2007.   
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He has received several awards during his time at VCU, including the 2003 Best 
Poster by a pharmacy student at the VCU School of Pharmacy Research Day, 
Membership into Rho Chi Pharmaceutical Honor Society in 2004, the VCU Kamlesh 
M.Thakker award in 2006, awarded Fellowship of the American Foundation for 
Pharmaceutical Education from 2007-2009, Doctoral Scholars Dissertation Year Award 
from the Southern Region Education Board 2008-2009 and a Student Award from the 
American College of Clinical Pharmacology in 2009. 
He is a member of the American Society of Clinical Pharmacology and 
Therapeutics, American College of Clinical Pharmacology, American Association of 
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